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Platinum (II) anticancer drugs are used in over 50% of all chemotherapeutic 
treatments worldwide, however, platinum-resistance is a major clinical concern. 
Platinum-group complexes are of significant interest in the development of 
anticancer drugs which overcome such resistance, with improved selectivity for 
cancer vs. healthy cells, ultimately enhancing the drug efficacy and reducing patient 
side effects. In this thesis, three families of metal complexes have been investigated: 
(i) OsII half-sandwich complexes for catalytic therapy, (ii) cyclometallated IrIII 
complexes for photodynamic therapy (PDT) and (iii) diazido-PtIV prodrugs for 
photoactivatable chemotherapy (PACT). Determination of the chemical speciation 
of such complexes in cancer cells is essential for understanding the antiproliferative 
mechanisms of action. Herein, the speciation, distribution and stability of such 
complexes in cancer cells have been probed using Inductively-Coupled Plasma 
Mass Spectrometry (ICP-MS), synchrotron X-ray Fluorescence (XRF), Differential 
Phase Contrast (DPC) imaging and synchrotron X-ray Absorption Near Edge 
Structure (XANES) spectroscopy. Complementary to this, cryogenic fluorescence 
microscopy, Structured Illumination Microscopy (SIM) and synchrotron soft X-ray 
Tomography (XRT) have been used to investigate the 3D drug distribution and 
morphological changes in cancer cells down to a subcellular resolution (40 nm). 
OsII half-sandwich complexes of the general formula OsII[(η6-p-
cymene)(BsDPEN)] (where BsDPEN=benzyldiphenylethylene diamine) show 
promise as catalysts for transfer hydrogenation in cancer cells. In this thesis a total 
of six (1S, 2S) or (1R, 2R)-(R)BsDPEN ligands and their corresponding OsII[(η6-p-
cymene)((R)BsDPEN)] complexes have been synthesized and characterized (where 
R=Br, I, OCH3). These complexes exhibited moderate antiproliferative potencies 
(IC50~20-30 µM) against four human cancer cell lines. A 16-electron Br-labelled 
complex (OsII[(η6-p-cymene)(p-Br)BsDPEN)]) showed similar chemical properties 
(x-ray crystal structure, DFT, LogP, solution stability and transfer hydrogenation 
catalytic activity) to that of parent compound OsII[(η6-p-cymene)((CH3)BsDPEN)]. 
The Br-probe did not significantly alter the in vitro activity, or in-cell catalytic 
activity, thus, was a suitable analogue to probe the intracellular stability and 
distribution these complexes by ICP-MS (189Os; 79Br) and synchrotron-XRF (Os 
L3M5=8.91 keV; Br KL3=11.92 keV). The Os and the Br-labelled sulfonamide 
iv 
 
ligand strongly co-localised in the cytoplasm. ICP-MS and synchrotron-XRF 
revealed significantly higher levels of the Br-labelled sulfonamide ligand compared 
to the Os, implying intracellular degradation. Surprisingly, the Br-labelled 
sulfonamide ligand was distributed in cell nuclei, whereas Os was not, but it is not 
yet known whether this contributes to the anticancer activity. Synchrotron-XRF 
also revealed the co-localisation of Os with the Br-labelled ligand in lysosomes. 
Cyclometallated luminescent IrIII complexes show promise as photosensitizers for 
PDT. Potent complex [IrIII(C,N)2(O,O)] (where C, N=2-phenylpyridine and 
O,O=diketonate) can generate toxic singlet oxygen (1O2) and was investigated by 
cryo-XRT, revealing significant 3D mitochondrial damage in cancer cells treated 
with this photosensitiser, likely caused by the selective generation of 1O2 in close 
proximity to mitochondria. Additionally, the stability and localisation of a potent 
photodynamic-photochemotherapeutic IrIII-PtIV conjugate under dark conditions 
was investigated in cancer cells using synchrotron-XRF. This revealed significantly 
higher levels of Pt vs. Ir, suggestive of in-cell complex cleavage. Pt was distributed 
homogenously in cells, whereas Ir localised in organelle-like cytoplasmic regions, 
providing evidence for a multi-targeting mechanism of action.   
The antiproliferative mechanism of action of a potent coumarin-labelled diazido-
PtIV prodrug trans, trans, trans-[PtIV(OH)(coumarin)(N2)2(pyridine)2] was 
investigated using cryo-SIM and cryo-XRT. Cryo-XRT revealed the presence of 
endosomes in treated cells exposed to dark conditions, suggesting that active 
processes may be involved in the efflux of PtIV prodrugs prior to light activation. 
Upon irradiation, cells treated with this diazido-PtIV prodrug caused severe cellular 
damage, including vacuolisation, membrane-blebbing, vesicle-shedding and 
increased cell granularity. Synchrotron-XRF demonstrated the targeting of cell 
nuclei by diazido-PtIV prodrugs, in addition to the increased Pt accumulation upon 
blue light irradiation. XANES studies suggest the presence of predominantly PtIV 
vs. PtII in treated cancer cells exposed to blue light.  
This thesis has utilized a variety of advanced synchrotron imaging techniques to 
probe the intracellular distribution, speciation and cell damage induced by Os, Ir 
and Pt complexes in cancer cells in their near-native state, demonstrating how new 
biological imaging techniques can be exploited in metals in medicine. 
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Chapter 1: Introduction 
 
The thesis reports the use of cutting-edge synchrotron-based techniques to investigate 
the speciation, distribution and targeting of three different families of precious metal 
anticancer complexes: (i) [OsII(η-arene)(diamine)] catalysts; (ii) cyclometallated IrIII 
photosensitisers for photodynamic therapy (PDT); (iii) diazido-PtIV prodrugs for 
photoactivatable chemotherapy (PACT).  
In particular, synchrotron-X-Ray Florescence (XRF), Differential Phase Contrast 
(DPC) Imaging and X-ray Absorption Near Edge Structure (XANES) spectroscopy 
techniques are used to probe intracellular drug stability, distribution and speciation by 
mapping readily detectable exogenous elements (Os, Ir, Pt and Br). Contrastingly, 
correlative cryo-Structured Illumination Microscopy (cryo-SIM) and cryo-soft-X-Ray 
Tomography (cryo-XRT) are used to gain both insights into the localisation of 
fluorescent metallodrugs and drug-induced subcellular morphological changes as 
close to physiological state as possible. 
Platinum-based drugs are the most widely used in cancer treatment, but are limited by 
poor selectivity and resistance, which ultimately reduces drug efficacy and causes 
severe patient side effects. There is much potential in the design of metallodrugs which 
can circumvent platinum-resistance, however, design depends on the understanding of 
structure-activity relationships: role of the metal, the oxidation state, the coordination 
geometry, and the number and type of ligands. An understanding of drug speciation in 
biological media is crucial for elucidating the mechanisms of activation and in-cell 
antiproliferative activity for clinical translation. Determination of the chemical 
speciation of metallodrugs is challenging, but can be probed using complementary 
analytical techniques such as confocal microscopy imaging, mass spectrometry 
proteomics, Nano-Secondary Ion Mass Spectrometry (Nano-SIMS), Inductively-
Coupled Plasma Mass Spectrometry (ICP-MS), Laser-Ablation ICP-MS, synchrotron-








1.1     Metal complexes for the treatment of cancer 
 
1.1.1    Cancer and the Warburg Effect 
 
Cancer is a major global issue, and statistics from 2018 show that 1 in 2 people in the 
UK will develop cancer at some point in their lifetime,4 which puts increasing pressure 
on the development of new anticancer treatments which combat resistance and reduce 
off-target effects. Cancer is a generic term which describes the uncontrollable 
outgrowth or division of a clonal population of cells.5  In 2001, Weinberg and Hanahan 
postulated the six main hallmarks of cancer: evasion of apoptosis, sustaining 
antiproliferative signals, self-sufficient growth, sustained angiogenesis, tissue 
invasion and metastasis and limitless replication potential which are widely accepted 
worldwide.6 Genomic mutations of non-reproductive cells can cause uncontrollable 
multiplication, eventually producing a malignant cancer. The complication of the 
design of new treatments to eradicate these malignant tumours stems down to our 
understanding of the human genome - the sequence of nucleobases encoded into 
nuclear DNA which encloses our genetic information. If mutations of these 
nucleobases occur, then the they will generate mutated proteins, preventing normal 
cell function, allowing the cell to become cancerous.7  
Healthy human cells have a variety of coping mechanisms in response to disruptions 
or alterations to cell growth through the regulation of growth suppressor factors.8 
Cancer cells inactivate these growth suppressor genes, perturbing the cell homeostasis, 
ultimately leading to uncontrolled cell growth and division.9  As a result, premalignant 
healthy cells try other means of ‘cell suicide’ to counteract this, for example, the 
modification of metabolism or programmed-cell death. Cancers evolve and adapt to 
survive and proliferate under extreme conditions.10  
Cancer cells have dysfunctional mitochondria compared to healthy cells:11 one of the 
hallmarks of cancer. Mitochondria are rod-shaped organelles inside cells where energy 
(ATP) is generated in the electron-transport chain (ETC), located in the mitochondrial 
membrane. The ETC is the site of oxidative phosphorylation, a process in which 
nutrients are oxidised by oxygen to release energy – which plays an essential role in 




cellular and tissue metabolism.12 Non-cancerous cells cannot survive under aerobic 
conditions, whereas the altered metabolism in cancers permits growth and survival. 
Typical features of altered cell metabolism in cancer cells include enhanced glucose 
uptake and the increased production of lactate via glycolysis.13 Cancer cells increase 
their availability of energy sources to promote cell growth and survival under hypoxic 
conditions, primarily utilising aerobic glycolysis to facilitate the uptake and 
incorporation into biomass (i.e. nucleotides, amino acids and lipids) to promote cell 
growth and survival.14 They achieve this by increasing the rate at which glucose is 
taken into the cell – as defined by The Warburg Effect (Fig. 1.1). The Warburg Effect 
describes the phenomenon when cancer cells preferentially rely on aerobic glycolysis 
to generate energy under hypoxic conditions (as opposed to oxidation to form CO2).
14 
The distinct differences in redox homeostasis, dysfunctional mitochondrial and cell 
metabolism between cancer and healthy cells provides the opportunity to develop 
selective anticancer drugs through the generation of reactive oxygen species (ROS).15 
 
 
Figure 1.1. Schematic depiction of the aerobic glycolysis pathway predominant in cancer cells 
in the presence or absence of oxygen owing to the Warburg Effect.  
 




1.1.2    Metal-based chemotherapy 
 
Chemotherapy 
Chemotherapy is a treatment in which chemical compounds (drugs) are administered  
in an attempt to eradicate cancer cells by targeting the proliferation potential and 
metastasising ability of tumour cells,16 and has been used to treat cancer for over 70 
years. This method has shown to kill cancer cells and is commonly used in 
combination with other treatments such as surgery or radiotherapy. Interestingly, 
changes in levels of reactive oxygen species (ROS) and oxidative ‘damage products’ 
can be accelerated by both chemotherapy and radiotherapy,17 highlighting the 
potential advantages of combinational therapies. The overtreatment of cancers by 
current chemotherapeutics can lead to the development of both intrinsic and acquired 
multidrug resistance: a major clinical concern.  
 
Metal-based chemotherapeutics 
Over the years, transition metal complexes have been of increasing interest in 
medicine, showing promise for the design of viable scaffolds for therapeutic agents in 
cancer treatment.18 In particular, platinum-based drugs are used in approximately 50% 
of chemotherapeutic cancer treatments.19 However, drug-resistance and poor 
selectivity of current platinum drugs is becoming increasingly problematic, warranting 
the development of new anticancer treatments. 
In 1978, cisplatin was the first FDA-approved platinum-based anticancer drug for the 
treatment of testicular and bladder cancers,20 however (due to poor target selectivity) 
cisplatin causes severe side effects, including nephrotoxicity - which can lead to long-
term kidney problems.20 This led to the development of other platinum drugs (Fig. 
1.2), firstly carboplatin (approved in 1989, which reduced nephrotoxicity)21 and 
oxaliplatin (approved in 2002, a third-generation platinum drug which showed 
anticancer activity in cisplatin resistant cells lines).22 






Figure 1.2. Structures of clinically-used platinum drugs: cisplatin, carboplatin and oxaliplatin. 
 
 
The generally accepted mechanism of cisplatin exploits the 2+ oxidation state of 
platinum.23 Cisplatin is a square-planar Pt(II) prodrug which is intracellularly 
hydrolysed to form an activated Pt(II)-aqua species.24 This species interacts with the 
N7 nitrogen of guanine (and adenine) of DNA, located in cell nuclei.24 As a result of 
two available coordination sites on platinum, both intra-strand and inter-strand 
crosslinking occurs,24 allowing high mobility group (HMG) proteins to insert bulky 
phenyl groups in the newly-formed gaps. This in turn ‘kinks’ the DNA backbone, 
preventing the cancer cell from repairing its DNA.24 Furthermore, these Pt-based 
drugs induce apoptosis (programmed cell death) through S and G2/M phase cell cycle 
arrest,25 by preventing DNA replication.  
Interestingly, the mechanism of action of oxaliplatin does not involve DNA-induced 
cell damage (despite the structural similarities to cisplatin and carboplatin), but instead 
induces ribosomal biogenesis stress,26 highlighting the role of ligand diversity between 
these mainstay chemotherapeutics. Recent studies have also shown that cisplatin can 
induce apoptosis by disrupting signalling pathways including calcium signalling, cell 
death receptor signalling and the activation of mitochondrial pathways.27 This is 
somewhat over-looked in platinum-drug research, whereby DNA is considered to be 
the predominant cellular target of cisplatin, in spite of only 1% of intracellular drug 
reaching the cell nucleus and interacting with DNA.28 




1.1.3    Drug-resistance 
 
Platinum drug resistance 
For many cancers, there is growing resistance to chemotherapy – termed multi-drug 
resistance (MDR). For example, chemotherapy is used to treat early-stage lung cancer, 
however, as a result of chemotherapeutic resistance, it is ineffective against the 
treatment of advanced-stage lung cancer.29 Drug-resistance depends on the type of 
cancer and the individual patient variability, but mainly on the drug itself, highlighting 
the need for consideration of patient-specific treatments in the future development of 
chemotherapeutics. Growing resistance to these administered drugs may reduce 
patient survival rates, leading to increases in mortality. Additionally, the drugs used in 
current chemotherapy treatments are not selective for cancer cells, resulting in toxicity 
(towards non-cancerous cells) making the patient ill with unwanted (and often severe) 
side effects.30  
Resistance can be categorized as intrinsic or acquired, both of which have a significant 
effect on the efficiency of current anticancer treatments, and are considered to be the 
main reasons for chemotherapy failure. Intrinsic resistance is pre-existent: for 
example, when cancers do not respond to a drug despite no prior treatment to the drug  
(i.e. as a result of a failing anti-tumour cellular immune response either locally or 
systematically).31  In contrast, acquired resistance is drug-induced and can result from 
specific mutations of cancer cells upon repeated exposure to a drug.32  For the case of 
cisplatin, major contributors to resistance are the reduced cellular drug influx and 
enhanced efflux,33 DNA repair mechanisms,34 and over-expressed cellular reducing 
agents (i.e. gluthathione and L-ascorbic acid) - which can detoxify drugs in cancer 
cells.35 Both intrinsic and acquired platinum resistance are leading causes for the 
increasing failure of platinum-based cancer chemotherapy, hence, new approaches to 
drug design are essential to circumvent this. Over the years there has been extensive 
research into designing new platinum anticancer drugs with alternative cellular targets 
and mechanisms of action, with the aim of overcoming cisplatin resistance. 
 
 




1.2     Development of new metallodrugs 
 
1.2.1    Phototherapy: PDT and PACT 
 
Photodynamic therapy (PDT) 
Photodynamic therapy (PDT) is a non-invasive, clinically-approved therapeutic 
technique which exerts cytotoxic activity upon activation of a photosensitiser in the 
presence of oxygen.36 Metal based-photosensitizers can display selectivity towards 
cancer cells over healthy cells through selective tissue irradiation,37 and are most 
relevant for the treatment of surface-cancers (e.g. skin or prostate cancers) which are 
accessible to visible light (~mm penetration depth).38 In general, PDT works by stress 
response to mitochondrial damage and caspase-dependent apotosome formation, 
usually through the generation of toxic singlet oxygen (1O2)– resulting in cell death.
39  
Metal photosensitisers show advantages over organic photosensitisers as they promote 
rapid intersystem crossing (due to spin-orbit coupling) and have long excited state 
lifetimes. Notably, two transition metal photosensitisers are TOOKAD (palladium-
based photosensitiser clinically-approved for the treatment of prostate cancer) and 
TLD-1433 (a cyclometallated Ru(II) photosensitisers in clinical trials for the treatment 
of bladder cancer).37  
Cyclometallated luminescent organo-iridium(III) complexes have shown promise as 
photosensitisers for cancer treatment through the perturbation of intracellular redox 
balance via the generation of toxic singlet oxygen (1O2).
40 Mao et. al. reported a series 
of phosphorescent cyclometallated iridium(III) complexes containing 5-membered 
heterocyclic ligands which can act as both PACT and PDT agents by increasing levels 
of intracellular ROS and limiting the ATP energy supply.41 Due to the limited tissue 
penetration depths of visible light, complexes with extended structures which can be 
activated with near-IR light are of significant interest. For example, Bryant et. al. 
demonstrated cyclometallated IrIII photosensitisers with extended aromatic structures 
which could be activated with near-IR two-photon light (λ=760 nm).42 However, two-
photon photosensitisers reported previously have shown to have low PDT efficiency 
and usually require large cross sections,43 which likely hinders their clinical use. 




Cyclometallated IrIII photosensitisers have been reported to target organelles including 
mitochondria, lysosomes and endoplasmic reticula,44 providing an alternative 
mechanism to that of cisplatin. Although cyclometallated IrIII complexes are largely 
considered to be organelle-targeting, nuclear-specific complexes have also been 
reported through ROS-mediated DNA damage,45 highlighting the variety of cellular 
targets of this family of photosensitisers. In 2017, Sadler et. al. reported a series of 
cyclometallated luminescent IrIII complexes which displayed potent antiproliferative 
activity by inducing specific oxidative attack on proteins upon irradiation with blue 
light (Fig. 1.5).46 In particular, [Ir(C,N)2(S,S)] (where C, N=2-phenylpyridine and 
S,S=dithione) has a long phosphorescent lifetime, (promoting the generation of highly 
toxic 1O2 in cancer cells), and has shown to disrupt levels of glycolytic enzymes in 
cancer cells.46 Interestingly, [Ir(C,N)2(S,S)] is less selective for cancer vs. healthy cells 




Figure 1.5. Structure of cyclometallated iridium(III) octahedral complexes reported by Sadler 
et. al. in 2017: [Ir(C,N)2(S,S)]+ and [Ir(C,N)2(O,O)].46 
 
Cyclometallated IrIII complexes have applications in PDT, photocatalysis and as 
luminescent imaging probes,44, 47 however, they are limited by various factors. These 
complexes are highly lipophilic (poor aqueous solubility),44  and their mechanisms of 
action are highly oxygen-dependent (somewhat hindering use in hypoxic tumours). In 
addition, some photosensitisers exhibit high toxicity under dark conditions. Further 
approaches such as joining with biocompatible ligands or other metal centres may 
overcome these concerns by improving selectivity, solubility and cytotoxicity. 




Photoactivatable chemotherapy (PACT) 
Photoactivatable chemotherapy (PACT) is an important approach to the treatment of 
surface tumours which can be accessed by specific wavelengths of light. 
Photoactivatable platinum prodrugs are of increasing interest in the field of cancer 
therapeutics, with high photo-toxicity: providing both spatial and temporal 
selectivity.48, 49 PtIV prodrugs can release labile or bioactive ligands upon light 
irradiation to form reactive PtII species in situ by a dual-action approach.23, 50-52  
The photo-reductive properties of diazido PtIV complexes were first reported in 1978by 
Vogler et. al.,53  where it was noted that azidyl radicals can be released upon irradiation 
with UVA light. This has subsequently led to the development of remarkably stable 
diazido-PtIV prodrugs which exhibit promising cytotoxicity upon in situ 
photoreduction.51 Photoactivatable diazido-PtIV prodrugs, including trans-
[Pt(en)(N3)2(OH)2] and FM190 (Fig. 1.3),54, 55 have been reported to have potent 
anticancer activity against a variety of cancer cell lines.54-57  These complexes differ 
from cisplatin by their coordination environment, oxidation state and their ability to 
release ligands upon irradiation with light. Moreover, these PtIV prodrugs are 
remarkable stable under dark conditions (low dark toxicity) and can be activated with 
blue light (465 nm) to generate PtII species (which bind to DNA)58 and toxic radicals 




Figure 1.3. Structures of photoactivatable diazido-PtIV complexes: cis, trans-
[Pt(en)(N3)2(OH)2] and FM190.
54, 55   
 
 




The conjugation of biologically active moieties with PtIV prodrugs can improve drug 
properties such as the pharmacokinetics, cytotoxicity and selectivity through multiple 
cellular targets and synergistic modes of action. For example, Lippard et.al reported 
PtIV prodrugs conjugated to tumour-specific peptides can selectivity target tumour 
endothelial cells over healthy cells,60 significantly improving the antiproliferative 
effect over the non-conjugated analogue. Similarly, Yeow and Xing et. al. reported a 
diazido-PtIV complex conjugated to human serum albumin protein (HSA) which 
significantly enhanced the cytotoxicity through improved drug delivery and controlled 
ligand release.61 This design strategy has also been extended to di- and trinuclear PtIV 
complexes.62, 63  
The derivatisation of the axial ligands (OR) of FM190 (Fig. 1.3) can be used to tune 
the chemical and physical properties of diazido-PtIV PACT complexes, to improve the 
cytotoxicity, selectivity and targeting in cancer cells.51 This has been demonstrated by 
Sadler et. al. using TEMPO radicals,51 and more recently with coumarin (a natural 
compound which exhibits antitumour properties, Fig. 1.4).64 Dinuclear metal 
modalities can also be connected at this axial position to improve the potency 
compared to the mono-metal analogues, as demonstrated with a photodynamic-
photoactivatable IrIII-PtIV complex recently reported from the Sadler group (Fig. 
1.4).65 Diazido PtIV PACT prodrugs can provide a multi-targeting approach to cancer 
treatment, to overcome resistance to conventional PtII drugs. 
 
 
Figure 1.4. Photoactivatable diazido-PtIV complexes with varying groups at the axial position 
reported in the Sadler Group: coumarin and  IrIII-PDT conjugate.64, 65 




PDT vs PACT 
PDT and PACT are promising approaches to phototherapy for the treatment of cancer, 
both of which have potential clinical advantages and disadvantages. PDT is a photo-
catalytic process: photosensitisers catalytically oxidize biomolecules via electron-
transfer (Type I) or convert molecular oxygen (3O2) to toxic singlet oxygen (
1O2) via 
energy-transfer (Type II), without being chemically changed themselves. This 
provides significant advantages over PACT, which typically relies on photo-
dissociation and redox change.48 However, PDT is more dependent on cellular oxygen 
levels compared to PACT, somewhat hindering applications in hypoxia.  
One of the major limitations of both PDT and PACT agents is that they usually require 
photo-activation using UV/Vis light (200-700 nm), which has minimal tissue 
penetration depths (due to the strong absorption by proteins in this region), somewhat 
limiting the clinical relevance. In addition, they are both confined to localised diseases. 
 
1.2.2    Half-sandwich anticancer complexes 
  
Half-sandwich “piano-stool” complexes 
Half-sandwich metal complexes are of significant interest in the design of new 
anticancer metallodrugs.66 In general, half-sandwich complexes are pseudo-
octahedral, three-legged “piano stool” complexes containing a cyclic polyhapto 
ligand. Half-sandwich complexes of platinum-group metals have shown to exhibit 
antiproliferative activity in human cancer cells. These complexes are composed of four 
structural components: (i) metal centre; (ii) arene; (iii) bidentate ligand; (iv) leaving 
group (Fig. 1.6) – all of which contribute to the observed antiproliferative effect. 
 
Figure 1.6. Structure-activity relationships (SARs) of half-sandwich anticancer complexes. 




An understanding of structure-activity relationships (SARs) are crucial for the design 
of novel therapeutic drugs which circumvent platinum-resistance and reduces toxic 
side effects. The metal centre plays an essential role in redox activity, catalysis and 
the coordination geometries. The bidentate ligand contributes to the complex stability 
(via. the chelate effect), redox activity, biocompatibility and targeting of the metal 
complex. For example, metal complexes bound to natural antitumour organic 
compounds (such as curcumin) which exhibit pharmacological properties.67, 68 The 
arene hapticity controls hydrophobicity - which plays a major role in enhancing 
cellular accumulation (passage through phospholipid membranes), however, this is a 
compromise with aqueous solubility - a potential hindrance for clinical translation. 
Finally, anticancer half-sandwich complexes typically contain a leaving group which 
is essential for complex activation in a cellular environment (i.e. hydrolysis).69 
 
Ruthenium half-sandwich complexes 
Ruthenium complexes show desirable properties for use as antitumour drugs.70-73 A 
variety of ruthenium candidates have shown high selectivity towards cancer cells with 
different cellular targets and modes of action to clinical platinum drugs. Ruthenium is 
in the same group as iron in the periodic table, thus, can mimic Fe-binding to serum 
transferrin or albumin).74 Ruthenium-based therapeutics may give rise to novel ligand-
dissociation kinetics, cellular transport and activation mechanisms, which may 
circumvent platinum-resistance and reduce patient side effects. 
Two of the most well-known RuIII anticancer complexes are octahedral complexes 
NAMI-A and KP1019/1339 (Fig. 1.7), both of which reached clinical trials.75-78 
NAMI-A was found to inhibit tumour metatheses but lacked cytotoxic properties 
(limited efficacy), resulting in abandonment at phase II clinical trials.76 KP1019 
(indazole cation) did not make it past phase I of clinical trials due to low aqueous 
solubility, and was later replaced with its sodium salt KP1339, furthermore 
emphasizing the importance of the balance between lipophilicity and hydrophilicity 
for absorption, distribution, metabolism and excretion in a clinical scenario. More 
recently, an organometallic RuII protein kinase inhibitor (DW1/2, Fig. 1.7) has shown 
promise as an anticancer agent, but has not yet made it to clinical trials.76  





Figure 1.7. Structures of ruthenium anticancer lead compounds NAMI-A,76 KP101975  and 
DW1/2 (where * denotes a chiral centre DW1=R and DW2=S).76  
 
Half-sandwich ruthenium complexes exhibit remarkable chemical versatility,79 which 
makes them attractive pharmacological scaffolds. RuII “half-sandwich” complexes 
with the general formulae Ru[(arene)(DPEN)X] (where 
DPEN=diphenylethylenediamine and X=halide) are of great interest in the 
development of novel anticancer agents. One of the earliest RuII piano-stool 
complexes which showed promising antitumour activity against carboplatin-resistant 
cancer cell lines was RM175 (Fig. 1.8), which was discovered in 2001 by Sadler et. 
al.80 RM175 can induce G1/G2 growth arrest and apoptosis,
81 and can form 
hydrophobic interactions with nucleobases (DNA adducts).78 Notably, RM175 was 
shown to inhibit matrix metalloproteinase-2 (which contributes to tumour growth and 
survival),78, 82 providing a novel mechanism of action to that of conventional PtII drugs. 
An important biomolecule in cancer cells is glutathione (GSH), which is highly 
reactive and acts as a natural cellular antioxidant. RM175 can react with intracellular 
GSH to form species which may be involved in a postulated redox-mediated pathway 
towards DNA binding.83 GSH is over-expressed in many cancer cell lines,84 hence, 
novel anticancer agents can exploit these vulnerabilities of cancers. In 2013, organo-
ruthenium anticancer agent, plecstatin-1 (Fig. 1.7) demonstrated selectivity for the 
cytoskeletal linker protein plectin (which is involved in tumour cell migration).85 
However, RuII half-sandwich complexes are susceptible to hydrolysis86 – which has 
led to the development of more stable half-sandwich osmium complexes.   





Figure 1.8. Structure of RM175 and plectstatin-1 lead RuII half-sandwich complexes.80, 85 
 
Osmium half-sandwich complexes 
Osmium was discovered before ruthenium,87 yet its chemical applications are not as 
well understood (perhaps as a consequence of the known toxicity of osmium tetroxide) 
- hence, therapeutic applications of osmium are still in their infancy. The use of 
osmium-based drugs may have significant advantages over ruthenium, including: (i) 
higher available oxidation states, (ii) strong π-backbonding interactions (π-acceptor 
ligands, i.e. cyclopentadiene), (iii) slower ligand-dissociation kinetics and (iv) 
stronger spin-orbit coupling, however, this is dependent on the nature of the complex. 
Osmium anticancer complexes in a variety of different oxidations states have been 
reported.88 High-valent octahedral Os(VI) dinitrido complexes have shown to have 
potent anticancer activity through highly-controlled intracellular targeting,89 while 
octahedral Os(II) complexes can inhibit protein-protein interactions.90 Os(II), (III) and 
(IV) analogues of NAMI-A, KP1019 and RM175 were found to be more inert and 
stable towards hydrolysis in vitro, exhibiting moderate cytotoxicity against a variety 
of cancers.82, 88, 91 The osmium analogue of RM175 (named AFAP51, Fig. 1.9) was 
significantly more potent in vitro,82 however, showed limited activity in vivo 
compared to RM175,82 emphasizing the chemical diversity between ruthenium and 
osmium complexes. 





Figure 1.9. Structure of half-sandwich OsII complexes: AFAP5182  and FY26.92  
 
In 2010, Sadler et al. reported a family of half-sandwich OsII complexes containing 
imino or azo-pyridine bidentate ligands (second-generation analogues of RM175) 
which are remarkably stable and have promising in vitro potency against a variety of 
human cancer cells.92, 93 These complexes are comprised of (i) arene (p-cymene or 
biphenyl), (ii) imino- or azo-pyridine bidentate ligand and (iii) leaving group (chloride 
or iodide), all of which play essential roles in structure-activity relationships as 
described previously (Fig. 1.6).69, 73 In particular, FY26 with the formula [Os(p-
cym)(5-Azy-NMe2)I]PF6 (where p-cym=para-cymene, Azy-NMe2=N,N-dimethyl-4-
(pyridin-2-yldiazenyl)aniline, Fig. 1.9) is an average of 49× more potent than cisplatin 
against 809 cancer cell lines.94 Importantly, these complexes do not predominantly 
bind to DNA (unlike cisplatin and other platinum drugs) and have promising 
cytotoxicity in platinum-resistant cancer cells. 
Cellular fractionation ICP-MS (189Os) studies and synchrotron-XRF (Os L3M5=8.9 
keV) have implicated mitochondria as a cellular target of FY26.95, 96 Potential redox 
mechanism(s) of action have been investigated, showing that FY26 can  generate ROS 
both in vitro and in vivo,97 and induces S-phase cell cycle arrest.96  Interestingly, the 
potency of FY26 can further be improved upon co-administration with L-buthionine-
sulfoximine (which depletes GSH)98 compromising cellular defence against oxidative 
stress. Complementary to this, chemical in situ reactions (between FY26 and GSH)99 
and 131I-labelled FY26 cellular experiments demonstrated the rapid in-cell hydrolysis 
of FY26 and the formation of Os-GSH adducts.99, 100 Synchrotron-XAS studies have 
also provided information on the cellular speciation and binding moieties of FY26 in 
primary cells and to investigate tumour penetration in cancer spheroid models.101, 102  




1.2.3    Catalytic metallodrugs 
 
The development of catalytic therapies for cancer treatment is emerging in research. 
Catalytic therapies utilize endogenous biological substrates and an external catalyst to 
cause oxidative or reductive damage to cancer cells. The first in vitro application of 
catalytic therapy for cancer treatment was reported by Kimoto in 1983,103 where the 
antitumour activity of a copper(II) tripeptide complex was significantly enhanced in 
high concentrations of ascorbate (which is readily oxidised by molecular oxygen) to 
generate ROS.103 However, it is only in recent years that promising anticancer catalytic 
systems have been optimized. Catalytic drugs have additional advantages over non-
catalytic drugs: lower dosages (reduces toxicity and side effects)104, 105 and do not 
require activation with light or radiation  (unlike PACT and radiotherapy).  
A catalyst is defined as a species which can promote the progression of a chemical 
reaction by lowering the activation energy, without being consumed in the reaction 
itself. In cells, enzymes act as biological catalysts, which can interact with cofactors 
(e.g. NADH and FAD), acting as hydride donors and acceptors to facilitate electron-
transfer. In mitochondria there are a variety of enzymes and cofactors which are 
essential for energy generation under aerobic conditions via the ETC. This process is 
carefully regulated,106 and disruption to the cellular redox homeostasis (i.e. by 
oxidative stress) can hinder growth, ultimately leading to cell death. The redox 
vulnerability of cancer cells makes catalytic therapy a promising strategy. 
Catalytic therapies can be categorized into oxidative or reductive therapies, depending 
on the nature of cell death. The generation of ROS, hydrogen peroxide or hydroxyl 
radicals causes oxidative stress in cancer cells, disrupting the tightly-regulated redox 
homeostasis. Notably, Sadler et. al. reported an IrIII photocatalyst which can oxidize 
NADH to NAD+ even under hypoxic conditions.47 In contrast, reductive therapy relies 
on inducing reductive stress mechanisms of cell death. For example, RuII tethered half-
sandwich complexes have shown to catalyse the transfer hydrogenation of NAD+ to 
NADH in the presence of formate as a hydride source.107 This approach can also be 
extended to external substrates, for example, Meggers et. al. demonstrated the 
biorthogonal catalytic activation of caged anticancer drug doxorubicin by a RuII half-
sandwich complex in cancer cells.108 Other notable contributions to the field of 




biorthogonal catalysis includes the work of Salassa et. al., which demonstrated the 
photocatalytic reduction of PtIV to PtII in the presence of flavoproteins109 – with the 
metal complex acting as the substrate as opposed to the catalyst. 
Catalytic transition-metal complexes have advantages over organic catalysts as they 
can access a variety of different coordination geometries, oxidation states, and ligand 
binding modalities, giving rise to different chemical properties. Catalytic metallodrugs 
can exploit these properties to perturb redox balance and disrupt metabolic processes 
(e.g. oxidative phosphorylation or glycolysis) in cancer cells.110 One of the major 
limitations of the development of catalytic metallodrugs is catalyst deactivation due to 
limited stability in cancer cell environments, which likely hinders their clinical use. 
Additionally, many transition metal catalysts require activation by ligand dissociation 
prior to catalysis, with Noyori’s ruthenium asymmetric transfer hydrogenation (ATH) 
catalyst being an well-known example.111  
Noyori’s first generation ruthenium ATH catalysts contained chiral chelating groups; 
BINAP and diamine ligand (general formula RuII(diphosphane)(diamine)Cl2],
112, 113  
Fig. 1.10) which could enantioselectively convert ketones to chiral alcohols with high 
conversions. Second generation Noyori catalysts with the formula [RuII(p-
cymene)(TsDPEN)Cl] were developed (Fig. 1.10).111, 114-118 This bifunctional ‘piano-
stool’ complex contains a chiral diamine ligand which directs the enantioselectivity of 
the reaction to produce high enantiomeric excesses under acidic conditions.112, 119  
 
 
Figure 1.10. Structure of Noyori’s first and second generation catalysts111, 113 and [OsII(p-
cym)(TsDPEN)] catalyst reported by Sadler et. al.120 
 




Since the discovery of Noyori’s catalyst, there have been significant advances in the 
design of RuII half-sandwich complexes for the ATH of a diverse range of prochiral 
substrates under varying experimental conditions. For example, Wills et. al. reported 
a series of tethered [RuII(η6-arene)(TsDPEN)Cl] catalysts which proved effective for 
the reduction of amino-substituted ketone (which are relatively unreactive) in aqueous 
solution,121 achieving high conversions and enantioselectivity. 
In 2015, Sadler et. al. reported a series of  16-electron, pseudo-octahedral Noyori-type 
catalysts with the general formulae [OsII(p-cym)(BsDPEN)] (where p-cym=para-
cymene and BsDPEN=benzylsulfonyldiphenylethylene diamine; Fig. 1.10).120 
Correspondingly, these osmium-derivatives can also act as catalysts in the ATH of 
acetophenone-derived substrates - with high turnover frequencies and enantiomeric 
excess (>95%) in the presence of formic acid.120  These osmium complexes are easy 
to synthesize, remarkably stable and – unlike Noyori’s catalysts – do not require 
activation (e.g. ligand dissociation).  
This family of OsII complexes showed moderate cytotoxicity against a variety of 
human cancer cell lines.122 Perhaps more impressively, the antiproliferative activity 
can be significantly enhanced in the presence of non-toxic concentrations of sodium 
formate. In particular, parent compound [OsII(p-cym)(1R,2R)TsDPEN)] (where 
TsDPEN=tosyl-(1R, 2R)-diphenylethylenediamine), was the first reported Os-based 
ATH catalyst shown to enantioselectively convert pyruvate (an essential metabolic 
precursor) to unnatural D-lactate in cancer cells in the presence of formate.122 This 
process was specific for cancer cells,122 providing a platform for catalytic selectivity. 
In nature, cells predominantly produce L-lactate from pyruvate through a carefully 
NADH-balanced bio-system using lactate dehydrogenase.123 Upon co-administration 
of the RR-catalyst and formate, levels of intracellular D-lactate were significantly 
enhanced, implicating in-cell ATH. In comparison, the SS-catalyst produced natural 
L-lactate, suggesting the catalyst chirality is maintained intracellularly.122  
The catalytic cycle for the enantioselective reduction of pyruvate using [Os(p-
cym)(TsDPEN)] is thought to be initiated through coordination of formate (via. O-
atom) at the vacant site, releasing CO2 to form an active Os-hydride bond (Fig. 
1.11).120 The prochiral substrate then forms favourable interactions with the N-H and 
Os-H in a 6-coordinate transition state,122 to release the chiral product and regenerate 




the catalyst.120 In 2019, Yang et. al. proposed a new catalytic cycle using involving a 
proton-coupled hydride mechanism for pyruvate reduction.124 The basis of the 
stereoselectivity is not fully understood for pyruvate, but it has been proposed that the 
C-H bond on p-cymene is slightly polar, hence, forms electrostatic interactions with 
the negatively-charged carboxylate of pyruvate in the transition state (Fig. 1.11).122  
 
Figure 1.11. Proposed catalytic for the enantioselective reduction of pyruvate to D-lactate by 
[Os(p-cym)(1R,2R)TsDPEN)], adapted from the literature.122  
 
One of the major vulnerabilities of cancers is their increased lactate concentrations 
(via the Warburg effect).14 It was deduced, however, that the increase in lactate 
concentration by these OsII 16-electron catalysts was likely not the predominant cause 
of cell death,122 but that the contribution of this change likely disrupts important 
cellular pathways involving lactate. Targeting the vulnerabilities of cancer is one of 
the most important approaches to cancer therapies. Interestingly, both in vitro and in 
vivo confocal microscopy studies of these osmium sulfonamide catalysts have linked 
the selective generation of ROS with the antiproliferative mechanism of action.122 
Importantly, this moves away from conventional platinum drugs with DNA-targeting 
mechanisms of action (i.e. cisplatin), which may overcome platinum-resistance and 
minimize off-target toxic effects. These 16-electron osmium catalysts could provide a 
novel catalytic approach to the treatment of cancer, by exploiting vulnerable redox and 
metabolic pathways. 




1.3     Synchrotron Radiation 
 
Synchrotron radiation has shown to be an invaluable tool for investigating in vitro and 
in vivo mechanisms of action of metallodrug candidates.125-127 Typically, hard x-rays 
can be used to directly monitor the distribution and chemical speciation of exogenous 
elements in relation to native biological elements. Contrastingly, soft x-rays can be 
used to gain insights into drug-induced morphological changes in cells or tissues under 
cryogenic (near-native) conditions. This thesis explores the potential mechanisms of 
action of metallodrugs using both hard and soft x-rays for XRF, XAS and cryo-XRT 
studies. 
Synchrotron radiation is generated from the acceleration of electrons when they pass 
through or are re-directed by an undulator, wiggler or bending magnet (dipole). A 
pulsed beam of electrons is accelerated using a linear accelerator, followed by 
acceleration with a small booster ring before finally being injected and “stored” in the 
main ring of the synchrotron. The ring, at Diamond Light Source (DLS, Oxford) is 
comprised of 24 straight sections and the x-rays generated by oscillating the electrons 
by the insertion device are directed along the straight section or at a tangent to point 
of bending into the next straight. Synchrotron radiation can cover a wide range of the 
electromagnetic spectrum – from ultraviolet and infra-red (<1000 eV) to hard x-rays 
(>12 keV) - depending on the particle acceleration, which can be exploited for a wide 
range of scientific applications. 
X-rays can generally be categorized as hard (12-120 keV) or soft (0.12-12 keV).128 
Hard x-rays are higher in energy, thus, are less strongly absorbed in materials 
compared to soft x-rays, but can excite different elements or edges. As a consequence, 
hard and soft x-rays are utilized in different ways, and can be used to gain diverse, but 
complementary information on chemical and biological systems. For example, hard 
x-rays can be used to monitor heavy exogenous metals in biological samples using 
synchrotron-XRF,126 whereas, soft-x-rays can be used for contrast of light elements 
(such as carbon) by exploiting the absorption of soft x-rays by lighter elements.  
 
 




1.3.1    X-ray fluorescence (XRF) 
 
When a sample is bombarded with x-rays with an energy which exceeds the electron-
binding energy of an element, a fluorescence phenomenon is observed.  This radiation 
is high enough in energy to eject electrons from lower energy orbitals (i.e. K or L-
shells), leaving vacant ‘holes’. As a consequence, electrons from higher-energy 
orbitals fill these holes, resulting in an emission of radiation known as x-ray 
fluorescence (Fig. 1.12). These emissions are elemental-specific and can be 
simultaneously detected at trace levels (100 ppb) using synchrotron radiation.129 
Multiple emissions of individual elements can be observed, and are categorized in 
terms of the final ground state configuration as primary (α) or secondary (β). For 
example, Kα emission is observed when an electron is ejected from an inner K-shell 
forming a vacant hole for which is filled by an electron from the L-shell, whereas, Kβ 
emission is observed when an electron from the M-shell (higher energy) relaxes into 
the vacated K-shell hole (Fig. 1.12). Synchrotron-XRF allows the simultaneous 
detection of multiple elements, thus, by selecting an incident beam energy greater than 
that of the element with the highest electron-binding energy, the x-ray emissions of all 
elements with lower electron-binding energies can be monitored. 
 
 
Figure 1.12. (a) XRF phenomenon which occurs when an atom is exposed to x-rays 
(synchrotron radiation), resulting in the ejection of inner-shell electrons and subsequent 
fluorescence emission by movement of higher-energy electrons into the vacant orbitals. (b) 
Kα/β  and Lα  emissions; where alpha (α) is the radiation emitted from one orbital above and 
beta (β) is the emission from two orbits above the vacated lower-energy shell. 
 




For samples of biological cells, the KL3-emissions of native endogenous elements 
(including Zn, K, S and P) occur within the 2-10 keV range, whereas, that of 
exogenous heavy elements (Os, Pt, Ir) occur at much higher energies (60-80 keV).130 
Instead, the L3M5-emissions of heavy metals can be monitored using lower energies 
(9-13 keV). The KL3-emissions of relevant endogenous biological elements, and the 
non-native elements of interest in this thesis (Pt, Ir, Os, Br) are specified in Table 1.1.  
Synchrotron-XRF can be used to investigate the bio-distribution, stability and 
localisation of the heavy metal components of metallodrugs in cancer cells (in addition 
to endogenous biological elements). The use of synchrotron-XRF for the analysis of 
metal anticancer complexes in vitro and ex vivo (tumour spheroids or xenograft 
models) is well-reported for platinum,131-136 ruthenium,137, 138 iridium139 and osmium 
anticancer agents.95, 101, 140 XRF can also be used to probe the in-cell stability of metal 
complexes using exogenous labelling atoms, which has been shown by Hambley et. 
al. for Br-labelled Pt complexes,141 and more recently by Harris et. al. for an I-labelled 
rhenium complex in cancer cells.142 Notably, cryo-XRF is emerging at various 
beamlines for the analysis of frozen-hydrated cells or tissues as close to their native 
state as possible including ID16A (ESRF, Grenoble)139 and 9-ID-B (APS, Illinois).143  
 
Table 1.1. Summary of the electron-binding energies and XRF emissions of endogenous 
biological elements and exogenous heavy elements investigated in this thesis.130 
Element Electron-binding energy  Relevant XRF emissions 
 Electron Energy (keV) XRF emission Energy (keV) 
Ca K1s 4.04 L3 (2p3/2−1) →K (1s-1) 3.69 
Cl K1s 2.82 L3 (2p3/2−1) →K (1s-1) 2.62 
Cu K1s 8.98 L3 (2p3/2−1) →K (1s-1) 8.05 
Fe K1s 7.11 L3 (2p3/2−1) →K (1s-1) 6.40 
K K1s 3.61 L3 (2p3/2−1) →K (1s-1) 3.31 
Mg K1s 1.30 L3 (2p3/2−1) →K (1s-1) 1.25 
Na K1s 1.07 L3 (2p3/2−1) →K (1s-1) 1.04 
P K1s 2.15 L3 (2p3/2−1) →K (1s-1) 2.01 
S K1s 2.47 L3 (2p3/2−1) →K (1s-1) 2.31 
Zn K1s 9.66 L3 (2p3/2−1) →K (1s-1) 8.64 
Os L3 2p3/2 10.87 M5 (3d5/2−1) → L3 (2p3/2−1) 8.91 
Br K1s 13.47 L3 (2p3/2−1) → K (1s-1) 11.92 
Ir L3 2p3/2 11.22 M5 (3d5/2−1) → L3 (2p3/2−1) 9.18 
Pt L3 2p3/2 11.56 M5 (3d5/2−1) → L3 (2p3/2−1) 9.44 




The I14 beamline (DLS, Oxford) is a hard x-ray nanoprobe which operates in the 
energy range of 5-23 keV, achieving spatial resolution of down to 50 nm. High energy 
x-rays are generated from an undulator source (forcing electrons into a wave or 
trajectory) to generate a high energy radiation beam (stabilised with monochromators) 
which is mirror-directed onto the sample. The sample can be scanned through the 
beam to obtain chemical and structural information by exploiting XRF. I14 does not 
yet have the capability for analysis of cryogenic samples (liquid nitrogen conditions), 
hence, cryo-fixed and freeze-dried cells have been analysed in this thesis. 
 
1.3.2    X-ray Absorption Spectroscopy (XAS) 
 
The I14 beamline is also optimized for XAS which uses a scanned energy range as 
opposed to a fixed energy. XAS can be determined by measuring a transition of an 
electron from a core energy level to an unoccupied state. When a sample is exposed 
to synchrotron radiation, a photon interacts with a core electron (typically 1s, 2s or 
2p),126 which causes an electronic transition into a vacant bound or continuum state, 
resulting in an XAS phenomenon according to Fermi’s Golden Rule (Equation 1.1). 
This equation describes the transition probability of a core electron to absorb a photon, 
which is proportional to the x-ray absorption coefficient and is used to predict XAS. 




Equation 1.1. XAS equation: µ(E)= x-ray absorption coefficient,  | i >= initial state of energy 
Ei, < f | = final (unoccupied) state of energy Ef, ε= photon polarisation, r= electron position, 
𝛿= density of states. 
 
XAS can be categorized as two main types, depending on the nature of their absorption 
regions: (i) X-ray Absorption Near Edge Structure (XANES) and (ii) Extended X-ray 
Absorption Fine Structure (EXAFS). When an atom absorbs synchrotron radiation, a 
rapid jump in energy is observed (referred to as an ‘edge’) followed by a unique and 
stable fingerprint region (Fig. 1.13). The ‘edge-jump’ corresponds to the XANES 
region (30 eV before the edge and up to 50 eV after the edge), and the fingerprint 
region corresponds to the EXAFS region (>50 eV from the edge).126 





Figure 1.13. Characteristic XAS showing the XANES and EXAFS regions.144 
 
XANES is observed between 50-100 eV above the ionisation energy of the core level 
in an atom, and is strongly sensitive to the chemistry of the absorbing atom. XANES 
spectroscopy can provide information on oxidation state and coordination 
environment of metal complexes,145 which may be crucial in understanding the 
mechanisms of activation of metallodrugs in cancer cells. 
In contrast, EXAFS is typically observed at energies greater than 50 eV above the edge 
of the absorbing atom, and is element-specific. EXAFS occurs as a consequence of 
the scattering of photo-electrons by neighbouring atoms. In EXAFS, the electrons are 
promoted from low to high energy states (a continuum), creating a photoelectron 
which can interact with surrounding atoms, resulting in oscillations in this region. As 
a result, EXAFS is sensitive to the neighbouring environment around the absorbing 
atom, providing information on chemical coordination environments (Equation 1.2). 
EXAFS can be used to determine the number and nature of neighbouring atoms up to 














Equation 1.2. EXAFS equation where f(k)=amplitude, 𝛿(k)=phase shift, R=distance from the 
wave to the inner shell, N= coordination number (number of scattering atoms),  σ=measure of 
disorder between neighbouring atoms, k= photoelectron wave vector. 




XAS is a well-established technique for analysing the chemical speciation of metal 
compounds in biological systems (in vitro and in vivo). XANES has been used to 
investigate the in vitro and ex vivo speciation of platinum,126 ruthenium126 and osmium 
complexes in cancer cells.99  This includes PtIV-prodrugs of cisplatin (Hambley et. 
al.),135 ruthenium lead compound KP1019 (Keppler et. al.)126 and half-sandwich OsII 
azopyridine complex FY26 (Sadler et. al.).102 In addition, chemical in situ experiments 
between metallodrugs and biomolecules (e.g. DNA, GSH, ascorbate and albumin) 
have been performed on various metallodrugs.99, 126 More recently, Hambley et. al. 
used XANES spectroscopy to demonstrate the stability of PtIV prodrugs in human 
blood serum, in addition to the rapid in-cell activation (PtIV→ PtII).146 
 
1.3.3    Cryo X-ray Tomography (cryo-XRT) 
 
The first report of synchrotron radiation microscopy with soft x-rays was that of 
Horowitz and Howell in 1972.147 By definition, soft x-rays have lower energies (longer 
wavelengths) than hard x-rays and an energy range of ca. 0.12-2 keV.128 These x-rays 
are less penetrating and more strongly absorbed in comparison to hard x-rays. This 
greater absorption provides stronger contrast for lighter materials which can be 
exploited for tomographic imaging of biological materials. 
Full-field cryo x-ray microscopy can provide 3D images of biological samples under 
frozen-hydrated conditions, close to their native state. X-ray tomograms (2D images 
representing slices of a 3D volume) are produced using x-rays (500 eV) close to the 
K-absorption edges of oxygen and carbon (Table 1.2),148 also referred to as the ‘water-
region’ (the region in which water is transparent to incoming soft x-rays). This region 
is exploited to produce 3D images of biological samples owing to the contrast between 
carbon-containing cellular components (i.e. lipid droplets or mitochondria) with 
natural ice on the vitrified sample.149 Cryo-XRT can provide information on 
subcellular morphology by the identification of carbon-based organelles down to a 25-
40 nm spatial resolution,150, 151 enabling the analysis of intact hydrated cells. This 
avoids problems induced by chemical fixatives. For example, Moscheni et. al. used 
cryo-XRT to analyse mitochondria in doxorubicin-resistant cancer cells, which may 
implicate impaired mitochondrial communications in resistant cells.152  




Table 1.2. Electron-binding energies and KL3 XRF emissions of C, N and O exploited in cryo-
XRT.130 
Element Electron-binding energy Relevant XRF emissions 
 
 Electron Energy (eV) XRF emission Energy (eV) 
C K1s 284 L3 (2p3/2−1) →K (1s-1) 277 
N K1s 410 L3 (2p3/2−1) →K (1s-1) 392 
O K1s 543 L3 (2p3/2−1) →K (1s-1) 525 
 
Cryo-XRT is an up-and-coming technique which can be used to probe drug-induced 
subcellular damage and cellular events which cannot be achieved using conventional 
electron or light microscopy.150 Cryo-XRT is available at various synchrotron 
beamlines worldwide, including MISTRAL (ALBA, Spain), XM2 (ALS, US), U41-
TXM (Bessy II, Germany) and B24 (DLS, UK) beamlines.153 The use of cryo-XRT in 
the field of cancer metallodrugs has been demonstrated for iron oxide nanoparticles 
(Carrascosa et. al. 2016)154 and half-sandwich iridium complexes (Pizarro et. al, 2020) 
in breast cancer cells,139 but also recently for cisplatin and gold nanoparticles in skin 
cancer cells (Gil et. al. 2020).155 In this thesis, cryo-XRT was performed at the B24 
beamline (DLS, UK): a transmission microscope operating at 500 eV, achieving a 
resolution of 30-40 nm.153 The B24 beamline is capable of analysing cryopreserved 
biological samples: cancer cells are grown on TEM grids and plunge-frozen in liquid 
ethane for cryogenic analysis using soft x-rays.  
In addition to cryo-XRT, the B24 beamline houses a super-resolution light microscopy 
facility which allows the analysis of vitrified samples using Structured Illumination 
Microscopy (SIM) before analysing the same samples by cryo-XRT.150, 156, 157 Cryo-
SIM has advantages over conventional microscopy, including rapid image acquisition 
(<100 ms), low light doses (minimize sample heating), compatibility with 
conventional fluorophores and an 8-fold greater volumetric resolution compared to the 
diffraction limit.157 Cryo-XRT and cryo-SIM provide cross-correlative analysis which 
can significantly enhance the understanding of biological systems. This means that 
biological samples treated with conventional fluorophores or fluorescent drugs can be 
detected inside cells, and overlayed onto 3D tomograms, providing unambiguous drug 
localisation in near-native state cells. This cannot be achieved using conventional 
microscopy as a consequence of the resolution limitations dictated by the Abbe limit. 




1.4     Aims of project 
 
The aims of this thesis were to elucidate the in vitro mechanism(s) of action of 
osmium, iridium and platinum anticancer metallodrugs in human cancer cells using a 
variety of synchrotron-based techniques. Specific project aims were as follows: 
 
• Synthesis, characterisation and screening of OsII 16-electron catalysts 
The aim in Chapter 3 was to synthesize and characterize novel OsII arene anticancer 
complexes containing halide-substituted benzylsulfonyldiamine ligands (Fig. 1.10) as 
potential in-cell transfer hydrogenation catalysts, and screen them for their chemical 
and biological activity in cancer cells. Further to this, the aim was to synthesise 
complexes with readily detectable labelling atoms in unreactive positions of the 
diamine ligand (e.g. Br or I) to monitor the in-cell stability, distribution and catalytic 
efficiency of these complexes by ICP-MS (189Os, 79Br, 127I) and synchrotron-XRF (Os 
L3M5=8.91 keV; Br KL3=11.92 keV; I L3M5=3.94 keV). 
 
• Distribution and cell damage by cyclometallated IrIII photosensitisers 
The aim of Chapter 4 was to investigate the distribution and cell damage induced by 
a potent IrIII photosensitiser [Ir(C,N)2(O,O)] (Fig. 1.5) in cryopreserved cancer cells 
using correlative cryo-SIM and cryo-XRT. Independently of this, the second aim was 
to probe the cellular distribution, stability and targeting of a potent photodynamic-
photochemotherapeutic IrIII-PtIV complex (Fig. 1.4) by synchrotron-XRF. 
 
• In-cell x-ray studies of diazido-PtIV photoactivatable prodrugs 
The aim of Chapter 5 was to investigate the concentration-dependent intracellular 
distribution and morphological damage induced by a fluorescent coumarin-labelled 
diazido-PtIV complex (Fig. 1.4) in cryopreserved cancer cells using correlative 
confocal microscopy, cryo-SIM and cryo-XRT. The second aim was to probe the 
cellular distribution and chemical speciation of diazido-PtIV complexes in cancer cells 
using synchrotron-XRF (Pt L3M5=9.44 keV) and XANES (L3 2p3/2=11.56 keV). 
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2.1     Materials 
 
2.1.1    Chemical reagents 
 
All commercial solvents were purchased from Sigma Aldrich and used as specified 
by the manufacturer. 
 
Table 2.1.  List of chemical reagents and suppliers. 
Reagent Supplier 
(1R,2R)-(+)-1,2-Diphenylethylenediamine (97%) Sigma Aldrich 
(1S,2S)-(-)-1,2-Diphenylethylenediamine (97%) Sigma Aldrich 
3-bromobenzene sulfonyl chloride (96%) Sigma Aldrich 
4-bromobenzene sulfonyl chloride (98%) Sigma Aldrich 
4-iodobenzenesulfonyl chloride (95%) Sigma Aldrich 
4-methoxybenzenesulfonyl chloride (99%) Sigma Aldrich 
5:2 Formic acid triethylamine azeotrope (>99%) Sigma Aldrich 
Acetophenone (98%) Sigma Aldrich 
d6-benzene (99.6%) Sigma Aldrich 
d-chloroform (99.6%) Sigma Aldrich 
d6-DMSO (99.7%) Sigma Aldrich 
Magnesium sulfate Sigma Aldrich 
Sodium acetate (>99%) Sigma Aldrich 
Sodium formate (>99%) Sigma Aldrich 
Sodium hydrogen carbonate Sigma Aldrich 
Triethylamine (99.5%) Sigma Aldrich 
Tris-(hydroxymethyl)aminomethane (>99%) Sigma Aldrich 
α-phellandrene (>85%) Sigma Aldrich 
Potassium hydroxide Fisher Scientific 
Sodium actetate anhydrous Fisher Scientific 








2.1.2    ICP-OES and ICP-MS reagents 
 
Osmium (1000±10 μg/mL hexchlorodiammonium osmate in 15% v/v hydrochloric 
acid, platinum (1001±12 mg/L TraceCERT® platinum in 5% v/v hydrochloric 
acid), ruthenium (995±4 μg/mL ruthenium chloride in 10% v/v hydrochloric acid), 
iridium (995±3 µg/mL, iridium chloride in 10% v/v hydrochloric acid) and bromine 
(1000±5 μg/mL potassium bromide in water) for ICP trace analysis were purchased 
from Inorganic Ventures and stored at 276 K. Thiourea (>99%), L-ascorbic acid 
(>99%) and sodium chloride (99.9999%) were purchased from Sigma Aldrich. 72% 
v/v nitric acid (HNO3) was freshly distilled and diluted with milliQ water.  25% m/v 
tetramethylammonium hydroxide (TMAH) in water was purchased from Fisher 
Scientific. 
 
2.1.3    Synchrotron membranes and grids 
 
Silicon nitride (Si3N4) membranes were purchased from Silson ltd (5×5 mm frame 
size, 200 µm frame thickness, 1.5×1.5 mm membrane size, 500 nm membrane 
thickness, catalogue number SiRN-5.0(0)-200-1.5-500). Quantifoil R2/2 holey 
carbon films (Au) 200 mesh F1 finder grids were purchased from Quantifoil Micro 













2.2     Biological Materials 
 
2.2.1    Human cell lines 
 
All cell lines were purchased from ECACC (European Collection of Authenticated 
Cell Cultures). Mycoplasma-free status was confirmed every 6 months. 
 
Table 2.2. Summary of human cell lines used in this thesis. 
Cell line Type Catalogue number 
A2780 Human ovarian carcinoma 93112519 
A549 Human lung carcinoma 86012804 
MCF7 Human breast adenocarcinoma 86012803 
PC3 Human prostate adenocarcinoma 90112714 
MRC5 Human lung fibroblasts (non-cancerous)  84101801  
 
 
2.2.2    Biological consumables 
 
Table 2.3. Summary of biological consumables used in this thesis. 
Consumable  Supplier 
Filter-capped tissue culture flasks  Greiner Bio-One Ltd 
F-bottom tissue culture plates  Greiner Bio-One Ltd 
Tissue culture dish (100×20 mm) Greiner Bio-One Ltd 
Tissue culture dish (145×20 mm) Greiner Bio-One Ltd 
C-chip disposable haemocytometers Labtech International Ltd 
15 mL falcon conical centrifuge tube Scientific Laboratory Supplies 
50 mL falcon conical centrifuge tube Scientific Laboratory Supplies 








2.2.3    Biological reagents 
 
Table 2.4. Summary of biological reagents used in this thesis. All reagents used in tissue 
culture were of biological grade. Further information about trace biological elements and 
their concentrations present in FCS, DMEM, RPMI-1640, PBS and HBSS are presented in 
Appendix (Table A1-5). This must be considered for synchrotron-XRF elemental mapping 
of endogenous elements in cancer cells, particularly for elemental quantification (and less 
so for elemental distribution). 
Reagent Supplier 
Dulbecco’s Modified Eagles Medium (DMEM) Fisher Scientific 
LysoTracker Red DND-99 (λex/em=577/590 nm) Fisher Scientific 
MitoTracker Deep Red FM (λex/em=644/665 nm) Fisher Scientific 
MitoTracker Red FM 580 (λex/em=581/644 nm) Fisher Scientific 
Phosphate Buffered Saline (PBS) Fisher Scientific 
Trichloroacetic Acid (TCA) Fisher Scientific 
Methyl-β-cyclodextrin  Sigma Aldrich 
Chloroquine diphosphate salt Sigma Aldrich 
Ethanol Sigma Aldrich 
Isopropanol Sigma Aldrich 
Poly-L-lysine solution (0.01%) Sigma Aldrich 
Propidium iodide (PI) Sigma Aldrich 
Sulforhodamine B  Sigma Aldrich 
Verapamil hydrochloride Sigma Aldrich 




Heat-inactivated fetal calf serum (FCS) PPA Laboratories 
Penicillin streptomycin (penn/strep) PPA Laboratories 
L-glutamine  PPA Laboratories 
Trypsin/EDTA PPA Laboratories 
FractionPREP (Biovision) cell fractionation kit Cambridge Bioscience Ltd 
Hank’s Balanced Salt Solution (HBSS) BIOCHROMM (Merck) 









2.3     Instrumentation at the University of Warwick 
 
2.3.1    Mass spectrometry (MS) 
 
All low resolution mass spectrometry measurements were performed on an ESI-MS 
Agilent 6130B, with samples prepared in acetonitrile (unless specified otherwise), 
using positive ion mode (m/z range=50-500 and 400-1000). High resolution mass 
spectrometry measurements were obtained by Dr Lijiang Song (University of 
Warwick) using a Bruker UHR-Q-TOF MaXis, with a scan range of 50-3000 m/z 
for positive ions. Samples were prepared in acetonitrile (unless specified 
otherwise). Analysis was carried out through direct infusion (2 μL/min) with a 
syringe pump. ESI positive ion source conditions were as follows: -500 V end-plate 
offset, -3000 V capillary, 0.4 bar nebulizer N2 gas, dry N2 gas flow rate 4 L/min, 
453 K dry temperature, RF of funnel 200 Vpp, RF funnel 200 Vpp, 250 Vpp 
ramping, 121 μsec transfer time, 1 μsec pre-pulse storage time. 
 
2.3.2    Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
High resolution 1H NMR and 13C NMR of ligands and complexes (Chapter 3) were 
obtained by Dr. Ivan Prokes on a HD500 Bruker Avance III HD 500 MHz high-
field NMR instrument. Samples were prepared in either CDCl3 or d6-DMSO in 5 
mm NMR tubes at 298 K using standard pulse sequences. The 1H NMR kinetic 
experiments presented in Chapter 3 were performed on an AV400 Bruker Avance 
III 400 MHz instrument, using a method published in the literature.1  Samples were 
prepared in d6-benzene under an inert N2 atmosphere at 310 K in a 5 mm N2-purged 








2.3.3    Inductively-coupled plasma (ICP) instruments 
 
Inductively-coupled plasma (ICP) instruments have been used to measure trace 
amounts of osmium, platinum, iridium and bromine in aqueous cell culture media 
or in acid or base cell pellet digests. For samples containing osmium, 3.6% v/v  
stabilized nitric acid was prepared using 10 mM thiourea and 100 mg/L L-ascorbic 
acid to chelate osmium in solution and prevent the formation of osmium tetroxide 
(OsO4).
2, 3  Stabilized solutions were also used for the analysis of platinum and 
iridium, which were unaffected by the presence of thiourea and L-ascorbic acid. 
 
ICP-OES. Solutions of complexes in 5% v/v DMSO and 95% v/v DMEM (or 
RPMI-1640 as specified) were analysed using PerkinElmer 5300DV ICP-OES. 
Calibration standards of analytes of interest were prepared in the range 50-700 ppb 
from a 10’000 ppm certified reference materials (Inorganic Ventures) in 3.6% v/v 
nitric acid (10 mM thiourea, 100 mg/L L-ascorbic acid). The salinity of the 
calibration standards were adjusted to the sample matrix of culture media using 
NaCl. Samples were diluted appropriately to fit the calibration range, so that 
dissolved solids did not exceed 0.1% w/v. Samples were analysed on a Perkin Elmer 
Optima 5300 DV Optical Emission Spectrophotometer: Os (λ=225.585; 228.226 
nm), Ir (λ=237.278; 208.882 nm) and Pt (λ=204.937; 265.945 nm). Data were 
processed in WinLab32 Offline 3.4.1 software for Windows. 
 
ICP-MS. ICP-MS analysis for cellular accumulation experiments were analysed on 
an Agilent 7900 series ICP-MS spectrometer in no-gas mode. Calibrations of the 
elements of interest (189Os, 79Br, 195Pt and 192Ir) were prepared in the range 0.1-1000 
ppb from 10’000 ppm certified reference materials (Inorganic Ventures) using 
either 3.6% v/v nitric acid (380.6 mg thiourea, 50 mg L-ascorbic acid in 500 mL) 
or 1% m/v TMAH, as specified. Dissolved solids did not exceed 0.1% w/v. For 
TMAH studies of 189Os and 79Br, 101Ru (50 ppb) was used as an internal standard. 
For all other ICP-MS experiments, 166Er (10 ppb) was used. 
 




2.3.4    Elemental analysis (CHN) 
 
Elemental analysis of ligands and complexes (Chapter 3) were performed by 
Exeter Analytical (Warwick Analytical Services) using a CE440 Exeter elemental 
analyser to analyse for carbon (C), hydrogen (H) and nitrogen (N) content. 
 
2.3.5    X-ray crystallography 
 
X-ray crystallography data of Os[(p-cym)(BsDPEN)] complexes (Chapter 3) were 
obtained by Dr. Guy Clarkson (University of Warwick) from crystals in 1:2 
DCM:hexane. A single crystal was mounted onto a glass fibre (using Fromblin oil) 
and analysed at 150 K on a Oxford Gemini diffractometer (with a ruby CCD). In 
Olex2,4 and SheIXL5 softwares (‘Direct calculation’) the chemical structure was 
determined,4, 5 and refined using ‘Least Square method’.5 The complexes were 
enantiospecific (synthesized from chiral reagents) and structure determination was 
refined using BASF/TWIN in Shelx2014 software to give relatively low Flack 
parameters. Data were visualised and analysed using Mercury 4.0.6  
 
2.3.6    Plunge-freezing and freeze-drying 
 
Silicon nitride (Si3N4) membranes were plunge-frozen using an in-house 
manufactured manual plunge-freezer with assistance from Dr Saskia Bakker and 
Mr Ian Hands-Portman (School of Life Sciences, University of Warwick).  Freezing 
was achieved using a 30% propane:ethane mixture liquefied using liquid nitrogen. 
Si3N4 membranes were freeze-dried using Alpha 2-4 LDplus Christ model, 









2.4     Biological methods 
 
2.4.1    In vitro biological studies  
 
In vitro cell culture work was carried out under the guidance of Dr James P. C. 
Coverdale, Dr Hannah E. Bridgewater and Mrs Ji-Inn Song (School of Life 
Sciences, University of Warwick). All cell lines) used is this thesis were adherent 
(grown as monolayers on a 2D surface). All cell lines are specified in Section 2.2.1. 
 
Preparation of cell culture media. DMEM or RPMI-1640 was supplemented with 
10% FCS, 1% penn/strep and 1% L-glutamine (2 mM), and incubated at 310 K 
prior to use.  
 
Defrosting cells. A vial of frozen cells (containing ca. 1×106 cells) stored in liquid 
nitrogen was rapidly defrosted at 310 K. The cell solution was re-suspended in fully 
prepared DMEM (4 mL) to obtain a single cell suspension. The sample was 
centrifuged (298 K, 5 min, 1000 rpm), the supernatant removed and the pellet re-
suspended in DMEM (3 mL). The solution was transferred to a T25 cell culture 
flask and incubated (310 K, 5% CO2) until a cell confluence of 80-90% was 
achieved. 
 
General Cell Maintenance. Upon 80-90% monolayer cell confluence on the 
surface of the cell culture flask, the supernatant was removed, cells washed with 
PBS and 0.25% trypsin/EDTA (1 mL) was added (5 min, 310 K). Once cells were 
detached and in solution, culture media was added to quench trypsin activity, and 
the resulting solution pipetted to form a single cell suspension. The cell suspension 
was transferred to a new culture flask for further incubation (310 K, 5% CO2).  
 




Stock solution preparation. Stock solutions of test compounds (Os, Ir and Pt) for 
biological investigations were prepared in 5% v/v DMSO in culture media (95% v/v 
DMEM or RPMI-1640, as specified) and analysed by ICP-OES to determine the 
metal concentration prior to use. For photoactivatable experiments (Chapters 4-5), 
RPMI-1640 non phenol red was used to prepare stock solutions, and samples were 
protected from light. Stocks of test compounds (100 µM) were diluted 50-fold in 
3.6% v/v stabilised nitric acid (Section 2.3.3). Total dissolved solids did not exceed 
0.1% w/v. A calibration of elements of interest were prepared in the range 50-700 
ppb and the salinity adjusted with NaCl, as described in Section 2.3.3.  
 
Sulforhodamine B (SRB) Assay. The antiproliferative activities of complexes 
were determined using the SRB assay.7 At 80-90% cell confluence, a single cell 
suspension was obtained as previously described. Cells were counted in duplicate 
(2×10 µL) using a haemocytometer and 96-well flat bottom plates were seeded 
(5000 cells per well in 150 µL) and incubated for 48 h (310 K, 5% CO2). ICP-OES 
corrected stock solutions of test compounds (100 µM) and CDDP (1000 µM) 
complexes were prepared in 5% v/v DMSO and 95% v/v culture media and diluted 
to six concentrations in the range 0.01-150 µM. The supernatant from each plate 
was removed and solutions of test compound were added to each well (in duplicate 
of triplicate), and incubated for a fixed time (24 h, unless specified otherwise). The 
supernatant was removed, cells were washed with PBS, and complex-free media 
(200 µL) was added (72 h, 310 K, 5% CO2). Cells were fixed with 10% TCA (1 h, 
277 K). The plates were washed with water (10×) and air-dried. SRB dye (0.4% 
prepared in 1% acetic acid) was added to each well (50 µL) and incubated for 30 
min. The plates were washed with 1 % acetic acid (7×) and heat-dried. 10 mM tris 
base pH 10.5 (150 µL) was added to each well and incubated for 1 h. The UV 
absorbance at 492 nm was measured using SkanIt multiplate analyser (Thermo 
Scientific). Data were processed in Excel and plotted as a sigmoidal dose-response 
curve (logarithm of concentration vs. percentage cell survival) in Origin Pro 2016 
normalised to the untreated (control) wells.  
 




2.4.2    ICP-MS acid digestion of cell pellets 
 
Cell pellets were digested using freshly-distilled 72% v/v nitric acid (200 µL) at 353 
K for 12 h. The samples were then diluted 20-fold using stabilised milliQ water 
(containing 10 mM thiourea and 100 mg/L L-ascorbic acid) to achieve a final 
concentration of 3.6% v/v nitric acid (total dissolved solids <0.2%  w/v). Data 
acquisition was performed using an internal standard of erbium (166Er=10 ppb) in 
no gas mode. Calibration standards of elements of interest were prepared as 
previously described (Section 2.3.3).  
 
2.4.3    ICP-MS alkaline digestion of cell pellets 
 
Cell pellets were digested using an aqueous solution of 25% m/v TMAH (500 µL) 
at 353 K overnight, adapted from methods published in the literature.8, 9 The 
samples were then diluted 25-fold to achieve 1% m/v TMAH (total dissolved solids 
<0.1% w/v) using milliQ water. Data acquisition was performed using an internal 
standard of ruthenium (101Ru=50 ppb). Calibration standards were prepared as 
previously described (Section 2.3.3).  
 
Os and Br ICP-MS method validation. A calibration containing osmium and 
bromine in 1% m/v TMAH was prepared in the range 0.1-1000 ppb. Calibration 
curves of R2=1.0000 and 0.9999 were obtained for osmium (189Os) and bromine 
(79Br), using 101Ru (50 ppb) as an internal standard. Known analyte solutions of 
osmium and bromine were prepared in 1% m/v TMAH in triplicate, in addition to 
known concentrations of combined osmium-bromine compounds. Spike solutions 
of potassium bromide (KBr) and osmium trichloride (OsCl3.3H2O) were prepared 
directly in 1% m/v TMAH, achieving >95% recoveries. Additionally, spike 
solutions of KBr, OsCl3.3H2O and osmium and bromine calibration standards were 
prepared following the alkaline digestion method (e.g. digestion in 500 µL 25% m/v 
TMAH followed by 25-fold dilution). A known concentration of SS-2 (see Chapter 
3) was also prepared following the alkaline digestion protocol to confirm 1:1 ratio 
of 189Os:79Br in aqueous solution prior to commencement of biological studies. 




2.5     Instrumentation at Diamond Light Source (DLS, Oxford) 
 
2.5.1    I14 beamline 
 
All synchrotron X-Ray Fluorescence (XRF) and X-Ray Absorption Near Edge 
Structure (XANES) experiments were performed at the I14 hard X-ray Nanoprobe 
beamline. I14 operates in the energy range 5-23 keV and received its first users in 
March 2017. High energy x-rays are generated by an undulator source, which are 
directed through an aperture (17 m) to the white beam slits which determine the 
beam size delivered to the optics. The beam is then directed onto a bent collimating 
(focussing) mirror, followed by a flat deflecting mirror and then onto the 
horizontally deflecting double-crystal monochromator (DCM). The beam then 
passes through a high-precision slit system which acts as a secondary source (50 m) 
to the focusing optics, a pair of pre-shaped mirrors in Kirkpatrick-Baez (KB) 
configuration (186m, in the end station), as shown in Fig. 2.1.  
 
Figure 2.1. Schematic for the hard x-ray nanoprobe I14 beamline at DLS (Oxford). 
 
Overall, the beamline is 186 m in length to improve beam demagnification and to 
provide a coherent beam (Figure 2.1).10 The focused beam can reach spot sizes 
down to sub-50 nm, with a slight dependence on photon energy (higher energy 
allows smaller spots). XRF data is collected by a 4-element silicon drift detector 
(SGX-RaySpec, UK) laid out in backscatter geometry, covering 0.6-0.8 sr solid 
angle and capable of 1.5 Mcps/channel. Additionally, a Merlin Quad detector 
(Quantum Detectors, UK) is available for simultaneous imaging techniques using 
the transmitted beam, such as Differential Phase Contrast (DPC) imaging. 
Alternative detectors to the Merlin are also available for different techniques such 
as XRD and near-field ptychography, which goes beyond the scope of this work. 




2.5.2    B24 beamline 
 
Cryogenic fluorescence microscopy 
Correlative microscopy analysis of plunge-frozen TEM grids was performed on a 
Zeiss Axioimager M2 (Carl Zeiss X-ray Microscope) coupled to a Linkam 
cryostage (CMS196M LED) for preliminary grid analysis and mapping (max 
resolution 50×, variable filters) by monitoring the fluorescence of trackers used.  
 
Cryo-Structured Illumination Microscopy (Cryo-SIM) 
Prior to cryo-soft X-ray Tomography (cryo-XRT), super-resolution fluorescence 
microscopy was performed on plunge-frozen TEM grids using the cryo-SIM 
facilities (B24 beamline, DLS). The cryo-SIM has 4 excitation lasers (405, 488, 561 
and 642nm; 10-100 Wcm-2 laser power) and a 100X long distance air objective (2 
mm, 0.9NA), and can achieve a lateral resolution of 360 nm (when using green 
light).11 Cryo-SIM in compatible with conventional fluorophores and can use low 
light doses, acquiring super-resolution fluorescence information on biological 
samples 8-fold greater than the diffraction-limit.11  
 
Cryo-XRT 
All cryo-XRT and super-resolution cryo-SIM measurements were performed at the 
full-field transmission microscope at beamline B24 (Fig. 2.2), which has a Zeiss 
UltraXRM-S220C microscope end station.12 The B24 beamline operates in the soft 
x-ray region (200-2600 eV), has a beam size of 20 µm (allowing a resolution of 40 
nm) and delivers a photon flux 108 photons/µm2.12 Data were collected by direct 
detection using a CCD (Pixis, XO 1024B; Princeton Scientific).12  
 
Figure 2.2. Schematic layout of the B24 cryo-XRT Beamline (DLS, Oxford). 




B24 uses a bending magnet source to generate x-rays, which are directed by a 
toroidal mirror onto a Variable Line Spacing (VLS) grating monochromator. The 
mirror focuses the beam onto a focal point downstream of the monochromator, 
where a slit system removes stray radiation and selects the desired wavelength for 
the experiment. The beam is then focussed onto the sample using a capillary 
condenser. Downstream from the sample, a zone plate (40 nm minimum spacing) 
projects the image onto the Charge Coupled Device (CCD) detector. A schematic 
diagram of the beamline is depicted in Figure 2.2. 
 
2.6     Synchrotron methods 
 
All synchrotron experiments were performed at Diamond Light Source, located in 
Harwell Campus, South Oxfordshire. 
 
2.6.1    Synchrotron-XRF at I14  
 
In this thesis, cryo-fixed and dehydrated human cancer cells grown on Si3N4 
membranes and treated with Os, Br, Pt or Ir complexes were analysed by 
synchrotron-XRF at ambient temperature using incident energies of 12-15 keV to 
monitor the L3M5 emissions of Os (8.91 keV), Ir (9.18 keV), Pt (9.44 keV), and the 
KL3 emission of Br (11.92 keV).13 Regions of interest (cancer cells) were identified 
under the beamline microscope by their endogenous elemental KL3 emissions (Zn, 
K, P and S) using large step sizes (300-500 nm). XRF maps were acquired using 
100 nm step size, 50 nm beamsize and 0.1 s exposure. Biological elements present 
in FCS, RPMI, DMEM, PBS and HBSS are specified (Appendix, Table A1-5). 
 
Sample preparation. Si3N4 membranes (suitable growth substrates for cells which 
are transparent to x-rays)14 were sterilised with 70% ethanol (5 min) and 100% 
ethanol (5 min) and air-dried. 0.01% Poly-L-lysine (1-2 drops) was added directly 
to the membrane and incubated at ambient temperature for 20 min. The poly-L-
lysine was removed using PBS (2×3 mL). Cell suspensions of 8-10×105 cells/mL 




were prepared in culture media, and 50 µL of this suspension was added directly to 
each membrane. The membranes were incubated for 2 h (310 K, 5% CO2). After 
this, 3 mL of the same cell suspension was added to each membrane and incubated 
for a further 24 h (310 K, 5% CO2). The supernatant was removed, and ICP-OES 
corrected solutions of Os, Pt or Ir complexes (prepared in 5% v/v DMSO, 95% v/v 
media) were added to each membrane (3 mL). The supernatant was removed and 
the membranes were washed with buffer (PBS, tris-glucose, or HBSS as specified). 
The membranes were dipped in sterile water (3 s), blotted (3 s) and plunge-frozen 
as previously described (Section 2.3.6). The membranes were transferred to cryo-
vials, covered in pierced parafilm, and freeze-dried for 24-48 h. 
 
Synchrotron-XRF. Photon energies of greater than the electron-binding energies 
of Os (L3 2p3/2=10.9 keV), Br (K1s=13.5 keV), Ir (L3 2p3/2=11.2 keV) and Pt (L3 
2p3/2=11.6 keV) were used in these experiments (12-15 keV).
13 The Kα-emissions 
of native biological elements (P, S, Cl, K, Ca, Zn) can be readily observed at these 
incident photon energies, and thus cell features such as nuclei or cell membranes 
can be identified (Chapter 1, Table 1.1). Raster scans were performed at the 
specified step-size (100 nm), using 0.1 s exposure time and a beam size ca. 50×70 
nm. The fluorescence was detected by Si drift four-element detector. 
 
Data fitting and analysis. Data fitting and analysis was performed using PyMCA 
software (Fig. 2.3-2.4).15 The XRF spectra were fitted to characteristic elemental 
peaks by specifying the incident energy, exposure time, the matrix composition, 
geometry and detector characteristics (Fig. 2.4; Chapter 1, Table 1.1). The fitted 
data were analysed in ImageJ software to gain information on cell size, 
morphology, elemental distribution and co-localisation statistics.16 A sample with 
known composition (AXO Dresden GmbH, Germany) was used to calibrate the 
fitting process and obtain quantitative information (Equation 2.1), assuming a 
density of 0.0012 g/cm3 and maximal cell thickness of 6 µm.17  







Equation 2.1. Formula for the quantification of elements from XRF spectra, where A=peak 
area, I0= flux, c=mass fraction, Ω/4π=detector-geometry efficiency, Rj=relative intensity 





Figure 2.3. Summary of the PyMCA workflow for analysing of XRF data. (i) Calibration: 
an internal (1st order) calibration is performed on a ROI to calibrate the energy (ii) Peak 
Identification: database proposes theoretical energy emissions, and the user identifies peaks 
based on knowledge of the sample. (iii) Fit configuration: insert instrumental and 
experimental parameters (detector, distance, matrix, incident beam angle) and user selects 
elements of interest in sample. The background was removed using strip background 
model, which applies a baseline to the fit. (iv) Quantification: by running an AXO silicon 
nitride standard contain known concentrations of elements, the photon-flux is back-
calculated and used to fit and quantify elements in the sample. 
 
 
Figure 2.4. Typical XRF fit of untreated cancer cells, showing abundant biological 
elements, in addition to elements prevalent at the synchrotron I14 beamline. (a) Data from 
a ROI in an untreated cancer cell with the continuum modelled by performing a fit in 
PyMCA software. (b) Peak identification of elements in the sample or at the beamline 
including phosphorus, sulfur, chlorine, potassium, calcium, chromium, manganese, iron, 
cobalt, nickel, copper, zinc and tungsten. 
 




Limitations of elemental quantification by XRF  
In order to quantify elements using synchrotron XRF, one must either have prior 
knowledge of the system (photon flux, solid angle and acquisition time) or use an 
internal standard (of known chemical composition). As the photon flux at the I14 
beamline can vary, an internal standard (AXO Dresden GmbH, Germany) was used 
for quantification. One of the major problems with quantifying trace biological 
elements using an internal standard is matrix-matching, in which it is assumed that 
the matrix in the standard (Si3N4) is an exact representation of the sample matrix 
(i.e. cells grown on Si3N4).
18 As a result of imperfect matrix-matching, XRF is only 
semi-quantitative.  
The quantification will also depend on the sample thickness (assumed to be 
maximum of 6 µm).17 Hard x-rays (>10 keV) can penetrate the full thickness of 
samples, thus, provides a sum of the XRF emissions from the entire thickness of 
biological cells. For example, XRF measurements using 100 nm step size achieves 
100 nm resolution in the xy-plane, however, the resolution in the z-plane (i.e. cell 
thickness) will be around 6000 nm. This ultimately affects the resulting elemental 
quantification and resolution in the elemental maps. Moreover, the quantification 
of biological samples on Si3N4 membranes is much more reliable with thin samples 
(<1 µm), where the sample matrix can be assumed to be the same as the Si3N4 
support (e.g. 200 nm thickness). A more reliable way to obtain the ‘real’ cell 
thickness is to use x-ray tomography, however, this can be time-consuming, 
expensive and can cause additional damage to samples prior to XRF analysis. 
In order to validate the quantification reliability of synchrotron-XRF, LA-ICP-MS 
(which has similar sensitivity and spatial resolution)19 can be used on cells prepared 
and exposed to the same conditions (e.g. cryopreserved and freeze-dried). In 
addition, single-cell ICP-MS could be employed to obtained to quantify elements 
in individual cells,20 although these samples will be subject to digestion. Both of 
these techniques can be used for future quantification validation; however, this goes 








2.6.2    Cryo-XRT at B24  
 
Sample preparation. Quantifoil finder grids (Au-C R2/2 F1 200 mesh, Quantifoil 
GmbH, Germany) were incubated in FCS (2 mL/well in 6-well plates) for 12 h (310 
K, 5% CO2). The FCS was removed and 1.5×10
5 cells/ mL of PC3 cell suspension 
was added to each well (2 mL/well) and incubated for 24 h (310 K, 5% CO2). Pt or 
Ir stock were prepared in non-phenol red RMPI-1640 under dark conditions. The 
supernatant suspension was removed and Ir or Pt compounds were added and 
incubated for specified times (310 K, 5% CO2). Plates were irradiated with blue 
light (465 nm, 4.8 mW/cm2) for the specified times. The supernatant was removed 
followed by recovery times in complex-free media. The grids were incubated in 
conventional fluorescent trackers (100 nM) for 20 min (310 K, 5% CO2) before 
blotting with AuNP fiducials (d=250 nm) and plunge-freezing in liquid ethane. 
 
Fluorescence Microscopy. PC3 cells grown as described above and exposed to Ir 
or Pt complexes were incubated with various trackers: (i) MitoTracker Red 
(λex/em=581/644 nm); (ii) MitoTracker DeepRed (λex/em=644/665 nm); (iii) 
LysoTrackerRed (λex/em=577/590 nm). Cells were plunge-frozen in liquid ethane 
and the fluorophores monitored by fluorescence microscopy on a Zeiss Axioimager 
M2 microscope coupled to a cryo-stage (model CMS196M, Linkam Scientific, UK) 
to identify suitable cell candidates for analysis by cryo-XRT. 
 
Cryo-XRT.  All cryo-XRT experiments were performed at beamline B24 (DLS, 
Oxford), using a Zeiss UltraXRM-S220C X-ray microscope which uses the 
synchrotron as the primary source and a direct-detection CCD camera (Pixis XO 
1024B, Princeton Scientific). The photon energy was 500 eV for all experiments. 
Plunge-frozen grids were loaded into the sample chamber of the beamline. X-ray 
mosaic images were obtained first using short exposures (0.5 s). Regions of interest 
were brought into focus by mapping the positions of fiducials and dense lipid 
droplets in the tilt range − 30 and + 30°. The image focus was adjusted by altering 
the position of the 40 nm zone plate objective. Tomograms were acquired with a 
tilt range of -65 to +65° using 0.2-0.5º rotations and 1-8 s/frame x-ray exposure. 




Alignment and reconstruction in IMOD. Tomograms (15.8×15.8 µm2) were 
aligned and reconstructed using the freely available IMOD software package.21 The 
tilt series were aligned to compensate drift and tilt by monitoring the positions of 
fiducials on the cell surface. Once aligned, tomographic reconstruction follows 
using standard algorithms (WBP and SIRT). The MRC files produced by the 
beamline were opened in IMOD using the following settings: single axis; single 
frame; pixel size=15.8 nm, fiducial diameter=250 nm; image rotation=0°, start 
angle (-65 to + 65°, unless specified otherwise); increment step=0.2–0.5°. From 
this, an x-ray model was generated, followed by a fixed stack. Cross-correlation 
was calculated (high cut-off radius=0.1), and a coarse aligned stack generated. The 
fiducial model was generated automatically, and corrected manually (by mapping 
the centre positions of each fiducial throughout the entire tilt series). Tomograms 
were fine-aligned (relative to neighbouring views; fixed magnification=1; no 
rotation). The tomogram was positioned (thickness=1000; binning=3) to generate a 
boundary model (to remove unwanted information). The final aligned stack was 
generated from the z-shifts and pitch angles (using linear interpolation) to generate 
tomograms with smooth rotations. The IMOD workflow is summarized in Fig. 2.5. 
 
Figure 2.5. IMOD workflow for aligning and reconstructing tomograms. (i) Build 
tomogram by inserting experimental parameters (x-ray exposure, tilt range, fiducial size, 
pixel size), exclude unwanted views (e.g. at high tilt angles) and generates an x-ray model. 
(ii) Pre-processing creates a second (fixed) stack with x-rays removed. (iii) Coarse 
alignment corrects for large shifts in xy plane. (iv) Fiducial model generation identifies 
and tracks fiducials through the tilt series. (v) Fine alignment solves for displacements, 
rotation, tilts and magnification and finds the best fit for the data. (vi) Tomogram 
positioning temporarily reduces volume to create a final alignment. (vii) Fine aligned stack 
applies the alignment and creates the final aligned stack of the full volume. (viii) Tomogram 
generation uses WBP or SIRT reconstruction algorithms to computer the tomogram. (IX) 
Post-processing is used to trim the volume and adjust image contrast. 




3D segmentation and visualisation. The reconstructed tomograms (.rec files) were 
segmented in SuRVoS software (Fig. 2.6),22 to quantify and image the 3D volumes 
of organelles of interest. The regions of interest were selected appropriately for each 
tomogram by deleting specific angle views which were obstructed by thick ice or 
by gridlines. A Gaussian filter feature channel was used to pre-process the data and 
supervoxels (hierarchical layers of super-regions, SP= 8×8×8) were generated in 
Gaussian mode. Organelles of interest were segmented (semi-automatically) using 
supervoxels for guidance. The exported files (.rec) were visualized in the software 
package Amira (FEI/Thermo Scientific, The Netherlands, 2016), using the volume-
rendering and ortho-slice features to generate 3D images and videos. 
 
 
Figure 2.6. SuRVoS workflow for volume segmentation analysis. (i) Data preparation: 
reconstructed tomograms (.rec) files are opened and the ROI is selected. (ii) Data pre-
processing: deionising filters are used to remove noise, adjust contrast and enhance features 
of interest for discrimination between different cell features. (iii) Data representation: 
voxels, supervoxels or megavoxels are generated to identify specific features (hierachiral 
layers of super-regions). (iv) Model training: user identifies regions of interest and 
supervoxels colour in these regions (semi-automated volume segmentation), to gain 3D 
qualitative and quantitative information (e.g. organelle volumes). The raw data and 










2.7    Statistical formulae 
 
• In vitro studies: All in vitro biological experiments (cell viability assays 
and ICP-MS cellular uptake) were performed in triplicate to obtain standard 
deviations and the standard error of the mean. Statistical significance 
between different samples was determined using Welch’s unpaired t-test 
above the 95% confidence interval throughout this thesis. 
 
• Synchrotron XRF: The co-localisation between elements in cryo-fixed and 
freeze-dried samples analysed by XRF were determined using Pearson’s R-
value and Spearman Rank Correlation. Statistically significant changes in 
mass fraction elemental quantities were determined using Welch’s unpaired 
t-test above the 95% confidence interval.  
 
• Cryo-XRT: Statistical differences in volume between segmented organelles 
in cryopreserved cells analysed by cryo-XRT were determined using 





Measures the variability between the individual data values and the mean value, 
and is given by the following formula, where xi= individual sample value, x̄=sample 
mean and n=sample size. 
𝑠 = √





Standard error of the mean 
A measure of how far the mean is away from the true mean value, and is given by 









Welch’s unpaired t-test 
Assumes that both groups of data have Gaussian distributions, but do not 
necessarily have the same standard deviation. Welch’s unpaired t-test (also known 
as the two unpaired t-test) is given by the following formula where x̄=sample mean, 













Describes the range of values for which the true value lies, and is given by the 
following formula where x̄=mean, se=standard error of mean, and t=critical value. 
?̅? ± (𝑠ⅇ ⋅ 𝑡) 
Pearson’s R-value 
Measures the linearity between two variables, where +1= positive correlation, 0=no 
correlation and -1= negative correlation. Pearson’s R-value is given by the 
following formulae where xi and yi= individual sample points, n=sample size, x̄ and 








Spearman’s Rank Correlation 
Measures the monotonic relationships between two variables to obtain a line of best 
fit. Spearman’s Rank Correlation is given by the following formula where xi and 




𝑖 − 𝑛𝑥𝑦̅̅ ̅
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Chapter 3  
 
 
Catalytic OsII arene complexes in 
cancer cells: ICP-MS and XRF 
 
  




3.1     Introduction 
 
In 2015, Coverdale et al. reported a series of coordinatively-unsaturated 16-electron 
pseudo-octahedral osmium(II) complexes with the general formula ([OsII(p-
cym)(TsDPEN)] (where p-cym=para-cymene, TsDPEN=tosyldiphenylethylene 
diamine, RR-1, Fig. 3.1)1, 2 as second-generation Noyori ruthenium transfer 
hydrogenation catalysts. Asymmetric transfer hydrogenation (ATH) is a well-
established reaction in which prochiral substrates are enantioselectively converted 
to chiral products. This is of great industrial interest owing to the importance of 
optically-active alcohols and amines in both agrochemicals and pharmaceuticals. In 
the late 20th century, Noyori et al. reported a series of ruthenium(II) octahedral 
complexes which can enantioselectively catalyse the reduction of ketones and 
imines with high enantiomeric excesses, conversions and turnover frequencies.3 
First-generation Noyori catalysts containing asymmetric phosphine (BINAP) and 
diamine (DPEN) ligands enhanced the catalytic efficiency through steric and 
electronic effects.4, 5 Second-generation half-sandwich ruthenium(II) Noyori 
catalysts were developed, containing: (i) chiral bidentate tosyl-
diphenylethylenediamine (TsDPEN(H)) ligand (which directs the 
enantioselectivity), (ii) η6-arene and (iii) halide (leaving group) which dissociates 
to provide an available coordination site for catalysis (Fig. 3.1). 5, 6  
 
 
Figure 3.1. (a) Coordinatively-unsaturated 16-electron osmium(II) complex [OsII(η6-p-
cym)((1R, 2R)TsDPEN] (RR-1).1 (b) Noyori second-generation half-sandwich 
ruthenium(II) pre-catalyst [RuII(η6-p-cym)((1R, 2R)TsDPEN(H))Cl].5, 6 Where * denotes 
chiral centres. 
 




Notably, the amine group of 16-electron [OsII(η6-p-cym)(TsDPEN)] (RR-1) is 
deprotonated (NH-), whereas, the [RuII(η6-arene)(TsDPEN(H)Cl] pre-catalyst is 
protonated (NH2), leading to initial differences in their catalytic mechanisms. The 
first stage in the catalytic cycle of Noyori’s catalyst requires the base-mediated 
dissociation of chloride (Cl-) to form an active Ru(η6-arene)(TsDPEN(H)) species. 
Formate (which acts as a hydride source) then directly interacts with both the Ru 
and the NH2 group (via O-atom), and releases CO2 to form a highly active Ru-H 
bond. This mediates the indirect (outer sphere) enantioselective reduction of the 
prochiral substrate, by forming favourable CH-π interactions on the Re or Si face in 
the 6-membered coordination state.7-9  
The OsII analogues are remarkably stable and can catalytically reduce ketones to 
optically-pure alcohols with high enantiomeric excesses (>97%) and turnover 
frequencies in the presence of formic acid.1 Unlike previous generation RuII 
catalysts, the OsII analogues do not require activation via ligand dissociation. It is 
proposed that formate can bind directly to the vacant coordination site of RR-1 to 
form an active Os-H bond (via decarboxylation), for which the prochiral ketone (i.e. 
acetophenone) interacts with NH2 (via O-atom) and hydride (H
-, via the carbonyl 
C-atom). Subsequently, this mediates substrate reduction at the Si or Re-face 
(depending on steric interactions between the substrate and the catalyst) – providing 
an outer sphere catalytic mechanism (Chapter 1, Fig. 1.11).10 Furthermore, the RR 
and SS catalysts yield R and S chiral products, respectively. 
These OsII complexes have also demonstrated catalysis in a biological context,10 as 
an alternative approach to cancer treatment. A hydride source is still required, and 
the sodium salt of formic acid (an approved food additive) is well-suited for 
biological use and has been used previously with great success.11, 12 The potential 
for half-sandwich OsII complexes as anticancer agents with new mechanisms of 
action(s) has been reported,13  including this family of “unconventional” 16-
electron piano-stool catalysts.10, 14 Both the SS/RR isomers of 1 (Fig. 3.1) exhibit 
moderate antiproliferative activity against a variety of cancer cell lines (in vitro).10 
Complex RR-1 was the first reported osmium-based synthetic catalyst to 
enantioselectively convert pyruvate (an essential precursor in cell metabolism) to 
unnatural D-lactate in the presence of non-toxic concentrations of sodium formate 
in cancer cells,10 providing a platform for catalytic selectivity. As a consequence of 




the Warburg Effect, cancer cells have increased levels of lactate:15 making 
metabolism a viable therapeutic target. Interestingly, confocal microscopy studies 
also revealed that these complexes can selectively generate reactive oxygen species 
(ROS) both in vitro and in vivo,14 providing the opportunity to exploit the redox 
vulnerability of cancers through catalytic therapy. 
Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) is an analytical 
technique which can be used to quantify elements down to ppb concentrations and 
has previously been used to quantify intracellular levels of osmium (189Os) in cancer 
cells treated with SS/RR-1 under varying conditions (time, temperature, 
concentration and efflux-inhibition studies),2 providing insights into the in-cell 
metal activity. However, this work does not provide information on the stability and 
speciation of the whole complex – just the osmium centre. Consequently, the fate 
of the bidentate sulfonamide ligand (which plays a vital role in directing the 
enantioselectivity of in-cell catalysis) has not yet been studied. Labelling this ligand 
with appropriate exogenous elements which are non-native to cancer cells, are 
readily detectable by analytical techniques and do not significantly affect the 
anticancer or catalytic properties, can provide insights into the complex stability, 
speciation and distribution in cancer cells. This may be crucial in elucidating the 
mechanism(s) of action for clinical translation. 
This Chapter explores the synthesis and characterisation of a series of catalysts 
derived from parent compound SS/RR-1 (Fig. 3.1), which contain halide 
substituents on the sulfonamide moiety. Catalytic activities, anticancer potencies 
and osmium cellular quantities are compared to that of parent compound (1). In 
particular, a Br-labelled complex with the formulae [Os(η6-p-cym)((p-
Br)BsDPEN)] has been used as a molecular probe to investigate the in-cell activity 
of this family of complexes in cancer cells by simultaneously monitoring the 
osmium centre and the bromine from the bidentate sulfonamide ligand using ICP-
MS (189Os; 79Br) and synchrotron-XRF (Os L3M5=8.9 keV; Br KL3=11.9 keV). 
 
 





Ligand R1 R2 
SS-L1 Br H 
RR-L1 Br H 
SS-L2 I H 
RR-L2 I H 
RR-L3 OCH3 H 
SS-L4 H Br 
 
Figure 3.2. Summary of the chiral (SS or RR) sulfonamide ligands synthesized in this 
chapter (L1-L4), where * indicates chiral centres SS or RR as specified.  
                                         
Complex Ligand R1 R2 
SS-1 N/A CH3 H 
RR-1 N/A CH3 H 
SS-2 SS-L1 Br H 
RR-2 RR-L1 Br H 
SS-3 SS-L2 I H 
RR-3 RR-L2 I H 
RR-4 RR-L3 OCH3 H 
SS-5 SS-L4 H Br 
RR-6 N/A F H 
 
Figure 3.3. Parent compound SS/RR-1.1 Summary of Os[(p-cymene)((R)BsDPEN)] 
complexes (2-5) synthesized in this chapter, where * indicates chiral centres SS or RR as 
specified. Previously reported complex RR-6 discussed in this Chapter.2 




3.2     Experimental 
 
3.2.1    Synthesis of BsDPEN ligands 
 
General synthesis of BsDPEN ligands 
 
Scheme 3.1. General synthetic scheme for the synthesis of BsDPEN 
(benzenediphenylethylene diamine) ligands using varying benzylsulfonyl chlorides and SS 
or RR-DPEN in the presence of base (triethylamine). 
 
To a solution of (1S, 2S) or (1R, 2R)-diphenylethylene diamine (DPEN, 1.28 g, 6 
mmol, 1 mol eq.) and triethylamine (0.83 mL, 6 mmol, 1 mol. eq.) in anhydrous 
DCM (15 mL) cooled in an ice bath was added dropwise benzenesulfonyl chloride 
(7.2 mmol, 1.2 mol eq.) in anhydrous DCM (10 mL). The ice bath was removed, 
the reaction warmed to ambient temperature and stirred for 2 h. Distilled water (30 
mL) was added. The organic phase was separated and the aqueous phase extracted 
with DCM (3×10 mL), combined with the organic phase and dried over magnesium 
sulphate. The resulting yellow solution was concentrated in vacuo, and diethyl ether 
















(1S, 2S)-BrBsDPEN (SS-L1). SS-L1 was synthesized using the general synthesis 
method using (1S, 2S)-DPEN (1.28 g, 6.03 mmol), triethylamine (0.8 mL, 5.77 
mmol) and 4-bromobenzenesulfonyl chloride (1.84 g, 7.2 mmol) to obtain a white 
solid (1.12 g, 2.60 mmol, 43%). 1H NMR (500 MHz, d6-DMSO, 298 K, TMS): 
𝛿=7.43 (d, 3J(H,H)=8.5 Hz, 2H, ArH), 7.31 (d, 3J(H,H)=8.5 Hz, 2H, ArH), 7.12-
7.0 (m, 5H, ArH), 7.00 (d, 3J(H,H)=6.6 Hz, 3H, ArH), 6.07-6.92 (m, 2H, ArH), 4.33 
(d, 3J(H,H)=7.2 Hz, 1H, CHNHTs), 3.97 (d, 3J(H,H)=7.2 Hz, 1H, CHNH). 13C 
NMR (125 MHz, DMSO): 𝛿=142.8, 140.9, 140.0, 132.0, 128.6, 128.1, 127.9, 
127.8, 127.7, 127.1, 126.9, 125.9, 65.3, 61.0. HRMS (ESI): m/z calculated for 
C20H20BrN2O2S [M+H
+]: 431.0429; found: 431.0427. Elemental analysis: found 
(calc for C20H19BrN2O2S): C 55.05 (55.69), H 4.31 (4.44), N 6.40 (6.49). 
 
(1R, 2R)-BrBsDPEN (RR-L1). RR-L1 was synthesized using the general synthesis 
method using (1R,2R)-DPEN (1.25 g, 5.9 mmol), triethylamine (0.8 mL, 5.77 
mmol) and 4-bromobenzenesulfonyl chloride (1.87 g, 7.32 mmol) to obtain a white 
solid (1.48 g, 2.91 mmol, 57%). 1H NMR (500 MHz, d6-DMSO, 298 K, TMS): 𝛿 = 
7.43 (d, 3J(H,H)=8.5 Hz, 2H, ArH), 7.31 (d, 3J(H,H)=8.5 Hz, 2H, ArH), 7.14-7.05 
(m, 5H, ArH), 7.00 (d, 3J(H,H)=6.7 Hz, 3H, ArH), 6.96-6.92 (m, 2H, ArH), 4.33 (d, 
3J(H,H)=7.2 Hz, 1H, CHNHTs), 3.97 (d, 3J(H,H)=7.2 Hz, 1H, CHNH). 13C NMR 
(125 MHz, DMSO): 𝛿=142.8, 140.9, 140.0, 132.0, 128.6, 128.1, 127.9, 127.8 127.7, 
127.1, 126.9, 125.9, 65.3, 61.0. HRMS (ESI): m/z calculated for C20H20BrN2O2S 
[M+H+]: 431.0423; found: 431.0429. Elemental analysis: found (C20H19BrN2O2S): 
C 55.02 (55.69), H 4.42 (4.44), N 5.74 (6.49). 
 






(1S, 2S)-IBsDPEN (SS-L2). SS-L2 was synthesized using the general synthesis 
method using (1S, 2S)-DPEN (1.27 g, 5.98 mmol), triethylamine (0.83 mL, 5.77 
mmol) and 4-iodobenzenesulfonyl chloride (2.19 g, 7.20 mmol) to obtain a white 
solid (0.62  g, 1.30 mmol, 22%). 1H NMR (500 MHz, d6-DMSO, 298 K, TMS): 
𝛿=7.60 (d, 3J(H,H)=8.4 Hz, 2H, ArH), 7.15 (d, 3J(H,H)=8.4 Hz, 2H, ArH), 7.13-
6.78 (m, 10H, ArH), 4.32 (d, 3J(H,H)=7.3 Hz, 1H, CHNHTs), 3.97 (d, 3J(H,H)=7.3 
Hz, 1H, CHNH). 13C NMR (125 MHz, DMSO): 𝛿=142.7, 141.2, 140.0, 137.8, 
128.3, 128.1, 128.0, 127.8, 127.7, 127.1, 126.9, 100.0, 65.3, 61.0, HRMS (ESI): 
m/z calculated for C20H20N2IO2S [M+H
+]: 479.0290; found: 479.0289. Elemental 
analysis: found (calculated for C20H19N2IO2S): C 49.72 (50.22), H 3.92 (4.00), N 
5.73 (5.86). 
                                                               . 
(1R, 2R)-IBsDPEN (RR-L2). RR-L2 was synthesized using the general synthesis 
method using (1R, 2R)-DPEN (1.03 g, 4.90 mmol), triethylamine (0.67 mL, 4.83 
mmol) and 4-iodobenzenesulfonyl chloride (1.73 g, 5.70 mmol) to obtain a white 
solid (0.75 g, 1.59 mmol, 27%). 1H NMR (500 MHz, d6-DMSO, 298 K, TMS): 
𝛿=7.60 (d, 3J(H,H)=8.3 Hz, 2H, ArH), 7.15 (d, 3J(H,H)=8.3 Hz, 2H, ArH), 7.13-
6.90 (m, 10H, ArH), 4.38 (d, 3J(H,H)=7.4 Hz, 1H, CHNHTs), 3.99 (d, 3J(H,H)=7.4 
Hz, 1H, CHNH). 13C NMR (125 MHz,  d6-DMSO): 𝛿=141.2, 140.1, 139.8, 137.8, 
128.3, 128.1, 128.0, 127.8, 127.7, 127.2, 126.9, 100.1, 65.1, 60.9. HRMS (ESI): 
m/z calculated for C20H20IN2O2S [M+H
+]: 479.0290; found: 479.0288. Elemental 
analysis: found (calculated for C20H20N2IO2S): C 49.70 (50.22), H 3.92 (4.00), N 
5.73 (5.86). 






(1R, 2R)-MeOBsDPEN (RR-L3). RR-L3 was synthesized using the general 
synthesis method using (1R, 2R)-DPEN (0.57 g, 2.70 mmol), triethylamine (0.35 
mL, 2.5 mmol) and 4-methoxysulfonyl chloride (1.06 g, 5.10 mmol) to obtain a 
white solid (0.21 g, 0.55 mmol, 22 %). 1H NMR (500 MHz, d6-DMSO, 298 K, 
TMS): 𝛿=8.76 (s, 1H, NH), 8.66 (d, 3J(H,H) = 9.6 Hz, 1H, ArH), 8.18 (d, 
3J(H,H)=8.5  Hz, 2H, ArH), 7.56 (d, 3J(H,H)=8.6  Hz, 2H, ArH), 7.28-7.13 (m, 9H, 
ArH), 4.50 (d, 3J(H,H)=8.6  Hz , 1H, TsNCH), 4.02 (d, 3J(H,H)=8.5 Hz, 1H, CH), 
3.70 (s, 3H OCH3). 
13C NMR (125 MHz, d6-DMSO): 𝛿=161.9, 159.9, 138.5, 133.5, 
128.6, 127.9, 127.6, 127.1, 114.0, 113.3, 62.9, 60.3, 55.9, 55.6. HRMS (ESI): m/z 
calculated for C20H23IN2O2S [M+H
+]: 383.1429 found: 383.1423. Elemental 
analysis: found (calculated for C21H22N2O3S): C 67.82 (65.94) H 5.45 (5.80), N 
6.12 (6.12).  
 
(1S, 2S)-m-BrBsDPEN (SS-L4). SS-L4 was synthesized using the general 
synthesis method using (1S, 2S)-DPEN (0.36 g, 1.84 mmol), triethylamine (0.25 
mL, 1.80 mmol) and 3-bromobenzenesulfonyl chloride (0.32 mL, 2.25 mmol) to 
obtain a white solid (0.35 g, 0.91 mmol, 50%).1H NMR (400 MHz, d6-DMSO, 298 
K, TMS): 𝛿=8.78 (s, 2H, NH), 7.55 (d, 3J(H,H)=8.0 Hz, 1H, ArH), 7.50 (d, 
3J(H,H)=7.9 Hz, 2H, ArH), 7.37 (d, 3J(H,H)=7.8 Hz, 2H, ArH), 7.15 (t, 3J(H,H)=7.7 
Hz, 6H, ArH), 6.83 (m, 3H, ArH), 4.47 (d, 3J(H,H)=8.2 Hz, 1H, CHNHTs), 4.15 
(d, 3J(H,H)=8.6 Hz, 1H CHNH). 13C NMR (125 MHz, d6-DMSO): 𝛿=142.0, 141.8, 
140.0, 139.7, 139.6, 137.8, 128.3, 128.1, 128.0, 127.8, 127.7, 127.1, 126.9, 100.0, 
65.3, 61.0. HRMS (ESI): m/z calculated for C20H20BrN2O2S [M+H
+]: 431.0429; 
found: 431.0425. Elemental analysis: found (C20H19BrN2O2S): C 55.89 (55.69), H 
4.50 (4.44), N 6.38 (6.49). 




3.2.2    Synthesis of Os[(p-cym)BsDPEN] complexes 
 
Synthesis of [Os(η6-p-cymene)Cl2]2 dimer 
 
Scheme 3.2. Synthetic scheme for [Os(η6-p-cym)Cl2]2 dimer, used as precursor dimer for 
the synthesis of [Os(p-cym)(BsDPEN)] complexes using an optimized microwave method 
(413 K, 150 W, 250 psi).16 
 
Synthesis of [Os(η6-p-cymene)Cl2]2. Methanol was sonicated and degassed with 
nitrogen immediately before use. OsCl3.3H2O (0.98 g, 2.78 mmol) was dissolved 
in degassed methanol (10 mL) and α-phellandrene (4.5 mL, 28 mmol) was added 
while stirring. The reaction vessel was placed in a CEM discovery-SP microwave 
reactor for 10 min (413 K, 150 W, 250 psi). An orange suspension containing 
crystalline, bright-orange precipitate was observed. The solid was washed with n-
pentane (3×10 mL) and dried with diethyl ether (10 mL). A pale orange crystalline 
solid was obtained (0.70 g, 0.88 mmol, 63%). 1H NMR (500 MHz, d6-DMSO, 298 
K, TMS): 𝛿=6.09 (d, 4H, 3J(H,H)=6.1 Hz, Ar-H), 6.04 (d, 4H, 3J(H,H)=6.1 Hz, Ar-
H), 3.00 (sept., 2H, 3J(H,H)=6.9 Hz, CH(CH3)2), 2.39 (s, 6H, Ar-CH3), 1.21 (d, 
12H, 3J(H,H)=6.9 Hz, CH(CH3)2).   
 
General synthesis of Os[(p-cym)BsDPEN] complexes 
 
Scheme 3.3. General synthetic scheme for [OsII(p-cym)(R-BsDPEN)] pseudo-octahedral 
complexes: where p-cym=para-cymene, RBsDPEN=R-benzyldiphenylethylene diamine 
with substituent R=Br, I or OMe. 




To a stirred solution of [Os(η6-p-cymene)Cl2]2 dimer (0.06 mmol, 50 mg, 1 mol eq.) 
in DCM (10 mL) was added ligand L1-L4 (0.14 mmol, 2.3 mol eq.) until a yellow 
solution was formed. Potassium hydroxide (50 mg, 15 mol eq.) was added,  
followed by distilled water (10 mL) and the solution mixed until a brick-red organic 
layer was formed. The organic layer was extracted with DCM (3×5 mL) and the 
resulting solution concentrated in vacuo. 
 
                        
[Os(η6-p-cymene)((1S, 2S)-BrBsDPEN)] (SS-2). SS-2 was synthesized using the 
general synthesis method using (1S, 2S)-BrBsDPEN (SS-L1, 60 mg, 0.14 mmol) to 
obtain a dark orange solid. The product was recrystallized in 1:2 ratio of 
DCM:hexane (52 mg, 0.07 mmol, 58%). 1H NMR (500 MHz, d6-DMSO, 298 K, 
TMS): 𝛿=8.21 (d, 3J(H,H)=3.7 Hz, 1H, NH), 7.46 (d, 3J(H,H)=7.5 Hz, 2H, ArH), 
7.31 (d,  3J(H,H)=8.4 Hz, 2H, ArH), 7.27-7.09 (m, 11H, ArH), 5.95 (d, 3J(H,H)=5.6 
Hz, 1H, Os-ArH), 5.83 (d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 5.71 (d, 3J(H,H)=5.4 Hz, 
1H, Os-ArH), 5.64 (d, 3J(H,H)=5.4 Hz, 1H, Os-ArH), 4.20 (s, 1H, TsNCH), 3.85 
(d, 3J(H,H)=4.3 Hz, 1H, NCH), 2.27 (s, 3H CH3), 1.28 (d, 
3J(H,H)=6.8 Hz, 3H, 
CH(CH3)2), 1.18 (d, 
3J(H,H)=6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 MHz, 
DMSO): 𝛿=146.8, 144.9, 143.9, 131.3, 128.5, 128.2, 127.9, 127.1, 126.7, 126.5, 
126.9, 91.1, 82.7, 80.2, 76.8, 73.8, 71.4, 67.9, 40.6, 40.2, 40.1, 32.6, 23.7, 23.5, 
20.8. UV/Vis λmax 259, 412, 477 nm; HRMS (ESI): m/z calculated for 
C30H32BrN2O2OsS [M+H
+]: 755.0977; found: 755.0946. Elemental analysis: found 
(C30H31BrN2O2OsS): C 47.17 (47.80), H 4.10 (4.15), N 3.51 (3.72). 
                         




[Os(η6-p-cymene)((1R, 2R)-BrBsDPEN)] (RR-2). RR-2 was synthesized using 
the general synthesis method using (1R, 2R)-BrBsDPEN (RR-L1, 60 mg, 0.14 
mmol) to obtain dark orange solids. The product was recrystallized in 1:2 ratio of 
DCM:hexane (48 mg, 0.06 mmol, 53%). 1H NMR (500 MHz, d6-DMSO, 298 K, 
TMS): 𝛿=8.21 (d, 3J(H,H)=4.0 Hz, 1H, NH), 7.46 (d, 3J(H,H)=7.5 Hz, 2H, ArH), 
7.31 (d,  3J(H,H)=8.5 Hz, 2H, ArH), 7.27-7.11 (m, 11H, ArH), 5.95 (d, 3J(H,H)=5.7 
Hz, 1H, Os-ArH), 5.83 (d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 5.71 (d, 3J(H,H)=5.5 Hz, 
1H, Os-ArH), 5.64 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 4.20 (s, 1H, TsNCH), 3.85 
(d, 3J(H,H)=4.4 Hz, 1H, CH), 2.27 (s, 3H CH3), 1.28 (d, 
3J(H,H)=6.9 Hz, 3H, 
CH(CH3)2), 1.18 (d, 
3J(H,H)=6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 MHz, 
DMSO): 𝛿=146.8, 144.8, 143.8, 131.3, 129.3, 128.5, 128.2, 127.9, 127.4, 127.1, 
126.9, 126.6, 91.1, 82.7, 80.2, 76.8, 73.8, 71.4, 40.6, 40.4, 40.3, 32.6, 23.7. 23.5, 
20.8. UV/Vis λmax 258, 412, 478 nm HRMS (ESI): m/z calculated for 
C30H32BrN2O2OsS [M+H
+]: 755.0977; found: 755.0969. Elemental analysis: found 
(calculated for C30H31BrN2O2OsS): C 48.48 (47.80), H 4.15 (4.15), N 4.04 (3.72).  
 
[Os(η6-p-cymene)((1S, 2S)-IBsDPEN)] (SS-3). SS-3 was synthesized using the 
general synthesis method using (1S, 2S)-IBsDPEN (SS-L2, 67 mg, 0.14 mmol) to 
obtain dark orange solids. The product was recrystallized in 1:2 ratio of 
DCM:hexane (47 mg, 0.06 mmol, 49%). 1H NMR (500 MHz, d6-DMSO, 298 K, 
TMS): 𝛿=8.19 (d, 3J(H,H)=4.1 Hz, 1H, NH), 7.49 (d, 3J(H,H)=8.4 Hz, 2H, ArH), 
7.46 (d,  3J(H,H)=7.7 Hz, 2H, ArH), 7.27-7.11 (m, 9H, ArH), 6.96 (d, 3J(H,H)=8.3 
Hz, 2H, ArH), 5.94 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 5.82 (d, 3J(H,H)=5.5 Hz, 1H, 
Os-ArH), 5.70 (d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 5.62 (d, 3J(H,H)=5.6 Hz, 1H, Os-
ArH), 4.19 (s, 1H, TsNCH), 3.84 (d, 3J(H,H)=4.4 Hz, 1H, CH), 2.27 (s, 3H CH3), 




1.27 (d, 3J(H,H)=6.9 Hz, 3H, CH(CH3)2), 1.18 (d, 
3J(H,H) = 6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 MHz, DMSO): 𝛿=146.9, 144.9, 144.2, 137.2, 128.3, 128.2, 127.9, 
127.4, 127.1, 126.9, 126.6, 98.3, 91.1, 82.7, 80.2, 76.8, 73.8, 71.4, 67.2, 40.6, 40.4, 
40.2, 40.1, 32.6, 31.2, 23.7, 23.5, 20.7. UV/Vis λmax 272, 412, 479 nm; HRMS 
(ESI): m/z calculated for C30H32IN2O2OsS [M+H
+]: 803.0839; found: 803.0832. 
Elemental analysis: found (calculated for C30H31N2IO2OsS): C 45.14 (45.00), H 
3.84 (3.90), N 3.60 (3.50). 
                                
[Os(η6-p-cymene)((1R, 2R)-IBsDPEN)] (RR-3). RR-3 was synthesized using the 
general synthesis method using (1R, 2R)-IBsDPEN (RR-L2, 68 mg, 0.14 mmol) to 
obtain a bright orange solid. The product was recrystallized in 1:2 ratio of 
DCM:hexane (68 mg, 0.08 mmol, 71%). 1H NMR (500 MHz, d6-DMSO, 298 K, 
TMS): 𝛿=8.20 (d, 3J(H,H)=4.0 Hz, 1H, NH), 7.49 (d, 3J(H,H)=8.4 Hz, 2H, ArH), 
7.46 (d,  3J(H,H)=7.8 Hz, 2H, ArH), 7.27-7.11 (m, 9H, ArH), 6.96 (d, 3J(H,H)=8.3 
Hz, 2H, ArH), 5.94 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 5.82 (d, 3J(H,H)=5.5 Hz, 1H, 
Os-ArH), 5.70 (d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 5.62 (d, 3J(H,H)=5.6 Hz, 1H, Os-
ArH), 4.19 (s, 1H, TsNCH), 3.84 (d, 3J(H,H)=4.4 Hz, 1H, CH), 2.27 (s, 3H CH3), 
1.27 (d, 3J(H,H)=6.9 Hz, 3H, CH(CH3)2), 1.18 (d, 
3J(H,H)=6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 MHz, DMSO): 𝛿=146.9, 144.9, 144.3, 137.2, 129.3, 128.3, 128.2, 
127.9, 127.4, 127.1, 126.9, 126.6, 98.3, 91.1, 82.7, 80.3, 76.8, 73.8, 71.4, 67.2, 40.6, 
40.4, 40.2, 40.1, 32.6, 31.2, 23.7, 23.5, 20.8.  UV/Vis λmax 271, 412, 479 nm; HRMS 
(ESI): m/z calculated for C30H32IN2O2OsS [M+H
+]: 803.0839 ; found: 803.0845. 
Elemental analysis: found (calculated for C30H31N2IO2OsS): C 44.71 (45.00), H 
3.80 (3.90), N 3.49 (3.50). 
                    




[Os(η6-p-cymene)((1R, 2R)-MeOBsDPEN)] (RR-4). RR-4 was synthesized using 
the general synthesis method using (1R, 2R)-(MeO)BsDPEN (RR-L3, 0.054 g, 0.14 
mmol) to obtain a bright orange solid (0.043 g, 0.06 mmol, 93%).1H NMR (400 
MHz, d6-DMSO, 298 K, TMS): 𝛿=8.10 (s, 1H, NH), 7.47 (d, 3J(H,H)=7.4 Hz, 2H, 
ArH), 7.29-7.09 (m, 10H, ArH), 6.68 (d, 3J(H,H)=7.4 Hz, 2H, ArH), 5.89 (d, 
3J(H,H)=5.6 Hz, 1H, Os-ArH), 5.77 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 5.58 (d, 
3J(H,H)=5.2 Hz, 1H, Os-ArH), 5.49 (d, 3J(H,H)=5.2 Hz, 1H, Os-ArH), 4.26 (s, 1H, 
TsNCH), 3.86 (d, 3J(H,H)=4.3 Hz, 1H, CH), 3.76 (s, 3H OCH3), 2.21 (s, 3H CH3), 
1.26 (d, 3J(H,H)=6.7 Hz, 3H, CH(CH3)2), 1.16 (d, 
3J(H,H)=6.6 Hz, 3H, CH(CH3)2). 
𝛿=161.1, 147.3, 145.1, 137.2, 129.3, 128.6, 128.2, 127.8, 127.4, 127.2, 127.0, 
126.6, 126.5, 90.8, 82.6, 79.9, 76.7, 74.0, 71.4, 71.3, 67.0, 55.9, 40.6, 40.4, 40.3, 
32.6, 24.5, 23.8, 23.4, 20.47. UV/Vis λmax 275, 412, 478 nm; C31H35N2O3OsS 
[M+H+]: 707.1978; found: 707.1970. Elemental analysis: found (calculated for 
C31H34N2O3OsS): C 52.32 (52.83), H 4.86 (4.86), N 3.89 (3.97) 
                                
[Os(η6-p-cymene)((1S, 2S)-m-BrBsDPEN)] (SS-5). SS-5 was synthesized using 
the general synthesis method using (1S, 2S)-(m-Br)BsDPEN (SS-L4, 0.019 g, 0.05 
mmol) to obtain a bright orange solid (0.043 g, 0.06 mmol, 93%). A bright red oil 
was formed. The oil was dissolved in a minimum amount of DCM and hexane (10 
mL) was added. The resulting cloudy red solution was concentrated in vacuo to 
produce a light orange solid (0.017 g, 23 mg, 45%). 1H NMR (400 MHz, d6-DMSO, 
25 °C, TMS): 𝛿=8.29 (d, 3J(H,H)=3.8 Hz, 1H, NH), 7.55 (d, 3J(H,H)=8.5 Hz, 1H, 
ArH), 7.46 (d, 3J(H,H)=7.1 Hz, ArH), 7.40 (s, 1H, ArH), 7.31 (d, 3J(H,H)=8.0 Hz, 
2H, ArH), 7.24 (d, 3J(H,H)=7.4 Hz, 2H, ArH), 7.22-7.13 (m, 7H, ArH), 5.92 (d, 
3J(H,H)=5.7 Hz, 1H, Os-ArH), 5.80 (d, 3J(H,H)=5.7 Hz, 1H, Os-ArH), 5.67 (d, 
3J(H,H)=5.2 Hz, 1H, Os-ArH), 5.58 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 4.23 (s, 1H, 
TsNCH), 3.85 (d, 3J(H,H)=4.4 Hz, 1H, CH), 2.29 (s, 3H, CH(CH3)2), 2.27 (d, 
3J(H,H)=6.8 Hz, 3H, CH(CH3)2), 1.20 (d, 
3J(H,H)=6.8 Hz, 3H, CH3). 
13C NMR 
(125 MHz, d6-DMSO): 𝛿=146.8, 146.7, 144.8, 133.8, 130.7, 129.3, 129.1, 128.3, 
128.0, 127.3, 126.7, 126.6, 125.6, 121.7, 91.1, 82.8, 80.3, 77.0, 73.6, 71.5, 71.1, 
67.6, 40.6, 40.5, 40.4, 33.5, 32.6, 24.5, 23.7, 23.6, 21.0, 20.8. UV/Vis λmax 272, 412, 
480 nm; C30H31BrN2O2OsS [M+H
+]: 755.0977; found: 755.0956. C 48.05 (47.80), 
H 3.56 (4.15), N 3.58 (3.72). 




3.2.3    X-ray Crystal Structures 
 
Complexes SS-2 (R=p-Br) and SS-3 (R=p-I) were recrystallized in a minimum 
amount of DCM (4-5 drops) and hexane (9-10 drops) at room temperature over 24 
h. X-ray crystal structures were obtained as described in Chapter 2 (Section 2.3.5). 
 
3.2.4    Density Functional Theory  
 
Density functional theory (DFT) calculations were carried out by Dr James P. C. 
Coverdale (University of Warwick) using Gaussian 03W software. Geometry 
optimization (lowest energy conformation) was calculated in the gas-phase using 
hybrid PBE0 (Perdew-Burke-Ernzerhof functional) with a combination of 75% 
DFT (Density functional theory) and 25% (Hartree Fock) computational methods. 
The Lan12DZ basis set including the effective core potential was used for Os and 
6-31+G** basis set for all non-metal elements. Structures were optimized based on 
the x-ray crystallographic data for RR-1 (p-CH3) and were altered appropriately 
using GaussView 3.0. EPS (electrostatic potential surfaces) were mapped to 
represent the electron density (isovalue=0.04), ranging from red to blue (-0.025 to 
+0.250 au). 
 
3.2.5    Solution stability studies  
 
Prior to commencement of biological studies (for which osmium complexes are 
prepared in 5% v/v DMSO, 95% v/v DMEM), complexes must be stable in DMSO 
for 24 h. The stabilities of complexes 2-5 in d6-DMSO were monitored over 24 h 
using 1H NMR (400 MHz, d6-DMSO) and UV-Vis spectroscopy (λ=200-800 nm) 
over 24 h. The 24 h solubility and stability of 2-5 in 5% v/v DMSO: 95% v/v PBS 
(physiological conditions) were also determined by UV-Vis spectroscopy (λ=200-
800 nm). 
 










[Os in water before] − [Os in water after]
[Os in water after]
 
Equation 3.1. Determation of the partition coefficient (LogP) as the ratio of concentrations 
of osmium complexes in octanol and water using ICP-MS under nitric acid conditions 
 
Octanol-saturated water (OSW) and water-saturated octanol (WSO) solutions were 
prepared by mixing equivalent volumes of octanol and milliQ water for 24 h. The 
aqueous and organic phases were extracted. Osmium complex (~3-4 mg) was 
dissolved in OSW (10 mL) in duplicate, shaken and sonicated (until the solution 
was fully saturated) and syringe-filtered (0.2 μm) to remove excess solid. From the 
filtered solution, 2 mL was mixed in triplicate with WSO (2 mL) and shaken (24 
h). The remaining filtered solution was analysed by ICP-MS (1:10 dilution) in 3.6% 
v/v stabilised nitric acid (Chapter 2, Section 2.3.3) to calculate the ‘before’ 
concentration. After 24 h, the OSW bottom (water) layer was extracted using a 2 
mL syringe. The resulting samples were diluted in 3.6% v/v stabilized nitric acid 
and analysed by ICP-MS. From ICP-MS, the quantity of osmium in the OSW layer 
was obtained, which was used to back-calculate the concentration of osmium in the 
octanol (WSO) layer, and thus, the LogP (according to Equation 3.1). 
 




Scheme 3.4. Enantioselective reduction of acetophenone to (S) or (R)-1-phenylethanol in 
the presence of osmium catalyst ([Os]=2-5), 5:2 formic acid/trimethylamine azeotrope 
(TEA/FA) and d6-benzene  monitored at 310 K by 1H NMR and chiral GC-FID. 
  




Catalytic reduction of acetophenone by 1H NMR 
Osmium catalyst (5 μmol, 0.5% mol eq.) was weighed into a small glass vial and 
dissolved in d6-benzene (100 µL) and 5:2 formic acid/triethylamine azeotrope (500 
µL) under nitrogen at 310 K. The mixture was stirred for 30 min. Acetophenone (1 
mmol, 200 mol eq.) was added and the mixture transferred to a nitrogen-purged 5 
mm NMR tube. 1H NMR spectra were collected every 2 min over 1 h at 310 K and 
the experiment was performed in triplicate. 1H NMR spectra were also acquired 
every 10 min over a 15 h period. The catalytic conversion of aceotphenone to 1-
phenylethanol was determined by monitoring the decrease in the integral for the 
acetophenone singlet (3H, 2.10 ppm) and the increase in the 1-phenylethanol 
quartet (4.75 ppm, 1H).  
 
Catalytic reduction of acetophenone by GC 
Formic acid: triethylamine 5:2 azeotrope (500 µL) was added to a round-bottom 
flask containing osmium catalyst (5 µmol, 1 eq.) under nitrogen and acetophenone 
(1 mmol, 0.17 mL, 200 eq.) was added and stirred at 310 K for 24 h. From the 
resulting solution, 2-3 drops were placed in 1:1 ethyl acetate/sodium bicarbonate (2 
mL). The organic ethyl acetate layer was extracted and filtered through a silica 
micro-pipette column. The samples were then analysed by chiral GC-FID to 
determine enantiomeric excesses and conversions. Chiral GC measurements were 
carried out by Jonathan Barrios-Rivera and Sam Forshaw (University of Warwick) 
on a Hewlett-Packard 5890 instrument linked to PC running DataApex Clarity 
software. Measurements were obtained using a CROMPAC CYCLODEXTRIN-β-
236M-19, 50 m×0.25 mm×0.25 μm, carrier gas=H2, T=383 K, pressure=15 psi, FID 
temperature=523 K, injection temperature=493 K. Data were analysed on Windows 
Clarity Chromatography Suite. 
 
  




3.2.8    Antiproliferative activity (IC50) 
 
IC50 determination  
Half-maximal inhibitory concentrations (IC50 / µM) of 2-5 were determined using 
the protocol described in Chapter 2 (Section 2.5.1) against A2780 (ovarian 
carcinoma), A549 (lung adenocarcinoma), PC3 (prostate adenocarcinoma) and 
MCF7 (breast adenocarcinoma) cancer cells and MRC5 healthy lung fibroblasts. 
 
Formate and acetate-dependent inhibition of cell proliferation 
The affect of formate and acetate on the cell viability upon co-administration with 
SS-2 and RR-2 was determined in A549 (lung) cancer cells using the general SRB 
protocol but co-administering a fixed concentration of osmium complex (0.5 or 
1.0×IC50) alongside variable concentrations of sodium formate or acetate (0-2 mM). 
 
3.2.9    Flow cytometry studies  
 
Membrane integrity 
Flow cytometry measurments were conducted by Dr Hannah Bridgewater from the 
School of Life Sciences (University of Warwick). A suspension of 1×106 A549 
cells were seeded in a 6-well plate (2 mL/well) for 24 h (310 K, 5% CO2). The 
supernatant medium was removed and cells were treated with 1×IC50 (30 µM) of 
SS-2 and sodium formate (0-2 mM) for 24 h (310 K, 5% CO2). The supernatant was 
removed, cells washed with PBS and 0.25% trypsin/EDTA (1 mL) was added to 
detach cells from the surface. The cell suspensions were centrifuged (1500 rpm, 5 
min, 298 K), the pellets collected, washed with PBS and re-suspended in a staining 
buffer containing 80 μg/mL RNAse and 50 μg/mL propidium iodide (500 μL) for 
30 min, under dark conditions. The cells were centrifuged (1500 rpm, 5 min, 298 
K) and the supernatant removed, before being re-suspended in PBS for analysis by 
flow cytometry on the BD LSRII flow cytometer with BD FACSDIVA V8.01 for 
Windows and processed using FlowJo V10. 




Cell cycle analysis  
Cell pellets treated with 1×IC50 (30 μM) of SS-2 were obtained as described in the 
membrane integrity section. The pellets were washed in PBS before re-suspending 
in ice-cold ethanol (fixation) for 30 min. The supernatant ethanol was removed and 
cells washed with PBS. The cells were then treated with 500 µL of staining buffer 
(as described for membrane integrity analysis) for 30 min. Cells were pelleted by 
centrifugation (1500 rpm, 5 min, 298 K), the supernatant removed, before being re-
suspended in PBS for analysis by flow cytometry. 
 
3.2.10  Zebrafish toxicity studies  
 
The University of Warwick is a member of the Laboratory Animal Science 
Association and the Institute of Animal Technology.14 All in vivo animal work was 
approved by the University Ethical Review Committee.14 Zebrafish experiments 
were carried out at the School of Life Sciences (University of Warwick) under 
project AWERB.10/16-17, in collaboration with Dr. Karuna Sampath (Warwick 
Medical School).14  
Experiments were carried out by Dr James P. C. Coverdale (University of 
Warwick). 12-well plates were seeded with a minimum of one Singapore wild-type 
(SG-WT) zebrafish embryo per well. Embryos were treated with different 
concentrations of SS-2 or RR-2 (0.01, 0.1, 1, 10 and 50 μM) and incubated at 301.5 
K for 96 h. The mortality of the embryos was categorized as non-viable upon 
fulfilment of any of the following: (a) tail detachment from body, (b) somite 
formation, (c) coagulation of embryo and (d) heartbeat.14 Sigmoidal dose-response 
curves were plotted by taking the logarithm of osmium complex concentration 









3.2.11    189Os ICP-MS cellular accumulation studies 
 
Osmium (189Os) ICP-MS cellular accumulation studies of SS-2 and RR-2 were 
conducted in A2780 (ovarian) and A549 (lung) cancer cells by varying conditions 
using the general cellular ICP-MS accumulation method. 
 
General ICP-MS cellular accumulation method 
Cellular accumulation studies were performed based on a previously reported 
method.17 A single cell suspension was obtained as previously described (Section 
2.5.1). Briefly, 4×106 cells were seeded into a 100 cm2 cell culture petri dish in 10 
mL of media for 24 h (310 K, 5% CO2). Cells were treated with specific 
concentrations of ICP-OES corrected test compounds under various conditions. The 
cells were then washed with PBS, detached with 0.25% trypsin/EDTA and 
quenched with a known volume of DMEM. Cells were counted in duplicate (using 
a haemocytometer) before centrifugation (5 min, 1000 rpm, 298 K) to obtain cell 
pellets. The supernatant was removed, and the cell pellets re-suspended in PBS (1 
mL) before further centrifugation (5 min, 1200 rpm). The supernatant was removed 
and the pellets and stored at 253 K before ICP-MS analysis. Cell pellets were 
digested using the ICP-MS acid digestion method (Chapter 2, Section 2.5.2). 
Variations in cellular accumulation have been specified: 
 
(i) Concentration:  Treated with 0.25, 0.5, 1, 1.5×IC50 (μM) for 24 h, (no 
recovery period; 310 K, 5% CO2) 
(ii) Time: Treated with 1×IC50 (μM) for 3, 6, 18 h, 24 h (no recovery in 
complex-free media) and 24 h exposure with 24, 48 and 72 h recovery 
in complex-free media (310 K, 5% CO2). 
(iii) Temperature: Treated with 1×IC50 (μM) for 3 or 6 h at 310 or 277 K 
(no recovery in complex-free media).  
(iv) Formate: Treated with 1×IC50 and co-administered with 0-2 mM 
sodium formate for 24 h (310 K, 5% CO2), with no recovery in complex-
free media. 
 




3.2.12    189Os and 79Br ICP-MS cellular accumulation studies 
 
Cell accumulation studies of SS-2 (R=p-Br) were conducted in A549 cells under 
varying conditions using the general ICP-MS cellular accumulation method. In 
these experiments, 4×106 cells per 20 mL were seeded in 145 mm cell culture petri 
dishes for 24 h (310 K, 5% CO2). Prior to centrifugation, the cell suspensions from 
two petri dishes were combined to form larger pellets, so as to ensure reliable 
detection of bromine (79Br) by ICP-MS. All cell pellets were analysed by ICP-MS 
using the alkaline digestion method (Chapter 2, Section 2.5.3). Variations in 
cellular accumulation have been specified: 
 
(i) Time: Treated with 1×IC50 of SS-2 (30 µM) for 3, 6, 18 h, 24 h (no 
recovery in complex-free media) and 24 h exposure with 24, 48 and 72 
h recovery in complex-free media (310 K, 5% CO2). 
(ii) Temperature: Treated with 1×IC50 SS-2 (30 µM) for 3 or 6 h at 310 or 
277 K (no recovery in complex-free media).  
(iii) Inhibition of caveolae endocytosis: The inhibition of caveolae 
endocytosis was investigated using methyl-β-cyclodextrin, a known 
endocytotic inhibitor.17 Cells were treated with with 1×IC50 SS-2 (30 
µM) and co-administered with 0.1-1 mM methyl-β-cyclodextrin 
(DMEM). 
(iv) Inhibition of efflux: The inhibition of efflux was investigated by 
recovering treated cells in verapamil – a known P-glycoprotein (PGP) 
inhibitor.17 Cells were treated with 1×IC50 SS-2 (30 µM) for 24 h, 
washed with PBS and allowed to recover in 20 µM of verapamil 
hydrochloride (5% v/v DMSO, 95% v/v DMEM) for 24, 48 and 72 h. 
(v) Cell fractionation: The cellular distribution of 189Os and 79Br was 
investigated using a FractionPREP BioVision Cell Fractionation Kit 
using 2× the volumes specified by the manufacturers (to account for 
larger cell pellet size). Cells were treated with 1×IC50 of SS-2 (30 µM) 
for 3, 6 and 24 h (no recovery) and 24 h exposure with 24, 48 and 72 h 
recovery in complex-free media.  




3.2.13    Synchrotron-XRF  
 
Preparation of Tris-glucose buffer. Tris-glucose buffer was prepared by mixing 
D-glucose (11.756 g, 0.065 mol), tris(hydroxymethyl)aminomethane (0.307 g, 2.53 
mmol), 9 mM acetic acid (12.9 mL) and made up to 250 mL in milliQ water 
(pH=7.42). The buffer was sterile-filtered using a 500 mL Millipore Stericup filter 
unit (Durapore PVDF membrane, low protein-binding, pore size 0.22 µm). 
 
Preparation of A549 cells on Si3N4 membranes. Si3N4 membranes were prepared 
using the general protocol described in Chapter 2 (Section 2.6.1), using a seeding 
density of 6×104 cells/mL of A549 cells. Cells were treated with 1, 3 and 5×IC50 of 
SS-2 (30, 90 or 150 µM, respectively) for 24 h (no recovery). Prior to blotting and 
plunge-freezing, cells were washed with tris-glucose buffer (2×3 mL). 
 
Beamline settings and data analysis. XRF maps were acquired using an incident 
energy of 15 keV, step size=100 nm, 0.1 s exposure and a beam size of 50×70 nm2 
(Chapter 2, Section 2.4.1). Data were fitted in PyMCA and analysed in ImageJ 
(Chapter 2, Section 2.6.1).18, 19 
 
 
3.2.14    Chloroquine inhibition of lysosomal activity 
 
Chloroquine-dependent IC50. Chloroquine toxicity was determined in A549 cells 
using the general SRB protocol (Chapter 2, Section 2.5.1). Cells were treated with 
chloroquine diphosphate (0-150 µM in DMEM) for variable exposure times, 
followed by fixing with TCA and continuation of the SRB assay (Chapter 2, 
Section 2.5.1). The chloroquine-dependent IC50 concentrations of RR-1 (R=p-CH3) 
and SS-2 (R=p-Br) were determined in A549 cancer cells using the general SRB 
protocol (Chapter 2, Section 2.5.1). Prior to treatment with RR-1 or SS-2, cells 
were pre-incubated chloroquine diphosphate (150 µM in DMEM) for 2 h. The 
chloroquine supernatant was removed, cells washed with PBS, and then treated with 
RR-1 or SS-2 (0.1-150 µM).                                                                       . 




Chloroquine-dependent 189Os cellular accumulation. The chloroquine-
dependent cellular accumulation of osmium was determined for A549 cells 
following the general accumulation protocol (Chapter 2, Section 2.5.2). Cells were 
pre-incubated with 150 µM chloroquine disphosphate (DMEM) for 2 h, washed 
with PBS and treated with 1×IC50 of RR-1 (21 µM) or SS-2 (30 µM) for 24 h (no 
recovery). Theis experiment was performed in duplicate for SS-2 to allow analysis 
by both the acid and alkaline digestion methods specified in Chapter 2 (Section 
2.5.3)..  
 
Chloroquine-dependent membrane integrity. The chloroquine-dependent effect 
on membrane integrity was investigated using the same membrane integrity 
protocol described in this chapter (Section 3.2.9). Cells were pre-incubated with 
150 µM chloroquine disphosphate (DMEM) for 2 h, washed with PBS and treated 









3.3     Results 
3.3.1    Synthesis and characterisation 
 
All ligands and complexes were characterised by 1H NMR, 13C NMR, HR-MS and 
elemental (CHN) analysis. A total of six BsDPEN ligands (L1-L4, including 
enantiomers) were synthesized from the reaction between (1R, 2R) or (1S, 2S)-
diphenylethylene diamine (DPEN) with different benzene sulfonyl chlorides from 
a method reported in the literature.20 Ligands L1-L4 were recrystallized from hot 
ethyl acetate, and cooled to 253 K to produce white solids. From these ligands, six 
OsII[(p-cym)BsDPEN] complexes (2-5, including enantiomers) were synthesized 
by reacting [Os(p-cym)Cl2]2 dimer with L1-L4 (BsDPEN ligands) in the presence 
of a base (potassium hydroxide) following a method reported in the literature.1                                                                                
Single crystals for SS-2 (R=p-Br) and SS-3 (R=p-I) were obtained by dissolving 
ca. 5 mg in a minimum amount of DCM (4-5 drops) and hexane (7-10 drops). 
Crystallographic data were obtained by Dr. Guy Clarkson (University of Warwick) 
using the methods and instrumentation described in Chapter 2 (Section 2.3.5). The 
crystal structures of SS-2 and SS-3 were closely comparable to that of parent 
compound SS-1 (R=p-CH3) – all with (1S, 2S) chiral centres, with orthorhombic 
space groups P212121 (Fig. 3.4; Appendix, Table A6).  
 
 
Figure 3.4. ORTEP x-ray crystal structures of osmium sulfonamide complexes showing 
carbon (■), nitrogen (■), oxygen (■), sulfur (■), osmium (■), bromine (■) and iodine (■) 
for (a) SS-2 (p-Br); (b) SS-3 (p-I), as viewed in Mercury 3.3 software. Thermal ellipisoids 
(atomic displacement parameters) are presented at 50% probability level.  




3.3.2    Density Functional Theory (DFT) 
 
Density Functional Theory (DFT) is a valuable tool in bioinorganic chemisty which 
can be used to model the structure and properties of complexes by providing a 
solution approximation obtained from the electron-density.21 Calculated Cartesian 
coordinates and electrostatic potential surfaces (EPS) for RR-2 (p-Br), RR-3 (p-I) 
and previously reported complex RR-6 (p-F) were calculated at the 
PBE0/Lanl2DZ/6-31+G** level (which is commonly used for organometallic 
compounds) with the EPS shown mapped onto total electron density (Appendix, 
Tables A7-10). The Mulliken partial charges calculated for complexes RR-6 (p-F), 
theoretical compound (p-Cl), RR-2 (p-Br) and RR-3 (p-I), at the 
PBE0/Lanl2DZ/6-31+G** level of theory were determined (Appendix, Fig. A1, 
Table A7). The electrostatic potential correlated with the electronegativity of the 
halide series: F>Cl>Br> I (Fig. 3.5).  
     
  
Figure 3.5. Calculated electrostatic potential energy surfaces for complexes RR-6 (X=F), 
theoretical compound (X=Cl), RR-2 (X=Br) and RR-3 (X=I), at the PBE0/Lanl2DZ/6-
31+G** level of theory. EPS shown mapped onto total electron density. Isovalue = 0.04. 
(R,R)-catalyst only. Surface mapping colours range from red (-0.025 au) to blue (+0.30 au). 
 
The x-ray crystal structures of SS-2 (R=p-Br) and SS-3 (R=p-I; Appendix, Table 
A6) were closely comparable to the ground state structures calculated by DFT 
(Appendix, Table A9-10). Halide-substitution (X=Cl, Br, I) at the para-position of 
the sulfonamide group resulted in localized charge effects, as previously reported 
for RR-6 (X=p-F).2 The charge at the osmium centre, the aromatic p-cymene ring 
and the nitrogen atoms of the sulfonamide ligand closely resembled that of parent 
compound RR-1 (R=p-CH3).
2   
 




3.3.3    Aqueous stability and solubility 
 
In order to probe the aqueous stability of complexes 2-5, solutions in PBS were 
monitored using UV-Vis spectroscopy over a 24 h period (310 K). The hydrophobic 
nature of 2-5 limits their solubility in aqueous media, thus a more hydrophobic 
solubilizing agent is required. Conventionally, aqueous solution stability by 
UV/Vis for organometallic half-sandwich complexes utilizes a mixture of methanol 
and water, however, the methanol poses two major issues. Firstly, methanol can act 
as a hydride source22 – affecting the catalytic nature of these complexes, and 
secondly, methanol is toxic to biological cells, so cannot be used as a solubilising 
agent for in vitro antiproliferative assays. As an alternative, complexes 2-5 were 
tested for their solubility and stability in DMSO over 24 h using 1H NMR revealing 
no spectral changes, indicative of high stability in all cases. This also suggests that 
DMSO is likely not coordinating to the vacant site on the osmium complex (i.e. 
forming a DMSO-complex adduct), or that adduct formation is immediate, hence, 
is represented in the initial 1H NMR spectra (t=0 h). 
The aqueous stability was investigated in 5% v/v DMSO and 95% PBS by UV-Vis 
spectroscopy over 24 h – revealing no changes in the absorption spectum. 
Importantly, both the 1H NMR and the UV-Vis spectra show that 2-5 were soluble 
and stable enough in aqueous media, hence suitable for in vitro biological studies. 
A balance between lipophilicity and hydrophilicity is essential for the 
bioavailability and targeting of drugs. Drugs have to be stable enough to pass 
through a variety of biological barriers (i.e. phospholipid membrane bilayers) or 
enter the cells using pathways such as passive diffusion.23 The hydrophobic nature 
of a test compound can influence the cellular influx and efflux pathways, i.e. 
whether the compound enters the cell via active transport (e.g. endocytosis) or 
passive diffusion (e.g. ion channels). For example, cisplatin enters cancer cells 
through CTR1 copper transporters, in addition to passive diffusion through cell 
membranes.24 Importantly, one major factor enhancing platinum-resistance is 
reduced drug uptake,25 thus, novel drugs with alternative uptake mechanisms may 
be essential to overcome this resistance. 




The partition coefficient (LogP) is a measure of the hydrophobic nature of a 
compound and is determined by its preferential solubility in octanol or water, as 
defined by Equation 3.1 (Section 3.2.6). The larger the LogP value, the more 
hydrophobic the complex. In the 1990s, Lipinski and co-workers postulated a set of 
five rules for which suitable drug candidates should adhere,26 one in particular states 
that the partition coefficient (LogP) must not exceed the value 5. The higher the 
LogP value (LogP>0) the more hydrophobic the compound; the lower the value 
(LogP<0) the more hydrophilic. The LogP values were determined for complexes 
2-5 and compared to that of RR-1 (p-CH3), RR-6 (p-F) and cisplatin (Table 3.1.).  
 
Table 3.1. Octanol-water partition coefficients (LogP) for complexes 1-6, and cisplatin. 
[a]Literature Log P value of RR-1 and RR-6.10 [b] Literature Log P value of cisplatin.27 
 
The LogP values of 2-5 were found to range between 1.01-1.11 implying moderate 
hydrophobicity. Substitution of larger, electron-withdrawing groups (R=p-Br or p-
I; 2 or 3) decreased the hydrophobicity compared to parent compound RR-1 (R=p-
CH3). Interestingly, RR-6 (R=p-F) was significantly less hydrophobic 
(LogP=0.30±0.03) compared to the latter halide-substituents. Substitution of the 
para-methyl group with a methoxy group (RR-1 vs. RR-4) also decreased the 
hydrophobicity, but to a lesser extent. A comparison of complexes 2 (R=p-Br) and 
5 (R=m-Br) revealed no differences in LogP. Likewise, the LogP values for 
enantiomers (SS/RR-2; SS/RR-3) were the same. Complexes 1-6 were all 
significantly more hydrophobic (higher LogP) compared to cisplatin (-2.21±0.06).27  
Complex Metal X LogP 
RR-1 Os p-Me 1.45±0.02[a] 
SS-2 Os p-Br 1.01±0.01 
RR-2 Os p-Br 1.02±0.02 
SS-3 Os p-I 1.02±0.03 
RR-3 Os p-I 1.01±0.01 
RR-4 Os p-OMe 1.11±0.01 
SS-5 Os m-Br 1.04±0.02  
RR-6 Os p-F 0.30±0.03[a] 
Cisplatin  Pt - -2.21±0.06[b] 




3.3.4    Asymmetric Tranfer Hydrogenation (ATH) Catalysis 
 
The ability of complexes 2-5 to catalyse the conversion of acetophenone – an 
important industrial substrate – to (S) or (R)-1-phenylethanol enantioselectively in 
the presence of formic acid (which acts as a hydride source for catalysis) was 
determined by both 1H NMR and GC-FID. The catalytic rection was monitored 
kinetically by 1H NMR using d6-benzene as the NMR lock solvent. The catalytic 
turnover (h-1) was determined from 1H NMR spectra by monitoring the decrease of 
the singlet of acetophenone (2.10 ppm) and the formation of the quartet of 1-
phenylethanol (4.75 ppm). As acetophenone is prochiral, the chirality of 1-
phenylethanol was determined by gas chromatography (GC) against known 
retention times of the (S) or (R) alcohol products. Complexes 2-5 all achieved high 
catalytic conversions (>95%) and enantiomeric excesses (>93%) and exhibited 
maximal turnover frequencies of greater than 76 h-1 (Appendix, Fig. A2) – 
significantly higher than that of parent compound RR-1 (Table 3.2).1 No statistical 
differences in turnover frequency of enantiomers SS/RR-2 (p-Br) or SS/RR-3 (p-I) 
were observed (Table 3.2). Bromine-substitution at the meta-position (SS-5) did 
not significantly alter the observed catalytic activity (compared to SS-2; para-Br). 
 
Table 3.2.  Catalytic conversion (%), enantiomeric excesses (%) and turnover frequencies 
(h-1) for the reduction of acetophenone to form (S) or (R)-1-phenylethanol for complexes 
2-5 in the presence of 5:2 formic acid/TEA azeotrope for 24 h at 310 K as determined by 
1H NMR and chiral GC.  
[a] Determined by chiral GC (24 h, 310 K). [b] Determined by 1H NMR spectra (1 h, 310 K). [c] 
Literature value. 
 




Enantiomer[a] TOF (h-1)[b] 
RR-1[c] p-CH3 99 99 R 63.6±0.6 
SS-2 p-Br 98  98 S 81±5 
RR-2 p-Br 99 97 R 81±2 
SS-3 p-I 96 94 S 88±5 
RR-3 p-I 97 95 R 85±5 
RR-4 p-O CH3 97 94 R 76±4 
SS-5 m-Br 98 98 S 79±4 




3.3.5    Antiproliferative activity (IC50) 
 
The antiproliferative activities (IC50 / µM) of 2-5 were determined in A2780 
(ovarian), A549 (lung), PC3 (prostate) and MCF7 (breast) cancer cells, and MRC5 
healthy (lung) fibroblasts upon 24 h exposure and 72 h recovery in complex-free 
media (Table 3.3). Biological studies were initially carried out in A2780 cells so as 
to compare directly to the parent compound RR-1 (p-CH3),
10 and then in A549 cells 
due to their large cell surface area,28, 29 making them an attractive cell line for 2D 
synchrotron-XRF imaging.30-32 
Complexes with para halido substitutents (2/3; where R=p-Br /I) were consistently 
less potent than parent compound RR-1 (ca. 2-fold), but, nonetheless, of the same 
order of magnitude. No statistically significant differences were observed between 
the antiproliferative activities of complexes 2/3. Interestingly, methoxy-substitution 
at the para-position (4) significantly enhanced the anticancer potency in A2780 
cells, compared to RR-1, but was less potent in A549 lung cancer cells (Table 3.3). 
Bromine-substitution at the meta-position (5) did not significantly alter the 
antiproliferative activity when compared to substitution at the para-position 
(SS/RR-2). Overall, the IC50 of halide-subtituted complexes (2, 3 and 5) were not 
statistically different when comparing to the same cell line. Complexes SS/RR-2 
exhibited poor selectivity for A549 (lung cancer) cells over MRC5 (healthy lung) 
fibroblasts (Table 3.3) – with comparable antiproliferative activities in both cell 
lines – closely resembling that reported for RR-1.10 
 
Table 3.3. Half-maximal inhibitory concentrations (IC50 / µM) of 1-5 and cisplatin against 
A2780 (ovarian), A549 (lung), PC3 (prostate) and MCF7 (breast) cancer cells and MRC5 
healthy lung fibroblasts upon 24 h exposure, 72 h recovery (complex-free media). 
Complex R A2780 A549 PC3 MCF7 MRC5 
RR-1[a] p-CH3 15.5±0.5 21.1±0.3 12±0.3 10.9±0.7 21.4±0.7 
SS-2 p-Br 31±2 31±1 41±2 32±1 37.8±0.7 
RR-2 p-Br 27.4±0.6 29.5±0.5 38.9±4.3 26.3±4.6 37±1 
SS-3 p-I 27.5±0.8 33±0.4 37±2 28±3 - 
RR-3 p-I 29±3 32±0.4 39.5±0.6 22.7±5.6 - 
RR-4 p-OCH3 7.3±0.3 33±3 - - - 
SS-5 m-Br 27±2 32±2 - - - 
Cisplatin - 1.2±0.3 3.2±0.1 4.1 ± 0.5 6.6 ± 0.4 12.8 ± 0.5 
[a] Literature IC50 values of RR-1 and cisplatin using the specified conditions.2 Note that all 
precursor BsDPEN ligands were dermined to be non-toxic (IC50> 100 µM), thus, are not displayed. 




3.3.6    In-cell catalysis 
 
It has previously been reported that the antiproliferative activity of parent 
compound RR-1 (R=p-CH3) in A2780 and PC3 cancer cells can be enhanced upon 
co-administration with non-toxic concentrations of sodium formate – which acts as 
a hydride source.10 Sodium formate has been reported to be non-toxic to cells up to 
2 mM,10, 11 thus can be utilized as a biologically-compatible hydride source. Herein, 
the formate-dependent antiproliferative activities have been determined for A549 
cells. Cells were treated with 0.5-1.0×IC50 concentrations of SS-2 (29.5±0.5 μM) 
or RR-2 (31±1 μM) with varying concentrations of sodium formate or acetate (0-2 
mM) for 24 h. The normalized cell proliferation of cells treated with SS-2 or RR-2 
reduced with formate concentration, achieving a maximal decrease of 67-77% (SS-
2, p<0.001) and 71-72% (RR-2, p<0.001), for cells treated with 0.5 or 1.0×IC50 
upon co-administration with 2 mM formate (Fig. 3.6). This closely correlates with 
the 80-83% decrease in cell viability for RR-1 (p-CH3) under the same conditions,
10 
suggesting a similar formate-dependent mechanism of action for SS-2 or RR-2 
inside cancer cells. No changes in cell viability were observed in the presence 




Normalised cell viability (%) 
 
 SS-2 RR-2 
[Formate] / mM 0.5×IC50 1.0×IC50 0.5×IC50 1.0×IC50 
0.0 100±3 100±7 100±2 100±4 
0.5 60±12  42±8  57±7  46±4  
1.0 36±8  20±3  38±8  34±7  
2.0 33±3  23±5  29±11  28±4  
 
Figure 3.6. Normalized cell proliferation (%) of A549 (lung) cancer cells treated with 0.5-
1.0×IC50 of SS-2 and RR-2 in A549 cancer cells upon co-administeration with sodium 
formate (0-2 mM) for 24 h, followed by 72 h recovery in complex-free media. 






Figure 3.7. Normalized cell proliferation (%) of A549 cancer cells treated with 0.5-
1.0×IC50  of SS/RR-2 upon co-administration with acetate (0-2 mM) for 24 h, followed by 
72 h recovery in complex-free media. 
 
The formate and acetate-dependent antiproliferative activity in MRC5 fibroblasts 
was assessed upon treatment with 0.5×IC50  of SS/RR-2 with sodium formate and 
acetate (0-2 mM) for 24 h (Fig. 3.8). No statistical differences in cell proliferation 
were observed upon co-administration with sodium formate or acetate.  
 
 Normalized cell viability (%) 
  SS-2 (0.5×IC50) RR-2 (0.5×IC50) 
mM Acetate Formate Acetate Formate 
0.0 100±14 100±12 100±11 100±10 
0.5 97± 0  92±16  92±11  99±11  
1.0 101±10  100±11  98±8  103±8  
2.0 96±10  95±17  96±9  89±7  
 
Figure 3.8. Normalized cell proliferation (%) MRC5 healthy lung fibroblasts treated with 
0.5×IC50  of SS-2 or RR-2 upon co-administration with sodium acetate or formate (0-2 mM) 
for 24 h, followed by 72 h recovery in drug-free media. 
 Normalized cell cell viability (%) 
 SS-2 RR-2 
[Acetate] / mM 0.5×IC50 1.0×IC50 0.5×IC50 1.0×IC50 
0.0 100±6 100±7 100±2 100±4 
0.5 97±7  96±5 100±8 (P>0.05) 97±5  
1.0 102±4  97±5  97±6  100±7  
2.0 99±4  94±8  98±2 95±5  




3.3.7    Flow cytometry studies 
 
Flow cytometry is a cell analysis technique which can be used to rapidly analyse 
morphological properties of a population of cells (i.e. cell size, DNA content and 
granularity). Flow cytometry focusses a laser onto biological samples, resulting in 
characteristic light scattering, allowing the high-throughput processing of a large 
number of cells. In particular, fluorescent-labelling of cells is commonly used to 
monitor fluorescence emission by flow cytometry – i.e. DNA intercalators such as 
propidium iodide (PI). In this Chapter, flow cytometry has been used to investigate 
membrane or cell cycle damage induced by SS/RR-2 in the presence of non-toxic 
concentrations of sodium formate (0–2 mM). 
 
Membrane integrity 
The membrane integrity of A549 cells treated with 1×IC50 of SS/RR-2 for 24 h upon 
co-administration of non-toxic concentrations of sodium formate (0-2 mM) was 
investigated (Fig. 3.9; Appendix, Table A11). Cells were stained with PI without 
fixation and analysed using flow cytometry. PI is non-permeable to cell membranes, 
hence, damaged membranes would enhance the fluorescence of  PI by ca. 20 to 30-
fold upon intercalation with DNA.33 The resulting cells were categorized into viable 
(FL2-) and non-viable (FL2+) membrane populations using FlowJo V10 software. 
No significant differences in PI fluorescence of cells treated with SS/RR-2 were 
observed when compared to that of the untreated controls (p>0.05, Fig. 3.9), with 
normalized viable (non-compromised) cell membrane populations of 99.9±0.1 and 
99.5±0.1% for SS-2 and RR-2, respectively. Similarly, no differences in PI 
fluorescence was observed for cells treated with SS/RR-2 and co-administered with 
formate (99.8±0.2 and 99.4±0.03%, respectively). This data suggests the 
membranes of A549 cells are not compromised by SS-2 or RR-2 in the presence or 
absence of sodium formate, correlating with the lack of membrane damage 
observed for parent compound RR-1 (R=p-CH3) under the same conditions.
10 





Figure 3.9. Membrane integrity assessed by PI (FL2) staining of A549 cancer cells treated 
with SS-2 (1×IC50) for 24 h (310 K, 5% CO2) upon co-administration with sodium formate 
(0-2 mM). (a) untreated control (■), SS-2 (■) and SS-2 + 2 mM sodium formate (■); (b) 
Overlay of propidium idodide fluorescence with gated bars indicating viable (FL2-) and 
non-viable membranes (FL2+). 
 
 
Cell cycle analysis 
Cell cycle analysis of A549 cells treated with 1×IC50 SS-2 or RR-2 for 24 h upon 
co-administration of non-toxic concentrations of sodium formate (2 mM) was 
investigated (Table 3.4). In contrast to membrane integrity analysis, cells were 
chemically-fixed with ice-cold ethanol to allow cellular influx of non-permeable 
PI.33 Cells were analysed by flow cytometry and the sub-G1, G1, S and G2/M-phase 
cell cycle populations were fitted using FlowJo V10 software. 
Cells treated with SS-2 or RR-2 for 24 h showed slight G1 cell cycle arrest with 
normalised G1 populations of 75.8±0.4 and 78.4±0.44%, respectively, compared to 
70.4±0.97% in the untreated control population (p=0.012 and p=0.0059). Similarly, 
cells treated with SS-2 or RR-2 and co-administered with formate (2 mM) showed 
a similar increase in G1-phase population compared to the untreated controls (Fig. 
3.10, p=0.031 and p=0.0069, respectively) – suggesting formate does not alter the 
mechanism of action, but merely enhnances the observed effect. This is in strong 
agreement with G1-arrest observed for cells treated with parent compound RR-1 
(R=p-CH3) over 24 h in the presence of sodium formate (0-2 mM).
10 
 




Table 3.4. Cell cycle analysis of a normalized population of A549 (human lung) cancer 
cells treated with 1×IC50 of SS-2 (30.8±1.6 µM) for 24 h (310 K, 5% CO2) upon co-
administration with sodium formate (0-2 mM), showing the percentage of cells in sub-G1, 
G1, S and G2/M phases of the cell cycle. P-values were calculated using a two-tailed t-test 
assuming unequal sample variance (Welch’s unpaired t-test). All t-tests were compared to 
the untreated controls. 
 
 
3.3.8    Zebrafish toxicity studies 
 
Zebrafish embryos are becoming of increasing interest in the translation of 
compounds from in vitro to in vivo models. Although zebrafish display obvious 
differences to humans, they possess high genetic homology to mammals,14, 34-36 
thus, can be utilized to as suitable vertebrates to model drug toxicity and efficacy 
for translation into humans.14, 37 Zebrafish are transparent (useful for fluorescence 
microscopy), cheap (unlike rodent models), rapidly reproduce and allow high-
throughput genetic and chemical screening of drug candidates.34-39 The half-lethal 
concentrations (LC50 / µM) have been determined in SG-WT zebrafish embryos 
upon treatment with SS/RR-2  (0.01-50 μM, 301.5 K, 96 h, Table 3.5).   
 
Table 3.5. Half-maximal lethal concentrations (LC50 / µM) for parent compound RR-1, 







[a]Literature LC50 values of RR-1 (R=p-CH3), RR-6 (R=p-F) and cisplatin.14 













































Complex R LC50 (µM) 
RR-1[a] p-Me 2.4 ± 0.4 
SS-2 p-Br 3.7 ± 0.3 
RR-2 p-Br 4.1 ± 0.1 
RR-6[a] p-F 0.7 ± 0.2 
Cisplatin[a] - 0.6 ± 0.2 




The LC50 concentrations for SS-2 and RR-2 were determined to be 3.7±0.3 and 
4.1±0.1 μM, respectively – implying that the complex chirality does not alter the 
observed toxicity (p>0.05). A comparison of SS-2 or RR-2 with  parent compound 
RR-1 (R=p-CH3) revealed a significantly lower LC50 (2.4±0.4 μM; p=0.0204 and 
p=0.019, for SS-2 and RR-2 , respectively).14 RR-6 (R=p-F) was found to be 
significantly more toxic than SS-2 and RR-2 (LC50=0.7±0.2 μM;  p=0.0007 and 
p=0.0014, respectively).14 Importantly, cisplatin was significantly more toxic than 
SS-2 and RR-2 (LC50=0.6±0.2 μM; p=0.0007 and p=0.0014, respectively).  
 
3.3.9    189Os ICP-MS cellular accumulation studies 
 
The cellular accumulation of Os of SS-2 and RR-2 was initially determined in 
A2780 ovarian cancer cells to enable a direct comparison with that reported for RR-
1 (R=p-CH3),
10 but later determined only for SS-2 in A549 cells for comparative 
studies by synchrotron-XRF.  
 
Equipotent 24 h accumulation 
A2780 cells were treated with equipotent (1×IC50) of SS/RR-2 or SS/RR-3 for 24 h 
(Table 3.6). No statistically significant differences in intracellular Os (ng/106 cells) 
were observed between enantiomers (p>0.05). The Os accumulation of SS/RR-2 
was the same as that of SS/RR-1. Statistically more Os was observed in cells treated 
with SS/RR-3 (p-I) compared to that of  SS/RR-2 (p-Br; p=0.0172 and p=0.0436).  
 
Table 3.6. Osmium (189Os) ICP-MS cellular accumulation (ng Os/106 cells) of 1-3 and RR-
6, 7 and 8 in A2780 cells when treated with equipotent 1×IC50 for 24 h (no recovery). 
Complex R-group ng Os / 106 cells 
SS-1[a] CH3 32±3 
RR-1[a] CH3 30±2 
SS-2 Br 29±3 
RR-2 Br 30±2 
SS-3 I 39±2 
RR-3 I 37±3 
RR-6[a] F 10±2 
RR-7[a] NO2 8.1±0.3 
RR-8[a] H 5.8±0.7 
[a] Literature values for the osmium cellular accumulation of SS/RR-1, RR-6, RR-7 and RR-8. 





The dependence of complex concentration on the drug influx or efflux was 
investigated by treating A2780 cells with 0.25–1.5×IC50 of SS-2 or RR-2 
(IC50=30.8±1.6 and 27.4±0.6 μM, respectively) for 24 h. Interestingly, the 24 h Os 
accumulation of SS-2 (29±3 ng Os/106 cells) and RR-2 (30±2 ng Os/106 cells) were 
identical to that of parent compound RR-1 (30±2 ng Os/106 cells) when treated at 
equipotent concentrations (Table 3.7). This suggests that the Br-substitutent of 
SS/RR-2 somewhat hinders the cellular accumulation of osmium with respect to 
RR-1, in agreement with the reduced potency (higher IC50) exhibited by SS-2 and 
RR-2. Similarly, A549 cells treated with 1×IC50 SS-2 or RR-2 for 24 h showed no 
statistical differences in Os accumulation compared to RR-1 (16±5, 14±3 and 18±2 
ng Os/106 cells, for SS-2, RR-2  and RR-1, respectively). 
 
Table 3.7. Concentration-dependent osmium (189Os) ICP-MS cellular accumulation (ng Os 
/106 cells) of RR-1, SS-2 and RR-2 in A2780 (ovarian) cells when treated with 0.25-
1.5×IC50 concentrations for 24 h (no recovery). 




Varying temperature  
Varying the drug incubation temperatures can provide insights into the dependence 
on active influx or efflux cellular pathways of drugs.17 A2780 cells treated with 
1×IC50 SS-2 or RR-2 for 3 or 6 h at lower incubation temperatures (277 K) revealed 
a significant decrease in intracellular Os (Table 3.8). After 3 h at 277 K, a decrease 
in intracellular Os (by ca. 77% and 75% for SS-2 and RR-2, respectively) was 
observed. Similarly, further decreases of 43% and 44% were observed upon 
incubation at 277 K for 6 h, respectively. Overall this suggests that the intracellular 
Os accumulation may involve active, energy-dependent transport, which was 
previously hypothesised for parent compound RR-1 (p-CH3).
2  
Complex R-group 0.25×IC50 0.5×IC50 1×IC50 1.5×IC50 
RR-1[a] p-CH3 7±1 16±1 30±2 53±7 
SS-2 p-Br 7±1 15±1 29±3 48±6 
RR-2 p-Br 7±1 16±1 30±2 52±7 




Table 3.8. Temperature-dependent osmium (189Os) cellular accumulation (ng Os/106 cells) 
of RR-1 (R=p-CH3), SS-2 (R=p-Br) and RR-2 (R=p-Br) in A2780 (ovarian) cancer cells 
when treated with 1×IC50 concentrations for 3-6 h (no recovery) at 310 K or 277 K. 
[a] Literature values for the temperature-dependent cellular accumulation of RR-1 (R=p-CH3) after 
24 h exposure (no recovery in complex-free medium) in A2780 cells.2  
 
Extent of efflux 
The time-dependent cellular accumulation of Os was investigated in A2780 cells 
treated with 1×IC50 of Br-labelled SS-2 by varying the exposure times (3, 6, 18 and 
24 h). Additionally, the extent of efflux was monitored by treating cells with 1×IC50 
SS-2  for 24 h, followed by 24, 48 and 72 h recovery periods in complex-free media. 
The maximal Os accumulation of SS-2 was observed at ca. 6 h exposure (35±3 ng 
Os/106 cells), which closely correlates with that of RR-1 (Fig. 3.10).10 Upon 
recovery in complex-free media, the osmium in cells treated with SS-2 was 
removed from cells in the same manner as RR-1 (Fig. 3.10; Appendix, Table 
A12)10 – suggesting Br-labelling has not changed the mechanism of uptake. 
  
Figure 3.10. Time-dependent cellular accumulation of 189Os in A2780 cells treated with 
1×IC50 concentration of RR-1 (■) or SS-2 (■) for 3-24 h, followed by 24-72 h recovery in 
complex-free media. 
 3 h 6 h 
Compound  T=277 K   T=310 K  T=277 K T=310 K 
RR-1[a] 3±2 32±4 10.2±0.1 42±1 
SS-1 9±1 37±2 20±2 35±3 
RR-2 8.9±0.9 35±3 20±3 36±3 





The osmium cellular accumulation in A2780 cells treated with 1×IC50 of SS-2 in 
the presence of formate (2 mM) was determined upon 24 h exposure (no recovery). 
No statistically significant differences in Os accumulation were observed between 
A2780 cells treated with SS-2 in the presence or absence of sodium formate 
(p>0.05), nor with that of RR-1 (Fig. 3.11; Appendix, Table A13). 
 
Figure 3.11. Cellular accumulation of osmium in A2780 cells treated with 1×IC50 of RR-
1 (p-CH3, ■) and SS-2 (p-Br, ■) for 24 h upon co-administration with sodium formate (0 
or 2 mM). 
 
 
3.3.10    189Os and 79Br ICP-MS cellular accumulation studies  
 
Up until now, ICP-MS cellular accumulation studies of half-sandwich 
organometallic osmium complexes has involved the quantification of osmium 
(189Os) in stabilised 3.6% v/v nitric acid by ICP-MS. However, this only provides 
information on the Os metal centre, and not the overall metal complex – thus, cannot 
provide information on the intracellular stability of complexes in cancer cells. In 
this Chapter, Br (at an apparent inert site of parent compound RR-1) has been used 
as a molecular probe to monitor the in-cell stability and catalytic efficiency of this 
family of complexes in A549 cells. Herein, a method for the simultaneously 
quantification of osmium (189Os) and bromine (79Br) in strongly alkaline conditions 
(1% m/v TMAH) by ICP-MS without the need for chemical stabilisers was used.  





It has previously been shown that incubating A2780 cells with RR-1 (R=p-CH3) or 
SS/RR-2 (R=p-Br) at lower temperatures (277 K) significantly reduces the cellular 
accumulation of Os after 3-6 h exposure (Section 3.3.9). Similarly, the Os 
accumulation in A549 cells treated with 1×IC50 of  SS-2 for 6 h was reduced by ca. 
48% when incubated at 277 K (Fig. 3.12, p=0.0043). The same trend was observed 
for Br, but with a more pronounced effect, revealing a ca. 75% decrease in 
intracellular Br (Fig. 3.12, p=0.0052).  
A comparison of the intracellular molar quantities of Os and Br in cells treated with 
SS-2 for 6 h at 310 K revealed ca. 12× more intracellular Br (Fig. 3.12, p=0.0039). 
Similarly, ca. 5× more Br than Os was present in cells treated with SS-2 for 6 h at 
277 K. Overall these results may suggest: (i) the cellular accumulation of both Os 
and Br is affected by lower temperatures, implying active, energy-dependent influx 
or efflux mechanisms; (ii) the Br-labelled sulfonamide ligand is dissociating from 
the Os centre – indicative of complex degradation; (iii) the Br-labelled ligand 
remains in cells for longer (significantly higher levels of intracellular Br).  
 
 
Figure 3.12. Temperature-dependent efflux of osmium and bromine in A549 cells treated 
with 1× IC50 (30 μM) of SS-2 at 310 and 277 K for 6 h, respectively: (a) 189Os (■) and 79Br 
(■) cellular accumulation; (b) Intracellularmolar  bromine-to-osmium (Br/Os) ratios at 310 
K and 277 K. Statistical analysis was performed using the Welch’s unpaired t-test, 
assuming unequal variables. 




Inhibition of endocytosis 
The potential involvement of active accumulation pathways of RR-1 (p-CH3) and 
SS-2 (p-Br) has already been probed by varying the drug incubation temperatures. 
Subsequently, the contribution of caveolae endocytosis in the cell uptake of SS-2 
has been probed using methyl-β-cyclodextrin - a known endocytotic inhibitor.17 
A549 cells were treated with 1×IC50 (30 µM) of SS-2 and co-administered with 
methyl-β-cyclodextrin (0-1 mM) for 24 h (Fig. 3.13).  
  
Figure 3.13. The effect of methyl-β-cyclodextrin co-administration (0-1 mM) on the 
osmium and bromine accumulation in A549 cells treated with 1×IC50 of SS-2 for 24 h: (a) 
189Os (■); (b) 79Br (■). Statistical analysis was performed using Welch’s unpaired t-test, 
assuming unequal variances, and compared to the positive controls (0 mM methyl- β-
cyclodextrin) 
 
The amount of intracellular Os (ng/106 cells) decreased with increasing methyl-β-
cyclodextrin concentration (p=0.0128, p=0.0044, p=0.0037 for 0.1, 0.5 and 1 mM 
methyl-β-cyclodextrin). In contrast, the intracellular quantity of Br decreased by ca. 
30% in the presence of 0.1 mM methyl-β-cyclodextrin (p=0.0011). However, the 
Br accumulation did not continue to decrease upon increasing methyl-β-
cyclodextrin concentration, but stabilized at ca. 400 ng/106 cells. The quantity of 
intracellular Br was found to be significantly higher than Os for all concentrations 
of methyl-β-cyclodextrin (p>0.05), with molar bromine-to-osmium ratios (Br/Os) 
ranging between 30-65 (Appendix, Fig. A3) – suggestive of complex degradation. 
Co-administration of SS-2 with methyl-β-cyclodextrin 0.5-1 mM revealed a larger 
Br/Os ratio compared to that of lower concentrations, suggestive of increasing 
complex degradation (Br-sulfonamide ligand dissociating from the Os centre) or 
decreased ligand efflux, with more of the ligand remaining in the cancer cells. 




Inhibition of efflux 
P-glycoprotein (PGP) is a down-regulated efflux membrane protein responsible for 
actively transporting drugs in cancer cells (particularly lipophilic and positively-
charged molecules),40, 41 and has shown to play a role in the development of 
platinum-resistance.42 Herein, verapamil – a known PGP inhibitor17 – was used to 
investigate the effect of efflux inhibition. A549 cells were treated with 1×IC50 of 
SS-2 (R=p-Br) for 24 h, followed by recovery in 20 µM verapamil hydrochloride 
(5% DMSO; 95% DMEM) for 24-72 h (Fig. 3.14). Statistically significant 
differences in Os accumulation in cells treated with SS-2 were observed after 48 h 
recovery in verapamil (p=0.0371) – suggesting the PGP-pump is involved in efflux 
of SS-2. This is in agreement with that reported for RR-1 (R=p-CH3).
10 In contrast, 
the intracellular Br was unaffected by recovery with verapamil when compared to 
that of recovery in medium alone (Fig. 3.14, p>0.05) – suggesting different efflux 
pathways of the free sulfonamide ligand and the osmium complex. For treated cells 
recovered in complex-free media the molar Br/Os ratio increased with recovery 
time (Appendix, Table A14-15), suggesting that the longer the recovery time the 
more the complex is degraded (ca. 60% increase in Br/Os ratio from 24 h to 72 h 
recovery). Similarly, the Br/Os ratios in treated cells recovered in verapamil 
increased, but overall maintained lower Br/Os ratios compared to recovery in 
complex-free media – suggesting SS-2 is more stable upon PGP-inhibition. 
 
 
Figure 3.14. Verapamil-dependent efflux of osmium and bromine in A549 cells treated 
with 1×IC50 (30 µM) of SS-2 for 24 h, and recovery in 0-20 μM of verapamil for 24-72 h: 
(a) 189Os (■); (b) 79Br (■). Statistical analysis was performed using Welch’s unpaired t-test, 
assuming unequal variances.  




Extent of efflux 
The extent of complex efflux of SS-2 from A549 cells was investigated by varying 
the exposure time. Cells were treated with 1×IC50 of SS-2 for 3, 6 and 24 h (no 
recovery) or 24 h with 24, 48 and 72 h recovery (Fig. 3.15; Appendix, Table A16). 
Significantly more intracellular Br vs. Os was observed for all exposure times, 
suggesting complex degradation and the preferential efflux of the Os modality over 
the Br-labelled sulfonamide ligand. 
The general trend of Os accumulation showed a maximum between 8-24 h, and 
upon recovery (complex-free media) Os was effluxed from the cells over 72 h, 
which correlates closely with that observed for parent compound RR-1 (p-CH3),
10 
and SS-2 in A2780 cells (Section 3.3.9). Maximal levels of intracellular Br were 
reached after 24 h exposure (no recovery) revealing a remarkable 571±11 ng Br/106 
cells. Upon recovery (complex-free media) Br is effluxed from the cells, however, 
even after 72 h recovery period, 151±45 ng Br/106 cells still remained 
intracellularly (Fig. 3.15).  
 
 
Figure 3.15. Time-dependent 189Os (■) and 79Br (■) intracellular accumulation in A549 
cells treated with 1×IC50 (30 μM) of SS-2 for different exposure times (3, 6, 18, 24 h) and 
24 h with different recovery times (24, 48 and 72 h) as analysed by ICP-MS. 




3.3.11    189Os and 79Br cellular distribution 
 
The cellular distribution of metals in cancer cells can be probed using cell 
fractionation kits (FractionPREP kit) which separates cells into four fractions: (i) 
cytoskeletal (containing insoluble proteins); (ii) nuclear (nuclear proteins and 
membranes); (iii) membranes (organelles and membrane proteins) and (iv) 
cytosolic (cytoplasmic proteins). From this, separate cell fractions can be digested 
and analysed for their Os content, as previously reported for RR-1 (p-CH3).
10 
Herein, A549 cancer cells treated with 1×IC50 of SS-2 for varying exposure times 
(3, 6 and 24 h) and 24 h exposure with 24-72 h recovery (complex-free media) were 
fractioned and analysed by ICP-MS for their Os and Br content (Fig. 3.16). 
Significantly more intracellular Br vs. Os was observed in cells treated with SS-2 
for all measured time points – implying dissociation of the Br-labelled chelated 
ligand. The majority of intracellular Os was present in the membrane fraction 
(>65%), but also in the cytoskeletal fraction (Appendix, Table A17). Similarly, the 
majority of intracellular Br was present in the membrane fraction (>58%). 
However, interestingly 10-20% of Br was distributed in the nuclear fraction (Fig. 
3.16, Appendix, Table A18), with neglibile quantities of nuclear Os (<6%)  – 
suggestive of a different cellular target for the “free” Br-sulfonamide ligand. 
 
 
 Figure 3.16. Time-dependent cellular distribution of (a) 189Os and (b) 79Br in A549 cells 
treated with 1×IC50 (30 μM) of SS-2 for different exposure times (3, 6, 24 h and 24 h 
exposure with 24, 48 and 72 h recovery) showing the cytosolic (■), nuclear (■), membrane 
(■) and  cytoskeletal (■) fractions, as reported in nmol per million cells. 




The moles of Os and Br per cell in the nuclear fraction were calculated by 
normalizing the ratios to the total cellular quantities (Fig. 3.17; Appendix, Table 
A19). Negligible quantities of Os were observed in the cell nucleus (<1.5×10-8 nmol 
per cell), whereas, significantly more Br was present (>25×10-8 nmol per cell) – 
achieving maximal nuclear quantities of ca 85×10-8 nmol per cell after 24 h (no 
recovery), as shown in Fig. 3.17. Overall, this suggests the nuclear localization of 
the Br-labelled sulfonamide ligand, but not the Os. 
 
Figure 3.17. Normalized fractional moles of osmium and bromine in the nuclear fraction 
in A549 cells treated with 1×IC50 of SS-2 (30 μM) for different exposure times: 189Os (■) 
and 79Br (■), as reported in fractional nmol ×10-8 per cell.  
 
 
3.3.12    Synchrotron-XRF 
 
Synchrotron-XRF is a well-established technique for probing the in-cell 
localization and distribution of metal complexes in cancer, including platinum,43-45 
ruthenium,43, 46, 47 iridium48 and osmium.49-51 Synchrotron-XRF is not limited to 
metals and can be used to monitor the emissions of other non-metals which are non-
native to cells – including bromine, for which the KL3-emission (11.92 keV) does 
not overlay with that of endogenous elements.52 Bromine is non-native to cells and 
has previously been used to monitor Br-labelled cyclic peptides and platinum 
complexes in tumour cells using synchrotron-XRF.31, 53 Complementary to ICP-MS 
studies, Os and Br in A549 cells treated with 1-5×IC50 of SS-2 for 24 h (no recovery) 
have been monitored in this work by synchortron-XRF in a dual-mapping approach. 




A population of A549 cells grown on Si3N4 membranes was treated with different 
concentrations of SS-2, before cryo-fixation and dehydration. Individual cells were 
selected on the membranes based on their distributions of endogenous elements 
(Zn, S, P, K). An incident energy of 15 keV (which exceeds the electron-binding 
energy of the elements of interest) was used to monitor the XRF emissions of Os 
(L3M5=8.9 keV) and Br (KL3=11.9 keV).
52 In cells, the K-emission of endogenous 
Zn is close to that of the Os L3-emission, hence, Zn K-lines were de-convolved from 
the Os L-lines using the PyMCA fitting toolkit to distinguish between endogenous 
Zn and exogenous Os (Fig. 3.18).18 
 
Figure 3.18. XRF spectrum and the corresponding fit configuration, showing copper, zinc, 
bromine, tungsten and osmium: (a) Untreated A549 cell; (b) Treated with 1×IC50 of SS-2 
for 24 h. Note that the Os Kβ emission has also been fitted as the Kα emission overlaps 
with Cu Kβ. XRF emissions from osmium and bromine were not evident in the untreated 
control, but were present in cells treated with SS-2. Graphs were fitted in PyMCA.18 




Elemental XRF maps of A549 cells 
Elements in four untreated (control) cells were mapped (C1-4, Fig. 3.19), showing 
typical elongated A549 morphologies,28, 29 with clear elemental distributions 
allowing the identification of cell nuclei from the highly-localized Zn (containing 
ca. 30-40% of total intracellular Zn).54 Importantly, Os and Br were not observed 
in these untreated cells (Fig. 3.18-19), thus, validating the experiment. 
 
Figure 3.19. Synchrotron-XRF elemental maps of untreated cryo-fixed and freeze-dried 
A549 cells grown on Si3N4 membranes (Cells 1-4, C1-4) showing: Zn (■); S (■); P (■); K 
(■); Os (■) and Br (■). Note that cells have been labelled C1-4 for convenience. Data were 
acquired using 15 keV energy, 0.1 s exposure, 100 nm step size with ca. 50×70 nm2 beam 
size. Data were analysed in PyMCA software,18 and images generated in ImageJ.19 




A549 cells were treated with 1×IC50 (C5-8, Fig. 3.20), 3×IC50 (C9-15, Fig. 3.21) or 
5×IC50 (C16-18, Fig. 3.22) of SS-2 for 24 h (no recovery), revealing strong 
cytoplasmic (non-nuclear) localization of both Os and Br in all cases. Interestingly, 
Br was also observed in the cell nucleus, but Os was not – suggesting in-cell 
complex degradation. Overall, the cells appear less elongated and cobble-stoned 
shaped compared to the untreated controls (C1-4, Fig. 3.19). Note that cells 
analysed by synchrotron-XRF have been numbered C1-18 for simplicity.  
 
 
Figure 3.20. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried A549 cells 
grown on Si3N4 membranes and treated with 1×IC50 (30 µM) of SS-2 for 24 h (Cells 5-8, 
C5-8), showing: Zn (■); Os (■) and Br (■). Note that cells have been labelled C5-8 for 
convenience. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm step size 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,18 and images 
generated in ImageJ.19 






 Figure 3.21. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried A549 cells 
grown on Si3N4 membranes and treated with 3×IC50 (90 µM) of SS-2 for 24 h (Cells 9-15, 
C9-15), showing: Zn (■); Os (■) and Br (■). Note that cells have been labelled C9-15 for 
convenience. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm step size 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,18 and images 
generated in ImageJ.19 





Figure 3.22. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried A549 cells 
grown on Si3N4 membranes and treated with 5×IC50 (150 µM) of SS-2 for 24 h (cells 16-
18, C16-18), showing: Zn (■); Os (■) and Br (■). Note that cells have been labelled C16-
18 for convenience. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm step 
size with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,18 and images 
generated in ImageJ.19 
 
Cellular morphology of A549 cells 
Changes in cell morphology were quantified by calculating the 2D areas (µm2) and 
roundness factors (a measure of the circularity of an object) of individual cells in 
triplicate using ImageJ analysis software (Appendix, Table A20).19 A statistically 
significant decrease in cell area (µm2) was observed between cells treated with 
3×IC50 of SS-2 compared to the untreated controls (p=0.0074, Fig. 3.22). However, 
at the highest concentration (5×IC50) an increase in 2D cell area was observed with 
respect to 3×IC50 (p=0.0236). No statistically significant differences in roundness 
were observed between cells treated with 1×IC50 of SS-2 when compared to the 
untreated controls (Fig. 3.23). However, cells treated with 3 and 5×IC50 were 
significantly more rounded compared to the untreated controls (p=0.0002 and 
p=0.0001, respectively). The area of cell nuclei were determined from the Zn XRF 
maps (Appendix, Table A21), revealing no statistically significant differences 
between nuclei in cells treated with 0-3×IC50 of SS-2 (p>0.05), however, upon 
exposure to 5×IC50 an increase in nuclei size was observed (p=0.0233, p=0.013, 
p=0.0234, respectively).  





Figure 3.23. Cell area (µm2) and roundness factor analysis of cryo-fixed and freeze-dried 
A549 cells grown on Si3N4 membranes and treated with 1-5×IC50 of SS-2 (0–150 µM) for 
24 h (no recovery), as identified from the S, K, P and Zn XRF elemental maps using ImageJ 
software:19 Controls (C1-4), 30 µM (C5-8), 90 µM (C9-15) or 150 µM (C16-18) of SS-2 
for 24 h with no recovery, as identified by S, K, P and Zn distributions in the obtained XRF 
elemental maps. (a) Individual cell areas (µm2). (b) Mean cell areas (µm2). (c) Individual 
roundness factors. (d) Mean roundness factors. Statistical analysis was performed using 
Welch’s unpaired t-test, assuming unequal variables. 
 
Co-localization of Os, Br and Zn 
The co-localization statistics (Pearson’s R-value and Spearman Rank correlation) 
between Os, Br and Zn in cells C4-18 were calculated using ImageJ (Appendix, 
Tables A22-24). Overall, the co-localization between Os and Zn in cells treated 
with 1-5×IC50 of SS-2 revealed r and rs values close to zero, implying little or no-
correlation (Appendix, Table A23). In contrast, the co-localization between 
intracellular Br and Zn ranged between r=0.09-0.36 (Appendix, Table A24), 
implying some correlation between them. There was moderate co-localization 
between Os and Br: 1×IC50 (r=0.15-0.45); 3×IC50 (r=0.07-0.56); 5×IC50 (r=0.10-
0.29) as shown in Appendix (Table A22). 




As the nuclei in cells treated with 1-3×IC50 of SS-2 were clearly identifiable by the 
high localization of Zn,54 the co-localization between Os, Br and Zn in the cell 
nucleus and the cytoplasm was estimated for each cell (Appendix, Tables A22-
24). Os did not strongly co-localise with Zn in the cell nucleus (r=-0.09 to 0.00) or 
the cytoplasm (r=-0.03 to +0.05), whereas, Br co-localized moderately with Zn in 
the nucleus (r=0.06-0.22) and in the cytoplasm (r=0.03-0.12), which varied between 
individual cells. Co-localization between Os and Br was prominent in the cytoplasm 
(r=0.13-0.48), but negligible in the nucleus (r=-0.11 to +0.10).  
The co-localization statistics between Os, Br and Zn were also determined for cells 
treated with 5×IC50 of SS-2, however, as the nucleus could not be confidently 
identified (C16-18, Section 3.3.12, Fig. 3.22), the interpretation of the data was 
more difficult. Nonetheless, Os and Zn did not strongly co-localise in the nucleus 
nor the cytoplasm (r=0.00-0.02 and 0.00-0.03, respectively); similarly, Br did not 
strongly co-localise with Zn in the nucleus (r=0.02-0.05), but co-localized strongly 
in the cytoplasmic region of the cell (r=0.16-0.21). Finally, Os and Br  moderately 
co-localised in the cytoplasm of cells treated with 5×IC50 of SS-2 (r=0.16-0.18), but 
not in the cell nucleus (r=0.02-0.08). 
 
Quantification of Os and Br 
The mass fractions of elements can be determined from synchrotron-XRF by 
calibrating the data to an AXO standard of known elemental concentrations, 
assuming a maximal cell thickness of 6 µm.55 Mole fraction quantities of both Os 
and Br were determined for cells C5-18 to gain an insight into the concentration-
dependent intracellular stability of SS-2 in A549 cancer cells (Table 3.9), revealing 
significantly higher levels of intracellular Br vs. Os (>3×) for all concentrations, as 
represented by the molar bromine-to-osmium ratios (Br/Os). Large variations in the 
mole fraction quantities of both elements were observed for cells treated under the 
same conditions, with Br/Os ranging from: (i) 4.2–8.6 (1×IC50); (ii) 3.8–11.3 
(3×IC50); (iii) 2.2–2.4 (5×IC50), emphasizing the variability in drug uptake in a 
population of unsynchronized cells. A comparison of the mean Br/Os ratios 
revealed a statistically significant decrease (by ca. 57%) between cells treated with 
3×IC50 (C9-15) and 5×IC50 (C16-18, p=0.0019) of SS-2. 




Table 3.9. Mole fraction quantities and molar bromine-to-osmium (Br/Os) ratios of Os and 
Br in cryo-fixed and freeze-dried A549 cells grown on Si3N4 membranes and treated with 
1-5×IC50 of SS-2 (30-150 µM) for 24 h (no recovery), as determined from synchrotron-
XRF in triplicate using ImageJ software.19  
 
 
Analysis of Os and Br in lysosomes of A549 cells 
For cells treated with 3×IC50 (90 µM) and 5×IC50 (150 µM) of SS-2  for 24 h (C9-
15), small localized regions of Os were observed in the cytoplasm – perhaps 
indicative of Os accumulation in organelles such as lysosomes, endosomes or 
mitochondria (Fig. 3.24; Appendix, Fig. A4-12). The areas of these compartments 
were initially determined in triplicate from the Os XRF maps, using the and 
multipoint selection tools in ImageJ software (and reaffirmed using the smoothing 
tools – see Appendix, Figure A4).19 Further to this, mole fraction quantities of both 
Os and Br in these compartments were determined. The total number of these 
cytoplasmic organelles per cell ranged between 16-25 (for 3×IC50) and 4-11 (for 
5×IC50), with average areas of 0.6±0.1 µm
2 and 0.78±0.25 µm2. More Br was 
present in these compartments than Os, with mean molar bromine-to-osmium ratios 
(Br/Os) of 4±1 and 1.48±0.17 (Table 3.10). No correlation was observed between 




[Os] × 10-8 
Mole Fraction 
of [Br] × 10-8 
[Br]/[Os] Mean [Br] / [Os] 
5 5.41±0.02 46.5±0.3 8.6 
 5±2.5 
6 5.22±0.01 14.86±0.04 2.9 
7 4.70±0.01 19.6±0.1 4.2 
8 5.54±0.02 23.48±0.15 4.2 
9 4.390±0.004 34.1±0.2 7.8 
7.1±2.4 
10 5.50±0.01 37.0±0.9 6.7 
11 6.82±0.01 25.9±0.1 3.8 
12 8.72±0.05 98.4±0.8 11.3 
13 9.91±0.07 86.4±0.9 8.7 
14 4.20±0.01 26.0±0.2 6.4 
15 6.53±0.01 33.7±0.1 5.2 
16 5.60±0.02 12.55±0.03 2.2 
2.3±0.1 17 5.29±0.01 12.89±0.02 2.4 
18 5.47±0.02 12.49±0.04 2.3 





Figure 3.24. Representative example of synchrotron XRF elemental maps of a 
cryopreserved and freeze-dried A549 cell treated with 3×IC50 (90 µM) of SS-2 for 24 h (no 
recovery) showing the co-localization of Os and Br in small, vesicle-sized compartments 
as represented identified with red circles (C13). Images were prepared in ImageJ using the 
16-colour settings, using the multipoint selections tools to identify small compartments. 
Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize with ca. 50×70 
nm2 beam size. Data were analysed in PyMCA software,18 and images generated in 
ImageJ.19 Note that, the presented images are shown as using the smoothing tool for clarity 
and presentation purposes, but all analysis was performed on the original pixelated mass 
fraction image. See Appendix Fig. A4 for more information. 
 
Table 3.10. A comparison of the average lysosomal area (μm2) and the average lysosomal 
bromine-to-osmium (Br/Os) ratio of A549 cells treated with 3 and 5×IC50 (90 µM) of SS-
2 for 24 h, no recovery time, as analysed in triplicate using ImageJ software.19 
 
 




9 17 0.63±0.29 3.4±0.4 
10 12 0.57±0.23 3.1±0.6 
11 12 0.70±0.17 2.6±0.3 
12 19 0.67±0.19 5.7±0.8 
13 25 0.45±0.15 8.5±0.8 
14 n.d n.d n.d 
15 12 0.58±0.18 3.6±0.4 
16 5 0.84±0.42 1.57±0.14 
17 11 0.80±0.18 1.53±0.12 
18 4 0.63±0.05 1.24±0.13 




3.3.13    Chloroquine inhibition of lysosomal activity 
 
Chloroquine is the main clinically-approved drug for the treatment of malaria, and 
has been reported to be relatively non-toxic towards cancer cells at low micromolar 
concentrations.56 Importantly, chloroquine can deactivate lysosomes by increasing 
the pH (decreasing the acidity),56-59 preventing them from working as efficiently – 
hence, is suitable for probing the role of lysosomes in A549 cells treated with RR-
1 or Br-labelled SS-2. Herein, A549 cells were pre-incubated in chloroquine 
diphopsphate (0 or 150 µM) for 2 h, washed with PBS and then treated with 1×IC50 
of RR-1 (21.1±0.3 µM) or SS-2 (29.5±0.5 µM) for 24 h and 72 h complex-free 
media (Fig. 3.25). A statistically significant increase in potency (decrease in IC50) 
was observed for cells pre-incubated in 150 µM chloroquine and treated with RR-
1 (ca. 50% increase) or SS-2 (ca 25% increase) when compared to their normal IC50 
concentrations (p=0.0001 and p=0.0003, respectively). Subsequently, the cellular 
accumulation of Os (ng/106 cells) was determined in A549 cells pre-incubated in 
chloroquine (0-150 µM, 2 h), washed with PBS, and treated with RR-1 or SS-2 for 
24 h (no recovery), as shown in Fig. 3.24. A statistically significant increase in Os 
accumulation was observed for cells pre-incubated in chloroquine (0 or 150 µM) 
and treated with RR-1 (ca. 69% increase) or SS-2 (ca. 35% increase) for 24 h (no 
recovery), when compared to the latter (p=0.0015 and p=0.0251, respectively). 
 
Figure 3.25. (a) Antiproliferative (IC50 / µM) of RR-1 and SS-2 in A549 (human lung) 
cancer cells pre-incubated in 0 or 150 µM of chloroquine diphosphate for 2 h, followed by 
24 h drug and 72 h recovery time in drug-free media. (b) Osmium cellular accumulation of 
A549 cells pre-incubated with 0 or 150 µM chloroquine diphosphate for 2 h and treated 
with 1×IC50 RR-1 (21 µM) and SS-2 (30 µM) for 24 h, no recovery time as analysed using 
the acid digestion method. Statistical analysis was performed using the Welch’s unpaired 
t-test, assuming unequal variances. 




The Os and Br cellular accumulation of  SS-2 was also determined using the 
alkaline digestion method. The Os accumulation increased by ca. 33% from 
42.5±1.4 to 57±5 ng Os/106 cells (p=0.0327) upon pre-incubation with chloroquine 
(Fig. 3.26). The Br accumulation was found to be statistically the same (p>0.05). 
Interestingly, the molar Br/Os ratio decreased by ca. 29% upon preincubation with 
chloroquine (from 33.7±0.1 to 23.2±0.2; p=0.0001), which implies that more of the 
complex may be intact upon deactivation of lysosomes. 
 
 
Figure 3.26. (a) Osmium and bromine cellular accumulation of A549 cells pre-incubated 
with 0 or 150 µM chloroquine diphosphate for 2 h and treated with 1×IC50 SS-2 (30 µM) 
for 24 h, no recovery time as analysed using the alkaline digestion method. (b) Molar 
bromine-to-osmium ratio (Br / Os).Statistical analysis was performed using the Welch’s 
unpaired t-test, assuming unequal variances. 
 
Although chloroquine can deactivate lysosomes in cancer cells, it may not just be 
affecting these vesicles (for example, chloroquine can also affect endosomes),60 
hence, the observed differences in antiproliferative activity (IC50) and Os 
accumulation (ng/106 cells) may not just be a result of lysosomal damage. In order 
to confirm that the increase in potency is a direct consequence of lysosomal 
deactivation and not membrane damage, chloroquine-dependent membrane 
integrity studies were performed. A549 cells were pre-incubated in chloroquine (0 
or 150 µM, 2 h), washed with PBS and then treated with 1×IC50 of RR-1 (p-CH3) 
or SS-2 (p-Br) for 24 h (no recovery), followed by staining with PI and analysis by 
flow cytometry as described in Section 3.2.9. 




The membrane viability of cells treated with RR-1 or SS-2  (negative controls) were 
comparable to that previously reported (Section 3.3.7), revealing negligable 
membrane damage (Fig. 3.27, Appendix, Table A25). No statistically significant 
differences in cell viability in cells pre-incubated in chloroquine or complex-free 
media were observed (Fig. 3.27). Similarly, no differences in the membrane 
viability was observed for cells pre-incubated in chloroquine and treated with RR-
1 or SS-2 suggesting chloroquine does not damage cellular membranes. 
 
 
Figure 3.27. Membrane integrity analysis determined by flow cytometry for a normalized 
population of A549 cells. (a) Cells were pre-incubated with either medium alone or with 
chloroquine diphosphate (CQ, 150 µM) for 2 h (b) Cells were pre-incubated with 
chloroquine diphosphate (CQ, 150 µM) for 2 h followed by treatment with 1×IC50 RR-1 














3.4     Discussion 
 
3.4.1    Synthesis of ligands and complexes 
 
A total of six BsDPEN ligands (SS/RR-L1, SS/RR-L2, RR-L3 and SS-L4) were 
synthesized through a SN2 nucleophilic substitution reaction between a sulfonyl 
chloride group and a primary amine group in the presence of a base (triethylamine, 
TEA). The addition of TEA was performed dropwise and at a low temperature to 
prevent deprotonation of both NH protons; additionally, the respective sulfonyl 
chlorides were added dropwise to prevent the formation of the disubstitued product. 
An excess of sulfonyl chloride was used to ensure that all of DPEN reacted (which 
would have consequences in further reaction with [Os(p-cym)Cl2]2). Any excess 
sulfonyl chloride was easily removed from the product by chromatography due to 
differences in polarity compared to the diamines (DPEN or BsDPEN). All ligands 
were recrystallized in hot ethyl acetate and estimated to be >95% pure (1H NMR, 
13C NMR, CHN analysis), suitable for further reaction with [Os(p-cym)Cl2]2.  
The precursor dimer [Os(p-cym)Cl2]2 for the synthesis of Os[(p-cym)BsDPEN] 
complexes was synthesised using the microwave-assisted synthesis previously 
reported.1 Microwave synthesis has advantages over reflux methods, including 
shorter reaction times (kinetic enhancement), higher yields and simplicity. A 
solution of [Os(p-cym)Cl2]2 and BsDPEN ligand (L1-4) in DCM were reacted 
together to form a yellow solution. This can be attributed to an 18-electron OsII 
species (previously isolated for RR-1),1 in which the BsDPEN ligand is bound via 
one nitrogen atom, with two chlorides (Cl-) coordinated to the metal centre. Upon 
addition of an excess of potassium hydroxide (KOH) and water (to dissolve the 
base), a red organic layer formed, proceeding through a biphasic (DCM:water) 
reaction.1 KOH acts as a base to deprotonate the already-coordinated N-atom, 
which subsequently eliminates Cl, forming highly stable 16-electron [OsII(p-
cym)(BsDPEN)] complexes (2-5).  
 
 




3.4.2    X-ray crystal structures and DFT 
 
Complexes SS-2 (p-Br) and SS-3 (p-I) were isolated as single crystals in 
DCM:hexane. The crystal structures of SS-2 and SS-3 (Section 3.3.1, Fig. 3.4) were 
closely comparable to that of the parent compound SS-1 (p-CH3) with (1S, 2S) 
chirality. The osmium is η6-coordinated to p-cymene, as reported for a variety of 
osmium and ruthenium half-sandwich pseudo-octahedral complexes.1, 61-63 
Complexes SS-2 and SS-3 both crystallise in the orthorhombic space group P212121, 
complementary to that of SS-1 (p-CH3).
1 Unlike SS-1, H-bonds between the N-H 
and an O-atom of the sulfonyl group was not observed for SS-2 and SS-3 (3.09 Å 
and 2.97 Å, respectively – which are too long to be H-bonds). Stacking (π-π) 
interactions of aromatic groups (p-cymene and phenyl) were not observed for either 
SS-2 or SS-3. Overall, the crystal structures of SS-2 and SS-3 were found to be 
remarkably similar to that of SS-1 and the analogous RuII 16-electron catalysts.1, 62  
DFT was used to provide insights into the effect of halide substitution on the 
chemical structure of this family of 16-electron OsII complexes, based on the 
electron density distribution. DFT calculations on organometallic complexes 
commonly use mixed basis sets (a set of functions which represents the electron 
wave-function) to provide approximations to Schrödinger’s equation.64 Herein, the 
DFT calculations revealed close similarities between RR-2 and RR-3 (Section 
3.3.2, Fig. 3.5), hence, suggesting the transition states in the ATH of acteophenone 
would be similar. The charge at the Os, arene or the BsDPEN (which are crucial for 
ATH catalysis)65 did not change with halide-substitution, reaffirming that only 
localised charge effects were observed. Comparison of RR-2 (p-Br) and RR-3 (p-I) 
with RR-6 (p-F) showed no significant changes in the Mulliken partial charges on 
non-carbon atoms (Appendix, Table A7, Fig. A1), except for the halide atom (X) 
for which the charge correlated with the electronegativity of the halide series 
(F>Cl>Br>I).   
The crystal structures of the RR enantiomers of 2 and 3 (not obtained) were assumed 
to closely resemble those of the SS crystal structures, thus, it can be deduced that 
their ground state geometries (DFT) closely resembled the crystal structures (mirror 
images have the same energy). Overall, both the x-ray crystal structures and DFT 
results of SS-2 and SS-3 are closely comparable to that of parent compound SS-1.2 




3.4.3    Hydrophobicity studies 
 
Strong similarities in LogP values were observed between enantiomeric pairs 
SS/RR-2 (p-Br) and SS/RR-3 (p-I), all with LogP values around 1.0 (Section 3.3.3, 
Table 3.1), implying they have similar lipophilic properties. This was not surprising 
considering their chemical compositions are identical. Similarly, variation of 
substitutent position did not affect the LogP: SS-5 (m-Br) and SS/RR-2 (p-Br). The 
LogP of SS/RR-3 (p-I) were closely comparable to that of SS/RR-2 (p-Br) which 
was expected as bromide and iodide have similar electronegativities, despite the 
larger size of iodide. This correlates with the electrostatic potentials of p-halide 
substituted OsII sulfonamide complexes determined by DFT (Section 3.3.2). 
The lipophilicity of RR-4 (p-OMe) was determined to be greater than that of the 
SS/RR-2 and SS/RR-3 (p-Br and I), implying increased hydrophobicity. Methoxy 
groups (OMe) are electron-donating by resonance, so can push electrons into the 
delocalized benzene ring and towards the SO2 group, further, strengthening the N-
Os bond. In contrast, halides (Br, I) are weakly electron-withdrawing from the 
aromatic ring, thus, somewhat weaken the N-Os bond. It was expected that the 
presence of non-polar methoxy group in RR-4 (p-OCH3) would increase the 
hydrophobicity, despite the addition of an O atom (which can H-bond with water), 
through hydrophobic interactions with octanol. Moreover, the LogP of RR-4 (p-
OCH3) was intermediate between that of SS/RR-2 or SS/RR-3 (R=p-Br, I) and 
parent compound RR-1 (R=p-CH3).
10  
Parent compound RR-1 (p-CH3) has an even larger partition coefficient of 
1.45±0.02 (increased hydrophobicity)2 than 2-5 as the methyl group in the para 
position is strongly electron-donating by the induction effect and can form 
favourable hydrophobic interactions with octanol. RR-6 (p-F) was significantly less 
hydrophobic than 1-5, which can be attributed to the strong electronegativity of 
fluoride and the ability to form additional H-bonds with water.  
One of the major aims with the development of organometallic complexes as 
anticancer agents is to optimise their solubility in physiological conditions and 
improve their accumulation in cancer cells – both of which are largely influenced 
by LogP. Cisplatin (a clinically-approved metal anticancer agent), is highly 




hydrophilic with a negative partition coefficient of -2.21±0.06,27 making it 
compatible for formulation in aqueous media. In comparison, many OsII and RuII 
complexes have significantly enhanced lipophilic properties,66, 67 thus, rely on other 
means to improve aqueous solubility: for example, changing the nature of counter-
anions of half-sandwich complexes.67 Consequently, lipophilic compounds are 
somewhat more-dependent on passive diffusion through hydrophobic bilayers of 
cell  membranes. In contrast, cisplatin relies on both passive diffusion and 
active/facilitated transport.24 This family of OsII sulfonamide complexes have low 
water solubility (LogP>1 for 1-5, compared to -2.21 of cisplatin), thus, require 
initial solubilisation in DMSO (5% v/v) - a common solubilising agent for screening 
of many therapeutic and toxic agents.68 DMSO is ampiphilic in nature and non-
toxic at diluted concentrations, thus, proves suitable for in vitro screening.68 
 
3.4.4    Asymmetric Transfer Hydrogenation (ATH) catalysis 
 
Acetophenone is a simple prochiral ketone which is a commonly used substrate in 
ATH.1 Parent compound RR-1 (R=p-CH3) can enantioselectivity convert 
acetophenone to (R)-1-phenylethanol with ca. 10-fold higher turnover frequency 
(TOF) compared to Noyori’s RuII catalyst, while maintaining high 
enantioselectivity and conversions.1, 2 Similarly, 2-5 all displayed high conversions 
(96-99%) and high enantiomeric excesses (94-98%) for the reduction of 
acetophenone in the presence of 5:2 formic acid/triethylamine azeotrope at 310 K 
over 24 h (Section 3.3.4, Table 3.2). The TOF (h-1) were calculated from the initial 
(linear) rate of reaction over a 3 h period using 1H NMR by exploiting the 
differences in hydrogen-environments between the ketone substrate and the alcohol 
product (Fig. 3.27). Interestingly, the TOF of SS/RR-2 and SS/RR-3 (ca. 80 h-1) 
were higher than that of RR-1 (63.6 h-1),1 suggesting that the size or electronic 
properties of Br or I somewhat enhance the rate of reaction. Nonetheless, the ATH 
catalytic activity of 2-5 were of the same order of magnitude to parent compound 
RR-1 (p-CH3) – suggesting that the para-position is an inert site which does not 
alter the catalytic ability of these osmium complexes. 





Figure 3.28. 1H NMR spectra for the reduction of acetophenone using SS-2 in the presence 
of 5:2 formic acid: TEA azeotrope over time at 310 K (400 MHz, d6-benzene): a reduction 
in singlet of acetophenone (3H, 2.3 ppm) and a formation of quartet (1H, 4.60 ppm) upon 
conversion to 1-phenylethanol. 
 
3.4.5    Antiproliferative activity  
 
Anticancer potency and accumulation 
In order to prove that changing the substitutent at the para-position of the 
sulfonamide ligand does not drastically change the in-cell activity, the 
antiproliferative activities of 2-5 were determined in four human cancer cell lines 
(A2780, A549, PC3 and MCF7) and in non-cancerous lung fibroblasts (MRC5). 
The half-maximal inhibitory concentrations (IC50 / µM) were determined using the 
well-established SRB colorimetric assay, which stains cells based on their protein 
content. Herein, cells were treated with 2-5 for 24 h, followed by 72 h recovery in 
complex-free media for pharmacological relevance. 
The IC50 concentrations of enantiomeric pairs were found to be identical across all 
the cell lines (SS/RR-2; SS/RR-3), suggesting that the sulfonamide chirality does 
not change the overall antiproliferative activity. In addition, changing the position 
of the Br-substituent (2=para; 5=meta) did not alter the anticancer potency. Overall, 
4 (R=p-OMe) was the most potent in A2780 cells, implying that increased electron-




donation into the benzene ring might increase the anticancer activity. The methoxy 
group of 4 is strongly electron-donating by resonance and  increases the activity in 
A2780 cells. Furthermore, it was hypothesized that the ether group pushes electrons 
through the delocalized ring system towards the N-atom, increasing the electron 
density on the nitrogen, thus strengthening the Os-N bond. This may improve the 
complex stability in a cancer cell environment, which may contribute to the 
improved anticancer activity. The resonance and induction effects of donating or 
withdrawing substituents on organometallic complexes may significantly influence 
the in vitro activity, which may prove necessary in future drug design. 
Complexes 2 (p-Br), 3 (p-I) and 5 (m-Br) were less potent than 1 (p-CH3) and RR-
6 (p-F) – which may be a consequence of reduced cellular accumulation. The 
improved antiproliferative potency of RR-6 (p-F) compared to 2 (p-Br) and 3 (p-I) 
may also be attributed to increased electronegativity and polarisation of fluorine 
and its ability to form additional H-bonds with water, ultimately lowering the LogP 
of the complex. The F-atom of RR-6 may also increase the complex stability in 
biological media by forming favourable H-bonds with molecules of itself, as 
previously hypothesised by Coverdale.2 Complexes 2-5 were not as potent as 
cisplatin against the analysed cell lines, however, current data implicates an ROS-
mediated mechanism of action which has the potential to circumvent Pt-resistance 
and reduce off-target effects.14 
The toxicities of SS/RR-2 in MRC5 (healthy lung) cells demonstrated similar 
activities in cancer vs. heathy cells (A549 vs. MRC5), which is a major clinical 
drawback and would likely cause side effects. This was also observed for RR-1 (p-
CH3).
2, 10 However, this family of osmium complexes have previously been shown 
to perform intracellular catalysis (when co-administered with sodium formate), 
which is selective for cancer cells,10 providing a platform for catalytic therapy.  
In order to validate Br-labelled 2 as a molecular probe for elucidating the in vitro 
mechanism(s) of action of parent compound RR-1 (p-CH3), 
189Os ICP-MS cellular 
accumulation studies were performed. A2780 cells treated with equipotent 
concentrations (1×IC50) of SS/RR-2 for 24 h (no recovery) revealed identical 
intracellular levels of Os to that found in cells treated with SS/RR-1.2, 10 This 
suggests that the Br substituent is somewhat hindering the cellular uptake, 




correlating with the reduced potency of 2 compared to 1 (2× less potent). The Br-
substituent likely does not alter the mechanism of Os accumulation, but merely 
reduces the amount of intracellular complex available for antiproliferative activity.  
Interestingly, the osmium cellular accumulation of SS/RR-3 (p-I) were significantly 
higher than SS/RR-2 (p-Br) despite their similar potencies (IC50~30 µM). This 
implies that more of the iodide-substituted complex (3) has to enter cancer cells to 
have the same antiproliferative effect. This may prove somewhat more desirable for 
catalytic therapy (with administered formate) as more of SS/RR-3 (p-I) may be 
available for in-cell ATH catalysis at lower drug doses. 
The cellular accumulation of drugs depend on a variety of factors, including 
lipophilicity, the type of substituent and the molecular size. A comparison of LogP 
and the Os cellular accumulation may suggest that the enhanced hydrophobicity of 
RR-1 (1.45±0.02) may promote passage through phospholipid membrane bilayers 
more readily than SS/RR-2 (1.01±0.01), hence, more accumulates intracellularly.  
A comparison of LogP and Os cellular accumulation in A2780 cells treated with 
equipotent (1×IC50) for 24 h for 2 (p-Br) and 3 (p-I) after 24 h drug revealed that a 
higher LogP is reflected in a greater Os accumulation in cancer cells (Fig. 3.27). 
These are compared to that of RR-6 (p-F), RR-7 (p-NO2), and RR-8 (p-H), all of 
which are less hydrophobic and exhibit lower intracellular quantities of osmium.2 
 
Figure 3.29. Comparison between the the partition coefficient (LogP) and the osmium 
cellular accumulation (ng Os/106 cells) in A2780 (ovarian) cancer cells. (i) Parent 
compound RR-1 (■).2 (ii) Complexes SS/RR-2 and SS/RR-3 synthesised in this Chapter 
(■). (iii) Complexes RR-6, 7 and 8 previously reported (■).2 




The concentration-dependence on the Os cellular accumulation was investigated for 
A2780 cells treated with 0.25-1.50×IC50 SS/RR-2 for 24 h (no recovery) to 
determine whether the system reaches saturation. The intracellular quantities of Os 
increased linearly with concentration (Section 3.3.9,Table 3.7), in agreement with 
that previously reported for RR-1.2 Concentration-dependent uptake has been 
reported for various other metallodrugs including RuII-half-sandwich complexes,17 
RuIII octahedral complexes,69 OsII octahedral complexes70 and clinical drug 
cisplatin,71 highlighting the importance of dose-dependent uptake in mediating drug 
efficacy. Upon treatment with 1×IC50 of 1 (p-CH3) or 2 (p-Br) the same amount of 
intracellular Os was observed. This means that upon equimolar treatment (equal 
concentrations) with 1 or 2, more of 1 will accumulate intracellularly: Br is 
somewhat hindering the cellular accumulation. 
Varying the incubation temperatures can provide information on the dependence of 
active cellular influx/efflux pathways of drugs. Active mechanisms are energy-
dependent and rely on electrochemical gradients to cross cell membranes and enter 
cells. The temperature-dependent Os accumulation in A2780 cells showed a 
significant decrease after both 3 and 6 h when treated with SS/RR-2 at 277 K 
compared to 310 K (Section 3.3.9, Table 3.8), suggesting energy-dependent 
processes (e.g. endocytosis or membrane pumps) are involved in the cell uptake of 
these complexes. The same trend was reported for parent compound RR-1 (p-CH3), 
but with a more drastic reduction in Os accumulation after 6 h (ca. 90% for RR-1,2, 
10 compared to ca. 45% of SS/RR-2).  Nonetheless, SS/RR-2 and RR-1 displayed 
the same temperature-dependent trend, hence, the Br substituent has likely not 
altered the mechanism of uptake of RR-1. 
The extent of efflux was investigated by monitoring the Os accumulation from SS-
2 (p-Br) over time, and after cells had recovered in complex-free media (Section 
3.3.9, Fig. 3.11). The time-dependent accumulation of Os in A2780 cells treated 
with SS-2 and RR-2 indicated very similar efflux to RR-1 (p-CH3).
2 The maximum 
amount of intracellular Os was observed after ca. 6 h of drug exposure, after which 
the Os was gradually removed from the cells (Section 3.3.9, Fig. 3.10; Appendix, 
Table A12). The amount of Os inside the cancer cells decreased by ca. 25% of its 
maximum (6 h) after 24 h. After recovery in complex-free media, the Os was 
removed from the cells at a rate of ca. 0.3 ng/106 cells.h-1 in a linear fashion, 




correlating closely with the efflux of RR-1 (ca. 0.34 ng/106 cells.h-1).2, 10 One of the 
major contributors to multidrug resistance is enhanced drug efflux,25 which reduces 
drug efficacy and thus, the anticancer effect. This has been reported for clinical 
anticancer drugs including cisplatin and oxaliplatin.72 Novel anticancer complexes 
with different influx and efflux pathways may be able to circumvent multidrug 
resistance. The Os of RR-1 and SS/RR-2 was slowly removed from cells over a 72 
h recovery period at the same rate when treated with equipotent concentrations,2, 10 
suggesting the Br substituent does not alter the cellular efflux kinetics. The slow 
rate of cellular efflux of these complexes may prove appropriate for catalytic 
therapy, extending the intracellular catalysts lifetime which may enhance catalytic 
turnover to contribute towards cell death.  
 
In-cell catalytic activity 
It has previously been demonstrated that RR-1 (R=p-CH3) can act catalytically 
inside cancer cells, converting pyruvate to unnatural D-lactate in the presence of 
non-toxic doses of formate (hydride donor).10 This work provided an opportunity 
to increase selectivity for cancer over healthy cells through a catalytic mode of 
action,10 by exploiting the redox vulnerability of cancer cells. Formate is a well-
established hydride source compatible with cells, and has been used to probe the in-
cell catalytic properties of hald-sandwich metal complexes, including ruthenium.11  
In 2018, Coverdale et al. proposed a catalytic cycle in which the pyruvate itself can 
directly interact with the p-cymene arene group of RR-1 via a transition state 
(Chapter 1, Section 1.2.3, Fig. 1.11).10 In this mechanism, formate binds directly 
to Os and releases CO2 to form an active Os-H bond, which then facilitates the 
preferential binding of pyruvate at the Re-face, subsequently releasing D-lactate.10  
The electrostatic interaction between pyruvate and p-cymene is thought to be 
essential for mediating the enantioselectivity of the reaction, however, no evidence 
has been provided for this proposed transition state.2 In 2019, Yang et. al. proposed 
a proton-coupled hydride transfer catalytic mechanism for the ATH conversion of 
pyruvate to lactate in the presence of formic acid, using DFT.73 In this scenario, 
formate binds directly to pyruvate on the Re-face via a cationic Os species which 
facilitates the release of D-lactic acid.73 The exact nature of the transition states (and 




the catalytic cycle) is unknown, however, both proposed mechanisms are in 
agreement that the electrostatic interaction between p-cymene and pyruvate has a 
crucial influence on the enantioselectivity of the catalytic reaction.10, 73  
In order to validate Br-labelled SS-2 or RR-2 as suitable probes for investigating 
the in-cell stability of parent compound RR-1 (p-CH3) by ICP-MS and XRF, the 
possible in-cell catalytic anticancer activity was investigated in A549 cells upon 
treatment with 0.5–1.0×IC50 of SS-2 or RR-2 and sodium formate (0-2 mM) for 24 
h, with a 72 h recovery period. Sodium formate was found to be non-toxic towards 
cancer cells (p>0.05). A significant decrease in the normalized cell proliferation 
(from 100% to 25%) was observed upon co-administration with increasing 
concentrations of formate (Section 3.3.6, Fig. 3.6), suggesting a catalytic 
contribution to the antiproliferative activity, similar to that reported for RR-1.2, 10 
Further affirmation of the role of a hydride source in promoting an increase in 
potency of 2 (p-Br) was obtained using sodium acetate which (unlike formate) 
cannot act as a hydride source for ATH.10 As such, no decrease in cell viability was 
observed upon acetate co-administration (Section 3.3.6, Fig. 3.7). In order to 
confirm that the observed decrease in activity with formate was a consequence of 
in-cell catalysis and not due to increased Os accumulation, cancer cells were treated 
with 1×IC50 of Br-labelled SS-2 and co-administered with sodium formate (0-2 
mM) for 24 h. No change in Os accumulation was observed (Section 3.3.9, Fig. 
3.11), in strong agreement with that reported for RR-1.2, 10  
The catalytic selectivity for cancer vs. healthy cells was investigated using MRC5 
cells treated with 0.5-1×IC50 of SS or RR-2 in the presence of sodium formate or 
acetate (0-2 mM), revealing no significant differences in cell viability (p>0.05; 
Section 3.3.6; Fig. 3.8), as reported for RR-1.2, 10 This suggests that intracellular 
catalysis is selective for cancer cells and that the biological properties of 2 (p-Br) 
are complementary to that of 1 (p-CH3). This is likely attributed to higher levels of 
intracellular pyruvate (Warburg Effect),74  where cancer cells preferentially rely on 
aerobic glycolysis to survive under extreme metabolic conditions. Complementary 
to this, formate-producing enzymes (e.g. peptide deformylase) are over-expressed 
in A549 cancer cells75 – which may further promote the catalytic activity in cancer 
cells vs. healthy cells. This has previously been probed for RR-1 by the inhibition 
of peptide deformylase with N-formylmethionine in PC3 prostate cancer cells.2 




Membrane integrity and cell cycle analysis 
Flow cytometry can be used to monitor drug-induced changes in a treated 
population of cells. The membrane integrity of A549 cells treated with SS-2 or RR-
2 (p-Br) in the presence of sodium formate (0-2 mM) was analysed by flow 
cytometry, to probe whether the cell membrane is compromised upon treatment. In 
this assay, a staining solution of red-fluorescent PI (a DNA intercalater with Λex/em 
of 493/636 nm) was used on non-chemically fixed cells.76 PI is not permeable to 
cell membranes, thus, only damaged or compromised cell membranes will allow PI 
to enter the cell and intercalate with DNA, with an approximate 20-fold increase in 
fluorescence compared to unbound PI.33 This change in fluorescence can be 
monitored using flow cytometry (FL2 channel, λ=488 nm laser), a laser-based 
technique which can assess different biological parameters (i.e. cell viability) of a 
population of cells on the basis of the excitation of fluorochromes.77 The data was 
‘gated’ into two population categories (viable and non-viable membranes), using 
FlowJo V10 software.  
It has been previously reported that A2780 cells treated with parent compound RR-
1 (1×IC50) in the presence of sodium formate (0-2 mM) showed no significant 
variation or disruption of membrane integrity after 24 h exposure when compared 
with the untreated controls.2, 10  The same was observed for cells treated with Br-
labelled SS/RR-2 (p>0.05, Section 3.3.7, Fig. 3.9; Appendix, Table A11), 
suggesting that the antiproliferative mechanism of action is not a result of 
membrane damage. No differences in the membrane integrity were observed 
between cells treated with SS/RR-2 in the presence or absence of formate, implying 
that the increased antiproliferative activity is not due to formate-induced membrane 
damage. This correlates with the formate-dependent osmium accumulation which 
revealed that co-administration with sodium formate (2 mM) did not enhance 
intracellular levels of osmium (Section 3.3.9, Fig. 3.11). 
Cell cycle analysis was performed on A549 cells treated with SS-2 (p-Br), again in 
the presence of sodium formate (0-2 mM). In this case, cells were fixed with ice-
cold ethanol to permit membrane-permeation of PI. The PI fluorescence was 
monitored using the FL2 channel (red-fluorescence) by flow cytometry and the cell 
cycle populations (sub-G1, G1, G2/M and S-phases) were fitted to experimental data 
using FlowJo V10 software.  




Cells treated with SS-2 in the absence of formate revealed slight G1-arrest compared 
to the untreated control cells (ca. 7% increase in the G1 population, Section 3.3.7, 
Table 3.4). Importantly, co-administration of SS-2 (p-Br) with formate revealed a 
similar extent of G1-arrest (ca. 11% increase in the G1 population) which suggests 
the formate does not alter the mechanism of action, but merely enhances the 
observed antiproliferative effect. The same trend was observed for RR-1 under the 
same conditions (0-2 mM sodium formate) but in A2780 cells.2, 10 Furthermore, it 
was deduced that the antiproliferative mechanism of action in A549 cells is likely 
enhanced by formate co-administration, but not altered – correlating with the 
observed increase in antiproliferative activity in the presence of formate (Section 
3.3.6, Fig. 3.6). 
Interestingly, this differs from the clinically-approved anticancer drugs cisplatin, 
which causes G2/M phase cell cycle arrest,
78 disrupting the growth and mitotic (cell 
division) stage through the formation of DNA crosslinking in the cell nucleus. 
When DNA is damaged, the G2-phase checkpoint prevents cells from entering 
mitosis (M-phase), further preventing the proliferation of cells. In contrast, the G1-
phase promotes cell growth in preparation for DNA synthesis (S-phase), thus, drug-
induced G1-arrest implies that DNA is likely not the primary target. Both parent 
compound RR-1 and Br-labelled SS-2 did not demonstrate G2/M arrest, which is 
suggestive of a non-DNA targeting anticancer mechanism of action.  This is in 
strong agreement with reported work demonstrating that RR-1 is non-apoptotic in 
nature,2, 10 and exhibits an antiproliferative effect through the intracellular targeting 
of pyruvate in response to metabolic stress.  
 
  




3.4.6    Zebrafish toxicity  
 
Zebrafish have been used as well-established models to predict drug toxicity in 
humans;79 75% of the human genes have at least one zebrafish orthologue and share 
a variety of phenotypes with humans.80 Zebrafish embryos can be used as high-
throughput vertebrate models: they are cheap, easy to handle and can readily be 
used to investigate solubilized compounds.14 It has recently been reported that a 
fluorescently-labelled OsII arene sulfonamide complex can selectively generate 
ROS in zebrafish.2, 14 Herein, the half-maximal lethal concentrations (LC50) of 
complexes SS/RR-2 (p-Br) in SG-WT zebrafish embryos were determined in order 
to gain an insight into the in vivo biocompatibility and selectivity of this family of 
osmium compexes (Section 3.3.8, Table 3.5). The LC50 concentrations (µM) of Br-
labelled enantiomers SS/RR-2 were determined to be the same (3.7±0.3 and 4.1±0.1 
µM, respectively), suggesting that the chirality does not alter the in vivo toxicity. 
Interestingly, comparison with parent compound RR-1 (LC50=2.4±0.4 µM) 
revealed that SS/RR-2 were 1.5× less toxic towards zebrafish.14 Nonetheless, the 
LC50 concentrations of RR-1 (p-CH3) and SS/RR-2 (p-Br) were of the same order 
of magnitude (ca. 3 µM), suggesting that substitution on the sulfonamide moiety 
does not drastically alter the in vivo toxicity. 
Drug toxicity is a major concern for clinical platinum drugs - a consequence of 
limited selectivity (for cancer vs. healthy cells), resulting in unwanted patient side 
effects. The undesired targeting of healthy tissue ultimately reduces drug efficacy, 
limiting the effectiveness of the treatment. Importantly, the toxicity exhibited by 
SS/RR-2 (p-Br) was less pronounced in zebrafish embryos compared to cisplatin 
(LC50=0.6±0.2 µM),
14 which is likely associated with the localised generation of 
ROS by these osmium complexes.14 Redox-mediated mechanisms of action have 
been implicated for various half-sandwich OsII and RuII complexes,61, 81, 82 
providing novel antiproliferative mechanisms of action compared to conventional 
PtII drugs. Importantly, due to the extreme redox stress exhibited by cancer cells, 
this may provide the opportuinity to increase drug selectivity to enhance efficacy 
and lessen toxic side effects. Overall, the toxicities of 2 (p-Br) in zebrafish embryos 
closely resembled that of parent compound 1 (p-CH3) - both of which were 
significantly less toxic compared to cisplatin.2, 14  




3.4.7    Combined 189Os and 79Br cellular accumulation  
 
189Os and 79Br ICP-MS methods optimisation 
All of the Os cellular accumulation data discussed thus far in this Chapter have been 
analysed in stabilised 3.6% v/v stabilised nitric acid (supplemented with 100 mg/L 
L-ascorbic acid and 10 mM thiourea), to prevent the formation of volatile OsO4 and 
stabilize Os in acidic conditions.83 The objective for synthesizing a Br-labelled 
catalyst was to quantify both Os and Br concentrations inside cancer cells, to gain 
information on the localization, speciation and stability of this family of complexes. 
ICP-MS quantification of Br is even more difficult than Os. Bromine exists as two 
stable isotopes: 79Br and 81Br with natural abundances of 50.54% and 49.46%, 
respectively.84 Quantification of Br by ICP-MS is challenging as a consequence of 
the high first ionisation potential (11.8 eV),85 and common polyatomic interferences 
with m/z=79 or 81, including 40Ar39K+ or 31P16O3
+ (m/z=79) and 32S16O3
1H+ or 
40Ar40Ar1H+ (m/z=81).86  
Initially, a calibration of Os and Br in stabilized nitric acid was analysed, which 
proved unsuccessful for Br detection. This was not surprising as nitric acid is a 
strong oxidizing agent, which can oxidize bromide to form molecular bromine 
(Br2),
87 which is readily volatile and is released as a gas. To overcome this, 
tetramethylammonium hydroxide (TMAH) – a strong base - was used as a chemical 
modifier to form thermally-stable tetramethylammonium (TMA) bromide salt,88 
which is retained until vaporization. A calibration of Os and Br in 1% m/v TMAH 
formed a linear calibration in the range 0.1-1000 ppb (R2=0.9999), and standard 
recovery experiments of known analyte concentration (complexes 1 and 2) were 
performed, achieving percentage recoveries of >95% for both 189Os and 79Br. 
Subsequently, a cell pellet digestion method in TMAH was optimized based on 
methods reported in the literature.89, 90  
Prior to commencement of cellular accumulation studies, triplicate solutions of Br-
labelled SS-2 (of known concentrations) were prepared in 1% m/v TMAH and 
analysed by ICP-MS. Percentage recoveries >95% were achieved for 189Os and 
79Br, and an osmium-to-bromine ratio (189Os:79Br) of 1:1 for SS-2 was confirmed. 
The amount of intracellular Os determined in A549 cells treated with 1 (p-Br) for 
24 h and analysed in nitric acid (16±5 ng Os/106 cells, respectively) was 




significantly lower than that in TMAH (46±3 ng Os/106 cells; p=0.0030). This may 
imply strongly alkaline conditions may be more efficient at stabilising Os than nitric 
acid supplemented with thiourea and ascorbic acid – potentially due to a reduction 
of memory effects. It must also be noted that the protocol for acid digestion involves 
non-stabilised 72% HNO3 for atleast 12 h (prior to thiourea and ascorbic acid 
addition), which likely contributes to the lower levels of Os observed. 
The use of alkaline solutions (as opposed to strong acid oxidizers) for the analysis 
of Os by ICP-MS has previously been proposed for the determination of osmium in 
natural waters.91  In addition, TMAH digestion of biological samples can promote 
complete solubilisation (protein and lipid matrices) which remain stable at room 
temperature (days to months), subsequently, reducing loss of volatile analytes.92 
Furthermore, this data warrants whether ICP-MS cell digest quantification of Os 
should alternatively be analysed for samples in TMAH. The use of TMAH to detect 
79Br by ICP-MS is well-established in the food industry,93, 94 with emerging 
applications in pharmaceutical research.95 Herein, the simultaneously 
quantification of 189Os and 79Br in TMAH has been optimized to probe the in-cell 
stability and distribution of Br-labelled SS-2 inside A549 lung cancer cells. 
 
189Os-79Br cellular accumulation  
The temperature-dependence on the cellular accumulation of Os in cells treated 
with SS-2 (p-Br) has previously been demonstrated in this Chapter (Section 3.3.9) 
and in the literature for RR-1 (p-CH3).
2 Lower temperatures were shown to 
significantly reduce the Os accumulation in A2780 ovarian cancers treated with 
RR-1 (p-CH3) or SS-2 (p-Br) – indicating an active contribution to the uptake of 
these complexes. The same experiment was conducted in A549 cells treated with 
SS-2 for 3-6 h, at 310 and 277 K, but analysed in TMAH (to simultaneously 
quantify Os and Br), revealing a ca. 48% reduction in intracellular Os at 277 K 
compared to 310 K (Section 3.3.10, Fig. 3.12). Again, this suggests a dependence 
on cellular energy (electrochemical gradients) in the cell uptake of SS-2. Similarly, 
a more pronounced reduction in intracellular Br was observed (ca. 75% decrease), 
which may suggest temperature-dependent changes in the rate of efflux of the Br 
and Os modalities. 




Interestingly, a comparison of the intracellular Br/Os ratio revealed ca. 12× more 
Br under physiological conditions (310 K), suggesting that after just 6 h exposure, 
the chelated Br-ligand dissociates from SS-2 inside cells. Of course, the potential 
cleavage of the C-Br aromatic bond must be considered, however, in general aryl 
halides are highly stable and unreactive towards nucleophilic substitution (SN1 or 
SN2) owing to steric hinderance, short C-X bonds (sp
2 hybridization) and resonance 
delocalisation (partial double bond nature),96 thus, C-Br bond cleavage likely does 
not occur in a biological environment. This concept has previously been 
demonstrated with Ar-Br and Ar-I bonds in rhenium,97 platinum53 and ruthenium32 
complexes in cancer cells using XRF. As the Br-substituent is in an apparent inert 
(unreactive) site of the benzene ring,14 it was deduced that the 79Br detected 
corresponds to either “free” BsDPEN ligand or intact SS-2, and not bromide (Br-). 
Furthermore, significantly higher levels of Br inside the cells may suggest the free 
BsDPEN ligand has dissociated from the Os centre and remains intracellularly for 
a longer time period. 
Cells treated with SS-2 at lower temperatures (277 K) showed ca. 5× more Br vs. 
Os, implying that at lower temperatures more of the complex may be intact, but at 
much lower overall quantities. This implies that the uptake of intact SS-2 is likely 
dependent on active uptake pathways. Cellular accumulation studies do not give a 
direct indication of cellular uptake, but instead a combination of both influx and 
efflux, thus, active efflux mechanisms may also be involved. Incubating cells at 
lower temperatures reduces the rate of cell growth, and may also affect the optimal 
activity of organelles or biomolecules responsible for the detoxification and 
excretion of drugs. For example, temperature changes can alter features including 
membrane nuclei acid topology and protein function.98 This may explain the 
increased intracellular stability of SS-2 (smaller Br/Os ratio) at 277 K compared to 
310 K. Overall, this data reaffirms that the cellular accumulation of Br-labelled SS-
2 and parent compound RR-1 (p-CH3) are somewhat reliant on active cellular 
accumulation mechanisms.2, 10  
The dependence on active cellular uptake pathways has been reported for a variety 
of organometallic complexes including half-sandwich OsII,99 RuII and IrIII 
complexes,17, 100 which may be essential in overcoming the reduced cellular uptake 
of PtII chemotherapeutics. This data also provides evidence into the poor 




intracellular stability of this family of OsII sulfonamide complexes, which may 
explain the low catalytic turnover of pyruvate to lactate of RR-1 (p-CH3) in cancer 
cells co-administered with sodium formate over 24 h.2 
To further explore the dependence of active mechanisms of uptake of SS-2 (p-Br) 
in cancer cells, accumulation studies were conducted using a known endocytotic 
inhibitor: methyl-β-cyclodextrin.101 Endocytosis is a process for which molecules 
are taken into cells via. membrane invaginations, which then bud off into vesicles 
inside cells. Endocytotic pathways are modified in cancer cells,102 which play 
crucial roles in the development of multi-drug resistance, thus, are of much interest 
in the development of chemotherapeutics. In particular, caveolae (lipid raft 
membrane invaginations) have an important role in endocytosis and is a highly-
regulated mechanism of uptake.101 Methyl-β-cyclodextrin is a known caveolae 
endocytotic inhibitor which prevents the uptake of small molecules via fusion with 
vesicles.101  Herein, A549 cells were treated with SS-2 for 24 h and co-administered 
with non-toxic concentrations of methyl-β-cyclodextrin (0-1 mM).  
The Os accumulation decreased by around 60% with increasing inhibitor 
concentration (Section 3.3.10, Fig. 3.13), suggesting that the uptake of SS-2 (p-Br) 
is caveolae-dependent. As RR-1 (p-CH3) and SS-2 (p-Br) are mildly hydrophobic 
(LogP=1.01 and 1.45, respectively), the dependence of these complexes on 
caveolae for cellular uptake is not surprising. In contrast however, the intracellular 
Br initially decreased by ca. 30% upon co-administration with the lowest 
concentration of inhibitor (0.1 mM), before plateauing at ca. 400 ng Br/106 cells 
(Section 3.3.10, Fig. 3.13). This may suggest that caveolae endocytosis mediates 
the uptake of the intact 16-electron complex SS-2, but upon entering the cell, the 
complex is degraded thus, demonstrating higher levels of Br-labelled BsDPEN (ca. 
30× more Br vs. Os) which are retained intracellularly. It can be hypothesized that 
Br-labelled SS-2 enters cells intact (where it can perform enantioselective in-cell 
catalysis), but is degraded intracellularly over time. Moreover, the free Br-labelled 
BsDPEN ligand may be less susceptible to efflux from the cell compared to the 
remaining Os fragment, thus, is retained intracellularly for longer. 
 




In cancer cells there are various reducing agents including GSH, L-ascorbic acid, 
and low molecular weight antioxidants (e.g. metalloproteins) which have been 
associated with drug detoxification.103 In particular, GSH has been implicated in 
the detoxification of RR-1 in cancer cells (shown using L-BSO assays),2 hence, the 
intracellular breakdown of SS-2 is not suprising. In addition, the dependence on 
active “energy-dependent” cell accumulation pathways may implicate active 
breakdown mechanisms, for example by lysosomes/endosomes or efflux pumps 
(including PGP) which are modified in cancers and are implicated in resistance.40   
The speciation of the dissociated sulfonamide ligand is not known, and requires 
further investigation using advanced techniques (e.g. XANES or EXAFS analysis). 
Overall, the hydrophobicity of RR-1 (p-CH3) and SS-2 (p-Br) likely facilitates 
cellular uptake via caveolae endocytosis (active transport). Caveolae-specific drug 
uptake can have benefits in the development of targeted drug delivery (e.g. through 
specific interactions with membrane receptors),104 however, caveolin-1 has also 
shown to promote chemotherapeutic resistance.105 This may have detrimental 
consequences in the future development of these OsII catalysts for sustainable use. 
Alternatively – although the BsDPEN ligand itself does not exhibit antiproliferative 
activity against cancer cells (IC50>100 µM) – this cannot rule out extracellular 
complex degradation and internalisation of the “free” ligand. Complex SS-2 
exhibits sufficient stability in DMSO and PBS (shown by NMR and UV-Vis), and 
exhibits a 1:1 ratio of Os:Br (ICP-MS) in aqueous solution, however, cell culture 
medium is highly supplemented with components including inorganic salts, amino 
acids and vitamins. This may alter the chemical speciation or stability of 
metallodrugs, which ultimately dictates the in vitro activity.106 For example, 
cisplatin can bind to serum proteins transferrin and albumin which can influence 
the Pt accumulation in cancer cells.107 Moreover, 79Br cellular accumulation studies 
of the Br-labelled BsDPEN ligand are required to confirm extracellular complex 
degradation (in culture medium), which may prove necessary for in vivo translation. 
Cellular influx and efflux mechanisms play a major role in multidrug resistance.25 
In order to investigate the potential active efflux of SS-2 from cancer cells, cellular 
accumulation studies in the presence of a known inhibitor of PGP were performed. 
Cells were treated with 1×IC50 of SS-2 for 24 h, washed with PBS and recovered in 




20 µM verapamil hydrochloride for 24, 48 and 72 h recovery. PGP is an efflux 
membrane transporter which is over-expressed in cancer cells,40 and is responsible 
for the enhanced efflux of chemotherapeutics leading to multidrug resistance.40 
Verapamil is an inhibitor of PGP which blocks “active” efflux via competitive 
inhibition,17 thus, can be used to gain an understanding on drug efflux.  
It has previously been shown for RR-1 (p-CH3) that verapamil significantly reduced 
Os efflux after 24 or 48 h recovery, however no significant change in intracellular 
Os was observed after 72 h.2, 14 Verapamil had the same effect on Br-labelled SS-2 
but only after 48 h (Section 3.3.10, Fig. 3.14) suggesting that Br-substitution does 
not change the PGP-dependent efflux compared to RR-1.2 Multidrug efflux pumps 
- like PGP - can recognize and excrete a wide variety of structurally diverse 
substrates,108 presenting a major challenge in the development of cancer 
chemotherapeutics. Interestingly, cisplatin is not a substrate for PGP, but over-
treatment with cisplatin can lead to MDR (e.g. it may cause PGP expression).109 
PGP-dependent efflux plays a considerable role in enhancing the efflux of clinical 
anticancer drugs,110 and for organometallic ruthenium,17, 111 osmium14 and iridium 
complexes.112, 113  Furthermore, the need for new anticancer drugs which can 
circumvent PGP-dependent efflux and other such efflux pathways may be crucial 
for overcoming resistance in cancer cells. For example, Dyson et. al. synthesised a 
half-sandwich RuII complex tethered to a PGP-inhibitor (phenoxazine) which 
improved drug cytotoxicity and reduced PGP-dependent efflux.114 This work would 
further benefit from investigating other means of cellular efflux, for example the 
inhibition of expression of epidermal growth factor receptor (EPGR) expression 
which reduced the efflux of Os and Ru complexes.115  
Interestingly, intracellular quantities of Br were unaffected by verapamil – 
revealing no changes in Br accumulation compared to recovery in complex-free 
media (Section 3.3.10, Fig. 3.14). This observation (in addition to significantly 
higher quantities of Br vs. Os) provides evidence for complex degradation via 
BsDPEN ligand dissociation. Importantly, the differences observed between Os and 
Br upon verapamil recovery suggest that the excretion of the Os moiety (assumed 
to be the intact complex) is PGP-dependent, but the ‘free’ Br-BsDPEN ligand is 
not. Moreover, it may be possible that the BsDPEN sulfonamide ligand is less 
susceptible to cellular excretion compared to the Os metal modality. 




Alternatively, the ligand may not be a compatible PGP substrate (which can further 
be predicted through molecular docking studies),116 or may be strongly bond to 
other cellular modalities (i.e. by metal chelation). Sulfonamides themselves 
constitute an important class of drugs,117 many of which have shown to exhibit 
antitumour activity both in vitro and in vivo. As Br-labelled BsDPEN alone is non-
toxic towards cancer cells (Section 3.3.5, Table 3.3), complexation with Os may 
facilitate passage into cells, where it can be released intracellularly. The delivery of 
bioactive ligands via transition metal complexes is emerging as a feasible approach 
in the design of chemotherapeutics. Notably, Hambley et. al. used fluorescence 
lifetime imaging and XAS to demonstrate the release of bioactive curcumin into 
cancer cells via a cobalt chaperone, which significantly enhanced drug stability and 
efficacy compared to the free drug.118 The formate-dependent antiproliferative 
activity of RR-1 (p-CH3) and SS-2 (p-Br) depend on the BsDPEN ligand remaining 
coordinated to Os, however, catalysis is likely not the only mechanism of action. It 
is not yet known whether the “free” organic sulfonamide moiety is contributing to 
the antiproliferative effect. 
The time-dependent intracellular stability of complex SS-2 (p-Br) was investigated 
in A549 cells treated with 1×IC50 for 3, 6 and 24 h (no recovery) and 24 h with 24, 
48 and 72 h recovery, respectively (Section 3.3.10, Fig. 3.15; Appendix, Table 
A12). The time-dependent influx/efflux of Os of SS-2 closely correlates with that 
of parent compound RR-1 (reaching a maximum at ca. 6-8 h),2, 10 reaffirming that 
Br-labelling of the sulfonamide ligand does not dramatically alter the Os efflux 
(Section 3.3.9, Fig. 3.10). Importantly, upon removal of the extracellular drug 
solution, the Os was slowly removed from the cell over 72 h – presenting a longer 
in-cell lifetime of SS-2 suitable for catalytic therapy (maximizing the catalytic 
efficiency). Similar accumulation properties of conventional half-sandwich OsII-
azopyridine complexes have also been reported,23, 119 suggesting that slow 
detoxification is non-specific for these 16-electron OsII complexes. Similarly, even 
slower influx/efflux profiles were observed for structurally-similar RuII half-
sandwich complexes – reaching maximal intracellular Ru quantities between 24-48 
h exposure, before gradual detoxification and excretion.17 Moreover, despite the 
poor antiproliferative potency of RR-1 (IC50=21.1 µM),
2, 10 slow complex 
influx/efflux proves more appropriate for intracellular catalytic activation.2, 10 




Significantly higher levels of intracellular Br were observed for all the time points 
monitored (Section 3.3.10, Fig. 3.15), reaffirming complex degradation and 
dissociation of the Br-labelled BsDPEN ligand. After just 3 h exposure to SS-2, ca. 
11×more Br vs. Os was present intracellularly, suggesting rapid complex 
degradation in a cellular environment. Again, this provides an explanation to the 
low 24 h catalytic turnover of pyruvate to lactate by RR-1 (p-CH3) in cancer cells.
10  
 
189Os-79Br cellular distribution studies 
In order to probe the potential intracellular targets of SS-2 (p-Br) in A549 cells, the 
subcellular distributions of both 189Os and 79Br were determined using a cell 
fractionation kit and ICP-MS (Section 3.3.11, Fig. 3.16; Appendix, Table A17-
18). Os was predominantly in the membrane fraction (>65%) – which contains 
particulates (e.g. mitochondrial and lysosomal organelles), in strong agreement 
with that reported for RR-1 (p-CH3).
2 The development of mitochondrial-targeting 
organometallic complexes is of significant interest as an alternative approach to 
DNA-targeting cisplatin, through redox mechanisms of action. In particular, OsII 
azopyridine half-sandwich complexes have been reported to localize in small 
elliptical compartments and induce mitochondrial-mediated apoptosis23, 50 – 
implicating mitochondria as a major therapeutic target. However, as the membrane 
fraction also contains other cytoplasmic organelles, the observed Os accumulation 
may be suggestive of other targeting moieties, such as lysosomes – which play a 
role in the excretion and degradation of unwanted cellular materials by exocytosis. 
Importantly, negligible amounts of Os (<6% of total cellular Os) were present in 
the nuclear fraction over the analysed period, which suggests the nucleus is not the 
primary therapeutic target – ruling out a DNA-binding mechanism of action. This 
is in strong agreement with the low nuclear quantities (<2%) of parent compound 
RR-1 (p-CH3) observed in A2780 cancer cells and quantified by ICP-MS.
2, 10 
Significantly higher quantities of intracellular Br vs. Os were observed in A549 
cells treated with SS-2 over the analysed period (Section 3.3.11, Fig. 3.16), in 
agreement with the cellular accumulation studies described in this Chapter. This 
supports the hypothesis of intracellular complex degradation via BsDPEN ligand 
dissociation, resulting in different quantities of intact Os complex and free 




sulfonamide ligand. This could mean that Os complexation acts as a chaperone for 
delivering sulfonamide ligands into cancer cells, where the (potentially) toxic 
ligand is released. However, further work is required to corroborate this: 79Br ICP-
MS uptake studies of the Br-BsDPEN ligand to see whether osmium complexation 
is crucial for cell permeation. 
The majority of intracellular Br was distributed in the membrane fraction (>58%), 
correlating with that of Os (Section 3.3.11, Fig. 3.16), suggesting there might be 
some intact complex present in cytoplasmic organelles (e.g. mitochondria or 
lysosomes). Significantly more intracellular Br was observed in the cytosolic 
fraction (6-12%), compared to Os (<3%), which may imply potential interactions 
of the BsDPEN ligand with cytoplasmic proteins. This may suggest different 
cellular targets of the intact Os complex (for in-cell catalysis) and the dissociated 
BsDPEN ligand – for which any possible binding moieties are unknown. Moreover, 
this may suggest a multi-targeting mechanism of action of this family of complexes.  
Remarkably, 10-20% of the intracellular Br was present in the nuclear fraction, 
which may implicate a potential DNA-binding antiproliferative mechanism 
mediated by the dissociated BsDPEN ligand. However, this contradicts cell cycle 
flow cytometry studies in cells treated with SS-2 (Section 3.3.7), which revealed 
slight G1-arrest (growth stage) and not S (DNA-synthesis) or G2/M-arrest (growth 
and mitosis), implying minimal DNA-damage. The nature of the interactions 
between BsDPEN ligand and DNA (if any) is unknown, and could involve binding 
to metals involved in the stabilisation of DNA (e.g. Zn2+ or Mg2+), interacting with 
nucleobases, intercalating DNA or high mobility group proteins (positively-
charged). This is difficult to probe without further knowledge of the ligand 
speciation in the nuclear environment.  
The overall intracellular micromolar quantities of Os and Br per cell were estimated 
from the cell fractionation data by normalizing total cellular quantities to the 
average volume of an A549 cell (1.67 pL).29 This revealed total cellular Os and Br 
concentrations of 0.14 and 4.3 mM, respectively, after 24 h exposure (no recovery). 
Although the overall intracellular Os quantity can be normalized to the average cell 
volume, the volume of individual fractions cannot be determined, thus, fractional 
nanomoles of Os and Br per fraction have been reported. Negligible nuclear 




quantities of Os (<1.5×10-8 nmol per cell) were observed, compared with that of Br 
(>25×10-8 nmol per cell), reaffirming that SS-2 is primarily non-DNA targeting – 
as reported for RR-1 (p-CH3).
2, 10 This also supports the hypothesis of multiple 
mechanisms of action: in-cell catalysis, ROS generation and intracellular targeting 
of the sulfonamide ligand. 
 
3.4.8    Synchrotron-XRF  
 
The elemental preservation of biological elements in frozen-dehydrated cells on 
Si3N4 membranes has been reported in the literature.
120 Ideal analysis would be 
performed on frozen-hydrated samples (cryogenic temperatures) as demonstrated 
at beamlines ID16A (ESRF, Grenoble)48 and 9-ID-B (APS, Chicago),121 however, 
these facilities are not yet available at DLS (Oxford). Nonetheless, room 
temperature analysis of frozen-dried cells reported in this thesis have avoided the 
use of chemical fixatives (which can distort morphology chemical integrity). 
 
Elemental preservation and cellular morpology  
A population of A549 lung cancer cells was grown on Si3N4 membranes and treated 
with SS-2 (1-5×IC50, 24 h), cryo-fixed and dried were analysed by synchrotron-
XRF. An incident x-ray energy of 15 keV – exceeding the electron-binding energies 
of Os (L3 2p3/2=10.9 keV) and Br (K 1s=13.5 keV) was used - resulting in element-
specific XRF. Individual cells in the population were selected for high-resolution 
XRF analysis (100 nm resolution), with at least 3 cells mapped per condition. In 
turn, the XRF of native biological elements (Zn, S, P and K) were monitored 
allowing cells to be identified and imaged. It must also be noted that cellular 
elements are also present in biological media (FCS and DMEM) used in this 
experiment (Appendix, Table A1-2), which may affect the elemental quantities but 
likely does not affect the distribution. 
 
 




Zn, S, P and K are highly abundant elements, distributed within the cell in different 
regions and concentrations. Sulfur has roles in energy-generation (i.e. ferredoxins 
in the mitochondrial electron-transport chain), and is a major component of proteins 
(e.g. cysteine and methionine), which are essential for enzymatic catalysis in 
metabolic processes. Phosphorus is present in the cell in a variety of different forms, 
from phospholipid bilayers in membranes to the phosphodiester backbone of DNA, 
in addition to ATP (energy molecule) and RNA.  Potassium is the primary cation 
found intracellularly (ca. 140 mM)122 and is necessary for the regulation of 
metabolism and intercellular communication. Finally, intracellular zinc (0.2-0.3 
mM)123 plays essential roles in enzyme catalysis, protein regulation and DNA 
synthesis, allowing cell nuclei to be identified through highly localized zinc.54 The 
high biological abundance of these elements has been exploited to locate cells on 
the supporting membrane, but also to identify the overall shape of the cell nucleus. 
In general, the untreated cells (C1-4, Section 3.3.12, Fig. 3.19) were largely 
stretched out (cobblestone-shaped) on the membrane, with a clear distribution of P, 
S and K showing the overall cell outline, with nuclei visible from the strongly 
localized intracellular Zn. Importantly, the endogenous distributions of Zn, S and 
K observed correlate with the XRF maps of A549 cells previously reported.31, 32 
Cells C1-4 ranged in size from 624–925 µm2 (766±126 µm2) and an average 
roundness factor of 0.33±0.04 (where perfect circularity=1; Appendix, Table A20) 
supporting the elongated nature typical of that of A549 cells.28, 29 As expected, these 
untreated A549 cells did not contain detectable Os or Br, thus, validating the 
experiment. It must be noted that differences in transparency of this population of 
A549 cells were observed (Fig. 3.30), most likely as a result of damage during cryo-
fixation or freeze-drying. To address this, cells exposed to the same conditions but 
on independent Si3N4 membranes were selected to ensure a reliable representation 
of the population of cells. In general, A549 cells have elongated 2D morphologies 
with large cytoplasmic-to-nuclear volume ratios.28, 29  The mapped cells showed 
consistent morphologies and elemental distributions typical of native A549 cells. 





Figure 3.30. Light microscopy images of cryo-fixed and dried A549 cells grown on Si3N4 
membranes and exposed to the same conditions (24 h complex-free media), showing the 
differences in cell transparency. Differences are likely attributed to blotting and washing. 
 
Cells were treated with 1, 3 and 5×IC50 of SS-2 (p-Br) for 24 h, and a total of 14 
cells were mapped by XRF (Section 3.3.12, C5-18, Fig. 3.20-22): (i) 1×IC50 (C5-
8); (ii) 3×IC50  (C9-15); (iii) 5×IC50 (C16-18). Cells treated with 1×IC50 of SS-2 
(C5-8) showed variance in cell morphologies, with respect to their 2D shape 
(circular, rounded or elongated), size (area, length and width) and their nuclear-to-
cytoplasm ratios (Section 3.3.12, Fig. 3.20). The ‘rounding-up’ of a cell can be 
indicative of significant cell damage, and commonly accompanies cell death 
pathways.124 The efficiency of surface adhesion of cells also decreases upon 
increasing damage, resulting in less stretched-out cells (C5-8, Section 3.3.12, Fig. 
3.20). Cell nuclei in these treated cells (C5-8) were clearly distinguishable from the 
rounded and highly-localized Zn distributions, indicative of an intact and non-
compromised cell nucleus. 
Correspondingly, cells treated with a higher concentration (3×IC50) of Br-labelled 
SS-2 (C9-15, Section 3.3.12, Fig. 3.21) were significantly smaller in size compared 
to those treated with 1×IC50 (C5-8, Fig. 3.20) and the untreated controls (p=0.0074; 
C1-4, Fig. 3.19), with significantly more rounded features (ca. 2× more rounded, 
mean RF=0.33±0.04 and 0.75±0.16, respectively). This observation may be 
suggestive of dose-dependent cell death, complementing the linear concentration-
dependent Os accumulation studies reported in this Chapter (Section 3.3.9). 
 




Cells treated with the highest concentration of SS-2 (5×IC50) exhibited similar 
roundness properties compared to 3×IC50 (C16-18, Section 3.3.12, Fig. 3.22), 
however, showed an increase in cell area compared to 3×IC50 (p=0.0288) 
subsequently deviating from the observed trend in cell ‘shrinkage’. In these cells 
(treated with 5×IC50), the nuclei appear elongated, and take up a large proportion 
of the now-rounded cells (mean RF=0.88±0.04). Identification of the nucleus in 
C18 is ambiguous due to the sparse intracellular distribution of Zn owing to cell 
damage. No trends in the size of individual cell nuclei of cells treated with 0-3×IC50 
of SS-2 were observed (Appendix, Table A21), with mean areas of 130±21 µm2, 
however, nuclei in cells treated with 5×IC50 were significantly larger (266±34 µm
2) 
suggesting that high concentrations of SS-2 inflict increased intracellular damage. 
It is hypothesised that at high doses of SS-2, nuclear membranes are damaged 
allowing Zn to leak freely into the cytoplasm. Cell shrinkage, membrane-blebbing 
and nuclear fragmentation are typical morphological changes which are indicative 
programmed-cell death.124 Nuclear membrane blebbing and fragmentation can also 
be associated with mitochondrial damage, through the generation of ROS49 – a 
mechanism which has been implicated for these complexes.14  
It is known that this family of OsII complexes do not induce apoptosis,10 thus, the 
observed swelling and membrane damage may be suggestive of a potential necrotic 
cell death pathway.124 Necrosis is defined as a type of cell death which lacks the 
features of apoptosis or autophagy and is somewhat uncontrollable.124 Necrotic cell 
death can be either unregulated (chaotic breakdown under intolerable conditions) 
or programmed (i.e. specific signalling pathways or regulation by 
genetic/epigenetic factors). Typical features of necrosis includes swelling of cells 
and organelles, rupturing of the plasma membrane and leaking of cellular 
contents,124 and been reported for a variety of organometallic complexes including 
rhenium,125 rhodium,126 gold,127 ruthenium and osmium.128 Importantly, necrosis is 
more efficient in reducing cell survival compared to autophagic and apoptotic cell 
death124 – which may be crucial in circumventing cisplatin resistance (which 
predominantly causes apoptosis).126 Although a necrotic (non-apoptotic) cell death 
pathway induced by SS-2 can be proposed, further experimental evidence is needed 
to substantiate this.  
 




Elemental co-localization  
As predicted, Os and Br co-localised moderately in the cytoplasm of cells treated 
with 1-5×IC50 of SS-2 (Appendix, Table A22) which has been represented by 
Pearson’s R-value (r), suggesting that some of the BsDPEN ligand remains 
coordinated to the metal centre: a necessity for the enantioselective catalytic 
conversion of pyruvate to lactate.10 Moreover, the co-localization of Os with Br in 
non-nuclear regions of cancer cell supports the hypothesis that ATH catalysis 
occurs in the cytoplasm.10 Os and Zn showed very little correlation (mean r=-0.03, 
Appendix, Tables A23), implying the Os likely does not localize in the nucleus, 
complementing cell fractionation data reported in this Chapter (Section 3.3.11). 
Interestingly, Br moderately co-localized with Zn in the cell nucleus (mean r=0.21; 
Appendix; Table A24), confirming dissociation of the BsDPEN ligand from the 
Os centre after 24 h. 
The coordination of this BsDPEN ligand to the Os centre is essential for catalysis 
as it provides a chiral platform for the reaction to proceed. The observation of Br in 
the cell nucleus may therefore provide an explanation for the previously reported 
low catalytic conversion of pyruvate to lactate after 24 h exposure to RR-1 (p-CH3), 
in the presence of formate.10 Although SS-2 is stable in aqueous conditions (water, 
PBS), the coordinatively-unsaturated nature of these 16-electron complexes makes 
them vulnerable in the highly reducing environment of cancer cells. For example, 
GSH has shown to alter the potency of RR-1 (L-BSO assays),2 implicating GSH as 
a cellular defence mechanism. The limited stability of Br-labelled SS-2 in the 
intracellular environment of A549 cells is therefore not surprising. However, it can 
be hypothesized that some complex must remain intact after 24 h in order to perform 
in-cell catalysis, in agreement with formate-enhanced potency (Section 3.3.6). 
The co-localization statistics seem to support that SS-2 (p-Br) remains intact in 
cytoplasmic regions of cells, however, is not fully stable due to the distribution of 
the Br-labelled ligand within the cell nucleus, indicative of complex degradation 
and instability after 24 h. Nonetheless, these statistics support the hypothesis that 
intact SS-2 is not primarily DNA-targeting (due to the lack of nuclear Os), and may 
act as a chaperone to deliver the BsDPEN ligand into the nucleus. 
  




Quantification of Os and Br 
In order to calculate mole fraction quantities of elements in individual cancer cells, 
a reference AXO Si3N4 membrane (of known elemental concentrations) was 
analysed by XRF and used to estimate the photon flux (photons/second), assuming 
a maximal cell thickness of 6 µm.55 When quantifying element by XRF, two factors 
must be considered: (i) matrix-matching between the sample and the internal 
standard is difficult and imperfect129; (ii) an assumption about sample thickness and 
homogeneity is assumed. As a consequence, XRF quantification is only semi-
quantitative, and requires cross-correlation with techniques such as LA-ICP-MS.130 
The Os in cells treated with 1 or 3×IC50 SS-2 revealed predominant cytoplasmic 
(non-nuclear) localization (ca. 80%), implying that the cell nucleus is not the major 
in-cell target. This is in agreement with 189Os-79Br ICP-MS cellular fractionation 
studies of SS-2, which revealed <6% of Os in the cell nucleus (Section 3.3.11). 
Additionally, flow cytometry analysis of parent compound RR-1 (p-CH3) 
demonstrated non-apoptoic cell death,2 supporting the hypothesis of a non DNA-
mediated mechanism of action. However, the lack of Os in the cell nucleus cannot 
completely eliminate the prospect of DNA-targeting: DNA is a major target of 
cisplatin, despite only 1% reaching the cell nucleus.131 
Correspondingly, cells treated with 5×IC50 of SS-2 revealed ca. 60% of Os in the 
cytoplasm. A reduction in cytoplasmic Os was observed in cells treated with 5×IC50 
of SS-2 compared to those treated with lower concentrations. This is likely 
attributable to concentration-dependent cell damage (membrane damage, elemental 
leaching and cell swelling – typical features of necrosis)124 which made 
distguinishing between the cell nucleus and cytoplasm ambiguous. In comparison, 
the localization of Br in the cytoplasm decreased from ca. 70% to 50% with 
concentration (1-5×IC50) of SS-2, whilst the nuclear Br increased from ca. 30% to 
50%. An increase in intranuclear Br with concentration may be a consequence of 
cell damage: for example, ruptured nuclear membrane or nuclear fragmentation.49  
Significantly higher intracellular levels of Br vs. Os were observed in cells treated 
with SS-2, with at least 3× more Br in all of the individually analysed cells (Section 
3.3.12, Table 3.8), which is indicative of complex degradation (as previously 
discussed). The reduced intracellular levels of Os may also suggest that the Os 




moiety is more susceptible to rapid excretion from the cell, with more Br-labelled 
BsDPEN remaining intracellularly. Herein, ICP-MS cellular accumulation studies 
revealed the potential PGP-dependent efflux of the Os component of SS-2, but not 
the Br component (Section 3.3.10, Fig. 3.14) - implicating different excretion 
pathways of intact complex and the unbound sulfonamide ligand. The excretion of 
Os is likely facilitated through binding to efflux proteins, whereas the chelating 
sulfonamide may favour binding to alternative cellular modalities, for example, 
chelating endogenous metal ions (e.g. Zn, Cu, Fe – although the concentration of 
“free” unbound ions is low) or forming interactions with biomolecules (proteins, 
lipids, DNA) – which may enhance the intracellular lifetime compared to Os. 
The mean bromine-to-osmium (Br/Os) molar ratio in cells treated with 1-5×IC50 of 
SS-2 revealed a significant decrease between 3 and 5×IC50 (p=0.0019), implying 
more of the complex is intact at higher concentrations of SS-2. Furthermore, it may 
be possible that either detoxification is less pronounced (due to increased cell 
damage) at higher drug concentrations, or that the uptake of SS-2 is faster.  
It has already been shown by 189Os ICP-MS that the accumulation of osmium is 
linearly dependent on the concentration of SS-2 (Section 3.3.9, Table 3.7), in 
addition to sigmoidal dose-response in cell viability assays, thus, it is likely that the 
antiproliferative activity is enhanced with concentration. Moreover, treatment with 
higher drug concentrations likely causes increased cell damage – potentially a 
consequence of reduced cellular defence mechanisms. Drug-induced changes in 
cell homeostasis renders cells more vulnerable, preventing the efficient excretion 
of drugs, which usually leads cell death. Furthermore, this may explain why cells 
treated with 5×IC50 showed a higher percentage of intracellular intact complex 
(mean Br/Os=2.3±0.1; Section 3.3.12, Table 3.8). As the linear dependence on 
concentration of Os accumulation in cells treated with SS-2 was only demonstrated 
up to 1.5× IC50, this hypothesis can be further probed by performing 
189Os-79Br 
uptake studies at 5×IC50 concentration (however, this will require a larger cell 
seeding population to account for expected increases in cell death). Likewise, time-
dependent 189Os-79Br accumulation at higher doses of SS-2 can be performed to 
probe whether the rate of uptake / efflux changes with drug concentration. 




Drug-induced damage to the plasma membrane of cells treated with 5×IC50 of SS-
2 may also cause elemental-leeching of Os, Br and Zn making the discrimination 
between intracellular and extracellular elements challenging. High concentrations 
of SS-2 may cause the cancer cells to swell or burst, supporting the hypothesis of 
necrotic-mediated cell death.124 This can be probed using membrane integrity flow 
cytometry at higher concentrations of SS-2 to determine whether very high 
concentrations of these osmium catalysts compromise cell membranes.  
 
Lysosomal sequestration  
The most intriguing discovery from synchrotron-XRF was the co-localization of Os 
and Br in small, vesicle-sized compartments in the cell cytoplasm, which were 
identified only in cells treated with 3-5×IC50 of SS-2 (p-Br). The area of each 
compartment was calculated in triplicate using the multipoint selection tools in 
ImageJ,19 which also enabled the quantification of both Os and Br in each ‘vesicle’. 
These compartments revealed mean areas of 0.59±0.22 and 0.78±0.25 µm2 for 3 
and 5×IC50, respectively. The mean bromine-to-osmium ratio (Br/Os) in the 
vesicle-sized compartments in 6 different cells (treated with 3×IC50 of SS-2) was 
calculated to be 4.5±2 (Section 3.3.12, Table 3.10) again implying ca. 4× more 
intracellular Br vs. Os. Interestingly, the vesicle-like structures observed in cells 
treated with 5×IC50 of SS-2 revealed mean Br/Os ratios of 1.48±0.18. This may 
suggest some co-localisation between Os and the Br-labelled BsDPEN ligand 
(intact complex) in these vesicle-like structures, which may be attributed to 
cytoplasmic organelles. As there are significantly higher levels of Br vs. Os for all 
cases, this may implicate degradative organelles (e.g. lysosomes or endosomes) in 
the breakdown of these complexes. 
Lysosomes are acidic intracellular organelles in eukaryotic cells (0.1-1.2 µm in 
diameter)132 which have important roles in the excretion and degradation of 
unwanted cellular components, and also partake in cellular processes including 
repairing membrane damage and apoptosis. Lysosome-targeted anticancer therapy 
is becoming of increasing interest to mediate multidrug resistance, providing new 
modes of action through sub-organelle localization. The sequestration of 
hydrophobic anticancer agents (e.g. doxorubicin) in lysosomes has been reported in 




the literature,133 which impacts lysosomal biogenesis and exocytosis. This may 
provide the opportunity to overcome resistance, and prevent procurement of 
aggressive tumour phenotypes. 
The acidic nature of lysosomes (pH 4.5–5) may promote the protonation of complex 
SS-2 – most likely at the basic NH- of the coordinated BsDPEN ligand – facilitating 
ligand dissociation and complex degradation. Upon protonation, the altered 
structure of the complex may prevent passage through the lysosomal membrane, 
subsequently becoming entrapped in the lysosome.133 Furthermore, the potential 
lysosomal sequestration of SS-2 (p-Br) likely reduces the drug efficacy by 
preventing it reaching its chemotherapeutic in-cell target. This is well-documented 
for platinum in tumour cells,59 and is a major concern in drug resistance. The 
quantity of Br in these compartments was significantly higher than Os which 
suggests that lysosomes may detoxify both the intact complex and the excess 
dissociated Br-labelled BsDPEN ligand. The lysosomal accumulation of weak 
bases is well-reported in the literature, and is predominantly attributed to pH-
partitioning,134 preventing membrane permeation out of the lysosomes. Both the 
intact osmium complex and the unbound sulfonamide ligand can be considered as 
weak bases, hence, it may be conceivable that both the intact complex and the 
BsDPEN ligand may be encapsulated within lysosomes. Moreover, as there is 
significantly more Br vs. Os in the cell cytoplasm, it may be hypothesised that 
complex breakdown occurs in both the cytoplasm and in endosomes/lysosomes. As 
synchrotron-XRF alone cannot identify different cellular organelles, further 
lysosomal-based in vitro assays were performed. 
 
  




3.4.9    Chloroquine inhibition of lysosomal activity 
 
Chloroquine is the mainstay clinically-approved drug for the treatment of malaria, 
and has been reported to be relatively non-toxic towards cancer cells at low 
micromolar concentrations, thus can be utilized as a lysosomotropic agent.56-59 
Incubation of cells with chloroquine causes de-acidification of lysosomes by 
preventing autophagy,57, 58 hence, can been used to investigate the potential for 
lysosome-targeting chemotherapeutics. Cells pre-incubated with non-toxic 
concentrations of chloroquine diphosphate (150 µM, 2 h), followed by 24 h 
exposure to RR-1 (p-CH3) or SS-2 (p-Br) revealed a significant increase in potency 
(by  50% and 25%, respectively), implying that lysosomes may be contributing to 
the detoxification and reduced efficacy of these complexes (Section 3.3.13, Fig. 
3.25). Chloroquine has been reported to improve the cytotoxicity of multiple 
anticancer drugs, including doxorubicin and cisplatin,135, 136 with considerable 
implications on reversing multi-drug resistance in cancer cells. 
It must be considered that chloroquine itself may not just affect the lysosomes,60 
hence, to demonstrate that the enhanced potency of RR-1 and SS-2 is a consequence 
of lysosomal activity and not due to membrane damage, chloroquine-dependent 
membrane integrity analysis was performed by flow cytometry upon treatment with 
RR-1 and SS-2 (Section 3.3.13, Figure 3.27). Treatment of cells with chloroquine 
prior to exposure to RR-1 or SS-2 did not reveal cause membrane damage, thus, the 
increased potency was not due to a compromised membrane.  
Further to this, the Os cellular accumulation in A549 cells pre-incubated with 
chloroquine (150 µM, 2 h) with 24 h exposure to RR-1 or Br-labelled SS-2 (1×IC50) 
showed a significant increase in intracellular Os (p=0.0015 and p=0.0251, 
respectively). This implies that the deactivation of lysosomes results in higher 
intracellular levels of Os (ng/106 cells, which is accompanied by increased 
antiproliferative potency (Section 3.3.13, Fig. 3.25). In addition, the molar Br/Os 
ratio decreased in cells preincubated with chloroquine  and exposed to SS-2, 
implying that more of SS-2 remains intact intracellularly upon deactivation of 
lysosomes (Section 3.3.13, Fig. 3.26). Overall, this implicates lysosomes in the 
detoxification of this family of osmium catalysts. 




3.5     Conclusions and future work 
 
A series of OsII 16-electron sulfonamide catalysts with the formula [OsII(p-cym)(R-
BsDPEN)] (2-5, where R=p-Br, I, OMe and m-Br, respectively) have been 
synthesized and characterised. Their properties were closely comparable to parent 
compound RR-1 (R= p-CH3) with respect to structure (x-ray crystallography; DFT), 
hydrophobicity (Log P), solvent stability (DMSO; PBS) and catalytic activity (ATH 
reduction of acetophenone). Complexes 2-5 exhibited high enantiomeric excesses 
(>95%) and turnover frequencies (ca. 80 h-1) in the presence of formic acid (hydride 
source), for the catalytic conversion of acetophenone to (S/R)-1-phenylethanol. 
Substituents which were large, and electron-withdrawing (2 and 3, R=p-Br, I, 
respectively) moderately improved the turnover frequency reported for 1 (p-CH3) 
by approximately 27%.1, 2 Overall, it was deduced that substitution of Br at the para 
site of 1 (R= p-CH3) did not significantly alter the chemical activity of the catalyst. 
Remarkably, the Br-probe did not significantly alter the in vitro biological activity, 
demonstrating similarities in antiproliferative potency (IC50), selectivity factors 
(A549 vs. MRC5), in-cell catalytic activity, alterations in membrane integrity and 
cell cycle and osmium cellular accumulation (concentration; time; temperature; 
extent of efflux; formate-dependent) to that of RR-1 (p-CH3). Notably, the cellular 
accumulation of Os in cells treated with SS/RR-2 (p-Br) was found to be identical 
to that of RR-1 (p-CH3) when using equipotent concentrations (1×IC50), despite the 
difference in potency between RR-1 (IC50=21.1±0.3 µM) and SS-2 (IC50=29.5±0.5 
µM), which implies Br is somewhat hindering the cellular accumulation. This 
correlated with the increased hydrophobicity of RR-1 vs. SS-2  (LogP=1.45 and 
1.01, respectively), which may promote cellular accumulation of RR-1 through the 
highly lipophilic cell membrane. Overall, it was deduced that the antiproliferative 
mechanism of action of RR-1 was unchanged upon Br-substitution, hence, Br-
labelled SS-2 can be utilized as a suitable analogue to elucidate the in-cell activity 
of this family of OsII complexes by correlative ICP-MS and synchrotron-XRF.  
A method for the simultaneous quantification of both Os and Br by ICP-MS was 
optimised using alkaline digestion in TMAH, allowing analysis of readily-oxidised 
analytes (189Os and 79Br) in a matrix with sufficient reactivity to achieve complete 
digestion of cell pellets. Cellular accumulation of Os and Br in A549 lung cancer 




cells treated with SS-2 (p-Br) was determined under varying conditions 
(temperature, methyl-β-cyclodextrin, verapamil, time and cell fractionation). In all 
cases, significantly higher concentrations of Br compared to Os were found (>10-
fold) suggesting that these complexes may have limited stability in a cellular 
environment. This begins to provide an explanation as to why the intracellular 
catalytic turnover of parent compound RR-1 (p-CH3) was so low.
2, 10 
The endocytic contribution to the accumulation of SS-2 (p-Br) was investigated 
using a known endocytotic inhibitor (methyl-β-cyclodextrin), which was shown to 
reduce the quantity of intracellular Os with increasing concentration of inhibitor (by 
ca. 65%). Interestingly, intracellular levels of Br were initially reduced at the lowest 
inhibitor concentration (0.1 mM), but plateaued with increasing concentration, thus 
it may be hypothesized that caveolae endocytosis mediates the uptake of the intact 
complex, but once inside the cell the complex is degraded to release the Br-labelled 
ligand, which is retained intracellularly for longer. 
Similarly to SS-2, the dependence on drug efflux via. pathways associated with 
PGP (determined by incubating cells in verapamil - a known PGP-inhibitor – after 
Os treatment) revealed that the efflux of the Os moiety (assumed to be intact 
complex) is dependent on PGP.2 As verapamil is not entirely specific for PGP-
inhibition, it was deduced that efflux of these complexes is reliant on pathways 
associated with verapamil-inhibition. However, Br accumulation was unaffected by 
verapamil treatment, suggesting that the Br-labelled BsDPEN ligand is not removed 
from cells by PGP. The extent of cellular efflux of SS-2 was monitored using 
varying exposure times and recovery in complex-free media, revealing maximum 
intracellular levels of Os after ca. 3-6 h, as reported for parent compound RR-1.2 
Contrastingly, the intracellular Br reached a maximum after 24 h exposure with 
around 30× more Br vs. Os, indicative of severe complex instability. 
Cellular fractionation studies of A549 cells treated with SS-2 revealed significantly 
more Br vs. Os (>10-fold), with the majority of Os and Br observed in the 
membrane and cytoskeletal fractions. This suggests that some of complex SS-2 is 
intact in the cell cytoplasm, where in-cell catalysis likely occurs, as previously 
hypothesized for RR-1.2, 10 Negligible quantities of Os were present in the nuclear 
fraction (<6%) – which may rule out a DNA-binding mechanism of action. 




Interestingly, 10-20% Br was present in the nuclear fraction, perhaps as unbound 
Br-labelled BsDPEN. Approximately 32× more Br vs. Os was present in the nuclear 
fraction after 24 h exposure to SS-2. It may be hypothesized that the Os complex 
may facilitate the delivery of the BsDPEN into the cell (verified by the lack of 
toxicity of BsDPEN, IC50>100 µM), where it can then be released and tenter the 
nucleus. Whether the presence of BsDPEN is contributing to the anticancer activity 
is unknown, and requires further investigation.  
Synchrotron-XRF confirmed that some of SS-2 is likely to remain intact as judged  
by the co-localization of Os and Br in the cytoplasm of A549 cells, but again with 
significantly higher levels of Br vs. Os – in agreement with ICP-MS accumulation 
studies. Interestingly, XRF revealed the co-localization of Os and Br in small, 
spherical compartments (ca. 0.6 µm2) in A549 cells treated with 3-5×IC50 of SS-2, 
which may imply lysosomal breakdown and complex efflux. This was probed using 
chloroquine (which de-acidifies lysosomes), revealing a significiant increase (ca. 
25-50%) in potency, accompanied by an increase in Os accumulation (ng/106 cells). 
Future work confirming the lysosomal-mediated detoxification of this family of 
osmium catalysts may involve utilizing complementary lysosomotropic bioassays, 
including Neutral Red (eurhodin dye that stains lysosomes of viable cells) or 
LysoTracker staining assays (fluorescence microscopy). Furthermore, correlative 
cryo-SIM (Structured Illumination Microscopy) and cryo-XRT (X-Ray 
Tomography)137 can be used on cryopreserved cancer cells treated with the 
fluorescent sulforhodamine complex (used in zebrafish toxicity studies)14 will 
provide complementary information into the in-cell localisation, distribution and 
detoxification of this family of Os complexes in cryopreserved cells (as close to 
their native state as possible). Correlative cryo-XRT and cryo-XRF can also provide 
unambiguous information on the subcellular distribution metallodrugs.48  
The potential necrotic (non-apoptotic and non-autophagic) mechanism of cell death 
induced by RR-1 (p-CH3) or SS-2 (p-Br) can be further probed using flow 
cytometry using immunofluorescent staining with 7-aminoactinomycin D or 
annexin V.125, 138 Consideration of the formate-dependent distribution of SS-2 
requires investigations either using cellular fractionation (ICP-MS) or synchrotron-
XRF studies. In addition, as SS-2 is only ca. 2-fold selective for cancer vs. healthy 




cells (without formate), the in-cell distribution and localisation in MRC5 fibroblasts 
can be investigated by ICP-MS and synchrotron-XRF, to gain an insights into the 
in vitro toxicity. 
The Br molecular probe of complex SS-2 can further be utilized to perform both Os 
and Br XANES analysis of treated cancer cells,139-141 to gain essential insights into 
the potential in-cell binding moieties of the ‘intact’ complex and the unbound 
sulfonamide ligand. Complementary to this, mass spectrometry proteomics of 
osmium and bromine (79Br; 81Br) can be performed.142 Finally, the concept of triple-
mapping via molecular labelling may be possible, to elucidate the overall complex 
stability: labelling the para-cymene arene group with a molecular probe (i.e. iodine) 
and monitor this by ICP-MS (189Os, 79Br and 127I), or by synchrotron-XRF (Os 
L3M5=8.9, Br KL3=11.9 and I L3M5=3.9 keV).  
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Chapter 4  
 
 
IrIII photosensitisers in cancer cells: 












4.1     Introduction 
 
In this Chapter, synchrotron cryo-X-Ray Tomography (XRT) has been used to 
probe the effect of a potent cyclometallated IrIII photodynamic therapy (PDT) 
photosensitiser (7, Fig. 4.1) on cancer cell organelles. Such studies can provide new 
information on cellular damage and mechanisms of cell death down to a remarkable 
30-40 nm resolution. Additionally, synchrotron-XRF and differential phase contrast 
(DPC) imaging have been used to gain insights into the distribution, targeting and 
intracellular stability of a photodynamic-photochemotherapeutic IrIII-PtIV conjugate 
(8, Fig. 4.1) by monitoring the L3M5 XRF emissions of Ir and Pt (9.18 and 9.44 
keV, respectively). 
 
Figure 4.1. Graphical representation of the techniques used to investigate the intracellular 
mechanisms of action and cellular targets of iridium photosensitisers (7; 8). (a) Structure 
of 7. (b) Structure of 8 (c) Cryo-XRT of PC3 cancer cells treated with 7. (d) XRF and DPC 
imaging of frozen-dehydrated A549 cancer cells treated with 8. 
 
PDT is a non-invasive therapeutic approach in which a non-toxic photosensitiser is 
irradiated locally in tumours by spatially-directed light,1 often generating reactive 
oxygen species (ROS) and inducing cellular apoptosis.2, 3 PDT photosensitisers are 
usually activated by longer wavelength visible light (λ=500-800 nm).4 The limited 
penetration depths means that use in cancer treatment is somewhat confined to 
light-accessible cancers such as prostate or lung cancers.5, 6 The lack of 
photosensitiser toxicity under dark conditions, combined with the controlled 
activation with light may reduce unwanted patient side effects compared to 
conventional chemotherapeutics.7  





Cyclometalated luminescent organo-iridium(III) octahedral complexes have been 
reported as promising photosensitisers for PDT,8-10 and have been shown to induce 
oxidative attack on proteins in cancer cells upon irradiation with light.11 The 
photophysical properties of such complexes mediates their PDT efficiency: fast 
singlet to triplet intersystem crossing (ISC) allows longer excited state lifetimes, 
leading to high yields of toxic ROS and singlet oxygen (1O2).
12 In particular, 
[Ir(C,N)2(O,O)] (7, where C,N=2-phenylpyridine and O,O=diketone; Fig. 4.2) has 
a moderate phosphorescent lifetime (τp=59 ns, λex=458 nm; λp=620 nm) which 
promotes the generation of toxic 1O2 in carcinoma cells through energy transfer.
11  
In addition, oxidative stress induced by 7 in cancer cells was shown to increase the 
expression of glycolytic enzymes (including aldehyde dehydrogenase),11 




Figure 4.2. (a) Structure of 7. (b) Jablonski diagram showing the one- and two-photon 
excitation of 7 in the presence of oxygen: (i) hv=photon energy required for irradiation, (ii) 
S0=singlet ground state; (iii) S1=singlet excited state; (iv) T1=triplet excited state; (vi) 
ISC=intersystem crossing; (vii) P=phosphorescence. 
 
The conjugation of cyclometalated IrIII complexes with additional metal modalities 
may significantly improve the antiproliferative activity and other pharmacokinetic 
factors, which has been shown for various photoactivatable di-iridium and di-
platinum complexes.13-15 The combination of a photosensitiser (PDT) with a 
photoactivatable drug (PACT) in the same compound may improve the 
antiproliferative activity by providing a dual mechanism of action, and improving 
factors such as solubility, pharmacokinetics and cell uptake. In 2020, the Sadler 
group reported the synthesis of a IrIII-PtIV conjugate with the formula trans, trans, 






III(bpy)2]Cl (8, where 
py=pyridine, N3=azide, OH=hydroxyl, bpy=bipyridine), which is comprised of a 
cyclometalated IrIII photosensitizer conjugated to a diazido-PtIV complex (Fig. 
4.2).16 Diazido-PtIV PACT complexes show promising antiproliferative activity 
towards a variety of cancer cells upon irradiation with blue light (465 nm).17-21 
Some cyclometallated iridium complexes have limited aqueous solubility and dark 
cytotoxicity (owing to their increased lipophilicity) and are highly oxygen-
dependent. In contrast, diazido-PtIV compounds exhibit high dark stability and can 
release toxic radicals and O2 upon photoactivation.
18 Combining these modalities 
may improve the solubility, lower the dark cytotoxicity and overcome the hypoxic-
limitations of IrIII photosensitisers (by utilising O2 release from diazido-Pt
IV 
complexes for PDT),22 providing a synergistic mechanism of action.  
Interestingly, combining these IrIII-PDT and PtIV-PACT agents together 
significantly enhanced the photocytotoxicity compared to their mono-metal 
analogues. Photoactivated complex 8 can oxidize NADH to NAD+ via radical 
formation (•NAD) and can generate ROS inside cancer cells, causing severe 
damage to cell nuclei.21 The mechanism of action of 8 has previously been probed 
using LC-MS through reactions with 5’-guanine monophosphate (GMP, a model 
DNA base) upon irradiation with indigo light.21 This revealed the formation of 
platinum - but not iridium-GMP adducts – implying the cell nucleus may not be a 
predominant target for the iridium moiety. Since 8 is luminescent (λex/em=405/460-
560 nm), the cellular accumulation in A549 cells was monitored by confocal 
microscopy (using conventional fluorophores), revealing the predominant 
localisation in the cytoplasm.21  
This Chapter utilises cryo-XRT to probe the effects of a cyclometallated IrIII 
photosensitiser (7) on cellular organelles in cryopreserved PC3 prostate cancer cells 
– as close to their native state as possible. Separately, the intracellular stability, 
distribution and localisation of the potent IrIII-PtIV conjugate (8) in frozen-dried 
A549 lung cancer cells was probed using nano-focussed synchrotron-XRF and DPC 
imaging, to gain insights into the intracellular stability and localisation of both the 
Ir and Pt metal centres. 







Figure 4.3. Chemical structures of complexes 7-11 investigated in this Chapter. The 
complexes investigated by synchrotron techniques are 7 (Cryo-XRT) and 8 (synchrotron-
XRF and DPC imaging).  
 
 
4.2     Experimental 
 
4.2.1    Antiproliferative activity (IC50) 
  
The half-maximal inhibitory concentration (IC50 / µM) of 7 was determined in PC3 
(prostate) cancer cells. Cells were treated with 7 for 2 h (protected from the light), 
washed with PBS and complex-free medium was added. Plates were then irradiated 
(λ=465 nm, 4.8 mW/cm2) or kept in the dark for 10 min, before incubation for 24 h 
protected from light (310 K, 5% CO2). Cell viability was determined using the SRB 
protocol (Chapter 2, Section 2.5.1). 
IC50 concentrations of 8-11 were determined by Dr. Huayun Shi and Dr. Huaiyi 
Huang (University of Warwick).21 A549 (lung) cancer cells were treated with 8-11 
for 1 h followed by 1 h exposure to blue light (λ=465 nm, 4.8 mW/cm2) or kept in 
the dark, before 24 h recovery in complex-free medium (310 K, 5% CO2). Cell 
viability was determined using the SRB protocol (Chapter 2, Section 2.5.1).  





4.2.2    Cryo-XRT at B24 Beamline (DLS, Oxford) 
 
Preparation of TEM grids for cryo-XRT 
Quantifoil Au-C R2/2 F1 200 mesh finder grids were irradiated with UV light for 
20 min (Chapter 2, Section 2.6.2) and 1×105 PC3 cells/well were seeded, and 
incubated for 24 h (310 K, 5% CO2). Cells were treated with 0 or 1 µM of 7 for 2 
h, then washed with PBS followed by either (i) irradiation (10 min, 465 nm, 4.8 
mW/cm2), or (ii) kept in the dark (10 min), before a 24 h recovery period in 
complex-free media (protected from light). The medium was removed, and cells 
washed with PBS (×2) followed by sterile water (×1). Fiducials (AuNP, d=250 nm, 
ca. 3.5×107 particles in 10 μL) were added to each grid, before blotting with pin 
filter paper and plunge-freezing in 30% liquid propane:ethane mixture using an in-
house manufactured plunge-freezer (Chapter 2, Section 2.3.6). Samples were 
stored in liquid nitrogen (110 K) until cryo-XRT analysis at the B24 beamline. 
 
Fluorescence mapping of TEM grids 
Preliminary correlative microscopy analysis of cryopreserved grids was performed 
on a Zeiss Axioimager M2 fitted with a Linkam Scientific cryostage by monitoring 
the fluorescence of MitoTracker Red (λex/em=647/665 nm) and the phosphorescence 
of 7 (λex/em=458/620 nm) using the YFP and GFP filters, respectively.  
 
Sample loading onto the beamline     
Up to four pre-mapped quantifoil grids were loaded into the sample holder at B24 
beamline under cryogenic conditions (110 K). Initial 2D inspection was performed 
by generating a mosaic (consecutive images stitched together) of a 100×100 µm2 
regions using short x-ray exposure (0.5 s, 500 eV) in continuous acquisition mode 
(Pixis, XO 1024B; Princeton Scientific; Chapter 2, Section 2.4.2). The view was 
brought into focus by monitoring the positions of lipid droplets or fiducials at -30° 
and +30° sample tilt angles and the depth altered by moving the zone plate 
objective. Once focussed, the tilt limit was identified by rotating the sample to no 
more than -70° and +70°, respectively. Depending on sample thickness, varying x-
ray exposure times were required to collect tomograms (Table 4.1). 





Table 4.1. Summary of the x-ray exposure times used for different samples at high (< -30, 
> +30°) and low tilt angles (0°). 
Conditions High tilt exposure (s) Low tilt exposure (s) 
Untreated (Dark) control 6 3 
Untreated (465 nm) control 2 1 
 7 (Dark) 4 2 
7 (465 nm) 8 4 
 
 
Tomogram reconstruction in IMOD 
Tomograms were aligned and reconstructed manually by registering the positions 
of AuNP fiducials (d=250 nm) using IMOD imaging software,23 as described in 
Chapter 2 (Section 2.6.2). Representative tomograms for each condition were 
selected for further 3D analysis: (i) T1 (untreated, dark); (ii) T2 (untreated, 465 
nm); (iii) T3 (7, dark); (iv) T4 (7, 465 nm).  
 
3D segmentation and visualization  
The mitochondria and nuclei in each representative (reconstructed) tomograms (T1-
4) were volume segmented using SuRVoS imaging software to determine average 
mitochondrial volumes (µm3) per tomogram (Chapter 2, Section 2.6.2).24 The 
segmented tomograms were visualised in Amira (FEI/Thermo Scientific, The 















4.2.3    Synchrotron-XRF at I14 Beamline (DLS, Oxford) 
 
Preparation of Si3N4 membranes for XRF 
Silicon nitride (Si3N4) membranes were prepared as described in Chapter 2 
(Section 2.6.1) using a seeding density of ca. 7×104 cells/mL of A549 cells. 
Following an incubation period, A549 cells were treated with 500 µM of 8 (dark 
IC50>100 µM) for 2 h under dark conditions. The supernatant medium was removed 
and cells washed with HBSS (2 mL/well). 
 
Beamline settings 
XRF data were acquired at I14 beamline (DLS, Oxford) using a beam size=75×47 
nm2; incident energy=12.5 keV and step size=100 nm. Differential phase contrast 
(DPC) imaging was simultaneously performed using a Merlin Quad detector 
(Quantum Detectors, UK). Data were fitted using the PyMCA software developed 
by the ESRF,25 assuming a cell thickness of 6 µm.26 Fitted data were analysed in 
ImageJ software.27 All other information is specified in Chapter 2 (Section 2.4.1 
and Section 2.6.2). 
 
4.3     Results 
 
4.3.1    Cryo-XRT of PC3 cells treated with 7  
 
Fluorescence microscopy 
The antiproliferative activity (IC50 / µM) of 7 was determined in PC3 prostate 
cancer cells under dark (protected from light) and blue light (direct irradiation, 
λ=465 nm) conditions using the SRB assay. Under dark conditions (2 h), 7 was 
inactive (IC50>100 µM), however, upon irradiation with blue light (10 min, 465 nm) 
the IC50 was determined to be 6±1 μM. Fluorescence microscopy imaging was used 
to locate cryopreserved cells on the TEM grids by monitoring the red fluorescence 
of MitoTracker Red (λex/em=581/644 nm) using the YFP filter (Fig. 4.4). 
Subsequently, suitable cell candidates for cryo-XRT were identified.  






Figure 4.4. Microscopy images of cryopreserved PC3 cells grown on carbon-gold TEM 
grids treated with 7 (0 or 1 µM) for 2 h (protected from light), followed by 10 min exposure 
to (i) dark conditions or (ii) blue light conditions (465 nm, 4.8 mW/cm2), before 24 h 
recovery (complex-free media). Images were recorded on a Zeiss Axioimager M2 coupled 
to a Linkam cryostage, monitoring the fluorescence of MitoTracker Red (λex/em=581/644 
nm): (a) Untreated control (10 min, dark); (b) Untreated control (10 min, 465 nm); (c) 
Treated with 7 (1 µM, dark); (d) Treated with 7 (1 µM, 10 min, 465 nm). Images were 
generated in ImageJ software.27 The yellow box indicates the 15.8×15.8 µm2 region of 
interested mapped my cryo-XRT. 
 
Faint green fluorescence was observed in cells treated with 7 upon blue light 
exposure (λex=465 nm, Fig. 4.5) when using the GFP microscopy filter 
(λex/em=488/510 nm). This was attributed to the tail of the phosphorescence 
emission band of 7 (deep-red emission, λp=620 nm).
11 Green fluorescence was not 
observed for the untreated PC3 cells. An overlay of brightfield, red-fluorescent 
microscopy images allowed the determination of suitable PC3 cancer cell 
candidates for cryo-XRT. Grid samples were cryogenically loaded into the 
autosampler chamber at the B24 beamline (DLS, Oxford) and transferred to the x-
ray microscope, where they were maintained under cryogenic conditions (liquid 
nitrogen, 110 K) throughout cryo-XRT data acquisition. 
 






Figure 4.5. Microscopy images of two cryopreserved PC3 cells (Figure 4.3, d) treated 
with 7 (1 µM) for 2 h (protected from light), followed by exposure to blue light (465 nm, 
10 min, 4.8 mW/cm2) and 24 h recovery (complex-free media, protected from light). 
Images were recorded on a Zeiss Axioimager coupled to a Linkam cryostage, monitoring 
the phosphorescence of 7 (λp=620 nm) using the GFP filter (λex/em=488/510 nm). The 
yellow box indicates the 15.8×15.8 µm2 region of interested mapped by cryo-XRT.  
 
X-ray tomography 
Cryo-XRT can be used to gain ultrastructural information on cancer cells in 3D as 
close to their native physiological state, avoiding the use of chemical fixatives.28, 29 
X-ray tomograms were obtained using soft x-rays (500 eV), producing contrast 
between carbon-containing structures and natural ice on the sample. Cryopreserved 
PC3 cells treated with 1/6th× irradiated IC50 of 7 were analysed under both dark and 
irradiated (λ=465 nm) conditions by cryo-XRT at B24 (Table 4.2). 
 
Table 4.2. Summary of the tomograms of cryopreserved PC3 cells treated with 0 or 1 µM 
of 7 for 2 h, followed by 10 min in the dark or irradiated with blue light (465 nm, 4.8 
mW/cm2) and 24 h recovery in complex-free media (protected from light).  
Tomogram number Conditions Figure Video 
T1 Untreated (Dark) 4.6 C4_Video_T1 
T2 Untreated (465 nm) 4.7 C4_Video_T2 
T3 7 (Dark) 4.8 C4_Video_T3 
T4 7 (465 nm) 4.9 C4_Video_T4 
T5 Untreated (Dark) Appendix A13 C4_Video_T5 
T6 7 (Dark) Appendix A14 C4_Video_T6 
T7 7 (Dark) Appendix A15 C4_Video_T7 
T8 7 (Dark) Appendix A16 C4_Video_T8 
T9 7 (465 nm) Appendix A17 C4_Video_T9 
T10 7 (465 nm) Appendix A18 C4_Video_T10 







Figure 4.6. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid under dark conditions (protected from light) followed by 24 h recovery in complex-
free medium (310 K, 5% CO2; T1, C4_Video_T1). Images were generated in IMOD 
software.23 Two different sample views (tilt angles): (a) 0°; (b) +28°, showing 1. 
mitochondria, 2. nucleolus, 3. nucleus, 4. nuclear membrane, 5. features of lamellipodium, 







Figure 4.7. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid under dark conditions and irradiated for 10 min followed by 24 h recovery in complex-
free medium (310 K, 5% CO2; T2, C4_Video_T2). Images were generated in IMOD 
software,23 showing two different sample views (tilt angles): (a) 0°; (b) + 8°,  showing 1. 
mitochondria, 2. nucleolus, 3. nucleus, 4. nuclear membrane, 5. features of lamellipodium, 
6. plasma membrane, 7. spherical vesicles, 8. AuNP  fiducials (d=250 nm). 
 
 







Figure 4.8. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid and treated with 7 (1 µM) for 2 h (protected from the light), followed by 24 h recovery 
in complex-free medium (310 K, 5% CO2; T3, C4_Video_T3). Images were generated in 
IMOD software,23 showing two different sample views (tilt angles): (a) 0°; (b) +54°,  
showing 1. mitochondria, 2. nucleolus, 3. nucleus, 4. nuclear membrane, 5. features of 




Figure 4.9. 2D projections of a reconstructed X-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid and treated with 7 (1 µM) for 2 h (protected from the light), 10 min irradiation (465 
nm) followed by 24 h recovery in complex-free medium (310 K, 5% CO2; T4, 
C4_Video_T4). Images were generated in IMOD software,23 showing two different 
sample views (tilt angles): 0°; (b) +10°, showing 1. mitochondria, 2. nucleolus, 3. nucleus, 
4. nuclear membrane, 5. features of lamellipodium, 6. plasma membrane, 7. spherical 
vesicles, 8. AuNP fiducials (d=250 nm).  
 
 





Prior to cryo-XRT analysis, short bursts of x-rays (0.5 s; 500 eV; 40×40 nm2 spot 
size) were used to identify regions of interest (15.8×15.8 µm2) within individual 
PC3 cells (2D projections). For the four conditions analysed, a total of 10 
tomograms were obtained and manually reconstructed in IMOD imaging 
software.23  One tomogram for each condition is presented in this Chapter (T1-4, 
Fig. 4.6-9), with the additional tomograms presented in Appendix (Fig. A13-18). 
Mitochondria can be identified by their ellipsoidal shape and the presence of cristae 
(T1, Fig. 4.6), and features of lamelipodia (flat cellular protrusions) affiliated with 
vesicle-shedding at the plasma membrane are visible in the tomograms (T1, Fig. 
4.6; Appendix, Fig. A13). Analysis of the tomograms demonstrated that irradiation 
with blue light (465 nm, 10 min) in the absence of complex 7 did not significantly 
alter the morphology of native PC3 cells when compared to cells exposed to dark 
conditions: revealing defined cell nuclei, and similarities in cytoplasmic organelles 
(T2, Fig. 4. 7).  
PC3 cells treated with 1 µM of 7 (T3, Fig. 4.8; Appendix, Fig. A14-16) and under 
dark conditions (non-irradiated and protected from light) revealed organelle 
morphologies comparable to those of the untreated cells in the dark (T1, Fig. 4.6; 
Appendix, Fig. A13) or blue light (T2, Fig. 4.7) conditions. Tomograms in the 
latter showed uncompromised plasma membranes, vesicle-shedding, lamellopodia, 
well-defined nuclei and unambiguous mitochondria. In contrast, cells treated with 
1 µM of 7 and exposed to blue light (T4, Fig. 4.9; Appendix, Fig. A17-18) revealed 
significant morphological differences in organelles compared to the treated cells 
under dark conditions. The size of mitochondria in cells treated with 7 under photo-
conditions appeared significantly smaller, and severe membrane-blebbing was 
observed. To further probe the mitochondrial damage induced by 7 (upon blue light 
exposure), 3D volume segmentation of individual mitochondria in T1-4 was 
performed using SuRVoS imaging software.24 It must also be noted that samples 
treated with 7 (regardless of the photo-conditions) were significantly darker in 
appearance, likely due to increased x-ray absorption caused by the presence of Ir in 
the samples. Consequently, longer x-ray exposure times at high tilt angles were 
required to obtain tomographic information (6-8 s, for T3-4).  
 





3D segmentation and visualisation  
The 3D volumes of mitochondria and cell nuclei were segmented from tomograms 
T1-4 using SuRVoS imaging software (Fig. 4.6-9),24 and visualized using Amira 
(Fig. 4.10). Total numbers of mitochondria per tomogram (15.8×15.8 µm2) were 
determined: (i) T1=14; (ii) T2=20; (iii) T3=26; (iv) T4=19), and individual 
mitochondrial volumes (µm3) in each tomogram were calculated (Fig. 4.11; 
Appendix, Table A26). Statistical analysis was performed using Welch’s unpaired 
t-test (assuming unequal sample variance) which revealed significant reductions in 
mitochondrial size in the cell treated with 7 under photo-irradiation conditions (T4), 
compared to both untreated controls (T1-2; p<0.05 and p<0.01, respectively) and 
cells treated with 7 under dark conditions (T3; p<0.001), as shown in Fig. 4.11.  
 
 
Figure 4.10. 3D projections of segmented tomograms (T1-4) showing the mitochondria 
(■) and nuclei (■) of cryopreserved PC3 cells grown on carbon-gold TEM grids. (a) 
Untreated controls under dark conditions (T1, C4_Video_T1_Seg). (b) Untreated controls 
exposed 10 min blue light irradiation (465 nm; T2, C4_Video_T2_Seg). (c) Treated with 
1 µM of 7 under dark conditions (2 h, followed by 24 h recovery period; T3, 
C4_Video_T3_Seg). (d) Treated with 1 µM of 7 under irradiated conditions (2 h + 10 min 
465 nm, 24 h recovery period; T4, C4_Video_T4_Seg). 






Figure 4.11. Comparison of the calculated mitochondrial size (µm3) in cryopreserved PC3 
cells treated with 0 or 1 µM (T1-4) of 7 for 2 h, and exposed to 10 min in the dark (protected 
from light) or irradiation (blue light, 465 nm), followed by 24 h recovery in complex-free 
media (310 K, 5% CO2). Statistical analysis was performed using Welch’s unpaired t-test, 
revealing statistically smaller mitochondrial volumes in T4, compared to the untreated 




4.3.2    Synchrotron-XRF of A549 cells treated with 8 
 
The antiproliferative activities (IC50 / µM) of complexes 8-11 (Table 4.3) were 
determined by Dr. Huayun Shi and Dr. Huaiyi Huang (University of Warwick).21  
 
Table 4.3. Antiproliferative activities (IC50 / μM) in A549 (lung) cancer cells treated with 
8-11 and cisplatin as determined using the SRB assay. 
 [a] 2 h drug exposure followed by 24 h recovery in drug-free medium. [b] 1 h drug exposure, 1 h 
irradiation (465 nm, 4.8 mW/cm2) and 24 h recovery in drug-free medium. [c] Photocytotoxicity 
indexes (PI) as determined by comparing the antiproliferative activities under dark and irradiated 
(465 nm) conditions. [d] Literature IC50 values.21 
Complex IC50/μM (dark)[a] IC50 /μM (irradiated)[b] 
Photocytotoxicity 
index (PI)[c] 
8 >100 3.5±0.1 >28.5 
9 >100 20.2±2.3 >4.9 
10 >100 n.d. n.d. 
  11[d] >100 51.9±2.5 >1.9 
Cisplatin >100 >100 n.d. 





Cell morphology, co-localization and quantification 
Synchrotron-XRF was used to probe the intracellular localisation, distribution and 
stability of 8 in A549 lung cancer cells. A population of A549 cells were grown on 
Si3N4 membranes and treated with 8 (500 µM, IC50>100 µM) for 2 h under dark 
conditions (protected from light), before cryo-fixation (liquid ethane) and freeze-
drying. Unfortunately, cells treated with 8 under blue light conditions could not be 
mapped by synchrotron-XRF due to poor sample quality (poorly preserved and 
damaged cells), but nonetheless, information on the dark stability and distribution 
of 8 was obtained. The Ir (L3M5=9.18 keV) and Pt (L3M5=9.44 keV) emissions 
were monitored by synchrotron-XRF using an incident energy of 12.5 keV.30 A 
total of 6 elemental maps of cells were obtained: (i) Untreated A549 cells (C1-3, 
Fig. 4.12); (ii) treated with 8 (C4-6, Fig. 4.13). The XRF maps of K, P, S and Zn 
were used to locate cells on the membrane using XRF, as previously described 
(Chapter 3).  
 
 Figure 4.12. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried A549 cells 
grown on a Si3N4 membrane (C1-3) exposed to 1 h irradiation (465 nm) as obtained using 
an incident energy of 12.5 keV: K (■), P (■), S (■) and Zn (■).30 Note that the observed 
spots in the K maps are likely due to K from residual HBSS (contains KCl) prior to plunge-
freezing. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm step size with 
ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,25 and images generated 
in ImageJ.27 






Figure 4.13. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried A549 cells 
(C4-6) grown on a Si3N4 membrane and treated with 5×IC50 (500 µM) 8 for 2 h under dark 
conditions as obtained using incident energy 12.5 keV: K (■), Zn (■), Ir (■) and Pt (■).30 
Note that the observed spots in the K maps are likely due to K from residual HBSS (contains 
KCl) prior to plunge-freezing. Data were acquired using 15 keV energy, 0.1 s exposure, 
100 nm step size with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,25 
and images generated in ImageJ.27 
 
The untreated cells (C1-3, Fig. 4.12) showed elongated morphologies typical of 
healthy A549 cells,31-33 with cell nuclei identified by the highly-concentrated 
intracellular Zn. The mean cell area (µm2) of the untreated cells was determined to 
be 438±82 µm2 (Appendix, Table A27), which was statistically different from 
A549 cells reported in Chapter 3 (766±126 µm2: p=0.0143). However, the mean 
roundness factor (where perfect circularity=1) of the untreated cells in this Chapter 
strongly correlated with that of the cryo-fixed and dehydrated A549 untreated cells 
in Chapter 3 (0.37±0.07 and 0.33±0.01, respectively), reaffirming the elongated 
nature of this cell line.31, 33 Importantly, XRF from Ir or Pt was not observed for the 
untreated cells. Furthermore, no statistically significant differences in cell area 
(µm2) were observed for cells treated with 8 (C4-6, Appendix, Table A27) 
compared to the untreated controls (438±82 and 407±31 µm2, p=0.7185, 
respectively). However, upon treatment with 8 (C4-6), cells were significantly more 
rounded compared to the untreated controls (p=0.0056; Appendix, Table A27). 





In cells treated with 8 (C4-6), Pt was well-distributed, localizing in nucleus and the 
cytoplasm, closely resembling the elemental map of K. In contrast, Ir seemed to be 
distributed in the cytoplasm and somewhat concentrate in small, intracellular 
compartments (Fig. 4.13). The region of interest was selected from the K map, and 
used to determine the co-localisation between elements in the cells: Pearson’s R-
value (r) and Spearman Rank Coefficient (rs) in ImageJ software (Appendix, Table 
A28-29).27 Pt co-localized strongly with Zn (mean r=0.65±0.05; mean 
rs=0.55±0.08), which may implicate nuclear localization. In contrast, Ir only 
moderately co-localized with Zn (mean r=0.33±0.12; mean rs=0.26±0.08). 
Intracellular Ir and Pt were found to co-localize partially in cells treated with 8 
(mean r =0.51±0.10; mean rs=0.44±0.07). 
Mole fraction quantities of Ir and Pt were determined for each cell by calibrating 
the data to an AXO thin-film standard (Chapter 2, Section 2.6.1), assuming 
uniform cell thickness. XRF images revealed that cells treated with 8 (C4-6, Fig. 
4.13) contained significantly more intracellular Pt than Ir (Fig. 4.14; Appendix, 
Table A30). The molar ratios of platinum-to-iridium (Pt/Ir) for C4-6 were 
determined to be 4.13, 4.63 and 4.15, respectively.  
 
 
Figure 4.14. Normalized mole fraction quantities of Pt (■) and Ir (■) in cryo-fixed and 
freeze-dried A549 cells grown on Si3N4 membranes and treated with 8 (500 µM) for 2 h 
under dark conditions, as determined from synchrotron-XRF (C4-6, Fig. 4.13). Data were 
acquired using 15 keV energy, 0.1 s exposure, 100 nm step size with ca. 50×70 nm2 beam 
size. Data were analysed in PyMCA software,25 and images generated in ImageJ.27 





Differential Phase Contrast (DPC) Imaging 
Differential phase contrast (DPC) imaging is a well-established technique used in 
microscopy, which provides structural information by measuring the deflection of 
x-rays as they pass through an object. DPC imaging differs from XRT in that it 
provides phase-contrast (phase-sensitive), whereas, XRT provides full-field 
absorption-contrast.34 Phase contrast is a consequence of the imaginary character 
of the refractive index (Equation 4.1),35 which is enhanced with hard x-rays 
(stronger coherence). The real part of the refractive index describes the phase delays 
as light pass through a sample, whereas the imaginary part describes the 
absorption.35 Phase contrast provides the opportunity the quantify values for both 
the real and imaginary parts of refractive indices, whereas, absorption contrast is 
only concerned with the imaginary part.34  
𝑚(𝜆) = 𝑚𝑟(𝜆) + ⅈ𝑚𝑖(𝜆) 
Equation 4.1. Equation for complex refractive index, m(λ), where λ=free-space 
wavelength, mr is the real part of the refractive index and mi is the imaginary part. 
 
DPC imaging relies on a change in refractive index when passing through a sample 
and the resulting deflections which are more easily observed compared to 
absorption changes. More specifically, DPC imaging exploits differences in 
electron density when x-rays pass through a sample (monitors changes in phase). 
Synchrotron DPC imaging has recently been implemented at the I14 beamline 
(coherent hard x-rays), enabling the simultaneous acquisition of XRF and phase-
contrast images to monitor 8 in A549 cancer cells. 
The DPC images of C4-6 show dark indentations surrounding nuclei (Fig. 4.15) 
which may be attributed to cytoplasmic organelles (e.g. mitochondria, endoplasmic 
reticula, lysosomes or lipid droplets). As DPC imaging monitors the changes in 
phase when x-rays pass through a sample (rather than phase-retrieval), the observed 
indentations may also be attributed to holes in the cell (e.g. vacuoles).  
These dense bodies were perinuclear as identified by overlaying the DPC images 
with the Zn XRF maps (Fig. 4.15). Pt strongly correlates with Zn, but did not 
closely correlate with the dense structures. In contrast, Ir was localized in small 
compartments, most likely in the cytoplasm, but did not closely correlate with the 





dense bodies (Fig. 4.15). Overall, the nature of these structures cannot be identified 
using just DPC imaging, but nonetheless highlights the capabilities of hard x-ray 
nanoprobe beamlines for biological applications. 
The lengths and areas of the darker and more elongated dense structures 
(represented in red, Fig. 4.16) were determined for C4-6 using ImageJ (Appendix, 
Table A31-32).27 The mean organelle lengths in C4-6 were 1.2±0.4, 2.5±1.1 and 
2.6±0.6 µm, respectively (Appendix, Table A31). The elongated nature of these 
organelles may correspond to mitochondria (e.g. fused interconnecting networks), 
or even the perinuclear endoplasmic reticula. The individual 2D areas (µm2) of 
these structures were also determined (Appendix, Table A32), revealing mean 
areas of 1.5±0.6, 1.6±0.8 and 1.9±1.0 µm2, for C4-6, respectively.  
 
 
Figure 4.15. Overlay of DPC images with Zn, Pt and Ir synchrotron-XRF elemental maps 
of cryo-fixed and dehydrated A549 lung cancer cells grown on a Si3N4 membrane and 
treated with 8 (500 μM) under dark conditions (2 h), as analysed using synchrotron-XRF 
(12.5 keV, 100 nm step, 0.1 s).  
 
 







Figure 4.16. DPC images of cryo-fixed and dehydrated A549 cells grown on a Si3N4 
membrane and treated with 8 (500 μM, 2 h) under dark conditions, as analysed using 
synchrotron-XRF and DPC imaging at I14 (12.5 keV, 100 nm step, 0.1 s), Showing the cell 
nucleus in blue and dark, elongated structures in red: (a) C4; (b) C5; (c) C6. 
 
 
4.4     Discussion 
 
4.4.1    Cryo-XRT of PC3 cells treated with 7 
 
Cryo-XRT can provide near-native state information down to subcellular 25-40 nm 
resolution, and can be combined with other techniques (e.g. super-resolution 
fluorescence or cryo-XRF) to gain essential insights into drug-targeting, cell death 
mechanisms and drug-induced physiological damage.28, 29, 36 Cryo-XRT imaging of 
intact cells has been performed at various synchrotron beamlines worldwide, 
including XM-2 (ALS, US), MISTRAL (ALBA, Spain), U41-TXM (Bessy II, 
Germany) and B24 (DLS, UK).28 Of interest in this research, cryo-XRT has 
previously been used for imaging in vitro cancer cells,36, 37  including probing the 
cellular effects of a half-sandwich iridium complex and iron oxide nanoparticles in 





breast cancer cells.38, 39 Recently, cryo-XRT has been used to probe the effect of 
cisplatin and gold nanoparticles in skin cancer cells.40 A similar approach has been 
adopted here to gain insights into the ultrastructural and morphological changes to 
cellular organelles induced by a potent organometallic IrIII photosensitiser (7) under 
dark (non-toxic) and irradiated (blue light) conditions.  
Complex 7 ([Ir(C,N)2(O,O)] (where (C,N)=2-phenylpyridine and O,O=diketone) 
exhibits good antiproliferative activity (IC50=6±1 µM) in PC3 cells upon irradiation 
with blue light (λ=465 nm), and is non-toxic to the same cells under dark conditions. 
Its high photo-stability, long luminescence lifetime and ability to form toxic 1O2 
makes 7 of significant interest as a PDT photosensitizer.11 The generation of 1O2 by 
7 is highly-confined through spatially-directed light,11 with the hope of reducing 
patient side effects experienced by current chemotherapeutics.7 Generation of ROS 
by 7 is known to cause oxidative damage to proteins (e.g. HSP-70 – a heat shock 
protein that is expressed in response to stress), and can disrupt glycolysis by 
increasing enzyme expression.11 The dependence of glucose metabolism in cancer 
cells can be described by the Warburg Effect,41 allowing them to survive under 
extreme conditions. This makes the glycolytic pathway a viable therapeutic target. 
Since glycolysis is indirectly associated with mitochondrial organelles,42 the 
observed photocytotoxicity may implicate mitochondrial damage in the mechanism 
of action of 7. This hypothesis was probed using cryo-XRT to investigate the effect 
of 7 on cancer cell organelles under both dark and irradiated conditions. 
The preparation of cryopreserved samples for soft x-ray analysis is challenging for 
various reasons: (i) delicacy of quantifoil grids; (ii) rapid accumulation of ice on 
grid surface (which prevents soft x-ray penetration); (iii) multi-step process 
(increased risk of sample damage). A general problem with the majority of grids 
imaged was the accumulation of thick ice on the surface, likely caused during 
plunge-freezing. Tweezer-damage (from the handling of grids in tissue culture, 
plunge-freezing and sample loading) were also evident, which led to tears and 
perforation of grids. Furthermore, cells preferentially adhere to the mesh grid – a 
more supportive environment for cell growth - compared to the thin carbon 
material. Thick ice layers present challenges for cryo-XRT as low energy x-rays 
can only penetrate ca. 10 μm of ice.43 Thick ice and mesh grid lines will produce 
darkened tomograms (higher x-ray absorbance) with limited tomographic 





information (e.g. restricted views at high tilt angles). Nonetheless, suitable cell 
candidates from each population of PC3 cancer cells were identified on the grids, 
and analysed by cryo-XRT. 
Cryo-XRT is a soft x-ray synchrotron technique that can probe the 3D structures of 
biological samples without the need for chemical staining.28 Chemical fixation can 
alter biomolecules including proteins and nucleic acids, which can indirectly affect 
morphological features such as cell volume and ATP content.44 If these fixatives 
interact with the same cellular targets as the therapeutic agents, then they may 
disrupt the observed drug distribution. To overcome this, cryogenic analysis of 
samples can be used to monitor cellular response to drugs close to their native state. 
Cryo-XRT operates in the “water-window” (the energy of x-rays at which the 
absorbance of O is significantly lower than that of C and N, 280-530 eV).45 This 
not only provides natural contrast, but also permits the analysis of vitrified samples 
down to 25-40 nm resolution.43 Herein, cryo-XRT has been utilized to monitor 
morphological changes of PC3 cells treated with 7.  
A comparison of the untreated dark controls (Section 4.3.1, Fig. 4.6; Appendix, 
Fig. A13) and the irradiated controls (Section 4.3.1, Fig. 4.7) reaffirmed that 10 
min irradiation with blue light (of this intensity) did not alter the ultrastructure of 
the cell – with uncompromised nuclear membranes, features of lamellopodia and 
vesicle-shedding, correlating with that reported for prostate cancer cells (including 
this cell line).46-48  
In order to probe mitochondrial damage induced by 7, volume segmentation was 
performed, which has previously been demonstrated by cryo-XRT for doxorubicin 
sensitive and resistant colon cancer cells.37 In x-ray tomography, the entirety of 
biological samples (tilt range±180°) cannot be analysed due to the ‘missing-wedge’ 
problem, which results in loss of 3D information at high tilt angles.49 Consequently, 
3D structures are distorted or elongated along the z-axis.50 In order to reduce 
artefacts and limit the amount of missing 3D information, tomographic data can be 
acquired from multiple tilt axes (i.e. conical tilt or double tilt axes).49 The 
mitochondrial volumes reported in this Chapter were obtained under the same 
experimental parameters, hence, mitochondrial volumes between different samples 
are directly comparable.  





Volume segmentation revealed wide variations in mitochondrial size (0.98±1.20 
and 0.65±0.35 µm3, for T1-2, respectively), but no statistically significant 
differences (p=0.335; Appendix, Table A26). This correlates with the area of 
mitochondrial organelles in healthy cells, typically ranging from 0.75–3 μm2 in 
size.51 Furthermore, this confirms that blue light (of this intensity and dosage) does 
not significantly damage or alter mitochondrial physiology. Representative 
mitochondria in the untreated control tomograms (T1-2) are shown in Fig. 4.17.  
 
Figure 4.17. Representative 2D regions (1×1 µm2) of mitochondrial organelles in 
cryopreserved PC3 cells treated with 7 (0 or 1 µM) for 2 h followed by 10 min of dark or 
blue light (465 nm), followed by 24 h recovery in complex-free media (T1-4, 310 K, 5% 
CO2). Images were generated in IMOD imaging software.23 
 
Cryo-XRT analysis of cells treated with 7 under dark conditions did not reveal any 
obvious damage to PC3 cells, which showed typical vesicle-shedding, lamellopodia 
and unambiguous mitochondria (identified by cristae in the mitochondrial matrix; 
T3, Fig. 4.8; Appendix, Fig. A14-16). Moreover, the mean mitochondrial volume 
in T3 was determined to be 0.77±0.38 μm3, which was statistically the same as the 
mitochondria found in untreated controls (p=0.534 and p=0.273, respectively, Fig. 
4.17). As the sizes of mitochondria in cells treated with 7 under dark conditions 
(T3) were not statistically different from the controls (T1-2), this reaffirms that 7 
in dark conditions did not result in morphological changes to mitochondria (Section 
4.3.1, Fig. 4.8). This also correlates with the low dark cytotoxicity of 7 determined 
by cell viability assays (IC50>100 µM). 





In contrast, the mitochondria in cells treated with 7 followed by direct irradiation 
with blue light (465 nm) were significantly smaller than the ones in untreated cells 
or cells exposed to the drug under dark conditions (Section 4.3.1, Fig. 4.9; Fig. 
4.17). Severe plasma membrane-blebbing on drugged and irradiated cells also 
suggested the initiation of cell death pathways, and can be commonly associated 
with apoptosis and necrosis.52 As 1O2 is short-lived (<200 ns),
53, 54 and possesses 
inadequate diffusion capacity (<1 μm)55 the mitochondrial damage observed upon 
photo-activation of 7 may be attributed to the generation of 1O2 in close proximity 
to mitochondria. This is in strong agreement with the cytosolic distribution of 7 in 
cancer cells, as probed using optical microscopy.11  
Complementary to this, cells treated with 7 under dark conditions revealed dark 
mitochondrial membranes and cristae compared to the untreated controls, with light 
(low-density) interiors (Section 4.3.1, Fig. 4.8; Appendix, Fig. A14-16). Heavy 
metals have high x-ray absorption properties in comparison to cellular material (due 
to increased electron scattering), hence, iridium localised in the mitochondria would 
impede x-ray penetration. This coincides with the increased x-ray exposure (6-8 s) 
required to obtain tomographic information at high tilt angles (x< -30 °, x> +30 °) 
from cryopreserved PC3 cells treated with 7, regardless of the photo-conditions. 
The mitochondria in cells exposed to 7 and irradiated with blue light appear overall 
darker in contrast (Section 4.3.1, Fig. 4.9, Appendix, Fig. A17-18) - which was 
not observed for cells treated with 7 and protected from light. This is likely a result 
of a reduced volume (e.g. condensation of cristae or volume reduction of the 
mitochondrial outer membrane). Overall, this provides complementary evidence 
that the increase in levels of glycolytic enzymes in cells treated with 7 upon 
exposure to blue light is associated with changes in mitochondria physiology.11 
Glycolysis is controlled by various metabolic enzymes (i.e. hexokinase and 
pyruvate kinase) which are up-regulated in various cancers.56 The inherent 
differences in metabolism between healthy tissues and tumours can be exploited to 
selectively target cancer. Interestingly, the enhanced glycolysis phenotype in cancer 
cells has been implicated in chemotherapeutic resistance (including cisplatin),57 
which has major consequences on drug efficacy. Various inhibitors of glycolysis 
have been shown to reverse platinum resistance in cancer cells,58 rendering it a 
viable approach to improving cytotoxicity and selectivity.  





Unlike the majority of cancers which utilize aerobic glycolysis, prostate cancer cells 
exhibit higher levels of activity involving the Krebs cycle.59 The Krebs cycle differs 
from glycolysis in that it occurs within the mitochondria and pyruvate is oxidised 
to carbon dioxide, whereas glycolysis occurs in the cytoplasm and involves the 
metabolism of glucose in 10 enzyme-catalysed steps to form pyruvate. The 
mitochondrial damage observed in PC3 cells treated with 7 under photo-conditions 
(465 nm) may therefore also be associated with disruption to the Krebs cycle. The 
nature of mitochondrial damage caused by 7 may also be a consequence of direct 
disruption of the Krebs cycle or indirectly perturbation of glycolysis via the 
generation 1O2 in the vicinity of mitochondria. Evidence directly linking 7 to the 
Krebs cycle might be achieved by use of fluorometric or colorimetric assays 
specific to the Krebs cycle (citrate synthase) or by mass spectrometry metabolomic 
studies. Overall, cryo-XRT has provided direct insights into the morphological and 
structural damage induced by a cyclometallated IrIII photosensitier, which may 
accelerate their progression towards in vivo studies. 
 
4.4.2    Synchrotron-XRF of A549 cells treated with 8 
 
The concept of dual-mapping of anticancer complexes by synchrotron-XRF was 
demonstrated with Br-labelled OsII catalysts in Chapters 3. In this Chapter, 
correlative mapping of the two metal centres (Ir and Pt) of a photodynamic-
photochemotherapeutic complex (8) in cancer cells was monitored by synchrotron-
XRF. The intracellular distribution and stability of 8 in cryo-fixed and freeze-dried 
A549 (lung) cancer cells was probed using synchrotron-XRF, by directly 
monitoring the XRF emissions of Ir (L3M5=9.18 keV) and Pt (L3M5=9.44 keV).
30 
 
Elemental preservation and cellular morphology 
The sufficient preservation of endogenous cellular elements in cryo-fixed and 
dehydrated cells grown on Si3N4 membranes has been reported with great success 
in the literature,60 and in Chapter 3. The Zn, S and K XRF distributions allowed 
the identification of the cell nuclei and the cell outline, comparable to that of A549 
cells in the literature – with elongated morphologies, and rounded cell nuclei 





(identified by localised Zn).61-63 Ideally, frozen-hydrated samples (e.g. cryo-XRF) 
would provide information closer to the native state of the cells so as to avoid 
alterations to subcellular structures, membranes and cell morphology upon drying. 
Cryo-XRF enables the 2D of biological elements with their close-to-native state 
cells, in addition to mapping exogenous metallodrugs, and is emerging at various 
synchrotron beamlines worldwide including ID16A (ESRF, Grenoble)40 and 9-ID-
B (APS, Illinois).64 Cryo-XRF facilities are not yet available at the I14 beamline, 
thus, cells were cryo-fixed and dried for analysis at room temperature. Importantly, 
chemical fixatives were avoided by cryo-fixation and drying of samples, providing 
much more reliable elemental distributions. 
Synchrotron-XRF maps of three untreated (control) A549 cells grown on Si3N4 
membranes were obtained (C1-3, Section 4.3.2, Fig. 4.12), revealing elongated 
morphologies, correlating closely with the typical morphology of A549 cells,31, 33  
and those reported in Chapter 3. The elongated nature of these untreated cells was 
reflected in the mean roundness factor (0.37±0.07), in strong agreement with that 
of A549 cells prepared under the same conditions in Chapter 3 (0.33±0.01). 
Interestingly, the A549 cells reported in this Chapter were smaller than others 
imaged (Chapter 3; p=0.0143). This may be attributable to factors including the 
differences in the stage of cell growth of individual cells in a population, the cell 
seeding density (6-7×104 cells/mL), the buffer system used to wash cells before 
cryogenic fixation (tris-glucose or HBSS), or the efficiency of cryo-
fixation/dehydration. In contrast, cells treated with 8 (500 µM, 2 h protected from 
light) demonstrated more rounded morphologies compared to the untreated controls 
(C4-6, Section 4.3.2, Fig. 4.13). Rounding of a cell can be associated with cell 
damage and commonly accompanies cell death pathways.65 This may imply that 
high concentrations of 8 (500 µM) causes morphological damage to cells under 
dark conditions. Furthermore, analysis of cells treated with lower concentrations of 
8 in the dark, and upon irradiation are required to provide further insights into the 
antiproliferative mechanism of action. 
 
 





Distribution of Ir and Pt 
Iridium in cells treated with 8 somewhat localising in small compartments which 
may be indicative of organelle-targeting (C4-6, Section 4.3.2, Fig. 4.13). This 
correlates with the predominant cytoplasmic localization of 8 observed in A549 
cells using fluorescence microscopy with conventional trackers (LysoTracker Deep 
Red and MitoTracker Red) upon irradiation.21 For the case of C6, Ir appears 
localised within the nuclear region (with concentrated Zn), however, it cannot be 
determined whether this is within the nucleus or not. Synchrotron-XRF provides 
information in 2D, however cells grown on a monolayer surface are not entirely flat 
(as shown from XRT), hence, the distribution of elements is a 2D projection of an 
inherently 3D object. For example, the ‘bulky’ cell nucleus has been reported to 
take up ca. 28% of the volume of A549 cells.66 Subsequently, this may mean that 
observed Ir may reside above the cell nucleus (in the cytoplasmic space), and not 
in the cell nucleus. This correlates with the lack of adducts formed between the Ir-
PDT counterpart of 8 or the analogous Ir complex (9) with model DNA 
nucleobases.21 Complementary to this, only moderate co-localisation between Ir 
and Zn was observed (r=0.20-0.42; Appendix, Table A28). Methods involving 
cellular fractionation 192Ir ICP-MS studies (which separates cells into nuclear, 
cytosolic, membrane and cytoskeletal fractions) or correlative cryo-SIM and XRT 
could be used in future studies to probe the organelle-localisation of intact and 
cleaved 8.  
Multi-targeting drugs with synergistic mechanisms of action might improve drug 
efficacy and circumvent multidrug resistance. In particular, it is hypothesized that 
diazido-PtIV PACT complexes can be photo-reduced in situ (PtIV→ PtII) to form 
square planar PtII species (which can bind to nuclear DNA), whilst releasing toxic 
azidyl radicals intracellularly – presenting a synergistic mode of action.18 In 
contrast, IrIII photosensitisers have been reported to target a variety of cytoplasmic 
organelles. In general, IrIII PDT agents are highly lipophilic and cationic,8 
promoting localization in negatively-charged mitochondria or lysosomes. The 
mitochondrial-targeting of IrIII photosensitizers is well-reported,67, 68 where they 
can generate highly reactive and toxic singlet oxygen (1O2)  (with high quantum 
yields, ΦΔ 0.5-0.9)69 to disrupt cancer redox homoestasis. In this Chapter, 
mitochondrial damage by photosensitiser 7 was also demonstrated by cryo-XRT 





(Section 4.4.1). Lysosomal targeting has also been reported for various 
cyclometallated IrIII complexes.70-72  Lipophilic compounds can pass freely through 
lysosomal membranes and can become protonated in the acidic lysosomal 
environment (pH 4-5),73 ultimately becoming entrapped. This has led to the 
development of pH-activated IrIII photosensitisers,72 to control the selective 
production of 1O2 inside lysosomes. The ER has also been explored as a target for 
cyclometalated IrIII photosensitisers.74 Combining diazido-PtIV PACT modalities 
with cyclometalated IrIII PDT complexes provides a novel multi-modal approach to 
treating cancer. 
The XRF of Pt revealed 2D distributions in the nucleus and cytoplasm, with 
significantly higher levels of Pt vs. Ir (4× more; Section 4.3.2, Fig. 4.14). The sparse 
intracellular distribution of Pt has been reported for a variety of platinum 
compounds (including cisplatin),75-77 hence, the observed Pt distribution in cells 
treated with 8 is perhaps not surprising. Further to this, Pt strongly co-localised with 
Zn in cells treated with 8 (r=0.59-0.69, Appendix, Table A28-29) - supporting the 
hypothesis of nuclear-targeting of the Pt component. Diazido-PtIV prodrugs can be 
photo-reduced in situ to form square planar PtII species (via. the loss of azidyl 
radicals), which can bind to nuclear DNA in a different manner to that of cisplatin.78 
In the absence of light, it is conceivable that the reductive cancer cell environment 
can cause the chemical reduction of PtIV→PtII, though this conflicts with the 
apparent lack of antiproliferative activity in dark conditions and the ‘inertness’ of 
the PtIV prodrug.  
Confocal microscopy of A549 cells treated with 8 under dark conditions revealed 
the predominant cytoplasmic localization of 8 (λex/em=405/460-560 nm),
21 however, 
the cleaved Ir-PDT fragment of 8 likely exhibits luminescence itself, hence, the 
observed fluorescence may not be directly mapping intact complex 8, but cleaved 
9 instead (providing no information on the cleaved Pt PACT component). The 
cleavage of the Ir part may explain the lack of the fluorescence of 8 observed in the 
nucleus by confocal microscopy,21 compared to the nuclear-localised Pt observed 
by XRF (C4-6, Section 4.3.2, Fig. 4.13). This highlights the advantages of XRF 
mapping combined with conventional fluorescence microscopy techniques. 
 





The higher levels of Pt vs. Ir are strongly indicative of intracellular cleavage of 8. 
When quantifying elements by XRF, assumptions are made about cell thickness and 
density,26 whereas, biological cells are inhomogenous (non-uniform). 
Subsequently, these assumptions are likely only valid for very thin samples,79 thus, 
the quantification of Ir and Pt in or above the thick cell nucleus may not be entirely 
reliable. Moreover,  ICP-MS cellular fractionation studies of 8 prove necessary for 
reaffirming the Pt/Ir ratio. Alternatively, techniques such as hard x-ray 
ptychography or nanotomography can be used to gain insights into 3D cellular 
features for more reliable elemental quantification.80, 81 Nonetheless, it is evident 
that there is more intracellular Pt vs. Ir, which is suggestive of two things: (i) the Ir 
fragment may be more susceptible to efflux compared to Pt; (ii) less Ir is entering 
the cells (influx). 
It is hypothesized that the antiproliferative mechanism of action of 8 involves 
photodecomposition upon irradiation with blue light (465 nm),21 through a 
combined PDT-PACT effect. In chemical HPLC/LC-MS experiments, 8 has shown 
to release the axial carboxylato ligand upon irradiation with light.21 The amide bond 
of 8 may also be susceptible to cleavage by proteolytic enzymes, for example by 
cathepsins (an over-expressed group of lysosomal cysteine proteases) which play a 
role in drug resistance.82 The higher levels of Pt vs. Ir is suggestive of intracellular 
cleavage, with the cleaved Ir-PDT moiety being more susceptible to cellular efflux. 
Cancer cells have various reducing agents (i.e. metalloproteins and low molecular 
weight antioxidants) which can reduce PtIV→ PtII,83 which likely contribute to the 
breakdown of 8. The intracellular reduction of the Pt centre of 8 may explain the 
nuclear localisation of Pt observed by XRF – which is a well-known target for PtII 
drugs (including cisplatin).18  
The co-localisation statistics between Ir and Pt for A549 cells treated with 8 under 
dark conditions, revealed moderate co-localization (0.44-0.63; Appendix, Table 
A28), suggesting that some of 8 is likely intact intracellularly– which may prove 
essential for enhancing the antiproliferative activity compared to the mono-metal 
complexes (upon photo-activation). The protocol for screening the antiproliferative 
activity of 8 under dark conditions involves 2 h (dark) drug exposure, followed by 
24 h recovery. In contrast, the antiproliferative activity upon photoactivation 
involves 1 h drug exposure followed by 1 h irradiation with blue light. With this in 





mind, the low dark toxicity of 8 in cancer cells may also be a consequence of 
intracellular complex cleavage after 2 h (longer) exposure. The extent of complex 
cleavage of 8 after 1 h drug exposure (irradiated protocol) is likely less pronounced 
compared to 2 h (dark protocol), which may be why photoactivation after 1 h leads 
to photocytotoxicity. Herein, the lack of toxicity of 8 under dark conditions 
(IC50>100 µM) was assumed to be due to absence of 
1O2, azidyl radicals and Pt
II 
square-planar species (all formed upon blue light exposure),21 however, this may 
also be ascribed to enhanced drug efflux prior to photoactivation. This may reduce 
quantities of complex available for photo-activation, limiting the photodynamic-
photochemotherapeutic effect. However, XRF  quantification of cells treated with 
8 under photo-conditions is required to confirm this. 
In aqueous cell culture media, 8 exists in a 1:1 ratio (as confirmed by ICP-OES),21 
however, this does not necessarily verify whether the Ir and Pt moieties are intact 
or not. The differences between intracellular levels of Ir and Pt may be a 
consequence of different influx mechanisms. For example, Pt complexes typically 
rely on copper transporters and organic cation transporters to enter cells,84 whereas, 
lipophilic IrIII photosensitisers may rely more heavily on passive transport.85 
Moreover, an alternative hypothesis may be that the cellular influx mechanism of 
intact 8 may vary from that of the cleaved Ir and Pt modalities, hence, complex 
dissociation prior to uptake may be preferential for cell permeation. The chemical 
speciation of metallodrugs in biological media is of great importance in 
understanding drug activation mechanisms, and usually requires techniques such as 
ICP-MS, XANES, EXAFS, NMR or MS-proteomics.86  For example, Hartinger et. 
al. used capillary electrophoresis ICP-MS to demonstrate the vulnerability of 
cisplatin in extracellular culture media.87 This research would benefit from further 
studies into the biological speciation of 8, which may prove necessary for 
elucidating mechanisms of drug activation and cell death. 
Synchrotron-XRF can be used to gain insights into the distribution of metallodrugs 
and endogenous biological elements both in vitro and in vivo down to a high spatial 
resolution (typically ca. 50-100 nm),88 however, cannot distinguish organelles or 
subcellular features without using complementary techniques. Additionally, beam 
damage upon repeated exposure to hard x-rays can damage biological samples, and 
disrupt metal distribution and speciation (particularly for nanofocussed XANES). 





Other analytical techniques can provide complementary information. For example, 
Laser Ablation ICP-MS (LA-ICP-MS) and NanoSIMS have been used to 
investigate metallodrug distributions in both cells and tissues down to a subcellular 
level.89-92 Single-cell ICP-MS is emerging as a high-throughput method for 
investigating metal quantities in individual cells,93 overcoming concerns of 
unsynchronized cells. Top-down FT-ICR-MS proteomics can be utilized to 
investigate potential biomolecule targeting of metallodrugs as demonstrated by 
O’Connor et. al. with platinum anticancer drugs.94  This work may also benefit from 
fluorescence sensor techniques (e.g. FRET ratiometric sensors), which can be used 
to quantify metal concentrations in biological systems.95, 96  
 
Differential Phase Contrast (DPC) Imaging 
Correlative DPC imaging has provided insights into 3D structures in A549 cells 
treated with 8 by exploiting the varying refractive properties of different objects. 
At I14, the XRF detector is located before the sample (to collect back-scattering), 
whereas, the DPC detector is after the sample (to collect transmitted beam). Objects 
refract light in different ways to produce phase-contrast images. Thus, objects 
appearing darker in DPC images implicate a stronger change in electron density. 
The nuclei in each of the DPC images were clearly identifiable from the lighter 
phase-contrast regions (overlayed with Zn XRF), as nuclei have lower mass 
densities and refractive indices than the cytoplasm (Section 4.3.2, Fig. 4.15).97 DPC 
imaging is sensitive to changes in density, which means that the contents of highly 
dense cell nuclei are difficult to identify (non-uniform electron density). Dark 
phase-contrast regions in the image appear to somewhat surround the central 
nucleus, implying they may be cytoplasmic organelles. When light passes through 
thicker regions of the sample (nucleus), there is a phase shift relative to the light 
passing through thinner regions of the sample (cytoplasm) which causes 
interference.98 This is exploited in DPC imaging to visualize cells. As a result, the 
thick cell nucleus appears lighter in the image, whereas, cytoplasmic organelles 
appear much darker. Alternatively – as DPC imaging relies on phase gradients- the 
observed dark contrast regions may be attributed to holes in the cell (e.g. vacuoles 
– which can be associated with cell damage and programmed cell death).99  





The dense cytoplasmic organelles ranged between 0.76-4.14 µm in length 
(mean=2.1±0.9 µm) and areas between 0.81-3.98 µm2 (Appendix, Table A31-32). 
These lengths were statistically smaller that the reported mean mitochondrial length 
in A549 cells determined independently using immunofluorescence assays - which 
reported mitochondrial lengths of between 7-8 µm length.100 The wide variability 
in 3D mitochondrial size has already been demonstrated in this Chapter by cryo-
XRT, which will also depend on the analysis conditions (i.e. fixed or live cells etc.). 
The elongated nature of these dense organelles somewhat resembled that of fused 
mitochondrial networks, which are atypical of other dense structures – including 
lipids droplets (dark and rounded, typically ranging between 0.1–5 µm)101 and 
lysosomes (ranging between 50-500 nm).102  Alternatively, these organelles could 
also comprise the endoplasmic reticulum.  
The Ir and Pt XRF maps of A549 cells treated with 8 were overlayed with the DPC 
images (Section 4.3.2, Fig. 4.15). Pt nor Ir did not strongly correlate or overlay with 
the resolved organelles/vacuoles from the DPC image. DPC imaging is limited in 
that it only provides a preliminary indication of potential 3D structures in a 2D 
sample, and cannot identify the nature of these organelles. DPC imaging can be 
used in combination with soft cryo-XRT to identify organelles/vacuoles once cryo-
XRF is implicated at the I14 beamline.43 Alternatively, hard x-ray ptychography 
can be used to monitor endogenous and exogenous cellular elements in addition to 
3D features, as demonstrated by Jacobsen et. al on frozen-hydrated cells at the 21-
ID-D beamline, APS (Chicago).80  
Overall, it can be postulated that some of intact 8 may concentrate in cytoplasmic 
organelles, with excess cleaved Pt species predominantly targeting the cell nucleus, 
providing a multi-targeted mechanism of action, however, more evidence is 











4.5     Conclusions and future work 
 
Soft cryo-XRT of cryopreserved PC3 prostate cancer cells treated with a neutral 
diketone IrIII photosensitiser (7) upon blue light exposure revealed extensive and 
significant alterations to mitochondria physiology (reduction in volume), most 
likely caused by the selective generation of singlet oxygen species (1O2) in close 
proximity to these organelles. The observed changes in mitochondrial morphology 
upon photo-treatment with 7 may be associated with the previously reported 
increase in the expression of glycolytic enzymes in cancer cells.11  
The mitochondrial-targeting of 7 can be probed further using correlative cryo-XRT 
and cryo-XRF to confirm the localisation of Ir using hard x-rays.40 XAS on 
localised regions of intracellular Ir may provide information on the oxidation state, 
coordination environment and binding modalities of 7 in cancer cells – although 
this is dependent on the in-cell metal concentration. Alternatively, mitochondrial-
dependent cell viability assays (e.g. inhibition of peptide formylase), can be 
performed to gain information on the mitochondria damage induced by 7. 
Information on the mechanisms of cell death induced by 7 can be further 
investigated using flow cytometry (e.g. using Annexin V/ PI assay). 
Synchrotron-XRF has been used to probe the intracellular distribution and stability 
of a potent photodynamic-photochemotherapeutic Ir-Pt complex (8) in A549 cancer 
cells under dark conditions. Interestingly, Pt was distributed in both the cell nucleus 
and cytoplasm, but Ir seemed to localise in non-nuclear regions (most likely in 
cytoplasmic organelles) – however, ICP-MS cellular fractionation studies are 
required to confirm this. Complementary to this, significantly higher intracellular 
levels of Pt vs. Ir were observed (ca. 4×), suggestive of the intracellular cleavage of 
8. The Ir and Pt of 8 co-localized in small cytoplasmic regions, most likely 
organelles - in agreement with similar IrIII photosensitizers reported in the 
literature.8 This correlates with confocal microscopy studies in which 8 (under dark 
conditions) predominantly localised in the cytoplasm (particularly with 
mitochondria).21 Cells treated with 8 were more rounded compared to the elongated 
untreated controls, suggesting some cellular damage upon drug exposure under dark 
conditions (likely owing to the high photosensitiser concentration). 





Differential phase contrast (DPC) imaging provided preliminary insights into dense 
elongated organelles located around the cell nucleus (perinuclear). The intracellular 
Pt or Ir did not correlate with that of the observed dense organelles from the DPC 
images. Since DPC only gives an indication of 3D features of a cell, the nature of 
these organelles cannot be identified using this technique alone.  
The conjugation of metal moieties with different mechanisms of action to form 
binuclear complexes may significantly improve the cytotoxicity, aqueous solubility 
and pharmacokinetics of organometallic anticancer complexes. Conjugation of 
potent Ir-PDT and Pt-PACT modalities may provide a combined PDT-PACT 
targeting mechanism of antiproliferative activity through the generation of singlet 
oxygen, toxic radicals and PtII-species. Additionally, 8 can readily be monitored by 
fluorescence microscopy (λex/em=405/460-560 nm) and synchrotron-XRF (Ir 
L3M5:9.18 keV; Pt L3M5:9.44 keV). 
ICP-MS studies (192Ir and 195Pt), may be employed to gain further insights into the 
cellular uptake mechanism(s) of intact or cleaved 8 under both dark and blue light 
(irradiated) conditions, and compared to that of the mono-metal complexes (9; 11). 
Antiproliferative screening and cellular accumulation ICP-MS studies of co-
administered Ir-PDT (9) and Pt-PACT (11) compared to intact Ir-Pt (8) will provide 
insights into the necessity of conjugation. The intracellular detoxification of 8 in 
cancer cells can further be explored using cellular antioxidants such as GSH,  either 
chemically (by monitoring the formation of metal-GSH adducts by HPLC/LC-
MS),103 or biologically (using L-buthionine sulfoximine – which depletes cellular 
levels of GSH).104  
The multi-targeting of 8 can be investigated using mitochondrial/lysosomal 
bioassays (peptide deformylase, NeutralRed) or more advanced biological 
techniques including PCR amplification of isolated mitochondrial DNA or 
cytochrome c release assays.105, 106  Correlative cryo-SIM, XRT and XRF would 
provide unambiguous information on the organelle-targeting of 8, as close to 
physiological state as possible.40 Moreover, advanced techniques such as LA-ICP-
MS and NanoSIMS can be used to gain information into the quantification and 
distribution of metals in cells.89-92 
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5.1     Introduction 
 
In this Chapter, the intracellular mechanisms of action of diazido-PtIV PACT 
prodrugs have been investigated using complementary synchrotron techniques. 
Firstly, the localisation of a coumarin-labelled diazido-PtIV complex which exhibits 
fluorescence upon photoactivation with light (12, Fig, 5.1, λex/em=405/450 nm)
1 in 
PC3 prostate cancer cells was investigated using cryogenic fluorescence 
microscopy and cryo-Structured Illumination Microscopy (cryo-SIM). Correlative 
cryo-X-ray Tomography (Cryo-XRT) was used to gain insight into the 
morphological and ultrastructural changes induced by 12 in PC3 cells down to a 
remarkable subcellular 40 nm resolution. These studies provide a crucial 
understanding of cellular targets, mechanisms of cell death and drug efficacy. 
Importantly, cells were analysed cryogenically (without the use of chemical stains 
or labels), allowing investigations of treated cancer cells close to their native states. 
Complementary to this, nanofocused synchrotron-XRF and XANES were used to 
probe the intracellular distribution of Pt (L3M5=9.44 keV) and its oxidation state in 
cryo-fixed and freeze-dried PC3 cancer cells to provide a further understanding into 
the cellular targets, drug activation and the mechanism of action. 
 
Figure 5.1. Graphical representation of the techniques used in this Chapter to investigate 
the intracellular mechanisms of action and cellular targets of complexes 11 and 12. 




In contrast to PDT (discussed in Chapter 4), PACT involves the chemical 
activation of a prodrug upon irradiation with a specific wavelengths of light (e.g. 
ligand loss) and is much less-dependent on oxygen levels.2 In particular, PtIV 
photoactivatable prodrugs are of significant interest in the development of 
chemotherapeutics which can circumvent cisplatin-resistance by utilizing in situ 
photodecomposition, allowing both temporal and spatial control over metal 
complex activation.3, 4 
In 1978, the photo-reductive properties of a series of PtIV diazidyl complexes were 
first reported.5 This has since led to the development of remarkably stable 
photoactivatable diazido-PtIV complexes with promising anticancer activity.6-14 The 
development of photoactivatable PtIV prodrugs has the potential to overcome 
intrinsic and acquired resistance of cancer cells towards PtII clinical drugs through 
a multi-targeting approach, while reducing off-target toxic effects using spatially-
directed light.15 In particular, trans, trans, trans-[Pt(N3)2(OH)2(py)2] (11, where 
py=pyridine, Figure 5.1) has shown promise as a PACT anticancer agent against a 
variety of human cancer cells,11 and is significantly more potent than cisplatin with 
lower dosages and shorter drug exposure times.11 It is hypothesised that 11 can be 
photo-reduced intracellularly to form an active PtII species in situ.16 As such, 11 is 
a prodrug which can be used to improve factors such as pharmacokinetics, targeting 
and toxicity.17, 18 The remarkable stability and slow ligand-exchange kinetics of PtIV 
compounds can be advantageous over PtII clinical drugs as they can resist premature 
aquation and the unwanted binding to plasma proteins, which ultimately reduces 
PtII drug efficacy.19  
The family of diazido-PtIV prodrugs from which 11 is derived achieve high 
photocytotoxicity through blue light activation (λ=465 nm), while retaining high 
chemical stability under dark conditions.4 These complexes can be photo-reduced 
to form both toxic PtII species and release cytotoxic ligands (e.g. azidyl or hydroxyl 
radicals, Fig. 5.2), as shown by UV-visible spectroscopy,13, 20 ESI-MS,11 IR 
spectroscopy21 and NMR (1H, 195Pt, 13C and 15N).11 The potential interactions of 11 
with nuclear DNA have also been investigated using electrophoresis, which 
revealed that the cellular response and the nature of DNA lesions were distinct to 
that of clinical drug cisplatin.11 This may provide an alternative mechanism of 
action to conventional PtII chemotherapeutics. 





Figure 5.2. The main proposed mechanism for the photo-reduction of 11 using blue light 
(λ=465 nm) via the release of azidyl radicals, to form a PtII species.4  
 
Interestingly, the antiproliferative activity of 11 can be significantly enhanced by 
coordinating detachable ligands in the axial position. For example, using the axial 
OR position to join different dinuclear Pt modalities using bisamide dicarboxylato 
linkers,22 bioactive ligands (i.e. biotin)23 or radical markers (e.g. TEMPO=2,2,6,6-
tetramethylpiperidine-1-oxyl).24 This labelling strategy provides an opportunity for 
multi-targeting by releasing pharmacologically-active ligands upon irradiation, 
whilst maintaining the “inactive” form in the dark. This has been previously been 
probed using FTIR which revealed that reduction of PtIV to PtII (in 11) proceeds via 
the release of at least one hydroxyl and one azidyl radical, or by two hydroxyl 
radicals upon irradiation.21 
Conjugation of coumarin (a biologically active fluorophore with antitumour 
properties)25 to the axial position of diazido-PtIV prodrugs (12, Fig. 5.1) 
significantly increased the potency in PC3 prostate cancer cells compared to parent 
compound 11 (by ca. 8×) upon blue light irradiation.26 Interestingly, photo-
activated 12 can exhibit blue fluorescence (attributed to 7-hydroxycoumarin-3 
carboxylate and radical photo-products containing hydroxido and coumarin-3 
carboxylato ligands),26 thus, can be used as a fluorescent probe to elucidate 
potential cellular targets using correlative cryo-SIM and cryo-XRT. As coumarin 
itself displays antitumour properties, it cannot be assumed that 12 has the same 
mechanism of action as 11. Nonetheless, it can still be used to gain essential insights 
into the potential in-cell activities of 12 and other such diazido-PtIV prodrugs.  
 




5.2     Experimental 
 
5.2.1    Synthesis of platinum complexes 
 
Complex 11 used in these experiments was synthesized by Dr Cinzia Imberti 
(University of Warwick) using a published literature method.11  Complex 12 was 
synthesized by Dr Huayun Shi (University of Warwick) as previously reported.26 
Both complexes were >95% pure and were stored under dark conditions prior to 
commencement of biological in vitro studies. 
 
5.2.2    Antiproliferative activity (IC50) 
 
The half-maximal inhibitory concentration (IC50 / µM) of 11 in PC3 cells was 
previously reported in the literature using an optimized protocol: 1 h incubation in 
the dark, followed by 1 h blue light irradiation (λ=465 nm, 4.8 mW/cm2), and 24 h 
recovery in the dark and complex-free media.11 The IC50 of 12 in PC3 cells was 
determined by Dr. Huayun Shi (University of Warwick) under the same conditions, 
using the SRB assay protocol (Chapter 2, Section 2.5.1).  
 
5.2.3    Cryo-XRT sample preparation 
 
Preparation of TEM grids  
Quantifoil Au-C R2/2 F1 200 mesh finder grids were prepared using the general 
method described in Chapter 2 (Section 2.6.2). Cells were treated with 0.25–1× 
irradiated IC50 (IC50=6.5 µM) of 12 (prepared in non-phenol red RPMI-1640, 
protected from light) for 1 h, followed by irradiation with blue light (465 nm, 1 h, 
4.8 mW J/cm2) or dark conditions (2 h, protected from light). The supernatant was 
removed and cells recovered in complex-free RMPI-1640 for 0 or 2 h (protected 
from light). Grids were then incubated in MitoTracker FarRed (100 nM) and 
LysoTracker Red (100 nM) for 20 min (310 K, 5% CO2) before blotting with AuNP 
fiducials (d=250 nm) and plunge-freezing in liquid ethane. 




Fluorescence mapping of TEM grids 
Preliminary correlative microscopy analysis on plunge-frozen grids was performed 
on a Zeiss Axioimager M2optical microscopy (50×) coupled to a Linkam Scientific 
cryostage (CMS196M LED) to monitor: (i) MitoTracker DeepRed, (ii) 
LysoTracker Red, and (iii) blue fluorescent photo-products of 12 (Table 5.1). 
Suitable cell candidates were selected for cryo-XRT analysis. 
 
Table 5.1. Excitation and emission wavelengths of MitroTracker DeepRed, LysoTracker 
Red and 12, and the fluorescence filters used to map them. 
Fluorophore Fluorophore 
λex/em (nm) 
Filter Filter λex/em (nm) 
MitoTracker DeepRed 644/665 mPlum 585/645 
LysoTracker Red 577/590 YFP 514/527 




Prior to cryo-XRT measurements, cryo-SIM was performed (B24 beamline, DLS). 
The cryo-SIM has a long distance air objective (100X, 2 mm, 0.9NA) with 4 
available excitation lasers: 405, 488, 561 and 642nm (10-100 Wcm-2 laser power).27 
A maximal lateral resolution of 360 nm (with green light) can be achieved at this 
facility, allowing the imaging of conventional fluorophores with low doses and 
rapid image acquisition (<100 ms).27, 28 Cryo-SIM was used to generate super-
resolution fluorescence information on cryopreserved PC3 cells treated with (i) 
MitoTracker Deep Red (λex/em=644/665 nm); (ii) LysoTracker Red (λex/em=577/590 
nm); (i) blue fluorescent complex 12 (λex/em=405/450 nm) on quantifoil grids (Table 
5.2). Three maps per grid were obtained: (i) z-stack brightfield mosaic; (ii) Red 
(λem=605 nm) + Blue (DAPI, λem=452 nm) and (iii) FarRed (λem=655 nm) + Blue 
(DAPI, λem=452 nm). A total of 15 images per z-plane were collected (3× angles at 
60° apart, 5× phases) at 125 nm increments.27, 28 The blue laser parameters were 
kept consistent throughout all sample measurements (λ=405 nm, 100 ms, 149.963 
mW). Images of 512×512 pixel were obtained and reconstructed for form stacks of 
images (voxel size=0.0625×0.0625×0.0125 µm3). 




Table 5.2. Excitation and emission wavelengths of MitroTracker DeepRed, LysoTracker 
Red and 11 with the excitation laser wavelengths and emission filters available at the B24 







MitoTracker DeepRed 644/665 642 655 
LysoTracker Red 577/590 561 605 
12 405/450 405 452 
 
 
Cryo-SIM data analysis 
Data were processed in SoftWoRX 6.5.2 (GE Healthcare) using real optical transfer 
functions (generated from 3D-SIM images of fluorescent beads of 175 μm) to 
produce image stacks. Processed data were then analysed in Fiji imaging software 
to separate the fluorescence channels.29 The brightness of the blue channel was 
adjusted to eliminate blue fluorescence in the untreated control cells. The same 
parameters were then used to separate the channels in cells treated with 1×IC50 of 
12 under dark and irradiated (465 nm) conditions. For all samples, the blue laser 
conditions were kept the same (λ=405 nm, 100 ms, 149.963 mW).  
 
Cryo-XRT Sample loading onto the beamline     
Pre-mapped quantifoil grids were cryogenically loaded into 4 sample holders at the 
B24 beamline (Chapter 2, Section 2.6.2). Cells of interest were analysed by cryo-
XRT in the tilt range -65 to +65° using an energy of 500 eV, 0.1 s exposure, 0.2-
0.5° sample rotation steps, as specified. 
                                                
Tomogram reconstruction in IMOD 
Tomograms were aligned and reconstructed automatically (unless specified 
otherwise). Tomograms which did not reconstruct sufficiently were manually 
modified in IMOD (Chapter 2, Section 2.6.2).30  
 




Volume segmentation and visualization 
Volume segmentation was performed in SuRVoS imaging software,31 as described 
in Chapter 2 (Section 2.6.2). Segmentation of mitochondria and lipid droplets in 
each tomogram was performed to determine 3D volumes (µm3). Full segmentation 
of two representative tomograms was performed (T3=dark, untreated control; 
T17=1×IC50 of 12; 1 h incubation followed by 1 h irradiation with 465 nm), which 
included: mitochondria, lipid droplets, nucleus, dense organelles/vesicles, the 
plasma membrane and cytoplasmic vacuoles.  
 
5.2.4    Synchrotron-XRF and XANES 
 
Preparation of Si3N4 membranes 
Silicon nitride (Si3N4) membranes were prepared as described in Chapter 2 
(Section 2.6.1) using a seeding density of 8×104 cells / mL of PC3 cells. Cells were 
treated with 5×IC50 of 11 (IC50=55 µM), 12 (IC50=6.5 µM) or cisplatin (IC50>100 
µM) for (i) 2 h in the dark or (ii) 1 h incubation (protected from light) followed by 
1 h irradiation (in drug) with blue light (λ=465 nm, 4.8 mW/cm2). The supernatant 
drug was removed and cells washed with HBSS (2 mL per well). 
 
Synchrotron-XRF beamline settings 
Si3N4 membranes were loaded into the sample holders provided at the I14 beamline 
(DLS, Oxford) and analysed at room temperature (298 K), as described in Chapter 
2 (Section 2.6.1). All synchrotron-XRF maps were obtained by raster scanning 
using an incident energy of 14 keV, 100 nm step size and 0.1 s exposure.  
 
Data analysis 
All elemental maps were fitted using PyMCA toolkit software developed by the 
ESRF.32  The photon flux (photons per second) was estimated by running an AXO 
standard Si3N4 membrane containing known elemental concentrations to further 
enable quantification of platinum. Data were analysed in Image J software.33 All 
other information is specified in Chapter 2 (Section 2.6.1). 





Reference samples were prepared for XANES analysis. In addition to a metallic Pt 
foil, solid pellet samples of cisplatin, potassium tetrachloroplatinate (K2PtCl4) and 
11 were prepared by grinding 3-4 mg with 25-30 mg of dried cellulose using a pestle 
and mortar and formed in a 10 mm die by applying a 1.5 T force with a pellet press 
(Specac, UK). The resulting pellets were sealed in Kapton tape to protect them from 
the environment and to allow labelling. Because of the light sensitivity of PtIV 
photoactivatable complex 11, the pellet was formed under dark conditions and 
taped in aluminized mylar to protect it from light.  
 
Experimental setup for XANES 
 
Solid pellets & metal sheet: In order to improve signal quality and offer a user-
friendly experience when dealing with pellets and foils, reference samples are 
measured upstream from the focusing optics by placing them between two ion 
chambers which monitor the position of the full beam (Fig. 5.3). XANES spectra 
were acquired in the energy range 11.46–11.73 keV, across the Pt L3-edge (11.57 
keV).34 The energy step was variable, with step sizes ranging from 8 eV away from 
the edge to 0.5 eV across the edge. Typical analysis of solid pellets and the metal 
sheet took no longer than 30 min each, as spatial resolution was not required. 
 
 
Figure 5.3. Schematic of the experimental hutch. Solid pellets and foils were analysed 
upstream with the full beam (left), whereas, Si3N4 cell samples were analysed further 
downstream with the focussed beam. There are two detectors used: Detector 1 (back-
scattered XRF detector) and Detector 2 (DPC detector used in Chapter 4). 




Si3N4 cell samples: In this case the beam was focussed to a 50 nm spot, and the 
sample is raster-scanned across the region of interest (ROI). At each point of the 
ROI a full XRF spectrum is acquired, and element-specific images are derived by 
extracting the corresponding signal from the spectrum. Two different 5×5 µm2 Pt-
containing regions (in cryo-fixed and freeze-dried PC3 cells treated with 5×IC50 of 
11 under blue light conditions) were analysed. XANES mapping of the Si3N4 cell 
samples were acquired in the energy range 11.46–11.73 keV, across the Pt L3-edge 
(11.57 keV).34 The energy step was variable, with step sizes ranging from 8 eV 
away from the edge to 0.5 eV across the edge (dwell time=0.2 s, 200 nm steps, 
50×70 nm2). Spatially-resolved XANES spectra were constructed from XRF scans 
at the specified energies, generating a full spatially-resolved XRF map at each 
energy over the Pt-edge. In addition to the traditional data acquisition method of 
scanning the energy with the monochromator, a compressed sensing approach 
currently in development at I14 was applied to some samples as a method test. This 
involved acquiring data at only 7 selected energy points in the energy range, rather 
than the 150 of the default method. The analysis of 5×5 µm2 region using 
conventional “Energy-scanning” method took ca. 10-12 h, whereas to analyse a 5×5 
µm2 region using the “Compressed-Sensing” method took ca. 1-1.5 h. 
 
Obtaining XANES spectra  
For in-cell Pt XANES measurements (for which we require spatial resolution using 
a focussed beam), multiple XRF spectra of the 5×5 µm2 ROI were acquired. The 
XRF peaks of alignment elements (known elements in the sample) were integrated 
to produce 1 value per pixel using Python software. The images were then stacked 
and unwanted information removed. From this, the same alignment parameters 
were applied to the Pt XRF peak (L3M5=9.44 keV).
34 Principle Component 
Analysis (mathematical decomposition) was performed on the XRF spectra, 








Normalisation of XANES spectra 
XANES spectra were analysed in Athena XAS Data Analysis Software.35 Data 
were normalised using edge-step normalisation formulae (Equation 5.1). Edge-
step normalisation extrapolates the difference between pre-edge subtraction and 
post-edge regression to the edge itself. In this case, pre-edge normalisation was 
performed in the energy range 11.47-11.54 keV and the post-edge normalisation 






Equation 5.1. Equation for edge-step normalisation of XANES spectra, where X(E) is the 
theoretical absorption coefficient, µ(E) is the experimental absorption coefficient and 
µ0(E0) is the energy-independent edge jump. 
 
 
XANES data analysis 
A linear combination fit (LCF) was performed on both sets of cellular Pt regions 
(obtained by the “Compressed sensing” and “Energy-scanning” methods, 
respectively) with respect to the solid pellets (cisplatin, K2Cl4Pt and 11) and 
platinum foil. Conventional curve-fitting techniques cannot be used to reliably 
determine the relative proportions of PtII:PtIV species in a mixture (due to 
similarities in peak energy and shape), hence, a method developed by Hambley et. 
al specifically for PtIV/PtII systems was also used to analyse the data. This method 
normalises the maximal edge-absorption (height of peak) with the post-edge 
minima after the white line (Fig. 5.4).36, 37  





Figure 5.4. XANES spectra of PtIV and PtII compounds, showing the maximum peak 
absorptions for each oxidation state (a) and the post-edge minima. Reprinted (adapted) with 
permission from (M. D. Hall, G. J. Foran, M. Zhang, P. J. Beale and T. W. Hambley, J Am 
Chem Soc, 2003, 125, 7524-7525.). Copyright (2003) American Chemical Society as 
modified from a literature figure.37 
 
5.3     Results 
 
5.3.1    Antiproliferative activity (IC50) 
 
The antiproliferative activities of 11 and 12 were determined in PC3 prostate cancer 
cells upon 1 h drug exposure (protected from light), 1 h light irradiation (465 nm, 
4.8 mW J/cm2) and 24 h recovery in complex-free media, protected from the light. 
Coumarin-labelled 12 was 8× more potent that of parent compound 11 in PC3 cells 
upon exposure to blue light of the same intensity and dosage (Table 5.3, p=0.0001). 
Additionally, antiproliferative activities of 11 and 12 were determined under dark 
conditions (2 h exposure under dark conditions, 24 h recovery in complex-free 
medium). Both complexes exhibited low dark antiproliferative activity (IC50>100 
µM). For comparison, the antiproliferative activity of cisplatin was determined 
under the same conditions, revealing inactivity (IC50>100 µM) under both dark and 
irradiated conditions (Table 5.3). 





Table 5.3. Half-maximal inhibitory concentration (IC50 / µM) and cellular accumulation of 
platinum in PC3 cancer cells treated with 11, 12 and cisplatin.26 
[a]1 h drug exposure + 1 h in dark conditions, then 24 h in drug-free media; [b]1 h drug exposure + 1 
h blue light irradiation (465 nm), then 24 h in drug-free media. [c] Literature IC50 value for 11.
11
 
**100 µM concentration is higher than the test range, thus, are deemed inactive. 
 
 
5.3.2    Synchrotron cryo-XRT  
 
Cryogenic light microscopy 
TEM grids were analysed under cryogenic conditions using correlative light 
microscopy. Bright-field mosaics of full grids were acquired to identify suitable cell 
candidates. YFP (λex/em=514/527 nm), mPlum (λex/em=585/645 nm) and DAPI 
(λex/em=358/461 nm) filters were used to map the LysoTracker Red (λex/em=577/590 
nm), MitoTracker FarRed (λex/em=644/665 nm and 12 (λex/em=405/450 nm).  
PC3 cells were located within the finder grid, looking for individual cells positioned 
in the centre of the different quadrants (not located on or near the mesh grid lines; 
to ensure they allow penetration of soft x-ray and can be accessed by cryo-XRT) 
and in areas showing a reduced ice layers and no tweezer damage.  Unfortunately, 
the blue fluorescence (λem=450 nm) of the photoproducts of 12 was not observed 
on the Zeiss Axioimager microscope under the concentration used to treat cells for 
the experiment (0.25–1.0×IC50; 1.5-6.5 µM). Nonetheless, suitable cells were 
selected and analysed by cryo-SIM prior to cryo-XRT. A representative example of 
suitable cryopreserved PC3 cells grown on TEM grids is shown in Fig. 5.5. 
Complex IC50 / μM (dark)[a] IC50 / μM (465 nm)[b] 
11 >100** 55.6 ± 0.9 
12 >100** 6.48 ± 0.84 
Cisplatin >100** >100**  





Figure 5.5. Representative example of a fluorescence microscopy image of cryopreserved, 
untreated PC3 prostate cancer cells (negative control) grown on a carbon-gold TEM grid 
under dark conditions, monitoring the fluorescence of LysoTracker Red (λex/em=577/590 
nm). The image were recorded on a Zeiss Axioimager coupled to a Linkam cryostage. 
Showing elongated, cobble-stoned typical morphologies of PC3 cells (ca. 30-40 µm in 
length),38, 39 with clear cell nuclei. 
 
CryoSIM 
Structure-Illumination Microscopy (SIM) can be used to gain super-resolution 
fluorescence information of biological samples beyond the Abbe diffract limit.40 
SIM is compatible with conventional fluorophores, including MitoTracker Deep 
Red (λ=644/665 nm) and LysoTracker Red (λ=577/590 nm).27 Herein, 
cryopreserved PC3 cells treated with 1×IC50 of 12 (which forms blue fluorescent 
photoproducts upon irradiation with light)26 and incubated with MitoTracker Deep 
Red and LysoTracker Red were monitored using cryo-SIM at the super-resolution 
light microscopy facility at the B24 beamline (DLS, Oxford).41 
Cryopreserved PC3 cells incubated with MitoTracker Deep Red and LysoTracker 
Red revealed strong fluorescence emissions (Fig. 5.6-9; Appendix, Fig. A19-23), 
allowing the identification of mitochondrial and lysosomal organelles, and 
subsequently the nucleus (characterised by a lack of fluorescence). Blue 
fluorescence was not observed in the untreated control cells (dark and light). 
Additionally, blue fluorescence was not detectable in cells treated with 1×IC50 12 
under dark or photo-conditions.  





Figure 5.6. Two cryopreserved PC3 cells grown on carbon-gold TEM grids and to dark 
conditions (2 h, protected from light) and incubated with MitoTracker DeepRed 
(λ=644/665 nm) and LysoTracker Red (λ=577/590nm). (a) Brightfield image. (b-d) Super-
resolution fluorescence images showing (b) LysoTracker Red (lysosomes), (c) 
MitoTracker Red (mitochondria) and (d) overlay of LysoTracker Red and MitoTracker 
Deep Red. Images were generated in Fiji software.29 Blue fluorescence was not observed. 
 
Figure 5.7. A cryopreserved PC3 cell grown on a carbon-gold TEM grids and exposed to 
dark conditions (1 h) followed by 1 h irradiation with blue light conditions (1 h, 465 nm) 
and incubated with MitoTracker DeepRed (λ=644/665 nm) and LysoTracker Red 
(λ=577/590nm). (a) Brightfield image. (b-d) Super-resolution fluorescence images 
showing (b) LysoTracker Red (lysosomes), (c) MitoTracker DeepRed (mitochondria) and 
(d) overlay of LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji 
software.29 Blue fluorescence was not observed. 





Figure 5.8. Two cryopreserved PC3 cells grown on a carbon-gold TEM grids and exposed 
1×IC50 of 12 for 2 h under dark conditions (2 h, protected from light) and incubated with 
MitoTracker DeepRed (λ=644/665 nm) and LysoTracker Red (λ=577/590nm). (a) 
Brightfield image. (b-d) Super-resolution fluorescence images showing (b) LysoTracker 
Red (lysosomes), (c) MitoTracker Deep Red (mitochondria) and (d) overlay of 
LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji software.29 
Blue fluorescence was not observed. 
 
Figure 5.9. Two cryopreserved PC3 cells grown on a carbon-gold TEM grids and exposed 
1×IC50 of 12 dark conditions (1 h) followed by 1 h irradiation with blue light conditions (1 
h, 465 nm) and incubated with MitoTracker DeepRed (λ=644/665 nm) and LysoTracker 
Red (λ = 577/590nm). (a) Brightfield image. (b-d) Super-resolution fluorescence images 
showing (b) LysoTracker Red (lysosomes), (c) MitoTracker Deep Red (mitochondria) and 
(d) overlay of LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji 
software.29 Blue fluorescence was not observed. 




Reconstructed x-ray tomograms 
Cryo-XRT can be used to gain 3D structural information on cancer cells as close to 
their native physiological state as possible (besides live analysis),42-44 avoiding the 
use of chemical fixatives. X-ray tomograms have been obtained using soft x-rays 
(500 eV), producing contrast between carbon-containing structures (i.e. organelles) 
and water (both from cells and the ice layer) on the sample.45 Cryopreserved PC3 
cells treated with 0.25–1.0× the irradiated IC50 of 12 were analysed under both dark 
and irradiated (λ=465 nm) conditions by cryo-XRT (Table 5.4). 
 





Tilt range (°) 
 
Figure Video number 
Untreated control  
(2 h, dark) 
T1 0.5 -70 to +70 
 
5.10 C5_Video_T1 
T2 0.2 -65 to +65 
 
5.10 C5_Video_T2 
T3 0.2 -70 to +70 
 
5.10 C5_Video_T3 
Untreated control  
(1 h+1 h 465 nm) 
T4 0.5 -70 to +60 5.11 C5_Video_T4 
T5 0.2 -65 to +65 5.11 C5_Video_T5 
T6 0.5 -65 to +65 5.11 C5_Video_T6 
1×IC50  
(2 h, dark)  
T7 0.2 -60 to +60 
 
5.12 C5_Video_T7 
T8 0.5 -65 to +65 
 
5.13 C5_Video_T8 




(1 h+1 h 465 nm) 
T10 0.5 -65 to +65 
 
5.14 C5_Video_T11 
T11 0.5 -65 to +65 
 
5.14 C5_Video_T11 




(1 h+1 h 465 nm) 
T13 0.5 -65 to +70 
 
5.16 C5_Video_T13 




(1 h+1 h 465 nm) 
T15 0.5 -55 to +60 5.18 C5_Video_T15 
T16 0.2 -60 to +60 5.19 C5_Video_T16 
T17 0.2 -65 to +65 5.19 C5_Video_T17 
1×IC50  
(1 h+1 h 465 nm)[a] 
T18 0.5 -55 to +55 5.20 C5_Video_T18 
T19 0.2 -65 to +65 5.21 C5_Video_T19 
[a] Cells treated with 1×IC50 (6.5 μM) of 12 for 1 h, followed by 1 h irradiation with blue light (465 
nm) and 2 h recovery in complex-free medium 
 
 




A total of six tomograms (15.8×15.8 µm2 regions) of cryopreserved untreated PC3 
cells were obtained: (i) 2 h protected from the light (T1-3, Fig. 5.10); (ii) 1 h 
(protected from light) + 1 h exposure 465 nm (T4-6, Fig. 5.11). In all of these 
tomograms (T1-6), healthy, unmodified PC3 cells have been identified (showing 
well-rounded nuclei, clear nuclear membranes, nucleoli, plasma membrane, 
mitochondria, lipid droplets). The remarkable spatial resolution of B24 beamline 
(down to 40 nm) enabled the identification of cristae in elongated mitochondria 
(e.g. T3, Fig. 5.10).41 Importantly, blue light (1 h, 465 nm) did not alter the 
morphology of PC3 cells – correlating with that reported in the literature.2  
A total of four tomograms (15.8×15.8 µm2) of cryopreserved PC3 cells treated with 
1×IC50 (6.5 µM) of 12 for 2 h in the dark were obtained (T7-9, Fig. 5.12-13). 
Typical features of an unmodified, healthy PC3 cell were observed, including a 
well-defined nuclear membrane and fused mitochondrial networks. Additionally, 
many lipid droplets were also observed, a common feature of prostate cancer 
cells.46, 47 Two significant observations were made from cells treated with 12 in the 
dark, compared to that of the untreated control tomograms (T1-6; Fig. 5.10-11): (i) 
the presence of endosomes (T7 and T9; Appendix, Table A35); (ii) dark, localised 
spots observed in cell nuclei (T8-9, Fig. 5.13).   
The overall morphologies of PC3 cells treated with 0.25×IC50 (1.5 µM) of 12 
exposed to blue light (T10-12, Fig. 5.14-15) were similar to that of cells treated 
with 12 under dark conditions. Nuclei were still clearly identifiable, in addition to 
mitochondria and lipid droplets. However, two significant differences were 
observed in these treated cells, compared to both the untreated controls (T1-6; Fig. 
5.10-11) and the cells treated under dark conditions (T7-9; Fig. 5.12-13): (i) 
presence of cytoplasmic vacuoles (T10, Fig. 5.14); (ii) membrane-blebbing and 
vesicle-shedding of the plasma membrane (T10-11, Fig. 5.14).  
Two tomograms of PC3 cells treated with 0.5×IC50 (3 µM) of 12 and exposed to 
blue light (465 nm) were obtained (T13-14, Fig. 5.16-17). Fused and separated 
mitochondria were clearly identifiable, with the nuclear membrane still defined. 
Interestingly, T14 (Fig. 5.17) was significantly more rounded and darker in 
appearance, compared to T13 (Fig. 5.16), despite exposure to the same conditions, 
highlighting the distribution and variability in drug uptake and dose response 




exhibited by a population of cells. This is an important consideration in the analysis 
of individual cells, which inevitably leads to a biased selection of cell candidates. 
A large vacuole was also observed in the cell nucleus, which was surrounded by 
lipid droplets (T14, Fig. 5.17) – potentially as a cell repair mechanism to close the 
vacuole and prevent cell death.  
Significant cellular damage was evident from the three tomograms obtained from 
cells treated with 1×IC50 (6.5 µM) of 12 for 1 h, followed by 1 h irradiation with 
blue light (T15-17, Fig. 5.18-19). Multiple cytoplasmic vacuoles were observed in 
all of the analysed cells. The outline of the nucleus can be identified, however, 
appears damaged, with increased granularity compared to that of the untreated 
controls (T1-6; Fig. 5.10-11). Mitochondria and lipids were difficult to identify in 
the cytoplasm, and severe membrane-blebbing was evident at the plasma membrane 
for T16 (Fig. 5.19).  
Finally, the extent of efflux of 12 from PC3 cells treated with 1×IC50 was 
investigated by treating cells with complex for 1 h exposure and 1 h irradiation (465 
nm), followed by 2 h recovery in complex-free media (T18-19, Fig. 5.20-21). This 
is important for clinical translation, where patients are only exposed to drugs (or 
light) for short time periods. Interestingly, the cellular morphologies of recovered 
cells were significantly less damaged than the latter (with no recovery). Fused 
mitochondria, the nuclear membrane and lipids are visible in T18, with very few 
observable vacuoles (Fig. 5.20). The cell represented by T19 (Fig. 5.21) has a 
relatively healthy morphology, with significantly high numbers of lipid droplets 
observed (Total=88).  





Figure 5.10. (a) X-ray mosaic of cryopreserved PC3 cells grown on Quantifoil TEM grids 
and exposed to dark conditions for 2 h and the areas of interest (15.8×15.8 µm2) mapped 
using cryo-XRT; (b-d) reconstructed tomograms (T1-3, C5_Video_T1, T2, T3) showing 
cellular features: (1) nucleus; (2) nuclear membrane; (3) mitochondria; (4) lipid droplets; 
(5) plasma membrane; (6) vesicles; (7) nucleolus; (8) dense organelles; (9) endosomes.  





Figure 5.11. (a) X-ray mosaic of cryopreserved PC3 cells grown on Quantifoil TEM grids 
and exposed to 1 h irradiated (blue light, λ=465 nm) conditions for 2 h and the areas of 
interest (15.8×15.8 µm2) mapped using cryo-XRT. (b-d) reconstructed tomograms (T4-6, 
C5_Video_T4, T5, T6) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes.  
 
Figure 5.12. (a) X-ray mosaic of cryopreserved PC3 cells grown on Quantifoil TEM grids 
treated with 1× irradiated IC50 (6.5 µM) of 12 (2 h, dark conditions) and the areas of interest 
(15.8×15.8 µm2) mapped using cryo-XRT; (b) reconstructed tomogram (T7, 
C5_Video_T7) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes.  





Figure 5.13. (a) X-ray mosaic of cryopreserved PC3 cells grown on Quantifoil TEM grids 
treated with 1× irradiated IC50 (6.5 µM) of 12 (2 h, dark conditions) and the areas of interest 
(15.8×15.8 µm2) mapped using cryo-XRT. (b-d) reconstructed tomograms (T8-9, 
C5_Video_T8, T9) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. Tiny black spots (high x-ray absorption) were observed 
in the nucleus of two independent PC3 cells treated with 6.5 µM of 12 under dark 
conditions as represented in the blue boxed regions. Nuclear membrane invaginations were 
also observed (identified by the red box), a typical feature of cancer cells.48   





Figure 5.14. (a) X-ray mosaic of cryopreserved PC3 cells grown on Quantifoil TEM grids 
treated with 0.25×IC50 (1.5 µM) 12 for 1 h followed by 1 h irradiation (465 nm) the areas 
of interest (15.8×15.8 µm2) mapped using cryo-XRT. (b-d) reconstructed tomograms (T10-
11, C5_Video_T10, T11) showing cellular features: (1) nucleus; (2) nuclear membrane; 
(3) mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. A large cytoplasmic vacuole can be observed in T10 
independent PC3 cells (purple outline), a common feature of programmed cell death.49   
 
Figure 5.15. (a) X-ray mosaic of a cryopreserved PC3 cell grown on Quantifoil TEM grids 
treated with 0.25×IC50 (1.5 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) the areas 
of interest (15.8×15.8 µm2) mapped using cryo-XRT; (b) reconstructed tomogram (T12, 
C5_Video_T12) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. 





Figure 5.16. (a) X-ray mosaic of a cryopreserved PC3 cell grown on Quantifoil TEM grids 
treated with 0.5×IC50 (3 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) the areas 
of interest (15.8×15.8 µm2) mapped using cryo-XRT. (b) Reconstructed tomogram (T13, 
C5_Video_T13) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. A nuclear vacuole was observed. 
 
 
Figure 5.17. (a) X-ray mosaic of a cryopreserved PC3 cell grown on Quantifoil TEM grids 
treated with 0.5×IC50 (3 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) the areas 
of interest (15.8×15.8 µm2) mapped using cryo-XRT. (b) Reconstructed tomogram (T14, 
C5_Video_T14) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. A large nuclear vacuole was observed. 
 





Figure 5.18. (a) X-ray mosaic of three prostate cancer cells grown on Quantifoil TEM grids 
treated with 1×IC50 (6.5 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) the areas 
of interest (15.8×15.8 µm2) mapped using cryo-XRT. (b) Reconstructed tomogram (T15, 
C5_Video_T15) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. Cytoplasmic vacuoles were observed, which is a common 
feature of programmed cell death and is represented in purple.49  
 
Figure 5.19. (a) X-ray mosaic of two PC3 cells grown on Quantifoil TEM grids treated 
with 1×IC50 (6.5 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) the areas of interest 
(15.8×15.8 µm2) mapped using cryo-XRT. (b-d) Reconstructed tomograms (T16-17, 
C5_Video_T16, T17) showing cellular features: (1) nucleus; (2) nuclear membrane; (3) 
mitochondria; (4) lipid droplets; (5) plasma membrane; (6) vesicles; (7) nucleolus; (8) 
dense organelles; (9) endosomes. Cytoplasmic vacuoles were observed (shown in purple), 
which is a common feature of programmed cell death.49 Invaginations of the nuclear 
membrane were present in T16-17 (shown in red), a common feature of cancer cells.48    





Figure 5.20. (a) X-ray mosaic of prostate cancer cells grown on Quantifoil TEM grids 
treated with 1×IC50 (6.5 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) and 2 h 
recovery in drug-free media, the areas of interest (15.8×15.8 µm2) mapped using cryo x-
ray tomography. (b) Reconstructed tomogram (T18, C5_Video_T18) showing cellular 
features: (1) nucleus; (2) nuclear membrane; (3) mitochondria; (4) lipid droplets; (5) plasma 
membrane; (6) vesicles; (7) nucleolus; (8) dense organelles; (9) endosomes. Invaginations 
of the nuclear membrane were present (red), a common feature of cancer cells.48     
 
 
Figure 5.21. (a) X-ray mosaic of prostate cancer cells grown on Quantifoil TEM grids 
treated with 1× IC50 (6.5 µM) of 12 for 1 h followed by 1 h irradiation (465 nm) and 2 h 
recovery in drug-free media, showing the area of interest (15.8×15.8 µm2) mapped using 
cryo x-ray tomography. (b) Reconstructed tomogram (T19, C5_Video_T19) showing 
cellular features: (1) nucleus; (2) nuclear membrane; (3) mitochondria; (4) lipid droplets; 
(5) plasma membrane; (6) vesicles; (7) nucleolus; (8) dense organelles; (9) endosomes. 
Note that this PC3 prostate cancer cell has a significantly enhanced number of lipid droplets 
(total = 88) compared to the control cells.  




3D segmentation and visualisation 
Organelles from the reconstructed tomograms can be segmented to gain 
information on drug-induced morphological changes in 3D. The volumes of 
mitochondria and lipid droplets (µm3) in each tomogram (T1-19; Fig. 5.10-21) 
were determined (Table 5.5; Appendix, Tables A33-34), revealing no statistically 
significant differences in mean mitochondrial or lipid droplet size between cells 
treated with 0-1×IC50 of 12 under all conditions analysed. Endosomes (which can 
exhibit both dense and lucent interiors by cryo-XRT)41, 50 were identified in two 
independent PC3 cells treated with 12 under dark conditions (T7 and T9, Section 
5.3.2, Fig. 5.12-13), and their volumes were segmented (Appendix, Table A35). 
The mean endosomal size were determined to be 0.26±0.13 and 0.33±0.23 for μm3 
T7 and T9, respectively. Additionally, small, dark spots observed in the cell nucleus 
of PC3 cells treated with 12 under dark conditions were found to range in volume 
between 0.002-0.042 and 0.003-0.031 µm3 for T8 and T9, respectively.  
 
Table 5.5. The mean mitochondrial volume and lipid droplets (μm3) in cryopreserved PC3 
cells treated with 0.25–1×IC50 of 12 under dark (2 h) or blue light (1 h + 1 h 465 nm, 4.8 
mW/cm2) conditions (T1-19) as determined in SuRVoS.31 A minimum of 10 mitochondria 













T1 0.25 ± 0.12 68 0.07 ± 0.02 
T2 0.19 ± 0.08 44 0.09 ± 0.02 
T3 0.35 ± 0.14 53 0.23 ± 0.01 
Controls  
(465 nm) 
T4 0.13 ± 0.06 51 0.15 ± 0.05 
T5 0.11 ± 0.04 45 0.09 ± 0.02 
T6 0.15 ± 0.08 35 0.14 ± 0.05 
1 × IC50  
(Dark) 
T7 0.09 ± 0.06 24 0.05 ± 0.01 
T8 0.13 ± 0.09 26 0.25 ± 0.06 
T9 0.13 ± 0.09 28 0.03 ± 0.01 
0.25 × IC50  
 (465 nm) 
T10 0.12 ± 0.07 13 0.05 ± 0.01 
T11 0.24 ± 0.06 23 0.15 ± 0.04 
T12 0.13 ± 0.07 46 0.20 ± 0.06 
0.5 × IC50  
 (465 nm) 
T13 0.07 ± 0.04 42 0.15 ± 0.06 
T14 0.17 ± 0.06 36 0.13 ± 0.03 
1 × IC50   
(465 nm) 
T15 n.d 33 0.03 ± 0.02 
T16 n.d 26 0.03 ± 0.01 
T17 0.08 ± 0.03 28 0.03 ± 0.01 
1 × IC50   
(465 nm)[a] 
T18 0.09 ± 0.03 6 0.11 ± 0.04 
T19 0.14 ± 0.10 88 0.07 ± 0.04 
[a] Cells treated with 1×IC50 (6.5 μM) for 1 h, followed by 1 h irradiation with blue light (465 nm, 
4.8 mW/cm2) and 2 h recovery in complex-free media. 




Full segmentation of two tomograms was performed: (i) Untreated control (2 h dark 
conditions; T3, Fig. 5.10) (ii) 1× IC50 of 11 (1 h + 1 h blue light irradiation; T16, 
Fig. 5.18) to show the extreme morphological differences in 3D (Fig. 5.22-23). 
 
 
Figure 5.22. 3D representation of a 15.8×15.8 µm2 section of a cryo-preserved PC3 cell 
exposed to dark conditions (T3, Section 5.3.2, Figure 5.10), showing the volumes (μm3) 
of the nucleus (■), mitochondria (■), lipid droplets (■), dense organelles/vesicles (■) and 
the plasma membrane (■). Volume segmentation was performed in SuRVoS imaging 
software,31 and visualized in 3D in Amira 2016 (C5_Video_T3_Segmented). 
 
Figure 5.23. 3D representation of a 15.8×15.8 µm2 section of a cryopreserved PC3 cell 
treated with 1×IC50 (6.5 µM) 12 for 1 h followed by 1 h irradiation with 465 nm (T16, 
Section 5.3.2, Figure 5.18), showing the volumes (μm3) of the nucleus (■), damaged 
organelles (■), lipid droplets (■), dense organelles / vesicles (■), the plasma membrane (■) 
and cytoplasmic vacuoles (□). Volume segmentation was performed in SuRVoS imaging 
software,31 and visualized in 3D in Amira 2016 (C5_Video_T16_Segmented). 




5.3.3    Synchrotron-XRF 
 
Synchrotron-XRF has been used to probe the intracellular distribution of Pt in cryo-
fixed and freeze-dried PC3 cells treated with 5× irradiated IC50 of 11 (275 µM), 12 
(32.5 µM) and cisplatin (500 µM) for 2 h (protected from light) or 1 h exposure 
with 1 h irradiation with blue light (465 nm, 4.8 mW/cm2). The Pt L3M5-emission 
(9.44 keV) was monitored in cryo-fixed and freeze-dried PC3 cells (Table 5.6). 
 
Table 5.6. Summary of the XRF maps obtained in this Chapter. 
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Figure 5.24. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and exposed to 1 h irradiation at 465 nm (C1-3), obtained 
using incident energy 14 keV, showing potassium (K), phosphorus (P), zinc (Zn) and 
platinum (Pt). Images were generated in ImageJ software.33 





Figure 5.25. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and treated with 5×IC50 (275 µM) of 11 for 2 h in the dark 
(C4-6) obtained using incident energy 14 keV, showing potassium (K), phosphorus (P), 
zinc (Zn) and platinum (Pt). Images were generated in ImageJ software.33 
  
Figure 5.26. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and treated with 5×IC50 (275 µM) of 11 for 2 h  (1 h exposure, 
1 h irradiation at 465 nm) (C7-9) obtained using incident energy 14 keV, showing 
potassium (K), phosphorus (P), zinc (Zn) and platinum (Pt). Images were generated in 
ImageJ software.33 





 Figure 5.27. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and treated with 5×IC50 (32.5 µM) of 12 for 2 h in the dark 
(C10-11) obtained using incident energy 14 keV, showing potassium (K), phosphorus (P), 
zinc (Zn) and platinum (Pt). Images were generated in ImageJ software.33 
  
Figure 5.28. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and treated with 5×IC50 (32.5 µM) of 12 for 2 h (1 h exposure, 
1 h irradiation at 465 nm – no recovery) (C13-15) obtained using incident energy 14 keV, 
showing potassium (K), phosphorus (P), zinc (Zn) and platinum (Pt). Images were 
generated in ImageJ software.33 





Figure 5.29. Synchrotron-XRF elemental maps of cryo-fixed and freeze-dried PC3 cells 
grown on a Si3N4 membrane and treated with 5×IC50 (500 µM) of cisplatin for 2 h (1 h 
exposure, 1 h irradiation at 465 nm – no recovery) (C16-18) obtained using incident energy 
14 keV, showing potassium (K), phosphorus (P), zinc (Zn) and platinum (Pt). Images were 
generated in ImageJ software.33 
 
Area and roundness factor 
The area (µm2) and roundness factors of each individual cell (C1-18, Fig. 5.24-29) 
was determined in triplicate in ImageJ software (Table 5.7).33 No statistically 
significant differences in cell areas (µm2) were observed between treated cells (C4-
18, Fig. 5.25-29) and the controls (C1-3, Fig. 5.24). Similarly, no statistical 
differences in roundness factors were observed between treated cells (C4-18, Fig. 
5.22-26) and untreated cells (C1-3, Fig. 5.24). No significant differences in cell 
area (µm2) or roundness factor were observed between cells treated with 11 under 
dark and irradiated conditions (C4-6 with C7-9, p>0.05; Fig. 5.25–26) or with cells 
treated with 12 (C10-12 with C13-15, p>0.05; Fig. 5.27-28).  
Due to the diverse range of cell morphologies exhibited by cells, the area of cell 
nuclei and the percentage area of nuclei were obtained, revealing no statistically 
significant differences in the mean area of nuclei with respect to the whole cell area 
in cells treated with 11, 12 and cisplatin (Table 5.8). 




Table 5.7. Cell areas (µm2) and roundness factors of cryo-fixed and dried PC3 cells treated 
with 5× irradiated IC50 of 11 (IC50=55.6±0.9 µM), 12 (IC50=6.48±0.84 µM) or cisplatin 
(IC50>100 µM) under both dark (2 h) or light (1 h + 1 h 465 nm, 4.8 mW/cm2) as determined 
from the S, K, P and Zn XRF elemental maps. Data were analysed in triplicate in ImageJ.33 
 
 
Table 5.8. Individual areas of cell nuclei (µm2) and the percentage of intracellular area 
which is taken up by nuclei (%) in cryo-fixed and freeze-dried PC3 cells treated with 5× 
irradiated IC50 of 11 (IC50=55.6±0.9 µM), 12 (IC50=6.48±0.84 µM) or cisplatin (IC50>100 
µM) under both dark (2 h) or light (1 h + 1 h 465 nm, 4.8 mW/cm2) as determined from the 














0.69±0.20 C2 334±7 0.43±0.01 





0.94±0.03 C5 276±5 0.94±0.02 
C6 423±6 0.97±0.01 
11 




0.90±0.01 C8 355±6 0.82±0.01 





0.64±0.26 C11 287±2 0.37±0.02 
C12 212±2 0.59±0.02 




0.69±0.27 C14 141±2 0.86±0.02 






0.59±0.24 C17 313±7 0.88±0.02 
C18 324±6 0.37±0.01 
Conditions Cell number 







C1 139±4 30 
32±7 C2 136±3 41 
C3 92±3 28 
11 (Dark) 
C4 66±1 43 
35±7 C5 82±3 30 
C6 139±1 33 
11 
 (465 nm) 
C7 81±4 25 
30±5 C8 105±4 30 
C9 79±2 34 
12 (Dark) 
C10 91±2 68 
52±16 C11 106±5 37 
C12 107±3 50 
12 (465 nm) 
C13 94±1 36 
46±11 C14 82±2 58 
C15 53±2 45 
Cisplatin (465 nm) 
C16 123±1 31 
30±1 C17 92±3 30 
C18 97±5 30 




Elemental distribution and co-localisation 
The correlation between Pt and Zn were determined for cells treated with 11 (C4-
9, Fig. 5.25-26), 12 (C10-15, Fig. 5.27-28) and cisplatin (C16-18, Fig. 5.29) and 
are reported as Pearson R-values (r) and Spearman Rank Correlations (Appendix, 
Table A36). The intracellular Pt in cells treated with 11 under dark conditions (C4-
6, Fig. 5.25) showed a moderate co-localisation with Zn (r=0.14–0.23; 
mean=0.19±0.05). Interestingly, the co-localisation between Pt and Zn was 
significantly enhanced in cells treated with 11 and exposed to blue light (C7-9, Fig. 
5.26, ranging from r=0.40–0.49; mean=0.44±0.05) when compared to dark 
conditions (p=0.0036). The same trend was observed for cells treated with 12 in the 
dark (C10-12, Fig. 5.27, mean r=0.34±0.04) and irradiated (C13-15, Fig. 5.28, 
mean r=0.58±0.08; p=0.0423).  Finally, cells treated with cisplatin (C16-18, Fig. 
5.29) showed moderate correlation between Pt and Zn (mean r=0.34±0.03). 
Cryo-fixed and dehydrated PC3 cells exposed to blue light (1 h, 465 nm) revealed 
clear, stretched-out morphologies (identified by endogenous elements: K, P and Zn) 
and well-rounded cell nuclei (C1-3, Fig. 5.24). Cells treated with 11 (5×IC50) under 
dark conditions (C4-6, Fig. 5.25) appeared more rounded (compared to the 
untreated controls), with spherical nuclei. The Pt XRF in C4-6 was faint, but 
appears to somewhat co-localise with the spherical area of concentrated Zn in the 
cell nucleus. Cells treated with the same concentration of 11 but exposed to 1 h blue 
light (C7-9, Fig. 5.26) revealed significantly more intracellular Pt, sparsely 
distributed in the cell (including the cell nucleus). 
Cells treated with 12 under both dark or irradiated conditions (1 h, 465 nm) revealed 
a variety of morphologies. Cells treated with 12 under dark conditions (C10-12, 
Fig. 5.27) showed significantly less Pt compared to irradiated cells (C13-15, Fig. 
5.28). Overall, cells treated with 12 showed sparse distributions of Pt (cytoplasm 
and the nucleus). It is notable that one of the less damaged (elongated) cells treated 
with 12 exposed to blue light (C13, Fig. 5.28) showed highly localised Pt around 
the perimeter of the cell. Finally, PC3 cells treated with cisplatin (500 µM) for 1 h 
and exposed to 1 h irradiation exhibited a variety of cell morphologies (C16-18, 
Fig. 5.29), with Pt distributed in the cell nucleus and the cytoplasm. 
 




Platinum quantification in PC3 cells 
Mass fraction quantities of Pt were determined in PC3 cells treated with 11, 12 and 
cisplatin (Fig. 5.30) by calibrating the flux to an AXO standard as previously 
described (Chapter 2, Section 2.6.1). Cells treated with 11 under irradiated 
conditions (465 nm) showed Pt levels ca. 3× higher than that of cells under dark 
conditions (p=0.0002), with 8.2±0.8 and 2.8±0.3 ppm of Pt, respectively. The same 
trend was observed for 12, with 3.5× more intracellular Pt detected under irradiation 
with blue light compared to dark conditions (p=0.0001), with 17±7 and 4.9±0.6 
ppm, respectively. In general, significantly more Pt was observed in cells treated 
with 12 when compared with those treated with 11 (both under dark conditions, and 
blue light irradiation; p=0.0061 and p=0.0012, respectively). The mass fraction of 
Pt in cells treated with cisplatin (5.5±0.2 ppm) closely resembled that of 12 
(4.9±0.6 ppm) under dark conditions (Table 5.9). 
The percentage of intracellular Pt in nuclei in cells treated with 11 and 12 under 
dark conditions were determined to be 74±15 and 52±17%, respectively (Table 
5.9). Similarly, the percentage of intranuclear Pt in cells treated with 11 or 12 under 
photo-conditions were 57±9 and 55±15%, respectively. Finally, cells treated with 
cisplatin under blue light conditions revealed 42±8% of intracellular Pt in the 
nucleus (Table 5.9). 
 
Figure 5.30. Mass fraction quantities of Pt in cryo-fixed and freeze-dried PC3 cells treated 
with 5×IC50 of 11 (IC50=55.6±0.9 µM), 12 (IC50=6.48±0.84 µM) and cisplatin (IC50>100 
µM) under dark (2 h) or 1 h exposure followed by 1 h blue light conditions (465 nm, 4.8 
mW cm-2, 1 h) as analysed by synchrotron-XRF. 




Table 5.9. Intracellular quantities of Pt (ppm) in cryo-fixed and freeze-dried PC3 cells 
treated with 5× irradiated IC50 of 11 (IC50=55.6±0.9 µM), 12 (IC50=6.48±0.84 µM) or 
cisplatin (IC50> 100 µM) under both dark (2 h) or irradiated (1 h exposure + 1 h 465 nm, 
4.8 mW/cm2) conditions, as determined from the synchrotron-XRF maps. 
 
 
5.3.4    Pt XANES mapping 
 
Solid pellets of cisplatin, K2PtCl4 and 11, as well as a platinum sheet were analysed 
by XANES over the energy range 11.46–11.73 keV, to monitor the Pt L3-edge 
absorption (11.56 keV),34 as shown in Fig. 5.31-32. The XANES spectra of 
cisplatin and K2PtCl4 were closely comparable owing to their Pt
2+ oxidation state 
and square-planar coordination environments. The spectrum of 11 revealed a slight 
shift in energy (ca. 2 eV), and a sharp increase in the edge absorption compared to 
the Pt(II) compounds (cisplatin; K2PtCl4). The ROI in cryo-fixed and freeze-dried 
PC3 cells treated with 11 and exposed to blue light were identified from the XRF 
of Pt. Two independent 5×5 µm2 Pt-containing regions were monitored by XANES 
mapping using the nanofocussed beam in the range 11.46-11.73 keV (0.2s dwell 
time, 200 nm step size) using the  “Compressed Sensing” and “Energy-Scanning” 
methods (Section 5.2.4).  
 
Conditions Cell 
[Pt] per cell  
(ppm) 
Mean [Pt] / 
cell (ppm) 
% Pt / 
nucleus 







74±15 C5 2.75±0.02 55±2 
C6 2.51±0.01 78±3 
11 




57±9 C8 7.4±0.1 50±2 






52±17 C11 4.12±0.02 31±3 






55±15 C14 20.9±0.2 64±8 





42±8 C17 5.68±0.05 53±1 
C18 5.34±0.02 34±1 





Figure 5.31. XANES spectra of solid pellets of K2PtCl4 (■), cisplatin (■), 10 (■), and of 
platinum metal (■). XANES spectra of intracellular Pt in two independent 5×5 µm2 regions 
of cryo-fixed and dried PC3 cells treated with 5×IC50 of 11 (1 h exposure + 1 h 465 nm), 
where ‘In-cell 11a’ (■) and ‘In-cell 11b’ (■) correspond to the Compressed Sensing and 
Energy-Scanning methods, respectively. Data were normalised using edge-step 
normalisation extrapolates the difference between pre-edge subtraction and post-edge 
regression to the edge itself. Pre-edge normalisation was performed in the energy range 
11.47-11.54 keV and the post-edge normalisation was performed in the range 11.59-11.75 
keV, and a normalisation order=2. 
 
 
Figure 5.32. Stacked plot of XANES spectra of solid pellets of K2PtCl4 (■), cisplatin (■), 
10 (■), and of platinum metal (■). XANES spectra of intracellular Pt in two independent 
5×5 µm2 regions of cryo-fixed and dried PC3 cells treated with 5×IC50 of 11 (1 h exposure 
+1 h 465 nm), where ‘In-cell 11a’ (■) and ‘In-cell 11b’ (■) correspond to the Compressed 
Sensing and Energy-Scanning methods, respectively. Pre-edge normalisation was 
performed in the energy range 11.47-11.54 keV and the post-edge normalisation was 
performed in the range 11.59-11.75 keV, and a normalisation order=2. 




Data were processed using a method reported in the literature,36, 37  to obtain 
normalized peak ratios (Table 5.10), as described previously in Section 5.2.4. 
Comparison of the normalized peak ratios of solid pellet of 11 and Pt in cells treated 
with 11 revealed ca. 18% reduction of PtIV to PtII. Whereas, comparison of cisplatin 
with intracellular 11 revealed ca. 25% reduction of PtIV to PtII.  A linear 
combination fit (LCF) of the normalised data was also performed (between 11.55-
11.60 keV), revealing ca. 80% intracellular PtIV by the “Compressed Sensing” 
method and ca. 75% PtIV by the “Energy-Scanning” XANES method (Table 5.11). 
 
Table 5.10. Oxidation states, white line energies, normalised maximal absorption values 
and normalised peak ratios between the normalised maximum of the white line (a) and the 
post-edge minima (b) of cisplatin, K2PtCl4, 11 solid pellets, platinum metal and 
cryopreserved, freeze-dried PC3 cells treated with 11 under photo-conditions, as 









peak ratio (a/b) 
Cisplatin 2+ 11571.2 1.30 1.37 
K2PtCl4 2+ 11570.7 1.26 1.32 
Pt metal 0 11570.6 1.28 1.35 
11 4+ 11573.4 1.95 2.05 
In-cell 11a[a] n.d. 11572.9 1.64 1.73 
In-cell 11b[a] n.d. 11572.7 1.60 1.68 
[a] Determined from 5×5 µm2 regions of Pt in cryo-fixed and freeze-dried cells treated with 5×IC50 
11 and exposed to 1 h blue light (465 nm) using the “Compressed Sensing” XANES method.  [b] 
Determined from 5×5 µm2 regions of Pt in cryopreserved and freeze-dried cells treated with 5×IC50 
11 and exposed to 1 h blue light using the “Energy-Scanning” acquisition XANES method. 
 
Table 5.11. Percentages of intracellular PtIV and PtII in cryofixed and dried PC3 cells 
treated with 11 under blue light conditions, determined by performing a linear combination 
fit (LCF) on the normalised data. 
[a] Determined from 5×5 µm2 regions of Pt in cryo-fixed and freeze-dried cells treated with 5×IC50 
11 and exposed to 1 h blue light (465 nm) using the “Compressed Sensing” XANES method.  [b] 
Determined from 5×5 µm2 regions of Pt in cryopreserved and freeze-dried cells treated with 5×IC50 
11 and exposed to 1 h blue light using the “Energy-Scanning” acquisition XANES method. 




11 vs. cisplatin 80.3±2.2 19.7±2.2 
11 vs. K2PtCl4 81.8±1.9 18.2±1.9 
In-cell 11b[b] 
11 vs. cisplatin 76.5±1.7 23.5±1.7 
11 vs. K2PtCl4 74.2±2.0 25.8±2.0 





Figure 5.33. Representative example of  Linear Combination Fit (LCF) analysis of 5×5 
µm2 regions of cryo-fixed and dried PC3 cells treated with 5×IC50 of 11 (1 h exposure +1 
h 465 nm), using (a) “Compressed-sensing” and (b) “Energy-Scanning” methods, 
respectively. The 5×5 µm2 analysed region is shown in blue and the LCF fit in red. LCF 
analysis was performed in the region 11.55-11.60 keV (20 eV below the edge and 30 eV 
above the edge). 
 
 
5.4     Discussion 
 
The aim of this Chapter was to gain insights into to the antiproliferative 
mechanism(s) of action of diazido-PtIV PACT prodrugs (11; 12) in cancer cells as 
close to their native state as possible (without using chemical stains or labels). 
Correlative fluorescence microscopy, cryo-SIM and cryo-XRT can be used to 
investigate morphological or structural changes to cancer cells induced by 12 (a 
fluorescent, coumarin-labelled diazido-PtIV complex) down to a 40 nm resolution 
at the B24 beamline. This may provide information into the mechanisms of cell 
death and subcellular targets of this family of photoactivatable diazido-PtIV 
prodrugs. Complementary to this (although not analysed cryogenically) cryo-fixed 
and dried cells were analysed by nano-focussed XRF and XANES to probe the 
cellular distribution and speciation of Pt in cancer cells treated with the drug. 
 




5.4.1    Cryo-SIM of Pt-treated cancer cells 
Structured Illumination Microscopy (SIM) is a powerful super-resolution technique 
which pushes the resolution of optical microscopes past the Abbe diffraction limit 
(d=λ/2NA, where λ=wavelength and NA=numerical aperture),40 achieving 8-fold 
improved volumetric resolution compared to the diffraction limit.27 SIM works on 
the basis of using “striped” or “patterned” illumination to excite a sample of interest 
by altering both the position and orientation of the pattern (Moiré effect). 
Advantages of 3D SIM include compatibility with conventional fluorophores, high 
sensitivity (compared to widefield techniques), it can be used for thick samples (>10 
µm),51 uses low doses and allows rapid data acquisition.27 Importantly, cryo-SIM 
can be used in combination with cryo-XRT to gain insights into the intracellular 
localization and compartmentalization of fluorescent compounds in biological 
systems as close to their native state as possible.52  
In this experiment, the fluorescence emissions of MitoTracker Deep Red 
(λex/em=644/665 nm) and LysoTracker Red (λex/em=577/590 nm) were intense, 
showing clearly where the mitochondrial and lysosomal organelles were inside the 
PC3 cells, allowing the identification of cell nuclei – characterised by the lack of 
fluorescence (Section 5.3.2, Fig. 5.6–9). The morphology of cells treated with 
1×IC50 (6.5 µM) 12 and exposed to blue light (Section 5.3.2, Fig. 5.6) did not appear 
significantly different to that of the untreated controls, despite the known 
phototoxicity of 12,26 highlighting the limitations of 2D analysis. It is known that 
12 forms blue fluorescent coumarin radicals upon photoactivation with light 
(λex/em=405/450 nm),
26 however, the blue fluorescence could not be observed by 
cryo-SIM. This implies that, although 12 can release blue-fluorescent compounds 
in aqueous solution (7-hydroxycoumarin-3 carboxylate and radical photo-products 
containing hydroxido and coumarin-3 carboxylato ligands),26 the fluorescence 
inside cells is likely not strong enough (perhaps due to short fluorescence lifetimes 
of the organic radicals). Nonetheless, the fluorophore emissions from the 
MitoTracker and LysoTracker were observed, providing 2D information of the cell 
outline, nucleus and cytoplasm as close to their native state as possible (Section 
5.3.2, Fig. 5.6–9). As this was unsuccessful, future studies would aim to investigate 
a highly fluorescent diazido-PtIV compound, such as the Ir-Pt conjugate (7, Chapter 
4), to overlay the fluorescence with the 3D tomograms in a correlative approach. 




5.4.2    Cryo-XRT and Pt-treated cancer cells 
 
Untreated PC3 cells 
Cryo-XRT can provide morphological and subcellular information of cancer cells 
treated with diazido-PtIV complexes under both dark and blue light (465 nm) 
conditions as close to their native state as possible. Three tomogram sections 
(15.8×15.8 µm2) of representative untreated PC3 cells from a population of cells 
under dark conditions were obtained (T1-3, Section 5.3.2, Fig. 5.10). The 
tomograms were aligned (to account for drift and tilt) and reconstructed 
automatically in IMOD imaging software.30 Tomograms T1-3 exhibited features of 
typical PC3 cells, revealing well-defined nuclei (showing nucleolus and a thin 
nuclear membrane) and detailed cytoplasmic organelles, including mitochondria, 
lipid droplets and other (unassignable) dense organelles. Additionally, the plasma 
membrane can be identified in T3 (Section 5.3.2, Fig. 5.10).  
A particularly noticeable feature of these untreated PC3 cells was the presence of 
lipid droplets: carbon-dense spherical organelles,53 with high x-ray absorptions 
(with x-ray absorption coefficients ca. 1 µm-1 – almost 10× greater than that of 
vitreous ice).54 These are structurally distinct from the AuNP fiducials (d=250 nm), 
which are isotropic, homogenous and spherical, have increased electron density (Au 
vs. C) and have “dark disk” appearances even at high sample tilt angles. Lipids are 
essential cellular components and have been reported to be significantly altered in 
certain disease states.55 Lipid droplets are over-expressed in many prostate cancer 
cell lines, which can have detrimental consequences for cancer progression and 
pathogenesis,56 making them a viable target for chemotherapeutics. The volumes of 
lipid droplets in these untreated “native” PC3 cells (T1-3, Appendix, Table A34) 
were determined using volume segmentation to compare to that of cells treated with 
12. In T1-3 a wide distribution of lipid droplets was observed: ranging from 0.05-
0.38 µm3 in size (SuRVoS software),31 with between 44-68 lipids in each region 
(15.8×15.8 µm2). The distribution and size of lipid droplets can be dependent on: 
(i) cell growth / adhesion; (ii) cell crowding (neighbouring cells); (iii) stage of cell 
growth (i.e. cell cycle). The 3D volume of lipid droplets is not well-reported in the 
literature, however, they are typically less than 1 µm in diameter.57 Overall, the 
mean volumes of lipid droplets in T1-3 resides within the literature range.  




Mitochondria were clearly identifiable in the cell cytoplasm: elongated and thin in 
nature (Section 5.3.2, Fig. 5.10), with cristae identifiable in many cases (e.g. T3). 
This differs to the general mitochondrial shape observed from the dark control cells 
in the iridium experiment (Chapter 4), which is likely due to the improved quality 
of samples in this experiment. This will also dependent on the cell passage used. 
The average volumes of mitochondria from PC3 cells exposed to dark conditions 
(T1-3; Appendix, Table A33) ranged between 0.09-0.58 µm3, emphasizing the 
large variance in mitochondrial volume observed in PC3 prostate cancer cells, as 
reported in Chapter 4. The area of mitochondria of healthy cells have been reported 
to range between 0.75–3 μm2 in size,58 and exhibit diverse mitochondrial 
arrangements (depending on the static, fusing and dynamic dividing status),59  thus,  
the wide size variations are not surprising. Full 3D volume segmentation of T3 
(Section 5.3.2, Fig. 5.23) shows the nucleus, indisputable mitochondria, spherical 
lipid droplets, dense organelles/vesicles and the plasma membrane. 
Vesicular structures were observed at the plasma membrane of one of the cells (T2, 
Section 5.3.2, Fig. 5.10), most likely corresponding to extracellular exosomes or 
shedding vesicles. Extracellular vesicles can be defined as membrane-enclosed 
particles released by a cell into extracellular space,60 and are biomarkers for a 
variety of cancers.61 In prostate cancer, the trafficking of extracellular vesicles 
(exosomes and prostasomes) can promote interactions with adjacent cells,61 
allowing cancer cells to invade new spaces. The presence of extracellular vesicles 
(exosomes) is a common feature in PC3 cells,61 and was also observed in PC3 cells 
in the iridium experiment Chapter 4 (Section 4.5.2). 
PC3 cells exposed to 1 h irradiation with blue light (λ=465 nm, T4-6, Section 5.3.2, 
Fig. 5.11) closely resembled that of cells exposed to dark conditions (T1-3, Section 
5.3.2, Fig. 5.10). Nuclei, nucleoli and nuclear membranes were apparent, with 
elongated mitochondria (0.04–0.30 µm3; Appendix, Table A33), extracellular 
vesicles, lipid droplets (0.07–0.24 µm3; Appendix, Table A34) and well-defined 
cell membranes. No discernible morphological differences were identified between 
cells exposed to dark (T1-3, Fig. 5.10) or blue light (T4-6, Fig. 5.11) conditions, 
re-affirming that blue light (of this intensity and exposure) is non-toxic towards 
cancer cells, thus, can be utilized in PACT.2 Moreover, both sets of untreated PC3 
cells can be used as reliable negative controls in this experiment. 




Cells treated with 12 under dark conditions 
In order to probe the in-cell effects of 12 under dark conditions (reported to be non-
toxic, IC50>100 µM),
26 cryopreserved PC3 cells treated with 1× the irradiated IC50 
(6.5 µM) of 12 were analysed by cryo-XRT (T7-9, Section 5.3.2, Fig. 5.12-13). 
The cellular features showed attributes similar to that of the untreated controls (T1-
6, Section 5.3.2, Fig. 5.10-12), with comparable lipid droplets (0.05–0.33 µm3), 
elongated mitochondria (0.02–0.34 µm3) and well-defined cell nuclei (Appendix, 
Tables A33-34). However, two noticeable features not evident in the untreated cells 
were observed: (i) endosomes (T7 and T9, Section 5.3.2, Fig. 5.12-13); (ii) dark 
spots in cell nuclei (T8-9, Section 5.3.2, Fig. 5.13). 
 
Endosomes 
Endosomes are membrane-bound compartments responsible for sorting and 
delivering internalized material to lysosomes or vacuoles for removal from the 
cell.62 It has previously been reported that cisplatin-resistant cancer cells have 
altered endocytotic recycling pathways, which contributes to the development of 
acquired resistance.63 Herein, endosomes were observed in two independent PC3 
cells treated with 12 under dark conditions (T7, T9, Section 5.3.2, Fig. 5.12-13). 
The endosomal size in cells treated with 1×IC50 of 12 under dark conditions ranged 
between 0.09-0.99 µm3 (Appendix, Table A35), with a variety of different 
transparencies (dense or lucent interiors) correlating with that of endosomes 
analysed by cryo-XRT in the literature.41, 50 Endosomal size is dependent on the 
stage of post-internalisation (i.e. early, sorting or late endosomes) and can have 2D 
diameters of up to 1 µm,64 explaining the variation in endosomal size observed. The 
endosomes in T7 and T9 (Section 5.3.2, Fig. 5.12-13) are different in appearance, 
which is likely attributed to different stages of cell growth and recovery in response 
to treatment with 12. For example, it is evident from the x-ray mosaics that the cell 
mapped by T9 (Section 5.3.2, Fig. 5.13) is less crowded, making it more exposed 
or vulnerable, compared with T7 (Section 5.3.2, Fig. 5.12) which has more 
neighbouring cells (allowing extracellular interactions between adjacent cells, thus 
promoting cancer cell survival).65   




The presence of endosomes may imply that PC3 cells can recognize 12 as an 
invader and attempts to secrete it from the cell via endocytotic pathways, thus, 
reduce the quantity of intracellular complex available for photo-activation. 
Therefore, the lack of dark toxicity of 12 may not only be attributed to the apparent 
complex ‘inertness’, but also a result of the active excretion/efflux from cancer 
cells. It is not all that surprising that PtIV-prodrugs are being recognized by cancer 
cells in a similar manner to cisplatin, which emphasizes the crucial advantage of 
light-mediated selectivity in overcoming resistance. This may also warrant a further 
optimization of the antiproliferative screening protocol whereby cells are 
photoactivated earlier: for example, irradiation after 30 min dark drug exposure as 
opposed to 1 h drug exposure, which may increase the extent of cytotoxicity. 
The postulated efflux of diazido-PtIV complexes via active processes under dark 
conditions may be disadvantageous in the development of PACT prodrugs, 
however, this can also be exploited in general drug design. The conjugation of 
endosomal-targeting moieties to diazido PtIV complexes may exploit the endosomal 
localisation of 12 under dark conditions (e.g. complexes which can be activated in 
these recycling compartments). For example, using endocytic-targeting ligands 
(such as riboflavin or mannose-6-phosphate – which rely on clathrin-dependent 
receptor-mediated endocytosis)66 at the axial position of PtIV prodrugs. This may 
exploit the “dark” endosomal-localisation of diazido-PtIV prodrugs and enhance the 
overall antiproliferative effect. 
 
Nuclear spots and membrane invaginations 
The second major observation in cells treated with 12 (2 h, dark) was the presence 
of small black spots in the cell nucleus (T8-9, Section 5.3.2, Fig. 5.13), ranging 
from 0.002-0.042 and 0.003-0.031 µm3 in size, for T8 and T9. These dark spots 
were not attributed to fiducials as they are significantly smaller, non-spherical and 
inhomogeneous. Heavy metals have high atomic numbers, thus, causes strong 
electron scattering upon exposure to soft x-rays, appearing darker in tomography. 
This observation may provide evidence into the potential nuclear-targeting of 12 in 
PC3 cells. As soft x-rays (500 eV) cannot directly detect the XRF of heavy metals 
(e.g. Pt L3M5=9.44 keV), synchrotron-XRF was required to confirm this.
  




Nuclear membrane invaginations were also observed: 3D crevices formed when the 
nuclear membrane folds back on itself to encapsulate vesicles during endo- or 
exocytosis.67 Tumour cells acquire nuclear membrane invaginations to enhance cell 
signalling (i.e Ca2+ signal transduction – as key component in the cell cycle and cell 
survival).48 Moreover, as nuclear invaginations are common for many cancers,48 
this observation is likely not attributed to treatment with 12, correlating with the 
lack of cytotoxicity of 12 (IC50>100 µM) prior to photo-activation with blue light.  
 
Cells treated with 12 under photo-conditions 
In order to probe the photo effects of 12, PC3 cells were treated with 0.25–1×IC50 
(1.5–6.5 µM) for 1 h, followed by 1 h exposure to blue light (λ=465 nm) so as to 
compare directly to cell viability experiments (Section 5.3.1, Table 5.3). 
Significant differences in morphology were observed when treated with 12 under 
photo-conditions (T10-17, Section 5.3.2, Fig. 5.14-19), compared to those exposed 
to dark conditions (T7-9, Section 5.3.2, Fig. 5.12-13) including membrane-
blebbing, vesicle-shedding, vacuolisation (cytoplasmic and nuclear), varying lipid 
droplet distributions, increased granularity of the nucleus and cell shrinkage. No 
statistically significant differences in the mean size of mitochondria or lipid droplets 
were observed between the untreated controls and cells treated with 0.25-0.5×IC50 
of 12 upon irradiation, with a wide range of 3D volumes (0.03-0.35 µm3 and 0.04-
0.29 µm3 for mitochondria and lipid droplets, respectively). The extent of cell 
damage was highly dose-dependent, with significantly damaged morphologies at 
higher concentrations of 12. The mitochondria in severely damaged cells (treated 
with 1×IC50 of 12, T15-16, Fig. 5.18-19) could not confidently be identified in the 
cytoplasm, suggestive of drug-induced organelle damage. 
Cells treated with 12 with the inclusion of a recovery period (T18-19, Section 5.3.2, 
Fig. 5.20-21) were significantly less damaged compared to that of cells treated with 
12 without recovery (T15-T17, Section 5.3.2, Fig. 5.18-19): with healthy nuclei, 
well-defined lipid droplets, fused mitochondria and non-compromised plasma 
membranes. This may suggest a potential cytostatic contribution towards the 
antiproliferative activity of 12. This may be a consequence of enhanced drug efflux 
or reduced cellular influx of 12 upon removal of extracellular drug solution. A 




comparison of T18 and T19 (1×IC50 with recovery) revealed differences in 2D 
morphology, with T19 being more elongated and resembling that of untreated PC3 
cells grown on a 2D surface.38, 39 This correlates with reduced cell damage in T19 
induced by 12, emphasizing the differential uptake and efflux kinetics exhibited 
within cells in the population. 
 
Vesicle-shedding and membrane blebbing 
In general, there was a wide distribution in the 2D shape and morphology of cells 
treated with 12, highlighting the varying dose response kinetics (i.e. uneven drug 
uptake) exhibited by individual cells in a population. Cryo-XRT has the advantage 
that it allows the rapid analysis of individual cells, as opposed to making an 
assumption about a large population of cells (e.g. metal ICP-MS cellular 
accumulation studies). Cells exposed to the lowest concentration (0.25×IC50) of 12 
under photo-conditions revealed vesicle-shedding at the plasma membrane (T10, 
Section 5.4.2, Fig. 5.14). As vesicle-shedding is a common feature of many prostate 
cancer cell lines,61, 68  it cannot confidently be attributed to damage induced by 12 
– hence, complementary techniques are required to verify this.  
Severe membrane-blebbing was also observed for cells treated with the highest 
concentration of 12 (1×IC50), but to a much greater extent, reaffirming 
concentration-dependent cell death. Membrane-blebbing is commonly associated 
with programmed cell-death mechanisms including apoptosis and necrosis.69 
Fluorescence imaging of structurally-similar light-activated diazido-PtIV complexes 
did not exhibit the classical features of apoptosis (e.g. cell fragmentation), 
suggestive of predominantly non-apoptotic cell death.13 It must be considered that 
12 may exhibit multiple mechanisms of cell death, for example cisplatin induces 










Cytoplasmic vacuoles were observed in cells treated with 0.25-1×IC50 of 12 under 
photo-conditions (T10-17, Section 5.3.2, Fig. 5.14-19), with multiple cytoplasmic 
vacuoles at higher concentrations of 12: dose-dependent cell damage. Cytoplasmic 
vacuoles are formed in response to harmful materials which have entered the cell, 
which may implicate a cellular attempt to remove or detoxify 12, to evade cell 
death. Vacuolisation is commonly associated with autophagy or paraptosis.49 
Cytoplasmic vacuoles in autophagy are commonly double-membraned, whereas, in 
paraptosis they are single-membraned.71As the vacuoles in cells observed in these 
tomograms were predominantly enclosed by single-membranes, this may suggest 
paraptosis is involved in the cell death pathway induced by 12. 
The formation of vacuoles in cells treated with 12 (465 nm) may play an essential 
role in the initiation of non-apoptotic cell death. This is not the first report of drug-
induced formation of vacuoles by Pt compounds in cancer cells.72-74 Vacuolisation 
has also been linked to the generation of ROS, for example, curcumin (a compound 
with antitumour properties) can trigger extensive cytoplasmic vacuolation in PC-
3M cells (metastatic cells derived from hepatic metastasis of PC3 cells),75 which 
was attributed to the generation of ROS followed by non-apoptotic, non-autophagic 
cell death. As diazido-PtIV complexes can generate toxic hydroxyl radicals, the 
formation of vacuoles under irradiated conditions may be associated with the 
production of ROS, however, further studies are required to confirm this. Overall, 
the observed dose-dependent vacuolisation may suggest that 12 does not 
predominantly induce apoptosis (unlike cisplatin).76  
Interestingly, in T14 (0.5×IC50, 465 nm) a large nuclear vacuole surrounded by 
lipid droplets was observed (Section 5.3.2, Fig. 5.17). The cause of nuclear 
vacuoles is not well-understood, and have been postulated to be due to nuclear 
invaginations or direct formation of holes in the cell nucleus.77 The observed 
nuclear vacuole may be associated with morphological damage induced by 12 under 
photo-conditions, with the lipid droplets attempting to repair the damage. 
 
 




Distribution of lipid droplets 
No statistically significant differences in the mean 3D size (µm3) and number of 
lipids (per tomogram) were observed in cells treated with different concentrations 
of 12 under photo-conditions when compared to the untreated controls (Section 
5.3.2, Table 5.5). The distribution of lipids in 3 different cells treated with 
0.25×IC50 of 12 (T10-12, Section 5.3.2, Fig. 5.14-15) appeared to surround cell 
nuclei. Lipid droplets tend to congregate and cluster around cell nuclei (where they 
are synthesized at the endoplasmic reticulum),78 and are re-distributed in the 
cytoplasm in response to intruding bodies (i.e. drugs), to generate energy from 
mitochondria. As this was also observed in the untreated controls (T1-6, Section 
5.3.2, Fig. 5.10-11), hence, cannot be attributed to a cellular response to Pt 
treatment and requires further study. 
Interestingly, there was a wide variety of lipid droplet size (µm3) in cells treated 
with 0.25×IC50 of 12 when comparing individual cells (T11-12 vs. T10, p<0.001; 
Section 5.3.2, Fig. 5.14-15). This was likely due to the to the variation in the 
metabolic state of the cell (which can cause rapid alterations in the number and size 
of lipid droplets).79 Notably, the cell in T10 has a large cytoplasmic vacuole and is 
more damaged than that of the latter, which may influence the nature of lipid 
droplets. The size of lipid droplets can also reflect the cellular energy storage 
capacity, which can be altered by environmental factors.80 For example, HeLa 
cervical cancer cells treated with anticancer drug paclitaxel increased the size of 
lipid droplets in response to drug treatment.81 Changes in the size of lipid droplets 
may be associated with cellular response to drug treatment, and requires further 
investigation into the lipid profiles in PC3 cells. This may be of particular interest 
in lipid-enriched prostate cancer cells (where lipids are highly implicated in cancer 
progression).82 
The mean volume of lipid droplets in cells treated with 0.5-1×IC50 of 12 (T13-17) 
were closely comparable to the untreated controls (T1-6, Section 5.3.2, Table 5.5), 
and to that of cells treated with lower concentrations (T7-9). Remarkably, lipid 
droplets surrounding a large nuclear vacuole were observed in T14 (0.5×IC50). The 
physiological significance of lipid droplets in cell nuclei is not well-understood. 
Nuclear lipids have reported to be an alternative source of fatty acids and 




cholesterol for membrane biosynthesis, signalling and transcription in the 
nucleus.83, 84 It must be considered that the origin of these lipid droplets may be 
cytoplasmic, but become entrapped within the invaginations of the nuclear 
membrane (vacuoles).85 Moreover, the lipids surrounding this vacuole are likely 
associated with cell repair mechanisms in response to cell damage. This highlights 
the remarkable ability to capture cellular events by cryo-XRT compared to 
conventional microscopy techniques. 
Cells treated with 12 (465 nm) with the inclusion of a recovery period (T18-19, 
Section 5.3.2, Fig. 5.20-21) revealed significant differences in the number of lipid 
droplets. In contrast to T18 (total lipid droplets=6), a significant number of lipid 
droplets were observed in T19 (total=88), which may have been synthesized in 
response to cellular damage (e.g. releasing lipids for membrane biosynthesis, cell 
signalling or energy-generation). Both of the mapped cells (T18-19) resembled 
features comparable to that in the untreated PC3 control cells (T1-6, Section 5.3.2, 
Fig. 5.10-11). The difference in the number of dense lipids may be a consequence 
of different stages of cell growth or recovery in response to 12. This is evident from 
the wide variety in the number and size of lipid droplets in other cells in the mosaic 
image (not imaged by cryo-XRT; Fig. 5.20-21). The importance of extracellular 
interactions between adjacent cells on a 2D surface can mediate cancer cell survival 
towards chemotherapeutics, hence, cell crowding may influence cell vulnerability 
(e.g. enhanced metal complex accumulation) resulting in differences in cellular 
response.61 For example, the cell mapped in T19 is more elongated, exhibiting a 
healthier cell morphology and is more exposed compared to T18, thus, may have a 
greater need for increased lipid droplets for cellular energy and repair once the 
extracellular drug medium is removed. However, no experimental evidence has 










Increase cell granularity 
In cells treated with 1×IC50 of 12 under blue light conditions (T15-17, Section 
5.3.2,  Fig. 5.18-19) cell nuclei and nucleolus can be identified, but were less well-
defined compared to the untreated controls (T1-6, Fig. 5.10-11) and were more 
granular in appearance. An increase in cellular granularity can be associated with 
growth arrest and cell death (particularly autophagy) in response to 
chemotherapeutics or irradiation,86 which was demonstrated with organic test 
compounds in PC3 cells. Notably, the nuclei in cells treated with 12 (1×IC50, 465 
nm) were more granular, which may implicate the formation of nuclear stress 
granules: subnuclear compartments which form in response to stress stimuli as a 
means of protecting the cell,87 and have been reported for chemotherapeutics 
including 5-Fluorouracil.88 Cancer cells utilize the formation of stress granules in 
an attempt to evade drug treatment.89 The extent of cell damage observed indicates 
that any cellular stress response was unsuccessful in restoring cell function and 
homeostasis, subsequently resulting in cell death. Overall, the increased granularity 
may be associated with autophagic cell death and potentially the formation of 
nuclear stress granules induced upon photo-treatment with 12, however, techniques 
such as flow cytometry are required to probe this.  
 
Cytostatic vs. Cytotoxic 
Inclusion of a drug-free recovery period in antiproliferative screening is an 
important consideration for clinical translation, and can provide insights into the 
cytostatic or cytotoxic nature of drugs. Cells treated with 12 and recovered in 
complex-free media (T18-19, Section 5.3.2, Fig. 5.20-21) were significantly less 
damaged compared to the analogous cells without a recovery period (T15-17, 
Section 5.3.2, Fig. 5.18-19), which may implicate a cytostatic contribution to the 
antiproliferative activity of 12. 
Cytostatic drugs differ to cytotoxic drugs in that they can inhibit tumour growth 
upon drug exposure, whereas, cytotoxic drugs continuously kill the cancer cells 
even after drug removal. This may implicate a cytostatic contribution to the 
anticancer activity of 12, in addition to the cytotoxicity of the PtII species. Cytostatic 
drugs prevent the proliferation of cancer cells by stabilization of a disease state, 




which can be both beneficial and disadvantageous in cancer therapy. As cancer cells 
rapidly proliferative, they are extremely sensitive to cytostatic (growth-inhibiting) 
drugs,90 compared to cytotoxic drugs – which affect all dividing cells (healthy and 
cancerous). In general, cytostatic complexes are less toxic towards healthy cells due 
to their improved target-specificity,90 which can reduce off-target effects commonly 
experienced with cytotoxic drugs. Examples of drugs with cytostatic properties 
include 5-fluorouracil and rapamycin.91, 92 However, common disadvantages of 
cytostatic drugs is that they require prolonged dosages for effective therapy,90 thus, 
are frequently administered in combination with cytotoxic drugs. For example, 
rapamycin can enhance the cytotoxicity of cisplatin by inhibiting prostate cancer 
cell growth in a cytostatic manner.93  
Overall, this data may suggest that complex 12 overcomes the predominantly 
cytotoxic nature of cisplatin by providing an additional cytostatic contribution to 
cell death, combined with the light-controlled in situ formation of cytotoxic PtII 
species. This also correlates with the antiproliferative activity of coumarin, which 
exhibits both cytostatic and cytotoxic activity.94 As cryo-XRT was only performed 
on coumarin-labelled 12, the same conclusions cannot be drawn for all diazido-PtIV 
PACT complexes from this family and requires further investigations (e.g. 
antiproliferative screening with different recovery periods). 
 
5.4.3    Synchrotron-XRF 
 
Synchrotron-XRF can be used to gain insights into the intracellular localisation and 
distribution of heavy metal elements with respect to endogenous biological 
elements. Herein, synchrotron-XRF has been used to investigate the potential 
cellular targets and distribution of Pt in cancer cells treated with diazido-PtIV PACT 
complexes under both dark and blue light (465 nm) conditions. Synchrotron-XRF 
analysis was performed on cryo-fixed and dehydrated PC3 cells treated with 5× the 
irradiated IC50 of 11, 12 and cisplatin using an incident energy of 14 keV (100 nm 
step-size; 0.2 s exposure). Ideally, frozen-hydrated cells would be analysed by 
nano-focussed XRF to allow a direct comparison to cryo-XRT data. However, as 
these facilities were not available at the I14 beamline, cells were frozen and dried.  




Elemental maps of three individual PC3 cells (from cell populations grown on Si3N4 
membranes) exposed to 1 h irradiation (465 nm) were obtained (C1-3, Section 
5.3.3, Fig. 5.24). Overall, the cells revealed elongated, cobble-stoned morphologies 
ca. 30-40 µm length, with small, rounded nuclei – correlating with the typical 
morphologies of untreated PC3 cells grown as a monolayer.38, 39 Importantly, Pt 
L3M5-emission (9.44 keV) was not observed in these control cells. 
 
Cells treated with 11, 12 or cisplatin 
In order to analyse the in-cell effects of diazido-PtIV complexes, cells were treated 
with 5× the irradiated IC50 of platinum complex under both dark (2 h protected from 
the light) and irradiated (1 h drug exposure followed by 1 h 465 nm exposure) 
conditions. A wide variety of cell shapes and sizes were observed, so that no 
statistically significant differences were evident when comparing the area or 
roundness factors (RF) of cells treated with 11, 12 or cisplatin to the untreated 
controls. In general, Pt was distributed throughout cells treated with 11, 12 or 
cisplatin (in the cytoplasm and nuclei). Interestingly, significantly higher levels of 
intracellular Pt were observed in cells treated with 11 or 12 upon blue light 
irradiation, compared to that in the dark. 
 
Cell morphology 
Wide variations in 2D cell size (µm2) were observed in cells treated with 11 or 12, 
under both dark and blue light conditions. The stage of cell growth / death and the 
heterogeneity of drug uptake can greatly influence the observed cellular 
morphology of individual cells treated with test compounds,95 emphasizing the 
advantages of single-cell assays vs. population average data (e.g. ICP-MS). For 
example, a more elongated PC3 cell treated with 12 under dark conditions (C11, 
Section 5.3.3, Fig. 5.27) had an elongated cell morphology ca. 30 µm in length 
with a centralised nucleus, with a roundness factor of 0.37±0.02 and area of 287±2 
µm2. In contrast, analogous cell C10 was significantly more rounded in shape 
(RF=0.97±0.02, p=0.0001) and smaller in size (133±2 µm2, p=0.0001). Finally, 
C12 (Section 5.3.3, Fig. 5.27) revealed a morphology somewhat intermediate 
between C10 and C11, with a stretched-out morphology with a centred nucleus 




(Section 5.3.3, Fig. 5.27), moderate roundness properties (0.59±0.02) and cell area 
of 212±2 µm2. Furthermore, emphasizing the variation in drug influx and efflux 
profiles of cells in a monolayer population. Wide variations in cell size and 
roundness factors were also observed for cells treated with cisplatin under 
irradiated conditions (mean area=345±40 µm2; mean roundness factor=0.59±0.24).  
No statistically significant trends in the mean nucleus-to-cytoplasmic ratios were 
observed between cells treated with 11, 12 or cisplatin (Section 5.3.3, Table 5.8), 
with nuclei taking up ca. 30-40% of the overall cell area. Cell nuclei in PC3 cells 
have been reported to take up 66% of the cell volume,96 thus, highlighting the 
limitations of imaging 3D objects using 2D XRF. In cells treated with 12, the more 
elongated cells (roundness factor<0.4) had smaller nuclear-to-cytoplasm ratios 
compared to the more rounded cells under the same conditions. Changes in the 
nucleus-to-cytoplasm area ratios can significantly alter cellular drug response and 
the metastatic proliferation (as demonstrated with cisplatin in breast cancer cells),97 
giving an indication of nuclear stress. Further work (ideally in 3D) with a greater 
statistical representation is required to investigate whether the rounding of a cell or 
changes in nucleus-to-cytoplasm ratios are associated with increased drug 
accumulation or cell damage. 
 
Distribution of Pt under dark conditions 
The Pt XRF (L3M5=9.44 keV) was very faint in cells treated with 5× irradiated IC50 
of 11 (IC50=6.5 µM; C4-6, Section 5.3.3, Fig. 5.25) and 12 (IC50=55 µM; C10-12, 
Fig. 5.27) under dark conditions (assumed to be non-toxic), but appears to mildly 
localise with Zn in the cell nucleus. This complements the dark spots observed in 
the cell nucleus in cryopreserved PC3 cells treated with 12 under dark conditions 
from cryo-XRT (T8-9, Section 5.3.2, Fig. 5.13). Moreover, the low levels of in-
cell Pt may also be due to enhanced efflux under dark conditions, complementing 
the hypothesis of endosomal breakdown observed by cryo-XRT (T7-9, Section 
5.3.2, Fig. 5.12-13). It may be hypothesized that some of 11 and 12 localizes in the 
nucleus of PC3 cells prior to photo-activation, however, XRF or 195Pt ICP-MS cell 
fraction studies at higher drug concentrations are required to confirm this.  




The reduction of PtIV-prodrugs to kinetically-labile PtII square planar species is 
well-reported in the literature,4, 8, 10, 98 with very few hypotheses involving PtIV-
DNA interactions.99, 100 As cancer cells exist under redox stress, their intracellular 
environments are highly reducing and likely causes the unwanted chemical 
reduction of PtIV PACT complexes prior to photoactivation. The chemical in-cell 
vulnerability of diazido-PtIV complexes to form PtII species may explain the 
observed nuclear-localisation of Pt under dark conditions. Alternatively, it must be 
considered that the intra-nuclear localisation of 11 and 12 under dark conditions 
may be associated with PtIV interactions with nuclear DNA, however, this 
contradicts previous GMP-binding studies.4 Further analytical techniques are 
required to probe the speciation of nuclear Pt (e.g. XANES or EPR).  
 
Irradiation enhances Pt accumulation 
The Pt in cells treated with 5×IC50 of 11 and 12 irradiated under blue light 
conditions revealed distributions in the cytoplasm and nucleus (Section 5.3.3, Fig. 
26, 5.28), with more intense Pt XRF compared to that of analogous cells treated 
under dark conditions. This can be attributed to significantly higher concentrations 
of intracellular Pt upon irradiation (ca. 3× and 3.5× more for 11 and 12, 
respectively), implying that irradiation with 465 nm not only activates the PtIV 
complex, but may also enhance the cellular accumulation (influx/efflux). This has 
been reported for structurally-similar diazido PtIV complexes upon irradiation with 
UVA light, achieving intracellular Pt levels of up to 20 ng/106 cells after 2 h in 
bladder cancer cells, almost 20× greater than that under dark conditions.101 The 
enhanced accumulation of diazido-PtIV complexes exposed to 465 nm may indicate 
the selective accumulation of photolysis products compared to the starting “inert” 
complexes.101 Moreover, this may imply that reactive photoproducts can enter cells 
and irreversibly bind to cellular components,102 To further probe this, ICP-MS 
cellular accumulation studies of cancer cells treated with equimolar concentrations 
of 11 or 12 under dark and irradiated conditions can be performed. 
Alternatively, the increased levels of intracellular Pt may be attributed to photo-
induced membrane damage. As the antiproliferative screening protocol involves 
irradiation with 1 h blue light whist cells are still incubated with platinum test 




compound, the extracellular formation of photo-products (i.e. photolysis) to 
enhance complex accumulation must be considered. Free radicals can alter the 
physiology of cell membranes (i.e. membrane fluidity or rigidity),103 making 
biomembranes a viable target for attack by ROS.104 In particular, hydroxyl radicals 
(•OH) have roles in modulating membrane permeability of cells.105 As diazido-PtIV 
complexes can generate toxic hydroxyl (•OH) and azidyl (N3
•) radicals upon 465 
nm exposure, the extracellular formation of these radicals may influence the 
permeation of the now PtII square planer species (e.g. by lipid oxidation),106 
promoting the cellular accumulation. The extracellular activation of such PtIV-
diazido prodrugs by light provides a means of killing cancer cells via radical-
induced membrane damage, in addition to forming toxic PtII species which can bind 
to DNA. Moreover (providing the drug can reach the tumour microenvironment), 
this affords a combined extra- and intracellular mechanism to overcome resistance.   
Although not observed from the synchrotron-XRF images of cells treated with 11 
or 12 under 465 nm conditions, the extensive damage/blebbing of the plasma 
membrane was observed in analogous PC3 cells analysed by cryo-XRT (Section 
5.3.2, Fig. 5.23), which supports the hypothesis of compromised membrane 
integrity upon blue light irradiation. Overall, the formation of extracellular 
photolysis products (e.g. radicals) may promote accumulation of Pt by altering 
membrane physiology, and potentially binding to cellular components to contribute 
to the antiproliferative effect.  
 
Localisation of Pt in membrane 
Interestingly, in one of the cells treated with coumarin-labelled 12 under photo-
conditions the Pt XRF was strongly localised at the perimeter of the cell (C13, 
Section 5.3.3, Fig. 5.28), suggestive of distribution in the plasma membrane. The 
elongated cell morphology (resembling the untreated controls) suggests that this 
particular cell is not significantly damaged - most likely as a result of reduced 
cellular accumulation of 12 (Section 5.3.3, Fig. 5.30). The localisation of Pt in the 
plasma membrane may suggest that Pt is being encapsulated in the membrane, 
which may be indicative of a cellular response to prevent intracellular entry of 12. 
This may explain the minimal morphological damage observed in C13 compared 




to cells exposed to the same conditions (C14-15, Section 5.3.3, Fig. 5.28) – which 
were smaller, more rounded and exhibited higher intracellular Pt levels. The passive 
diffusion of lipophilic PtIV complexes into cancer cells via. the plasma membrane 
is well reported in the literature,16 hence, the presence of Pt in the cell membrane is 
not surprising. For example, PtIV-valproic acid derivatives of cisplatin primarily 
accumulated in the cell membrane of A2780 cells.107 The hydrophobic nature of 
coumarin may also promote the membrane accumulation of 12 by forming 
favourable interactions with the hydrophobic core. Coumarins have high affinities 
for membrane phospholipids, which acts as a driving force for coumarin entry into 
cells.108 The potential cellular efflux of 12 by membrane transporters must also be 
considered. The uptake pathways of diazido-PtIV complexes can be probed using 
ICP-MS cellular accumulation studies in the presence of influx/efflux inhibitors, 
such as, verapamil (PGP) or oubain (Na+-K+ pump).109 
Additionally, the potential targeting of the plasma membrane by 12 cannot be 
discounted. The lipophilic nature of coumarin may favour interactions with the 
phospholipid bilayer of plasma membranes. Pt-membrane interactions have been 
reported for cisplatin – which has shown to mediate cell uptake, cytotoxicity and 
resistance.110 Overall, the observed accumulation of Pt in the plasma membrane of 
PC3 cells may be associated with interactions between coumarin (and/or Pt) and 
hydrophobic core of the lipid bilayer, which may mediate cellular influx/efflux 
mechanisms. This complements the significant membrane damage observed in PC3 
cells treated with 12 by cryo-XRT (Section 5.3.2). 
 
Pt in the cell nucleus 
As Pt was found to mildly localize in the cell nuclei of PC3 cells treated with 11, 
12 or cisplatin (C4-18, Section 5.3.3, Fig. 5.25-29), the percentage of intracellular 
Pt in cell nuclei were determined (Section 5.3.3, Table 5.9). Note that when 
quantifying elements by 2D XRF mapping an assumption is made about the 
thickness and density of cells,111 presuming homogeneity, thus, the cell nucleus is 
most likely not flat. As a result, the increased Pt XRF observed in nuclei of cells 
treated with 11, 12 or cisplatin may be attributed to the increased cell thickness as 
opposed to increased concentrations of nuclear Pt. To overcome this, x-ray 




tomography is required to determine the ratio between the nucleus and the 
cytoplasm in the z-plane. Overall, mean levels of nuclear Pt were found to be greater 
than 40% in cells treated with 11 or 12, regardless of the photo-conditions, 
suggesting that the nucleus is likely a cellular target of these complexes. This 
correlates with the DNA-binding studies reported for this family of diazido-PtIV 
PACT complexes.11 
The nuclear-targeting of 11 and 12 (mean nuclear Pt percentages of 74±15 and 
52±6%, respectively) may be independent on the photo-conditions, which may be 
indicative of the intracellular chemical reduction of PtIV to PtII. In cells, PtIV 
complexes can be reduced by biological reducing agents to form active PtII species 
which then bind to DNA, hence, the nuclear localisation of 11 and 12 under dark 
conditions is not surprising. Adversely, it must be considered that the Pt may be 
entering the nucleus as PtIV under dark conditions, subsequently interacting or 
forming adducts with nuclear DNA.99, 100 The intracellular reduction of PtIV→PtII 
(photo- or chemical) is generally assumed to be favourable for PtIV prodrugs which 
rely on in situ reduction in their anticancer mechanisms of action. Further work is 
required to understand the intracellular stability, localisation and cellular 
accumulation profiles of different platinum species in order to elucidate the 
mechanism of action.   
 
Comparison of 11 and 12 
Higher quantities of intracellular Pt were determined in cells treated with 12 in the 
dark, compared to parent compound 11 – correlating with the lower potency of 11 
(8× less potent). Additionally, the increased lipophilicity (due to the coumarin 
ligand) of 12 may promote cellular uptake through the hydrophobic core of the cell 
membrane (improving the bioavailability),108 however, LogP studies are required 
to support this hypothesis.  
A comparison of the normalised mass fraction quantities of Pt in cells treated with 
12 and exposed to blue light showed ca. 2× more than that of 11, potentially due to 
the enhanced hydrophobic properties of the latter. The improved antiproliferative 
potency of 12 (compared to 11) may be facilitated by both the organic (coumarin) 
and inorganic (Pt modality) counterparts. This may have major implications in 




future studies involving the conjugation of metallodrugs with modalities exhibiting 
antitumour properties or targeting groups. Tethering of conjugates may 
significantly improve the antiproliferative activity of a metal complex, however, 
the mechanism of action and uptake of these complexes may be altered with respect 
to the non-conjugate parental complex, thus, the mode of action cannot be assumed 
the same. This phenomenon has been reported for a variety of metallodrugs, 
including PtIV-prodrugs,112 RuII complexes and OsVI nitride complexes.113, 114 
Additionally, fluorescent probes (which are typically large, conjugated structures) 
may also influence the cellular accumulation profiles, targeting and intracellular 
mechanism of actions of action compared to the parent compound.  
The co-localisation between Pt and Zn in cells treated with equipotent 
concentrations of 11 or 12 was more pronounced for coumarin-labelled 12, most 
likely due to the increased uptake of the coumarin derivative (2.8±0.3 and 4.9±0.6 
ppm for 11 and 12, respectively). Similarly, under blue light conditions the same 
trend was observed, with higher correlations between Pt and Zn for 12 vs. 11, in 
agreement with the increased potency of 12 (IC50=6.5 µM) compared to 11 
(IC50=55 µM). Intracellular Pt and Zn co-localised more strongly in PC3 cells 
treated with 11 upon blue light irradiation, compared to the those treated in the dark 
(r=0.44±0.05 and 0.19±0.05 for dark and irradiated, respectively). The same trend 
was observed for cells treated with 12 (r=0.58±0.08 and 0.34±0.04, respectively). 
Upon blue light irradiation, the accumulation of Pt from 11 and 12 is significantly 
enhanced which means that more of the now-cytotoxic PtII species may be available 
to target the cell nucleus and form strong interactions with biomolecules. This may 
provide an explanation into the enhanced co-localisation of Pt and Zn in treated 
cells exposed to blue light compared to those treated in dark conditions. Moreover, 
as Zn is highly abundant in the nucleus, this supports the hypothesised DNA-









Comparison to cisplatin 
Cisplatin has been used as a control in this study to allow a comparison to both the 
literature and to cancer cells treated with diazido-PtIV complexes (11 and 12) under 
the same conditions (vitrified and freeze-dried). Cells were treated with 5×IC50 of 
cisplatin (IC50>100 µM) for 1 h, followed by 1 h irradiation with 465 nm (C16-18, 
Section 5.3.3, Fig. 5.29). The cell nuclei in C16-18 were clearly identified from the 
Zn XRF map, enabling the identification of Pt in the nucleus as well as the 
cytoplasm. Complementary to this, cells treated with cisplatin revealed moderate 
Pt-Zn co-localisation statistics (r=0.34±0.04). This is not surprising considering that 
DNA-binding of cisplatin is well-known.115 In the literature, the localisation of 
cisplatin is accepted to be primarily cytoplasmic (>50%),76 with only 1% of 
cisplatin binding to nuclear DNA.116 Other targets of cisplatin include 
mitochondria, lysosomes and endoplasmic reticuli.117  
The disparity in the cellular distributions of cisplatin observed with that of the 
literature is likely dependent on factors including the type of cell, the stage of cell 
growth, sample preservation and the technique used to quantify them. For example, 
the predominant nuclear localisation of Pt of cisplatin (mean=42±8%) in vitrified 
and freeze-dried PC3 cells (Section 5.3.3, Fig. 5.29) correlates strongly with that 
of microprobe-XRF studies of cryo-fixed and freeze-dried A2780 cells treated with 
cisplatin (revealing the majority of Pt in the nucleus).118 This predominant nuclear 
localisation of Pt is likely due to the presumption made about uniformity in cell 
thickness in 2D XRF mapping (as previously described). This highlights the 
importance of using complementary analytical techniques when probing the 
mechanisms of action of metallodrugs in biological systems. 
The Pt XRF in cells treated with cisplatin (500 µM) was significantly lower than 
that of cells treated with much lower concentrations of 11 and 12 (5×IC50=275 and 
32.5 µM, respectively) under blue light conditions, with 1.5 and 3× more Pt for 11 
and 12, respectively. This highlights the significant advantages of light-enhanced 
cellular accumulation (or membrane damage) induced upon photo-activation of 11 
or 12. Overall, the cellular distributions of 11 and 12 were comparable to that 
observed for cisplatin under the same conditions. As cisplatin is inactive in cancer 
cells up to 100 µM after 2 h exposure (IC50>100 µM, Section 5.3.1, Table 5.3), the 




enhanced Pt accumulation in cells treated with equipotent concentrations of 11 or 
12 (5×IC50) is a significant observation. This emphasizes the remarkable potency 
exhibited by PtIV-diazidyl PACT complexes, permitting lower doses of Pt 
compound to achieve the same antiproliferative effect – with the future potential to 
reduce adverse side effects and prevent drug diversion (decreased efficacy). 
Comparison of Pt levels in cells treated with equipotent concentrations of cisplatin 
of 11 and 12 (dark conditions) revealed higher quantities for that of cisplatin. This 
is in strong agreement with low levels of intracellular Pt observed in cells treated 
with structurally-similar diazido-PtIV compounds compared to cisplatin when 
treated with equimolar concentrations under dark conditions.101 This may also 
imply that the accumulation of PtII species may be more favourable compared to 
PtIV species. The hypothesized extracellular photo-activation of PtIV→PtII (e.g. 
membrane damage) may be a major contributor to the enhanced intracellular levels 
of Pt. Furthermore, the light-enhanced accumulation of 11 and 12 is likely crucial 
for antiproliferative activity. 
 
5.4.4    Pt XANES analysis 
 
Pt XANES mapping 
Complementary to XRF, x-ray absorption spectroscopy (XAS) can be used to gain 
insights into the oxidation state, speciation and coordination environments to 
elucidate the in-cell chemical form of heavy metal complexes and their potential 
targets or binding moieties. The main difference between XRF and XAS is the 
energy: for XRF mapping of cells we use a fixed energy which exceeds the electron-
binding energy of elements of interest), whereas for XAS we acquire data using an 
energy range (in order to monitor the pre-edge, edge and post-edge regions). In 
particular, XANES (X-ray Absorption Near-Edge Spectroscopy) monitors the 
region within ca. 50-100 eV of the absorption edge.119  
XANES analysis was performed on solid pellets of three platinum compounds with 
different oxidation states and coordination environments: (i) K2PtCl4; (ii) cisplatin; 
(iii) 11, in addition to a platinum metal sheet in the energy range 11.46-11.73 keV 




(Section 5.3.4, Fig. 5.31-32). The XANES spectra of K2PtCl4 and cisplatin were 
indistinguishable owing to the shared Pt2+ oxidation state, square planar 
coordination geometry, and the similarities of the ligands forming their 
coordination sphere. The Pt0 metal sheet has a white line at 11.570 keV and a 
normalised absorption maximum at 1.28. The XANES spectrum of solid 11 (PtIV) 
was shifted to a higher energy (increased by ca. 2 eV), with a more intense 
absorption edge compared to PtII (white line=11.573 keV, maximum=1.95), 
correlating with that reported in the literature.36, 120 This is due to the higher 
oxidation state of 11, which requires a greater energy to excite core electrons. 
XANES was performed on cryo-fixed and freeze-dried PC3 cells treated with 11 
and irradiated with blue light using two methods: (i) “Compressed Sensing” (where 
7 energies were selected and the XANES spectra monitored at those points over 1 
h); (ii) “Energy Scanning” XANES (where a start and end energy were selected and 
the XRF spectra were collected every 0.5-1 eV around the edge and then 8 eV after 
the edge was monitored over a 12 h period). XANES spectra were obtained from 
XRF spectra by performing PCA and cluster analysis, as described in Section 5.2.4. 
The XANES spectra were normalised using edge-step normalisation in Athena.35 
Although there are clear differences in the XANES spectra of PtII and PtIV species, 
the relative proportions of species in a mixture cannot be determined accurately by 
conventional curve-fitting techniques due to similarities in peak energy and shape. 
To overcome this, Hambley et. al. proposed a method which normalized the 
maximal absorption of the edge (height of peak) with the post-edge minima 
immediately after the white line.36 This method has previously been validated with 
six known PtII and twelve PtIV compounds, to obtain average ratios for each 
oxidation state, respectively.36, 37  Herein, this method was used to evaluate the 
oxidation state of platinum in PC3 cells treated with 11 under blue light conditions 
(Section 5.2.3, Fig. 5.4). 
Initial observations revealed spectra comparable to that of an intracellular Pt4+ 
oxidation state (Section 5.3.4, Fig. 5.31-32) – which was reaffirmed for both 
XANES acquisition methods. Data were processed using the method proposed by 
Hambley et. al. (Section 5.4.4, Fig. 5.30, Table 5.3).36, 37 The calculated maximum 
peak absorption ratio of platinum was determined to be 1.71±0.04 (considering both 




the “Energy-scanning” and “Compressed Sensing” acquisition methods), which 
was found to be intermediate between the PtIV and PtII standards (2.05 and 1.35, 
respectively). The reduction in peak height from the solid pellet of 11 when 
compared to intracellular Pt revealed only an 18% decrease, whereas comparison 
to cisplatin revealed a 25% decrease – implying that the majority of intracellular Pt 
analysed exists at PtIV. 
This was reaffirmed by performing a LCF, revealing ca. 20% and 25% of 
intracellular platinum as PtII for the “Compressed-Sensing” and “Energy-Scanning” 
methods, respectively. This may suggest the majority of Pt in cells treated with 11 
under photo-conditions exists as PtIV. This was unexpected, as diazido-PtIV 
complexes are hypothesised to form PtII species upon blue light irradiation). This 
may explain the low phototoxicity of 11 (IC50=55 µM), which is likely non-toxic in 
as PtIV oxidation state. Alternatively, PtIV photo-products may also be formed. For 
example, the intensity and light dosage of Pt-diazido complexes may favour ligand 
dissociation vs. photo-reductive elimination, thus resulting in Pt(IV) photo-
products, as reported by Bednarski et. al.13, 121  
As this experiment was not statistically representative (only two 5×5 µm2 cell 
regions mapped), further XANES is required to corroborate this. Nonetheless, this 
preliminary data shows promise for the use of the “Compressed Sensing” XANES 
acquisition at the I14 beamline, which is significantly less time-consuming than 
conventional “Energy-Scanning”. 
In this experiment, the XRF maps at each energy in the range 11.46–11.73 keV 
were averaged as opposed to obtaining spatially-resolved (pixel-by-pixel). This is 
because the per-pixel spectrum is extremely noisy because of the small region that 
is being scanned (200 nm step-size; 50×70 nm2 beam size). The averaging of 
smaller pixels partially removes noise from the spectrum, giving a much higher 
confidence in the results. As a result, the averaging of spectra provides a ratio of 
oxidation states (PtIV:PtII) for the whole analysed region. Optimisation for spatially-
resolved per-pixel XANES mapping is part of future plans for the I14 beamline. 
 
 




Beam damage during XANES mapping 
In order to obtain high spatial resolution (<100 nm) during XANES mapping of 
cells, the sample is exposed to high energy x-rays for a long period energy-scanning 
mode. This is not only time-consuming but can cause damage to cellular features 
and also the elemental distribution and speciation.122 Likewise, even though the 
sample is exposed to the beam for a much shorter period of time (ca. 1.5 h vs. 12 h) 
using the “Compressed Sensing” method, sample beam damage may still occur. 
This may be detrimental for scientific reliability, particularly when studying 
photoactivatable drugs (some of which can be activated with x-rays). For example, 
a transferrin derivative of RuII PDT photosensitiser TLD-1433 (which is in clinical 
trials for the treatment of bladder cancer) can be activated with x-rays to treat brain 
cancer.123 Similarly, the continuous irradiation of A2780 ovarian cancer cells 
treated with an organo-osmium(II) complex by XANES mapping (100 nm 
resolution) caused oxidative damage.124 X-ray induced photo-reduction of metals is 
a major drawback in monitoring the oxidation state of metals by XANES 
spectroscopy.122, 125 Other concerns may also include the ablation of organic matter 
– endogenous elements in cells and tissues.126 For example, the main radiation 
damage for chemically-fixed cells exposed to soft x-rays is the loss of mass 
thickness and cell shrinkage127 – which can be reduced using cryo-preservation. 
Multiple factors must be considered when assessing beam damage to the integrity 
of biological cells, which includes (i) x-ray energy (e.g. hard vs. soft), (ii) exposure 
time, (iii) spatial resolution, (iv) synchrotron beamline (e.g. photon flux), (v) 
reproducibility and (vi) cell preservation. The easiest way to investigate beam 
damage is to deliberately damage the sample using different x-ray exposure times 
at the desired energy and spatial resolution. This will inform on the limitations of 
x-ray exposure threshold of the sample, and provide insights into any changes in 
elemental distribution within the cells. From there, you can then analyse samples 
with suitable replicates to ensure that the results are reliable and reproducible 
concerning the elemental distribution, quantification, chemical speciation and cell 
morphology. Beam damage also depends on the synchrotron beamline, which can 
vary with factors including photon flux, energy and beam size. Finally, the method 
of preservation (e.g. hydrated or temperature) of biological samples may also be 
associated with beam damage.126 For example, cryopreservation of samples can 




reduce x-ray beam damage due to reduced thermal energy at lower temperatures.128 
X-ray beam damage during XRF and XANES has been discussed in detail in the 
literature.129, 130 A proposed XANES mapping protocol to investigate sample beam 
damage is presented in Appendix (Table A37). In this work, no obvious changes 
in cell morphology of elemental distribution in the two 5×5 µm2 regions of interest 
were observed, however, future assessment of the sample beam damage threshold 
is crucial for scientific reliability in XANES mapping of biological cells. 
 
5.5     Conclusions and future work 
 
The intracellular morphological damage induced by a coumarin-labelled diazido-
PtIV PACT complex (12) was investigated in cryopreserved PC3 cancer cells using 
cryo-SIM and cryo-XRT. Unfortunately the blue fluorescence of 12 formed upon 
photoactivation with 465 nm was not observed in cryopreserved PC3 cells treated 
with 1×IC50 of 12 (1 h exposure followed by 1 h irradiation with light) by cryo-
SIM, likely owing to the short life time of organic radicals. Cryo-XRT of PC3 cells 
treated with 12 under dark conditions revealed the presence of endosomes, 
implicating active (energy-dependent) influx/efflux accumulation pathways. This 
is likely a cellular response to unwanted materials and an attempt to excrete the 
platinum complex prior to in situ activation and antiproliferative activity upon blue 
light exposure. This could be further probed by 195Pt ICP-MS using endosomal 
inhibitors such as chloroquine or methyl-β-cyclodextrin (as shown in Chapter 3).  
The extent of cell damage may also be associated with the synthesis of lipid droplets 
(which play important roles in cell repair, growth and survival), however, this goes 
beyond the scope of work in this thesis. The physiological significance (if any) of 
the lipid droplets distributions in cancer cells treated with 12 is not understood, but 
may be involved in a cellular response to drug treatment (i.e. repair of membranes 
or vacuoles). As part of future studies, lipid-specific biological assays could be 
performed to identify any trends or alterations in lipids upon treatment with diazido-
PtIV, for example, investigating lipid metabolism enzymes by Western blotting, or 
fatty acids by GC-MS.131  




Under photo-conditions, cells treated with 12 were significantly damaged – with 
multiple vacuoles (cytoplasmic and nuclear), membrane-blebbing, vesicle shedding 
and increased cell granularity– all of which are indicative of severe intracellular 
damage. Vacuolisation is not a classical feature of apoptosis, thus, it may be 
hypothesised that 12 does not predominantly induce apoptotic cell death, however, 
further studies are required to confirm this. In addition, cells treated with photo-
activated 12 with the inclusion of a recovery period (in complex-free medium) were 
less damaged than that of cells treated without recovery, which may implicate a 
cytostatic contribution to the antiproliferative activity. 
The distinct alterations in nuclear morphology (observed by cryo-XRT) may be 
attributed to Pt-induced damage, correlating with the nuclear localisation of 
platinum observed using nano-focussed synchrotron-XRF. Remarkably, XRF 
revealed that blue light significantly enhanced the cellular accumulation of Pt in 
PC3 cells treated with diazido-PtIV PACT complexes (11, 12). It can be 
hypothesized that this is most likely a consequence of increased Pt uptake as 
opposed to reduced efflux,132 which may be associated with photo-induced 
membrane-damage and extracellular photolysis products. This could be probed 
using flow cytometry (membrane integrity analysis) or 195Pt ICP-MS cell 
accumulation studies by irradiating cells in drug-containing medium (1 h) and 
comparing it to that of irradiation in drug-free medium. Determination of the 
chemical speciation of diazido-PtIV complexes in biological medium upon 
irradiation may be crucial in understanding the photo-enhanced Pt uptake, and can 
be probed using analytical techniques such as EXAFS or capillary-electrophoresis 
ICP-MS).120, 133  
Preliminary XANES analysis of PC3 cells treated with diazido-PtIV complex 11 
under photo-activated conditions revealed ca. 83% of intracellular Pt existed as 
Pt4+. This was unexpected as it is hypothesised that diazido-PtIV prodrugs are photo-
reduced to form toxic PtII species inside cancer cells. Further XANES work is 
required with a greater population of cells for statistical relevance is required to 
confirm this hypothesis. 
 




A further development on this research would be to perform correlative cryo-XRT 
and XRF on the same cells close to their native state (cryopreserved cells) to further 
understand the in-cell activity of PtIV-diazidyl PACT prodrugs (demonstrated by 
Pizarro et. al. with a potent half-sandwich Ir complex)134 or alternatively combined 
XRF and X-ray holographic nanotomography (as demonstrated for human 
macrophage cells).135 Finally, the use of a molecular probe (e.g. Br or I) at inert 
sites of the complex would allow dual-mapping by XRF and ICP-MS, to determine 
the fate of ligands in cancer cells, as demonstrated with Br-labelled Os complexes 
in Chapter 3 and I-labelled rhenium complexes in the literature.136 
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Conclusions and future work 
 
  




6.1     Conclusions 
 
The in vitro biological activity of a diverse range of precious metal complexes in 
cancer cells have been investigated using advanced synchrotron imaging techniques 
at DLS (Oxford), alongside complementary antiproliferative screening assays. 
Namely, synchrotron-XRF, DPC imaging and XANES (at the I14 beamline) have 
been used to probe the intracellular distribution, stability and speciation of metal 
complexes in cancer cells down to a 100 nm resolution. Complementary studies 
using  correlative cryo-SIM and cryo-XRT (at the B24 beamline) were used to 
investigate the localisation of fluorescent compounds at a subcellular level (40 nm 
resolution), in addition to drug-induced morphological changes and cellular events 
as close to their physiological state as possible. 
 
• Synthesis, characterisation and screening of OsII 16-electron catalysts 
One of the aims of Chapter 3 was to synthesize and characterize a series of 16-
electron OsII catalysts of the formulae [OsII(p-cymene)(RBsDPEN)] (where 
BsDPEN=benzyldiphenylethylene diamine), and assess their catalytic and 
biological activity in vitro. One of the main aims was to probe the in-cell stability 
of such complexes, which has been achieved using a Br-labelled complex [OsII(p-
cymene)(BrBsDPEN)] (RR/SS-2, Section 3.1, Fig. 3.3) using ICP-MS and 
synchrotron-XRF. RR/SS-2 exhibited similar chemical (x-ray crystal structure, 
DFT, LogP, solution stability and transfer hydrogenation catalytic activity) and 
biological activity (cytotoxicity, selectivity, cell accumulation, membrane integrity, 
cell cycle analysis, in-cell catalysis) compared to that of parent compound [OsII(p-
cymene)(TsDPEN)] (RR-1, where TsDPEN= tosyldiphenylethylene diamine).1-3  
Cellular accumulation studies of the Br-labelled OsII catalysts (RR/SS-2) were 
performed in cancer cells under varying conditions (temperature, inhibition of 
caveolae endocytosis, inhibition of efflux, time and cellular distribution), which 
consistently revealed significantly higher levels of Br vs. Os (>10-fold, Section 
3.3.10). This is highly indicative of intracellular complex degradation via 
dissociation of the Br-labelled sulfonamide ligand, which may account for the low 




intracellular catalytic turnover of pyruvate to lactate reported for parent compound 
RR-1 over 24 h.2, 3 The Os accumulation was highly-dependent on caveolae 
endocytosis and PGP-mediated efflux, whereas, the Br-labelled sulfonamide 
modality was much less dependent on these pathways. It is hypothesized that 
caveolae endocytosis can mediate the uptake of the ‘intact’ osmium catalyst (2), but 
once inside the cells, 2 is rapidly degraded, with the Br-labelled ligand being 
retained inside the cells for longer. Additionally, inhibition of the PGP efflux pump 
increased the levels of intracellular Os but not Br, which may implicate different 
efflux pathways for the ‘intact’ catalyst (RR/SS-2) and ‘free’ Br-labelled ligand. 
Cellular distribution ICP-MS studies revealed the predominant deposition of both 
Os and Br in the membrane and cytoskeletal fractions in cells treated with SS-2, 
implying that some of the complex is intact in the cytoplasm, where catalysis likely 
occurs. Negligible quantities of Os were present in the nuclear fraction (<6%) which 
may rule out an Os-DNA mechanism of action (Section 3.3.11), whereas, 10-20% 
of intracellular Br was present in the nucleus.  It is now hypothesized that the 16-
electron Os complex may facilitate cell permeation of the sulfonamide ligand where 
it can dissociate and enter the cell nucleus, however, its contribution to the 
antiproliferative activity (if any) is not yet understood and requires further work. 
The concentration-dependent cellular distribution of Br-labelled SS-2 was also 
investigated using synchrotron-XRF by monitoring the Br (KL3=11.92 keV) and 
Os (L3M5=8.91 keV) emissions. Os and Br co-localized in the cell cytoplasm 
(Section 3.3.12), with significantly higher levels of intracellular Br vs. Os, in strong 
agreement with cellular accumulation 189Os-79Br ICP-MS studies (Section 3.3.10). 
The Br was also distributed in the nucleus, corroborating cell fractionation ICP-MS 
studies. Os and Br co-localized in small cytoplasmic compartments of size ca. 0.7 
µm2, which are likely attributed to endosomes or lysosomes. Moreover, this may 
implicate the lysosomal breakdown and efflux of SS-2. This hypothesis was further 
probed using chloroquine (which can deactivate lysosomes):5, 6 cells pre-incubated 
in chloroquine followed by treatment with RR-1 or Br-labelled SS-2 revealed a 25-
50% increase in potency (IC50), which was accompanied by an increase in Os 
cellular accumulation (Section 3.3.13). Chloroquine-dependent membrane 
integrity analysis (by flow cytometry) was also used to reaffirm the increase in 
potency and intracellular Os was not due to membrane damage.  




Overall, the work in Chapter 3 successfully probed the in-cell mechanism of 
action, targeting and stability of a Br-labelled 16-electron Os(II) catalyst by 
utilising a dual-quantitative approach using correlative ICP-MS and synchrotron-
XRF. This provided direct evidence for the cellular distribution and instability of 
this family of OsII complexes in cancer cells, revealing a dependence on active 
(energy-dependent) influx/efflux mechanisms and the delivery of the dissociated 
sulfonamide ligand into the cell nucleus. The reduced intracellular amount of intact 
“active” catalyst observed may explain the low catalytic turnover number of 
pyruvate to lactate reported for RR-1.3  
 
• Distribution and cell damage by cyclometallated IrIII photosensitisers 
The main aim of Chapter 4 was to utilize both cryo-XRT and XRF to probe the 
cellular distribution and cell damage induced by potent cyclometallated Ir(III) PDT 
photosensitisers in cancer cells using correlative cryo-SIM, cryo-XRT and XRF, as 
close to their native state as possible.8-10 Cryo-XRT analysis of PC3 prostate cancer 
cells treated of a promising IrIII-diketonate photosensitiser (7, Section 4.1, Fig. 4.1) 
was successfully achieved, providing quantitative 3D insights into the changes in 
mitochondrial morphology and volume upon photo-activation. Although no direct 
evidence for the localization of this complex in the mitochondria was obtained, it 
can be hypothesized that the observed mitochondrial damage is likely caused by the 
generation of singlet oxygen (1O2) in close proximity to these organelles. 
Unfortunately, the phosphorescence of 7 (λex/em=458/620 nm) was not observed 
using fluorescence microscopy, thus, was not analysed by super-resolution cryo-
SIM. Nonetheless, cryo-XRT provided crucial 3D insights into the cell damage 
induced by 7 down to a subcellular resolution (40 nm), in their near-native state. 
The second aim of Chapter 4 was to probe the in-cell distribution of a potent Ir-Pt 
PDT-PACT conjugate (8, Section 4.1, Fig. 4.1) in cancer cells, using synchrotron-
XRF under both dark (non-toxic) and irradiated conditions. Unfortunately, due to 
poor sample quality (poorly preserved and damaged cells), only cells treated with 
8 under dark conditions could be mapped, and requires further study. Nonetheless, 
XRF revealed the localisation of Pt in the nucleus and cytoplasm, and Ir in small, 
concentrated regions (most likely in the cytoplasm).This is in agreement with the 




absence of adducts formed between Ir and model DNA bases, suggesting that the 
nucleus is not a major target for the Ir-PDT moiety,13 and may imply organelle-
targeting. The nuclear-targeting of Pt (which is well-reported for PtII drugs) may be 
associated with the chemical reduction of PtIV→ PtII (e.g. by low molecular weight 
antioxidants), correlating with the ability of Pt of 8 to form adducts with DNA after 
photo-activation. Interestingly, 5× more intracellular Pt vs. Ir was observed, which 
is indicative of IrIII-PtIV cleavage and different cellular targets of the cleaved Pt and 
Ir parts. Alternatively, the hypothesis of extracellular complex cleavage cannot be 
discounted, thus the speciation of 8 in biological media requires further study. 
Overall, the work in Chapter 4 successfully utilised cryo-XRT and XRF to 
investigate the cellular damage, distribution and stability and of IrIII PDT 
photosensitisers in cancer cells. 
 
• In-cell x-ray studies of diazido-PtIV photoactivatable prodrugs 
The main aims of Chapter 5 were to build on the x-ray techniques used in both 
Chapters 3 and 4 to investigate the concentration-dependent intracellular targeting 
and morphological damage induced by a fluorescent coumarin-labelled diazido-PtIV 
PACT complex (12, Section 5.1) in cancer cells using cryo-SIM, cryo-XRT, 
synchrotron-XRF and XANES. Unfortunately, the blue fluorescence photo-
products of 12 (upon blue light irradiation) were not observed by cryo-SIM, 
however, cryo-XRT produced significant results which may impact the future 
design of diazido-PtIV complexes for photoactivatable chemotherapy (PACT). 
Diazido-PtIV complexes are non-toxic to cancer cells up to 100 µM,13 which is 
assumed to be a consequence of the remarkable chemical stability exhibited by 
these complexes. However, cryo-XRT of cells treated with 1×IC50 (6.5 µM) of 12 
under dark conditions revealed endosomes which may implicate active mechanisms 
of efflux (i.e. removal of Pt complex) prior to photo-activation. In addition, small 
black spots were observed in nuclei of cells treated with 12 under dark conditions, 
which may implicate the nuclear-targeting of these complexes (dark absorption of 
heavy metals by soft x-rays). This was reaffirmed using synchrotron-XRF by 
directly mapping the Pt with respect to the highly localised Zn of cell nuclei.  
 




Cryo-XRT revealed that, under blue light conditions, diazido-PtIV complexes 
caused significant morphological damage including cytoplasmic/nuclear vacuoles, 
membrane-blebbing, vesicle-shedding, increased cell granularity and damaged 
cytoplasmic organelles. Interestingly, the cellular accumulation of Pt in cancer cells 
treated with diazido-PtIV complexes (11 and 12) was significantly enhanced upon 
blue light exposure (shown by XRF), which may implicate the formation of 
extracellular photolysis products to promote Pt influx.14 It may be hypothesized that 
12 can be activated with 465 nm both intracellularly and extracellularly (in drug-
medium) to exert its antiproliferative effect. Finally, cells treated with diazido-PtIV 
prodrugs under photo-conditions and recovered in complex-free media confirmed 
that cells did not continue to die, hence, revealing a cytostatic (growth inhibition) 
contribution to cell death, in addition to the cytotoxicity (tumour shrinkage) of the 
PtII species formed upon irradiation. Overall, the work in Chapter 5 has provided 
direct evidence into the cellular distribution and targeting of PtIV-diazido PACT 
prodrugs, in addition to providing insights into the morphological damage and 
mechanisms of cell death, which may be crucial for clinical translation. 
 
6.2     Future work  
 




Figure 6.1. Possible ways of improving the drug efficacy of half-sandwich 
[OsII(arene)(BsDPEN)] complexes: (a) Improving the in-cell stability; (b) nuclear-targeting 
studies of the sulfonamide ligand; (c) Overcome or exploit active cellular influx/efflux 
mechanisms. The micelle-encapsulation image was taken from the literature.15 




The in-cell catalytic activity of OsII para-cymene 16-electron sulfonamide 
complexes is dependent on the complex remaining intact, to facilitate favourable 
substrate binding in the transition state (via the Re or Si face). This research has 
demonstrated that these complexes have limited stability in cancer cells, which 
likely explains the low turnover of pyruvate to unnatural lactate over 24 h.2, 3 The 
stability of transition metal complexes is highly dependent on the coordinated 
ligands, hence, improving the stability of this family of complexes may be to 
synthesize tethered analogues,16 in which the diamine ligand is tethered to the arene 
group (as shown for many iridium and ruthenium half-sandwich complexes).10, 17 
Alternatively, polymer-coating or micelle-encapsulation of OsII 16-electron 
catalysts may significantly improve the stability in a cellular environment. This has 
previously been shown for 16-electron RuII and OsII carborane complexes 
encapsulated in P123 core-shell micelles,15 which enhanced the intracellular 
stability and aqueous solubility, whilst maintaining the antiproliferative activity. 
The dissociation of the bidentate sulfonamide ligand from Os was demonstrated by 
ICP-MS and synchrotron-XRF using a Br-probe at an apparent inert site (Chapter 
3). Remarkably, significantly higher levels of the unbound sulfonamide ligand were 
retained intracellularly, which was found to localise with the Os in the cytoplasm, 
but also independently in the cell nucleus. It is known that uncoordinated 
sulfonamide ligands are non-toxic to cancer cells (IC50>100 µM), thus, metal 
complexation may provide a means of delivering the sulfonamide ligand inside 
cells. The potential binding modalities of Br-labelled sulfonamide ligands to 
intracellular biomolecules could be elucidated using mass spectrometry proteomics, 
which has previously been used to identify the binding of organo-osmium(II) 
complexes to nucleobases.18 As Zn2+ and Mg2+ are abundant cell nuclei and stabilize 
DNA, hence, cell nuclei metal-binding studies or molecular docking may provide 
insights into the binding preferences of the sulfonamide ligand. In addition, FTIR 
can be used to gain insights into DNA or RNA inhibition of the intact OsII complex 
and “free” ligand by exploiting the hydrated and dehydrated forms of DNA.19  
Additional approaches to improving the efficacy of OsII sulfonamide complexes 
might be to overcome the dependence on active (energy-dependent) influx and 
efflux pathways. It is well-known that the cellular accumulation of lipophilic drugs 
is predominantly facilitated via. passive diffusion,20 since they readily diffuse 




across cell membranes. Hence, extending the hydrophobicity of these complexes 
may shift the dependence away from active pathways (i.e. endocytosis), however, 
this is a compromise with aqueous solubility. Alternatively, as lysosomes have been 
implicated in the breakdown of OsII sulfonamide complexes, this can be exploited 
through a targeting approach. For example, tethering pH-activated21 or lysosomal-
targeting drugs (i.e. doxorubicin)22 at inert sites of the OsII complexes may lead to 
enhanced antiproliferative activity.  
 
6.2.2    Targeting of iridium PDT photosensitizers  
 
 
Figure 6.2. Possible ways of further probing the targeting of iridium photosensitisers: (a) 
in-cell distribution of iridium; (b) mitochondrial in vitro assays; (c) targeting of glycolysis.  
 
Cryo-XRT revealed damage to mitochondrial organelles in cancer cells treated with 
7 (Chapter 4). The cellular distribution of 7 can be probed using synchrotron-XRF 
(Ir L3M5=9.18 keV) or cell fractionation 
192Ir ICP-MS studies. Mitochondrial-
dependent cell viability assays can be used to elucidate cellular targets of 
cyclometallated IrIII photosensitizers, including mitochondrial dysfunction ToxGlo 
assay and flow cytometry mitochondrial assays.23, 24 As 7 can enhance levels of 
glycolytic enzymes, further studies may involve investigating the effect of 
inhibiting glucose transporters or glycolytic enzymes. For example, screening 
against GLUT1 and using glucose analogues (e.g. 2-NBDG) to quantify and 
visualize inhibition of glucose uptake by fluorescence microscopy,25 or 
pyruvate/lactate colorimetric assays.3   




6.2.3    Cellular accumulation, targeting and stability of Ir-Pt  
 
 
Figure 6.3. Further work for investigating the in-cell targets of a potent PDT-PACT 
complex (8): (a) ICP-MS accumulation studies; (b) combinational in vitro screening; (c) 
organelle-targeting assays. 
 
The cellular influx and efflux mechanisms of 8 have not yet been probed, thus, ICP-
MS 192Ir and 195Pt studies under varying conditions (as described in Chapter 3) 
could be used to gain an insight into cleavage of the linker between the two metal 
centres under both dark and irradiation conditions (465 nm). As Ir was concentrated 
in small, cytoplasmic regions and the Pt was sparsely distributed throughout the 
cell, cellular fractionation ICP-MS studies could provide insights into the potential 
cellular targets and cleavage of 8. Complementary to this, organelle-specific cell 
viability assays can be employed to probe the therapeutic targets of intact and 
cleaved 8, for example lysosomal (chloroquine; NeutralRed assay)6, 26 or 
mitochondrial (ToxGlo assay or cytochrome c assays).25, 27 As the cellular 
accumulation of diazido-PtIV complexes was significantly enhanced upon blue light 
exposure (Chapter 5), the same concept can be probed for 8 using ICP-MS.  
Synchrotron-XRF alone cannot confirm the nature of specific organelles or cellular 
features, analytical techniques such as FT-ICR mass spectrometry can be used to 
elucidate specific binding of the metal fragments to biomolecules.28 The concept of 
combinational therapeutic screening can be employed to determine the whether the 
antiproliferative activity of 8 is dependent on the Pt-Ir modalities being intact prior 
to photoactivation: for example, performing cell viability assays with combinations 
of the individual IrIII-PDT and PtIV-PACT modalities (complexes 9 and 10, 
Chapter 4, Section 4.1, Fig. 4.3). 




6.2.4    Future design of diazido-PtIV PACT complexes  
 
 
Figure 6.4. Further work in optimising the antiproliferative activity of diazido-PtIV PACT 
prodrugs: (a) probing drug speciation in biological media; (b) optimisation of 
antiproliferative screening protocols; (c) combinational screening with other cytostatic 
drugs; (d) membrane-specific studies to assess membrane damage upon blue light 
exposure. The in situ EXAFS image was taken from the literature.29 
 
This thesis has demonstrated that the cellular accumulation of diazido-PtIV PACT 
complexes in cancer cells is highly dependent on the photo-conditions (ca. 3× more 
upon blue light irradiation), which may prove significant in the future development 
of these complexes for phototherapy (Chapter 5). Further research into the 
potential extracellular activation of diazido-PtIV complexes by blue light may 
involve membrane integrity flow cytometry (demonstrated in Chapter 3) to 
determine whether photoactivation damages the cell membrane, resulting in 
enhanced Pt influx. In addition, specific dose-dependent (blue light) cellular 
accumulation ICP-MS studies associated with cell membranes and / or influx 
mechanisms can be investigated: ouabain (inhibitor of Na+ / K+ pump), CTR1 
(copper transporters utilized by various Pt compounds), amphotericin B (protein-




mediated uptake) or methyl-β-cyclodextrin (inhibitor of caveolae endocytosis).30 
Alternative methods for investigating membrane damage induced by diazido-PtIV 
complexes at different light dosages might involve AFM-Raman and AFM-IR 
spectroscopy, biologically (live cells) or chemically (solution experiments with 
membrane saturated and unsaturated lipids).31 Further to this, 195Pt ICP-MS 
accumulation studies of cells treated with diazido-PtIV complexes but irradiated in 
complex-free medium (not in extracellular drug solution) may provide essential 
insights into the photo-mediated uptake of these complexes. 
The chemical speciation of test compounds in biologically-relevant media may be 
essential in elucidating extra- and intracellular mechanisms of drug activation for 
in vivo and clinical translation. With this is mind, this research would benefit from 
investigating the speciation of diazido-PtIV compounds in cell culture media using 
techniques such as capillary-electrophoresis ICP-MS, EXAFS or XANES in situ 
studies.32-34 Further in-cell Pt XANES studies are required to build on the 
preliminary work in Chapter 5. Additionally, a labelling approach can be employed 
using readily detectable exogenous elements (e.g. Br or I by ICP-MS/XRF),35, 36 
which can be used to monitor the fate of the axial OR groups of diazido-PtIV 
complexes and in a cellular environment. 
An optimization of methodology (exposure times, light intensity or dosage) may be 
essential in overcoming the endosomal-breakdown of diazido-PtIV complexes under 
dark conditions – which may be associated with the lack of toxicity observed. 
Complementary to this, investigations into the detoxification and efflux 
mechanisms of this family of PtIV complexes under dark and blue light conditions 
can be investigated using various endocytotic or lysosomal inhibitors by ICP-MS 
(as shown in Chapter 3).30  
Finally, the cytostatic nature of diazido-PtIV compounds can further be exploited by 
investigating the combination with other know cytostatic compounds (i.e. 
rapamycin or paclitaxel),37, 38 either by complex conjugation or combination 
therapy. This is important for the clinical translation of these complexes, as 
cytostatic drugs are commonly administered in combination with other drugs (i.e. 
cytotoxic drugs) to increase the drug efficacy.39 
 








Figure 6.5. Further utilisation of synchrotron techniques: (a) in vivo and ex vivo 
synchrotron imaging; (b) correlative cryo-XRF techniques; (c) XANES; (d) In situ EXAFS 
studies; (e) InfraRed microspectroscopy; (f) comparative techniques for metal speciation. 
The following images were taken from the literature: spheroids,40 ptychography,41 
nanotomography,42 serum proteins,43 live cell imaging44 and nanoSIMS.45 
 
This thesis has used a variety of synchrotron-based techniques, including soft cryo-
XRT, synchrotron-XRF, DPC imaging and XANES analysis to investigate the 
mechanisms of action of organometallic compounds in cancer cells. Further hard x-
ray synchrotron techniques can be utilized on the same complex systems to gain 
complementary information of the different families of complexes studied in this 
thesis. Synchrotron-XRF forms a large proportion of this thesis and has provided 
new information on the in-cell activities of Os, Ir and Pt anticancer complexes. XRF 
can also be applied to ex vivo (tumour spheroids or tissue) or in vivo models (tumour 
xenografts in mice). This is important as the translation from in vitro studies to a 
clinical scenario can be drastically different. Correlative cryo-XRF and cryo-XRT 
can provide native-state information on the morphological and targeting effects of 
metallodrugs in vitro and in vivo (e.g. using two different beamlines, or performing 
hard x-ray ptychography).9, 46 In addition, cryo-XRF can be coupled with hard x-
ray ptychography or nanotomography to provide further insights into the in-cell 
metal localisation in 3D,41, 42 to elucidate cellular targets to a higher resolution (e.g. 




sub-15 nm beam available at NSLS-II).42 As synchrotron-XRF is time-consuming, 
the need for high-throughput analysis of samples proves necessary for increasing 
the statistical relevance of mapped cells, which may be obtained using lower 
emittance sources – which is planned for the Diamond II synchrotron upgrade. 
The platinum XANES analysis of diazido-PtIV complexes in cancer cells in this 
thesis (Chapter 5) was a preliminary attempt to validate and optimize different data 
acquisition methods, thus, the “compressed-sensing” method can be employed for 
future in vitro and in vivo analysis of PtII and PtIV compounds at beamline I14. 
XANES analysis of both Os and Br would be particularly interesting for the Br-
labelled OsII catalysts reported in this thesis (Chapters 3),47-49 to gain insights into 
the intracellular speciation and binding modalities of the intact complex and the 
dissociated ligand. The potential adducts or binding modalities of the Os, Ir or Pt 
complexes reported herein can be investigated chemically by performing in situ 
EXAFS solution analysis (>100 eV from the absorption edge), which has 
previously been used to analyse the GSH-activation of half-sandwich OsII-
azopyridine complexes.29 For example, the interactions between OsII 16-electron 
catalysts with L-cysteine (which are highly abundant in lysosomes) can be 
investigated using EXAFS, which may elucidate potential chemical species which 
lead to complex detoxification and degradation. 
Other synchrotron techniques can be used to investigate the cellular changes and 
potential binding partners of organometallic complexes. Synchrotron InfraRed 
microspectroscopy can be used to monitor the changes in DNA, lipids and proteins 
in live, single cells (avoiding fixation),31, 50 which can provide direct insights into 
drug-induced biochemical and morphological changes. This may be particularly 
interesting for monitoring the C-Br band in Br-labelled Os complexes (Chapters 
3-4). Complementary to this, focal-plane array synchrotron InfraRed microscopy 
can provide high-throughput, depth-resolved chemical information of treated cells 
with high spatial resolution.51, 52 Finally, it would be interesting to utilize 
complementary techniques to investigate the distribution, speciation and 
quantification of elements in biological systems, and compare it to results obtained 
by synchrotron-XRF and XANES. Notably, techniques for the speciation of metals 
includes mass cytometry,53 LA-ICP-MS,54 NanoSIMS,55 single-cell ICP-MS56  and 
FRET ratiometric sensors.57-59 
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Table A2. Biological elements that exist in DMEM tissue culture media as salts, amino 
acids or vitamins, and the concentrations they exist at.[a] 
[a] Information was obtained from https://www.thermofisher.com/uk/en/home/technical-
resources/media-formulation.183.html (Accessed on 7th October 2020). 
Element Total Concentration 
(mM) 
Calcium (Ca) 3.6 
Chloride (Cl) 96 
Copper <0.001 
Manganese (Mn) <0.001 
Phosphorus (P) 3.35 
Potassium (K) 13.5 
Sodium (Na) 140 
Iron (Fe) <0.001 
Zinc (Zn) <0.001 
Element Chemical Form Concentration 
(mg/L) 
Calcium (Ca) Calcium chloride 200.00 
 D-Calcium pantothenate 4.00 
Chloride (Cl) Calcium chloride 200.00 
 Choline chloride 4.00 
 L-Arginine hydrochloride 84.00 
 L-Cystine 2HCl 63.00 
 L-Histidine hydrochloride-H2O 42.00 
 L-Lysine hydrochloride 146.00 
 Potassium Chloride 400.00 
 Pyridoxine hydrochloride 4.00 
 Sodium Chloride 6400.00 
 Thiamine hydrochloride 4.00 
Iron (Fe) Ferric Nitrate 0.10 
Magnesium (Mg) Magnesium Sulfate 97.67 
Phosphorus (P) Sodium Phosphate monobasic 125.00 
Potassium (K) Potassium Chloride 400.00 
Sodium (Na) L-Tyrosine disodium salt dihydrate 104.00 
 Phenol red 0.01 
 Sodium Bicarbonate 3700.00 
 Sodium Chloride 6400.00 
 Sodium Phosphate monobasic 125.00 
Sulfur (S)  L-Cystine 2HCl 63.00 
 L-Methionine 0.20 
 Magnesium Sulfate 97.67 
 Thiamine hydrochloride 4.00 




Table A3. Biological elements that exist in RPMI-1640 tissue culture media as salts, amino 
acids or vitamins, and the concentrations they exist at.[a] 
[a] Information was obtained from https://www.thermofisher.com/uk/en/home/technical-
resources/media-formulation.114.html (Accessed on 7th October 2020). 
 
 
Table A4. Biological elements that exist in PBS used in tissue culture.[a] 
[a] Information was obtained from https://www.thermofisher.com/uk/en/home/technical-
resources/media-formulation.160.html (Accessed on 7th October 2020). 
 
Element Chemical Form Concentration 
(mg/L) 
Calcium (Ca) Calcium Nitrate 100.00 
 D-calcium pantothenate 0.25 
Chloride (Cl)  Choline chloride 3.00 
 L-Cystine 2HCl 65.00 
 L-Lysine hydrochloride 40.00 
 Potassium chloride 400.00 
 Pyridoxine hydrochloride 1.00 
 Sodium chloride 6000.00 
 Thiamine hydrochloride 1.00 
Magnesium (Mg) Magnesium sulphate 48.84 
Phosphorus (P) Sodium phosphate dibasic 800.00 
Potassium (K) Potassium chloride 400.00 
Sodium (Na) L-Tyrosine disodium salt dihydrate 29.00 
 Sodium bicarbonate 2000.00 
 Sodium chloride 6000.00 
 Sodium phosphate dibasic 800.00 
Sulfur (S) Glutathione (reduced) 1.00 
 L-Cystine 2HCl 65.00 
 L-Methionine 15.00 
 Magnesium sulphate 48.84 
 Thiamine hydrochloride  1.00 
Element Chemical Form Concentration 
(mg/L) 
Chloride (Cl) Sodium chloride 8006.28 
 Potassium chloride 201.29 
Phosphorus (P) Sodium phosphate dibasic 1419.60 
 Monopotassium phosphate 250.00 
Potassium (K) Potassium chloride 201.29 
 Monopotassium phosphate 250.00 
Sodium (Na) Sodium chloride 8006.28 
 Sodium phosphate dibasic 1419.60 




Table A5. Biological elements that exist in HBSS used in tissue culture.[a] 
[a] Information was obtained from https://www.thermofisher.com/uk/en/home/technical-
resources/media-formulation.153.html (Accessed on 7th October 2020).                                           .      
 
Table A6. X-ray crystallographic data for SS-1, SS-2 and SS-3 (Chapter 3).  
[a] Literature crystallographic data.2 
Element Chemical Form Concentration 
(mg/L) 
Calcium (Ca) Calcium chloride 110.98 
Chloride (Cl) Calcium chloride 110.98 
 Magnesium chloride hexahydrate 203.30 
 Potassium chloride 373.75 
 Sodium chloride 8181.60 
Magnesium (Mg) Magnesium chloride hexahydrate 203.30 
 Magnesium sulfate hydrate 98.59 
Phosphorus (P) Disodium phosphate 53.40 
 Potassium dihydrogen phosphate 54.43 
Potassium (K) Potassium chloride 373.75 
 Potassium dihydrogen phosphate 54.43 
Sodium (Na) Disodium phosphate 53.40 
 Sodium bicarbonate 336.04 
 Sodium chloride 8181.60 
Sulfur (S) Magnesium sulfate hydrate 98.59 
Complex SS-1[a] SS-2 SS-3 
a (Å) 10.6100(3) 9.9784(1) 9.33638(14) 
b (Å) 13.8464(3) 14.2370(1) 14.31887(15) 
c (Å) 18.9530(5) 19.7954(2) 21.7165(3) 
α (°) 90 90 90 
β (°) 90 90 90 
γ (°) 90 90 90 
Crystal system Orthorhombic Orthorhombic Orthorhombic 
Temperature (K) 150 150 150 
Reported volume (Å3) 2788.79(11) 2812.18(4) 2903.21(6) 
Space group P212121 P212121 P212121 
Dx (g cm-3) 1.641 1.780 1.832 
Z 4 4 4 
Empirical formula C31H34N2O2OsS C30H31BrN2O2OsS C30H31IN2O2OsS 
MW (g/mol) 688.86 754.74 800.73 
µ (mm-1) 4.678 11.157 17.545 
F(000) 1368.0 1472 1544 
Reflections measured 33345 5531 5624 
WR2 reflections 0.0927 0.0771 0.0665 




Table A7. Mulliken partial charges calculated for complexes RR-6 (X=F), theoretical 
compound (EB1, X=Cl), RR-2 (X=Br) and RR-3 (X=I), at the PBE0/Lanl2DZ/6-31+G** 
level of theory (Chapter 3). 
 
 Mulliken partial charge 
 RR-6 EB1 RR-2 RR-3 
Os 1 0.566 0.566 0.566 0.566 
S 2 1.369 1.369 1.371 1.371 
O 3 -0.599 -0.597 -0.597 -0.597 
O 4 -0.551 -0.551 -0.550 -0.550 
N 5 -0.891 -0.890 -0.889 -0.889 
N 6 -0.821 -0.819 -0.820 -0.821 
X 68 -0.323 0.017 0.065 0.172 
 
  




Table A8. Cartesian coordinates and electrostatic potential surface (EPS) calculated for 
[Os(p-cymene)(N-(4-fluorobenzenesulfonyl)-1,2-diphenylethylenediamine)] (RR-6, X= F) 
calculated at the PBE0/Lanl2DZ/6-31+G** level. EPS is shown mapped onto the total 
electron density. Isovalue=0.04. (R,R)-catalyst only. Surface mapping colours range from 
red (-0.025 au) to blue (+0.30 au), Chapter 3. 
 
   
Atom x y z  Atom x y z 
Os 1 -0.6540 -0.7843 -0.6626  H 35 -2.1229 0.3546 1.8677 
S 2 0.7115 0.2380 2.1218  C 36 -3.7600 1.7012 2.2537 
O 3 0.0200 -0.8779 2.7792  H 37 -4.3343 0.9584 2.8013 
O 4 0.8909 1.4910 2.8562  C 38 -4.2570 2.9913 2.1021 
N 5 0.0344 0.5768 0.6629  H 39 -5.2224 3.2611 2.5208 
N 6 -0.8765 0.8563 -1.6271  C 40 -3.4964 3.9406 1.4228 
C 7 4.8976 -1.2587 1.2232  H 41 -3.8640 4.9572 1.3122 
C 8 4.4061 -0.1790 0.4999  C 42 -2.2585 3.5918 0.8940 
H 9 5.0303 0.2991 -0.2473  H 43 -1.6680 4.3487 0.3805 
C 10 3.1141 0.2636 0.7541  C 44 -0.1004 -2.7557 0.3184 
H 11 2.7022 1.0948 0.1913  H 45 0.5294 -2.8456 1.1955 
C 12 2.3380 -0.3848 1.7132  C 46 -1.4752 -2.4890 0.4993 
C 13 2.8472 -1.4611 2.4362  H 47 -1.8639 -2.4001 1.5071 
H 14 2.2233 -1.9400 3.1843  C 48 -2.3165 -2.1701 -0.6209 
C 15 4.1416 -1.9094 2.1885  C 49 -1.7516 -2.2266 -1.9334 
H 16 4.5695 -2.7456 2.7310  H 50 -2.3546 -1.9494 -2.7905 
H 17 -1.1952 0.9232 -2.5864  C 51 -0.3561 -2.3953 -2.0967 
C 18 -0.3919 1.9608 0.4335  H 52 0.0872 -2.2852 -3.0813 
H 19 0.3366 2.6472 0.8788  C 53 0.5010 -2.6387 -0.9616 
C 20 -0.3833 2.1137 -1.0993  C 54 1.9775 -2.8007 -1.1502 
H 21 -1.0820 2.9207 -1.3600  H 55 2.3403 -2.1619 -1.9598 
C 22 0.9861 2.5123 -1.6403  H 56 2.2123 -3.8407 -1.4071 
C 23 1.7889 1.6338 -2.3681  H 57 2.5203 -2.5390 -0.2399 
H 24 1.4249 0.6281 -2.5578  C 58 -3.7743 -1.8475 -0.3796 
C 25 3.0415 2.0334 -2.8340  H 59 -3.8208 -1.3884 0.6164 
H 26 3.6528 1.3355 -3.4005  C 60 -4.5851 -3.1478 -0.3515 
C 27 3.5084 3.3188 -2.5793  H 61 -4.5564 -3.6450 -1.3274 
H 28 4.4833 3.6308 -2.9431  H 62 -5.6324 -2.9395 -0.1113 
C 29 2.7117 4.2068 -1.8579  H 63 -4.1980 -3.8484 0.3946 
H 30 3.0639 5.2145 -1.6556  C 64 -4.3567 -0.8449 -1.3709 
C 31 1.4624 3.8058 -1.3989  H 65 -3.7412 0.0586 -1.4177 
H 32 0.8466 4.5074 -0.8390  H 66 -5.3648 -0.5568 -1.0586 
C 33 -1.7578 2.2925 1.0247  H 67 -4.4417 -1.2685 -2.3783 
C 34 -2.5191 1.3547 1.7215  F 68 6.1412 -1.6882 0.9780 
 




Table A9. Cartesian coordinates and electrostatic potential surface (EPS) calculated for 
[Os(p-cymene)(N-(4-bromobenzenesulfonyl)-1,2-diphenylethylenediamine)] (RR-2, X= 
Br) calculated at the PBE0/Lanl2DZ/6-31+G** level. EPS is shown mapped onto the total 
electron density. Isovalue=0.04. (R,R)-catalyst only. Surface mapping colours range from 
red (-0.025 au) to blue (+0.30 au), Chapter 3. 
  
 
Atom x y z  Atom x y z 
Os 1 -1.0486 -0.8113 -0.6906  H 35 -2.5927 0.0256 1.9443 
S 2 0.2446 0.3755 2.0625  C 36 -4.4217 1.0703 2.3955 
O 3 -0.2102 -0.8538 2.7228  H 37 -4.8428 0.2366 2.9514 
O 4 0.2540 1.6268 2.8207  C 38 -5.1369 2.2567 2.2735 
N 5 -0.5498 0.6199 0.6479  H 39 -6.1207 2.3540 2.7239 
N 6 -1.5834 0.7881 -1.6005  C 40 -4.5719 3.3267 1.5829 
C 7 4.5748 -0.3864 0.9239  H 41 -5.1112 4.2659 1.4954 
C 8 3.8801 0.6265 0.2721  C 42 -3.3106 3.1980 1.0122 
H 9 4.3653 1.2356 -0.4823  H 43 -2.8751 4.0480 0.4896 
C 10 2.5468 0.8444 0.6017  C 44 -0.0790 -2.6675 0.1747 
H 11 1.9821 1.6193 0.0934  H 45 0.6322 -2.6606 0.9920 
C 12 1.9336 0.0449 1.5629  C 46 -1.4587 -2.6585 0.4771 
C 13 2.6434 -0.9586 2.2160  H 47 -1.7666 -2.6541 1.5161 
H 14 2.1441 -1.5588 2.9704  C 48 -2.4353 -2.4698 -0.5569 
C 15 3.9804 -1.1830 1.8940  C 49 -1.9852 -2.3968 -1.9134 
H 16 4.5473 -1.9624 2.3908  H 50 -2.6994 -2.2138 -2.7081 
H 17 -1.9529 0.8207 -2.5432  C 51 -0.6015 -2.3204 -2.1992 
C 18 -1.2107 1.9167 0.4694  H 52 -0.2711 -2.1184 -3.2131 
H 19 -0.5917 2.7061 0.9094  C 53 0.3790 -2.4270 -1.1472 
C 20 -1.2818 2.0991 -1.0579  C 54 1.8401 -2.3348 -1.4631 
H 21 -2.1103 2.7864 -1.2777  H 55 2.0235 -1.6270 -2.2759 
C 22 -0.0113 2.7213 -1.6286  H 56 2.2158 -3.3156 -1.7788 
C 23 0.8691 2.0065 -2.4404  H 57 2.4153 -2.0130 -0.5925 
H 24 0.6375 0.9716 -2.6745  C 58 -3.9026 -2.4175 -0.1933 
C 25 2.0311 2.6028 -2.9300  H 59 -3.9466 -2.0536 0.8414 
H 26 2.7056 2.0300 -3.5613  C 60 -4.4854 -3.8344 -0.2315 
C 27 2.3277 3.9249 -2.6149  H 61 -4.4559 -4.2406 -1.2487 
H 28 3.2326 4.3903 -2.9952  H 62 -5.5297 -3.8263 0.0961 
C 29 1.4500 4.6515 -1.8113  H 63 -3.9297 -4.5164 0.4194 
H 30 1.6690 5.6859 -1.5616  C 64 -4.7154 -1.4520 -1.0509 
C 31 0.2909 4.0546 -1.3290  H 65 -4.2623 -0.4561 -1.0505 
H 32 -0.3880 4.6313 -0.7034  H 66 -5.7314 -1.3677 -0.6538 
C 33 -2.5914 2.0024 1.1110  H 67 -4.8039 -1.8005 -2.0863 








Table A10. Cartesian coordinates and electrostatic potential surface (EPS) calculated for 
[Os(p-cymene)(N-(4-iodobenzenesulfonyl)-1,2-diphenylethylenediamine)] (RR-3, X=I) 
calculated at the PBE0/Lanl2DZ/6-31+G** level. EPS is shown mapped onto the total 
electron density. Isovalue=0.04. (R,R)-catalyst only. Surface mapping colours range from 
red (-0.025 au) to blue (+0.30 au), Chapter 3. 
   
Atom x y z  Atom x y z 
Os 1 -1.3565 -0.8153 -0.6914  H 35 -2.8878 -0.0447 1.9708 
S 2 -0.0670 0.3984 2.0515  C 36 -4.7478 0.9318 2.4467 
O 3 -0.4760 -0.8468 2.7125  H 37 -5.1309 0.0823 3.0062 
O 4 -0.0865 1.6462 2.8155  C 38 -5.5075 2.0913 2.3362 
N 5 -0.8846 0.6254 0.6472  H 39 -6.4884 2.1518 2.7991 
N 6 -1.9504 0.7711 -1.5873  C 40 -4.9908 3.1823 1.6407 
C 7 4.2775 -0.2185 0.8501  H 41 -5.5653 4.1012 1.5613 
C 8 3.5297 0.7639 0.2060  C 42 -3.7327 3.1009 1.0544 
H 9 3.9737 1.3894 -0.5605  H 43 -3.3353 3.9673 0.5284 
C 10 2.1939 0.9362 0.5530  C 44 -0.3244 -2.6433 0.1626 
H 11 1.5929 1.6854 0.0477  H 45 0.3890 -2.6160 0.9773 
C 12 1.6240 0.1221 1.5278  C 46 -1.7026 -2.6778 0.4707 
C 13 2.3790 -0.8514 2.1747  H 47 -2.0064 -2.6862 1.5109 
H 14 1.9132 -1.4659 2.9391  C 48 -2.6892 -2.5171 -0.5589 
C 15 3.7184 -1.0284 1.8332  C 49 -2.2470 -2.4261 -1.9169 
H 16 4.3130 -1.7869 2.3305  H 50 -2.9698 -2.2646 -2.7086 
H 17 -2.3367 0.7962 -2.5235  C 51 -0.8677 -2.3028 -2.2074 
C 18 -1.5929 1.8991 0.4854  H 52 -0.5482 -2.0860 -3.2217 
H 19 -0.9968 2.7065 0.9245  C 53 0.1205 -2.3829 -1.1600 
C 20 -1.6864 2.0882 -1.0397  C 54 1.5757 -2.2384 -1.4829 
H 21 -2.5398 2.7485 -1.2466  H 55 1.7297 -1.5048 -2.2788 
C 22 -0.4438 2.7566 -1.6204  H 56 1.9796 -3.1988 -1.8253 
C 23 0.4432 2.0821 -2.4592  H 57 2.1470 -1.9191 -0.6088 
H 24 0.2400 1.0444 -2.7065  C 58 -4.1562 -2.5132 -0.1907 
C 25 1.5777 2.7213 -2.9592  H 59 -4.2084 -2.1573 0.8464 
H 26 2.2580 2.1792 -3.6109  C 60 -4.6943 -3.9474 -0.2352 
C 27 1.8396 4.0469 -2.6281  H 61 -4.6580 -4.3459 -1.2553 
H 28 2.7229 4.5456 -3.0165  H 62 -5.7365 -3.9743 0.0981 
C 29 0.9546 4.7334 -1.7978  H 63 -4.1140 -4.6160 0.4080 
H 30 1.1466 5.7700 -1.5350  C 64 -5.0017 -1.5686 -1.0400 
C 31 -0.1768 4.0937 -1.3049  H 65 -4.5818 -0.5582 -1.0319 
H 32 -0.8616 4.6396 -0.6584  H 66 -6.0196 -1.5214 -0.6416 
C 33 -2.9687 1.9325 1.1421  H 67 -5.0794 -1.9113 -2.0782 








Table A11. Viable (FL2-) and non-viable (FL2+) membrane integrity analysis of a 
normalized population of A549 (human lung) cancer cells treated with 1×IC50 of SS-2 
(31±1 µM) or RR-2 (29.5±0.5 µM) for 24 h (310 K, 5% CO2) and co-administered with 
sodium formate (0-2 mM) as determined by flow cytometry (Chapter 3). 
[a] P-values were calculated using a two-tailed t-test assuming unequal variables. All t-tests were 
comparison to the untreated control. 
 
Table A12. Time-dependent ICP-MS 189Os cellular accumulation in A2780 (human 
ovarian) cancer cells treated with 1×IC50 concentration of RR-1 (15.5±0.5 µM), SS-2 
(30.8±1.6 µM) or RR-2 (27.4±0.6 μM) for 3-24 h (Chapter 3). The extent of efflux was 
determined by 1×IC50 for 24 h, followed by recovery period in complex-free media (24, 48 
and 72 h). 
Time / h RR-1[a] SS-2 RR-2 
3 32±4 37±2 35±3 
6 42±1 32±7 39±8 
18 33±1 29±2 28±2 
24 30±2 29.5±0.5 22±3 
48[b] 19±2 18.3±0.6 22±4 
72[b] 13±2 16±5 18±2 
96[b] 5.1±0.5 7.2±1.5 7.7±2.5 
[a] Time-dependent cellular accumulation of RR-1 in A2780 cells as reported in the literature.2, 3  
[b] 24 h exposure, followed by 24, 48 or 72 h recovery in complex-free media. 
 
Table A13. Formate-dependent ICP-MS 189Os cellular accumulation in A2780 cells treated 
with 1×IC50 of RR-1 (15.5±0.5 µM) or SS-2 (30.8±1.6 µM) for 24 h upon co-administration 
with sodium formate (0 or 2 mM). 
 ng of Os/106 cells 
[Formate] / mM RR-1[a] SS-2 
0 29±3 30±1 
2 28±3 31±2 













99.73±0.07 0.27±0.07 1.0000 
Untreated + formate  
 
99.76±0.05 0.24±0.05 0.6184 
SS-2  
 
99.82±0.11  0.18±0.11 0.3079 
SS-2 + formate 
 
99.76±0.05 0.24±0.05 0.6668 
RR-2  
 
99.53±0.09  0.47±0.09 0.0382 
RR-2  + formate  
 
99.44±0.03 0.56±0.03 0.0099 




Table A14. Verapamil-dependent efflux of 189Os and 79Br in A549 cells treated with 1× 
IC50 of SS-2 (30.8±1.6 µM) for 24 h, and recovery in 0-20 μM of verapamil hydrochloride 
(prepared in 5% v/v DMSO, 95% v/v DMEM) for 24-72 h (Chapter 3). Statistical analysis 
was performed using Welch’s unpaired t-test, assuming unequal variances. 
 
 
Table A15. Intracellular ratio of bromine-to-osmium (Br/Os) in A549 (human lung) cancer 
cells treated with 1×IC50 of SS-2 (30.8±1.6 µM) for 24 h, and recovered in 0-20 μM of 
erapamil hydrochloride (prepared in 5% v/v DMSO, 95% v/v DMEM) for 24-72 h 
(Chapter 3). Statistical analysis was performed using the Welch’s unpaired t-test, 
assuming unequal variances. 
 
 
Table A16. Time-dependent ICP-MS 189Os and 79Br accumulation in A549 (human lung) 
cancer cells treated with 1×IC50 of SS-2 (30.8±1.6 µM) for different exposure times (3, 6, 
24 h) and 24 h with different recovery times (24, 48 and 72 h), Chapter 3.  




 Complex-free media Verapamil 
Recovery time / h Os ng/106 cells Br ng/106 cells Os ng/106 cells Br ng/106 cells 
24 9.1±2.4 275±54 11.5±2.4 243±35 
48 3.9±0.8 176±31 6.6±0.06  178±20 
72 3.0±0.9 151±44 5.7±2.3 187±64 
Br / Os molar ratio 
Recovery time / h Complex-free media Verapamil 
24[a] 72±23 51±13 
48[a] 107±29 64±7 
72[a] 48±21 76±40 
 ng/106 cells 
Time / h Osmium Bromine 
0 0.03±0.01 4.6± 1.8 
3 46±3 186±20 
6 46± 9 249±39 
24 46±3 571±11 
48 9.1±2.4 275±54 
72 3.9±0.8 176±31 
96 3.0±0.9 151±44 




Table A17. Time-dependent ICP-MS 189Os cellular distribution in A549 (human lung) 
cancer cells treated with 1×IC50 of SS-2 (30.8±1.6 µM) for 3-24 h and determined using a 
cell fractionation kit (Chapter 3). The extent of efflux was determined by 1×IC50 for 24 h 
followed by recovery in complex-free media (24-72 h). 
 Average % Osmium 
Time / h Cytosolic Membrane Nuclear Cytoskeletal 
3 3.4±0.6 84±12 5.7±0.5 7.1±1.4 
6 1.67±0.8 86±9 6.0±0.3 6.2±0.5 
24 5.6±2.8 81±9 5.5±0.4 8.2±1.4 
24+24 1.4±0.1 80±5.2 5.5±0.3 12.9±0.9 
24+48 1.6±0.2 84±18 4.6±1.6 9.4±2.1 
24+72 4.7±2.9 66±9 9.2±2.7 19.6±6.7 
 
 
Table A18. Time-dependent ICP-MS 79Br cellular distribution in A549 (human lung) 
cancer cells treated with 1 IC50 of SS-2 (30.8±1.6 µM) for 3-24 h and determined using a 
cell fractionation kit (Chapter 3). The extent of efflux was determined by 1×IC50 for 24 h 
followed by recovery in complex-free media (24-72 h). 
 Average % Bromine 
Time / h Cytosolic Membrane Nuclear Cytoskeletal 
3 17.2±1.4 58.1±7.4 19.7±1.2 4.9±2.1 
6 8.9±6.1 72.9±6.9 15.3±0.4 2.9±0.2 
24 10.6±2.6 74.9±9.8 11.8±0.8 2.7±0.004 
24+24 6.5±0.2 79.5±3.5 11.2±0.3 2.8±0.2 
24+48 7.1±0.8 77.6±16.2 11.1±1.4 4.2±0.9 
24+72 10.3±2.3 64.5±0.649 17.6±1.4 7.5±1.8 
 
 
Table A19. Normalized fractional moles of 189Os and 79Br in the nuclear fractions in A549 
cells treated with 1×IC50 of SS-2 (30.8±1.6 µM) for different exposure times, as reported 
in fractional nmol ×10-8 per cell and determined by ICP-MS (Chapter 3). 
 
 
 Fraction nmol × 10-8 per cell 
Time / h  Osmium Bromine 
3 1.4±0.4 46.4±15.5 
6 1.5±0.6 48±19 
24 1.3±0.3 85±13 
24+24 0.3±0.1 39±17 
24+48 0.10±0.05 25±11 
24+72 0.13±0.07 28±8 




Table A20. Cell areas (µm2) and roundness factors (RF) of cryo-fixed and freeze-dried 
A549 cells treated with 0-5×IC50 of SS-2 (0-150 µM) for 24 h (no recovery), as identified 
by S, K, P and Zn distributions in the synchrotron-XRF elemental maps (Chapter 3): C1-
4 (untreated controls), C5-7 (30 µM), C9-15 (90 µM) and C16-18 (150 µM). Data were 
analysed in triplicate using ImageJ.4  







C2 685±19 0.34±0.01 
C3 829±23 0.36±0.02 





C6 602±5 0.61±0.01 
C7 476±36 0.34±0.02 





C10 331±5 0.89±0.03 
C11 556±5 0.43±0.02 
C12 411±6 0.77±0.01 
C13 279±3 0.94±0.02 
C14 373±6 0.80±0.05 




0.88±0.04 C17 611±9 0.886±0.003 
C18 590±9 0.91±0.03 
 
 
Table A21. Area of cell nuclei (µm2) in cryo-fixed and freeze-dried A549 cells treated with 
0-5×IC50 of SS-2 (0-150 µM) for 24 h (no recovery), as identified by the Zn distributions 
in the synchrotron-XRF elemental maps: C1-4 (untreated controls), C5-7 (30 µM), C9-15 
(90 µM) and C16-18 (150 µM). Data were analysed in triplicate using ImageJ.4  




















266±34 C17 296±13 
C18 280±6 
 




Table A22. Pearson R-value and Spearman Rank Correlation between Os and Br in the 
cytoplasm, nucleus or whole cryo-fixed and freeze-dried A549 cells treated with 1-5×IC50 
of SS-2 (0-150 µM) as determined from the synchrotron-XRF maps (Chapter 3): C5-7 (30 




Table A23. Pearson R-value and Spearman Rank Correlation between Os and Zn in the 
cytoplasm, nucleus or whole cryo-fixed and freeze-dried A549 cells treated with 1-5×IC50 
of SS-2 (0-150 µM) as determined from the synchrotron-XRF maps (Chapter 3): C5-7 (30 




 Pearson R-value Spearman Rank Correlation 
Cell All Cytoplasm Nucleus All Cytoplasm Nucleus 
C5 0.45 0.13 -0.02 0.346 0.120 -0.022 
C6 0.29 0.19 0.10 0.284 0.178 0.093 
C7 0.15 0.21 0.00 0.125 0.206 -0.003 
C8 0.42 0.42 0.04 0.364 0.364 -0.030 
C9 0.48 0.42 -0.08 0.417 0.345 -0.073 
C10 0.56 0.48 0.03 0.510 0.469 -0.031 
C11 0.43 0.33 0.00 0.397 0.316 0.002 
C12 0.43 0.38 -0.08 0.406 0.349 -0.079 
C13 0.09 0.32 -0.05 0.139 0.301 -0.062 
C14 0.24 0.39 -0.05 0.160 0.356 -0.043 
C15 0.07 0.41 -0.11 0.074 0.423 -0.13 
C16 0.22 0.18 0.08 0.214 0.172 0.043 
C17 0.11 0.16 0.02 0.100 0.147 0.022 
C18 0.22 0.17 0.04 0.139 0.159 0.031 
 Pearson R-value Spearman Rank Correlation 
Cell All Cytoplasm Nucleus All Cytoplasm Nucleus 
C5 0.07   0.05 -0.03 0.077 0.049  -0.022 
C6 0.02 0.00 0.00 0.014 -0.012 0.000 
C7 0.00 -0.02 -0.01 -0.009 -0.018 -0.011 
C8 -0.01 0.00 -0.02 0.002 -0.003 -0.025 
C9 -0.03 -0.03 -0.03 -0.021 -0.040 -0.023 
C10 0.06 0.03 -0.09 0.078 0.028 -0.084 
C11 -0.03 -0.02 -0.01 -0.018 -0.027 -0.014 
C12 -0.02 0.03 -0.02 -0.007 0.031 -0.017 
C13 -0.15 0.03 -0.08 -0.145 0.025 -0.068 
C14 -0.08 0.03 -0.03 -0.083 0.020 -0.032 
C15 -0.02 0.03 -0.01 -0.015 0.014 -0.018 
C16 -0.02 0.00 0.00 -0.022 -0.005 -0.003 
C17 0.00 0.03 0.02 -0.002 0.020 0.024 
C18 0.01 0.01 0.01 0.005 0.006 0.004 




Table A24. Pearson R-value and Spearman Rank Correlation between Br and Zn in the 
cytoplasm, nucleus or whole cryo-fixed and freeze-dried A549 cells treated with 1-5×IC50 
of SS-2 (0-150 µM) as determined from the synchrotron-XRF maps (Chapter 3): C5-7 (30 




Table A25. Membrane integrity analysis determined by flow cytometry for a normalized 
population of A549 cells pre-incubated with either medium alone or with added 
chloroquine diphosphate (CQ, 150 µM) for 2 h, followed by treatment with 1×IC50 RR-1 
or SS-2 for 24 h, with no recovery (Chapter 3). P-values were determined using Welch’s 






 Pearson R-value Spearman Rank Correlation 
Cell All Cytoplasm Nucleus All Cytoplasm Nucleus 
C5 0.36 0.13 0.06 0.342 0.128 0.049 
C6 0.18 0.05 0.07 0.176 0.054 0.068 
C7 0.16 0.06 0.07 0.168 0.063 0.024 
C8 0.18 0.03 0.11 0.192 0.038 0.094 
C9 0.11 0.05 0.08 0.126 0.046 0.097 
C10 0.28 0.12 0.17 0.286 0.118 0.172 
C11 0.09 0.00 0.08 0.104 -0.001 0.077 
C12 0.21 0.11 0.13 0.207 0.105 0.116 
C13 0.33 0.08 0.22 0.278 0.077 0.204 
C14 0.17 0.08 0.08 0.185 0.079 0.087 
C15 0.26 0.09 0.08 0.246 0.088 0.081 
C16 0.29 0.21 0.05 0.214 0.173 0.043 
C17 0.10 0.16 0.02 0.099 0.147 0.022 
C18 0.22 0.17 0.04 0.139 0.158 0.031 
Conditions Viable membrane (FL2-) 
Non-viable membrane 
(FL2+) 
Untreated (control) 99.51±0.05 0.49±0.05 
CQ (control) 99.43±0.11 0.57±0.11 
1 98.92±0.13 1.08±0.13 
1 + CQ 98.78±0.16 1.22±0.16 
2 98.31±0.02 1.69±0.02 
2 + CQ 99.05±0.05 0.95±0.05 




Table A26.The average calculated volumes (µm3) of individually segmented mitochondria 
in cryopreserved PC3 cells grown on carbon-gold TEM grids and treated with 0-1 μM of 7 
for 2 h (protected from light), followed by 10 min in the dark  or irradiated with blue light 
(λ=465 nm, 4.8 mW/cm2), followed by 24 h recovery in complex-free media. One 
tomogram from each condition was volume segmented (T1-4, Chapter 4). Data were 
acquired in SuRVoS imaging software.5 A total number of mitochondria per tomogram 
were determined to be: (i) T1=14; (ii) T2=20; (iii) T3=26; (iv) T4=19. 
 [a] Exposed to 2 h protected from the light, followed by 24 h recovery in complex-free media. [b] 
Exposed to 10 min irradiation (465 nm, 4.8 mW/cm2) followed by 24 h recovery in complex-free 
media. [c] Exposed to 1 μM of 7 for 2 h, followed by 10 min (protected from light) and 24 h recovery 
in complex-free medium. [d] Exposed to 1 μM of 7 for 2 h, followed by 10 min irradiation (465 nm, 












Untreated control  




( λ = 465 nm)[d] 
1 1.193 0.785 1.444 0.0693 
2 0.725 0.638 1.454 0.0498 
3 0.401 0.952 1.001 0.0588 
4 2.221 1.393 0.864 0.1010 
5 4.405 1.132 0.733 0.1249 
6 0.252 0.481 1.283 0.1211 
7 0.553 0.568 0.384 0.0922 
8 0.258 0.368 1.217 0.0739 
9 0.167 0.619 0.564 0.0455 
10 0.945 0.494 0.236 0.1030 
11 0.228 1.293 0.223 0.0558 
12 0.361 0.638 0.914 0.1197 
13 1.650 0.304 1.348 0.0463 
14 0.312 0.204 0.609 0.0898 
15  0.292 0.410 0.0615 
16  1.019 0.722 0.0991 
17  0.562 1.197 0.0942 
18  0.702 0.602 0.0693 
19  0.313 1.026 0.0693 
20  0.315 0.511  
21   0.479  
22   0.569  
23   0.207  
24   0.487  
25   0.748  
26   0.656  
Mean  0.98±1.2 0.65±0.35 0.77±0.38 0.08±0.03 




Table A27. The cell areas (µm2) and roundness factors coefficients of cryo-fixed and 
freeze-dried A549 lung cancer cells treated with 0 (C1-3) or 5×IC50 (C4-6) of 8 (500 µM, 
2 h) under dark conditions as determined from the K, S, P and Zn synchrotron-XRF 
elemental maps (Chapter 4). Data were analysed in triplicate in ImageJ.4  





0.37±0.07 C2 415±11 0.40±0.02 




0.81±0.08 C5 427±34 0.85±0.03 
C6 418±21 0.71±0.05 
 
 
Table A28. The Pearson R-value statistical co-localization between Ir, Pt and Zn in cryo-
fixed and freeze-dried A549 lung cancer cells treated with 8 (500 µM, 2 h) under dark 
conditions as determined from the elemental synchrotron-XRF maps (Chapter 4). Data 
were analysed in triplicate in ImageJ software.4 




Ir-Pt Mean  
Ir-Pt 
C4 0.20  
0.33 ± 0.12 
0.59 
0.65 ± 0.05 
0.44 
0.51 ± 0.10 C5 0.38 0.66 0.47 
C6 0.42 0.69 0.63 
 
 
Table A29. The Spearman Rank Correlation statistical co-localization between Ir or Pt 
with Zn in cryopreserved and freeze-dried A549 lung cancer cells treated with 8 (500 µM, 
2 h) under dark conditions as determined from the synchrotron-XRF elemental maps 
(Chapter 4). Data were analysed in triplicate in ImageJ software.4 











0.44±0.07 C5 0.30 0.64 0.48 












Table A30. The mole fraction quantities and molar platinum-to-iridium ratios (Pt/Ir) in 
cryo-fixed and freeze-dried A549 lung cancer cells treated with 8 (500 µM, 2 h) under dark 
conditions as determined from the K, S, P and Zn synchrotron-XRF elemental maps 
(Chapter 4). Data were analysed in triplicate in ImageJ software.4 















C5 1.03±0.02 0.223±0.004 4.62 
C6 1.12±0.03 0.271±0.003 4.15 
 
 
Table A31. Individual lengths and mean lengths (µm) of the dark, elongated cytoplasmic 
organelles identified from the Differential Phase Contrast Images of cryo-fixed and freeze-
dried A549 cells treated with 8 (500 µM, 2 h) under dark conditions (Chapter 4). Data 
were analysed in ImageJ software.4 
 Organelle length (µm) 
Number C4 C5 C6 
1 2.04±0.08 3.08±0.12 2.73±0.13 
2 1.22±0.04 4.14±0.10 2.79±0.07 
3 1.60±0.05 2.20±0.03 3.66±0.09 
4 0.98±0.11 1.55±0.04 2.87±0.11 
5 1.24±0.07 2.67±0.04 2.43±0.16 
6 0.76±0.07 1.86±0.09 1.66±0.09 
7 0.94±0.12 2.07±0.02 1.86±0.07 
8 0.98±0.13 2.15±0.03 3.12±0.14 
9 1.04±0.08 5.14±0.12  
Mean 1.2±0.4 2.8±1.1 2.6±0.6 
 
 
Table A32. Individual and mean areas (µm2) of the dark, elongated cytoplasmic organelles 
identified from the DPC images of cryopreserved and freeze-dried A549 cells treated with 
8 (500 µM, 2 h) under dark conditions (Chapter 4). Data were analysed in ImageJ 
software.4 
  Organelle area (µm2) 
Number C4 C5 C6 
1 2.83±0.23 2.26±0.15 2.41±0.25 
2 1.66±0.19 2.59±0.26 3.98±0.38 
3 1.99±0.22 2.04±0.27 1.86±0.17 
4 1.432±0.30 0.59±0.11 1.66±0.19 
5 0.86±0.14 2.31±0.34 1.41±0.16 
6 1.04±0.11 1.15±0.19 1.04±0.14 
7 1.00±0.23 0.81±0.22 1.07±0.12 
8 0.98±0.31 0.93±0.10  
9 1.25±0.28   
Mean 1.5±0.6 1.6±0.8 1.9±1.0 
 




Table A33. Individual and mean mitochondrial volumes in cryopreserved PC3 cells treated 
with 0.25–1×IC50 of 12 under dark (2 h) or blue light (1 h exposure + 1 h 465 nm conditions, 
T1-15; T18-20) as determined in SuRVoS (Chapter 5).5 A minimum of 10 mitochondria 
per tomogram were segmented. 
T1 T2 T3 T4 T5 T6 
0.20 0.18 0.53 0.24 0.17 0.11 
0.49 0.21 0.42 0.14 0.12 0.05 
0.28 0.19 0.22 0.10 0.08 0.17 
0.09 0.26 0.25 0.17 0.13 0.21 
0.14 0.38 0.17 0.17 0.08 0.14 
0.17 0.20 0.58 0.09 0.16 0.10 
0.27 0.11 0.45 0.15 0.04 0.11 
0.34 0.12 0.31 0.11 0.10 0.30 
0.33 0.12 0.32 0.04 0.08 0.09 
0.17 0.13 0.29 0.10 0.10 0.23 
0.25±0.12 0.19±0.08 0.35±0.14 0.13±0.06 0.11±0.04 0.15±0.08 
T7 T8 T9 T10 T11 T12 
0.06 0.05 0.05 0.03 0.35 0.09 
0.08 0.34 0.19 0.04 0.24 0.14 
0.26 0.08 0.30 0.06 0.28 0.13 
0.09 0.07 0.15 0.07 0.20 0.15 
0.09 0.21 0.21 0.11 0.21 0.07 
0.12 0.08 0.07 0.15 0.15 0.09 
0.06 0.08 0.15 0.19 0.17 0.19 
0.09 0.19 0.04 0.23 0.21 0.28 
0.05 0.07 0.07 0.12 0.29 0.05 
0.05 0.13 0.03 0.16 0.27 0.13 
0.09±0.06 0.13±0.09 0.13±0.09 0.12±0.07 0.24±0.06 0.13±0.07 
T13 T14 T15 T18 T19 T20 
0.05 0.11 0.12 0.12 0.35  
0.11 0.14 0.13 0.03 0.15  
0.14 0.20 0.14 0.08 0.07  
0.07 0.13 0.08 0.09 0.30  
0.06 0.30 0.07 0.14 0.12  
0.11 0.17 0.09 0.08 0.12  
0.02 0.21 0.06 0.10 0.04  
0.06 0.23 0.05 0.11 0.07  
0.04 0.13 0.04 0.05 0.06  
0.04 0.11 0.07 0.05 0.11  














Table A34. Individual and mean lipid droplet volumes in cryopreserved PC3 cells treated 
with 0.25–1×IC50 of 12 under dark (2 h) or blue light (1 h exposure and 1 h 465 nm) 
conditions (T1-20) as determined in SuRVoS (Chapter 5).5 A minimum of 6 lipid droplets 
per tomogram were segmented.  
T1 T2 T3 T4 T5 T6 T7 
0.11 0.12 0.18 0.14 0.12 0.23 0.04 
0.09 0.10 0.13 0.12 0.09 0.10 0.05 
0.05 0.08 0.14 0.16 0.07 0.17 0.04 
0.05 0.09 0.26 0.24 0.09 0.09 0.04 
0.07 0.08 0.38 0.15 0.07 0.12 0.07 
0.06 0.09 0.31 0.10 0.12 0.12 0.04 
0.07±0.02 0.09±0.02 0.23±0.01 0.15±0.05 0.09±0.02 0.14±0.05 0.05±0.01 
T8 T9 T10 T11 T12 T13 T14 
0.32 0.02 0.04 0.11 0.12 0.17 0.14 
0.26 0.03 0.05 0.29 0.15 0.17 0.11 
0.24 0.02 0.05 0.20 0.23 0.13 0.15 
0.18 0.03 0.04 0.20 0.12 0.16 0.09 
0.20 0.03 0.06 0.20 0.12 0.11 0.16 
0.33 0.04 0.04 0.21 0.18 0.13 0.11 
0.25±0.06 0.03±0.01 0.05±0.01 0.15± 0.04 0.20±0.06 0.15±0.06 0.13±0.03 
T15 T16 T17 T18 T19   
0.04 0.05 0.05 0.11 0.09   
0.04 0.03 0.01 0.03 0.09   
0.02 0.03 0.02 0.09 0.11   
0.02 0.01 0.04 0.15 0.05   
0.05 0.02 0.03 0.14 0.10   
0.02 0.02 0.01 0.13 0.01   



















Table A35. Volumes (µm3) of endosome-like structures observed in two independent 
cryopreserved PC3 cells treated with 1× irradiated IC50 (6.48±0.84 µM) of 12 for 2 h under 
dark conditions (T7 and T9, respectively). Data were analysed in SuRVoS (Chapter 5).5 
 Endosomal volume (µm3) 
Number T7 T9 
1 0.58 0.99 
2 0.53 0.42 
3 0.19 0.20 
4 0.17 0.37 
5 0.39 0.21 
6 0.33 0.19 
7 0.21 0.33 
8 0.24 0.38 
9 0.16 0.27 
10 0.23 0.19 
11 0.14 0.26 
12 0.09 0.13 




15 0.30  
16 0.21  
17 0.16  
Mean 0.26±0.13 0.33±0.23 
 
 
Table A36. Pearson’s R-values and Spearman Rank coefficients between Pt and Zn in 
cryo-fixed and freeze-dried PC3 cells treated with 5× irradiated IC50 of 11 (IC50=55.6±0.9 
µM), 12 (IC50=6.48±0.84 µM) or cisplatin (IC50> 100 µM) under both dark (2 h) or 
irradiated conditions (1 h exposure 1 h 465 nm, 4.8 mW/cm2), as determined from the 









C4 0.23 0.17 
C5 0.20 0.12 
C6 0.14 0.11 
10 
 (465 nm) 
C7 0.49 0.44 
C8 0.42 0.38 
C9 0.40 0.41 
11  
(Dark) 
C10 0.35 0.38 
C11 0.29 0.24 
C12 0.37 0.34 
11  
(465 nm) 
C13 0.48 0.46 
C14 0.63 0.57 
C15 0.62 0.59 
Cisplatin 
C16 0.30 0.31 
C17 0.38 0.36 
C18 0.33 0.35 




Table A37. Proposed method for assessing sample beam damage during XANES mapping 
using a nano-focussed beamline, specifically in cryo-fixed and dried cells treated with 
photoactivatable drugs.                                                                                                       .  
 
Step  Overview Experiment  
1 Test the limits of x-ray beam 
exposure on the sample (e.g. what 
exposure time damages the 
sample) 
Expose cell sample to long exposure times (at the 
desired resolution and energy) until visible damage 
to the cell morphology is observed. This can be 
performed by obtaining brightfield microscopy 
images of specific cells before and after beam 
exposure.  
2 Identify the beam exposure time at 
which the cell morphology is not 
damaged 
Once the ultimate limit of beam damage is known, 
lower exposure times can be used to determine the 
maximum x-ray exposure time which does not 
damage the cell morphology. 
3 Assess whether the elemental 
distribution and quantification at 
this maximal x-ray exposure is the 
same as those in cells exposed for 
shorter periods. 
Analyse the differences in the distribution of 
endogenous elements (Fe, Zn, S, P, K etc.) in 
addition to the exogenous complex being 
investigated (e.g. Pt, Ir, Os). Additionally, estimate 
the quantity of these elements using an AXO 
standard to assess any differences. From this, the x-
ray exposure time which does not damage the cell 
morphology OR affect the elemental distribution or 
elemental quantities can be determined. 
4 Assess whether the chemical 
speciation of the element of 
interest changes (e.g. Pt, Ir, Os) at 
the edge of interest at this x-ray 
exposure. 
Perform XANES mapping at this x-ray exposure 
over the edge of interest, and at lower x-ray 
exposures to determine whether the chemical 
speciation changes at higher exposures. From this, 
a suitable x-ray exposure can be determined for the 
experiment.  
5 For photoactivatable drugs in 
which light may alter the 
oxidation state, solid pellets of the 
“inactive” and “active” drug can 
be prepared. 
“Dark” solid pellets protected from the light should 
be analysed at the optimised x-ray exposure using 
both the full beam or the nano-focussed beam 
(XANES mapping) to determine whether the 
oxidation state changes throughout analysis. This 
will allow identification of the x-ray exposure at 
which the chemical speciation changes as a result of 
repeated beam exposure, thus, the point at which the 
results become invalid. The “irradiated” slid pellet 
(irradiated with UV/Vis light prior to XANES 
mapping) should also be analysed to determine 
when the x-ray beam changes the elemental 
speciation.  
6 Start the experiment Perform XANES mapping on regions of interest in 
cells against solid pellets of known oxidation state 












Figure A1. Mulliken partial charges calculated for halide atom (X) in complexes RR-6 
(X=F), theoretical compound (EB1, X=Cl), RR-2 (X=Br) and RR-3 (X=I), at the 
PBE0/Lanl2DZ/6-31+G** level of theory (Chapter 3). 
 
 
Figure A2. The 1H NMR catalytic turnover number (TON) of acetophenone to (S) or (R)-
1-phenylethanol for complexes SS/RR-2 (p-Br) and SS/RR-3 (p-I) over 14 h (310 K) in 































Figure A3. The intracellular bromine-to-osmium (Br/Os) molar ratios calculated for A549 
(human lung) cancer cells treated with 1×IC50 SS-2 (30.8±1.6 µM) upon co-administration 
with 0-1 mM methyl-β-cyclodextrin for 24 h (Chapter 3). Statistical analysis was 
performed using the Welch’s unpaired t-test, assuming unequal variances, and compared 




Figure A4. Workflow for the analysis of lysosomes / endosomal structures from the XRF 
elemental maps of A549 cells treated with 2 (Chapter 3). Firstly, the fitted and calibrated 
.edf mass fraction files of both Os and Br were opened in ImageJ software and visualised 
using 16-colour imaging setting. Hotspots of Os were identified as ROI using the multipoint 
selection tool. The same ROI was identified in the Br map (Edit>Selection>Retain 
Selection). The area (µm2) and mass fraction of each ROI were measured 
(Analyze>Measure) for both Os and Br, and performed in triplicate. After this, the 
‘smoothing’ selection tool was used (Process>Smooth), which replaces each pixel with the 
average of its 3×3 neighbours (blurs the image). This is to see if the Os hospots are still 
clearly visible and reaffirm the ROI selection. For presentation and printing purposes, the 
‘smoothed’ 16-colour image was exported. 
 





Figure A5. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 
(human lung) cancer cell (C9) treated with 3×IC50 of SS-2 (90 µM) for 24 h (no recovery) 
as represented in 16-colour setting in ImageJ,4 showing small vesicle-sized co-localisation 
of Os and Br (Chapter 3) as represented identified with red circles. Images were prepared 
in ImageJ using the 16-colour settings, using the multipoint selections tools to identify 
small compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm 
stepsize with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and 
images generated in ImageJ.7 Note that, the presented images are shown as using the 
smoothing tool for clarity and presentation purposes, but all analysis was performed on the 
original pixelated mass fraction image. See Appendix Fig. A12 for more information. A 
total of 17 lysosomes were identified with an average area of 0.63±0.29 μm2 and a 
calculated average bromine-to-osmium (Br/Os) ratio of 3.4±0.4. 
 
Figure A6. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C10) treated with 3×IC50 of SS-2 (90 µM) for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information. A total of 12 
lysosomes were identified with an average area of 0.57±0.23 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 3.1±0.6. 





Figure A7. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C11) treated with 3×IC50 of SS-2 (90 µM) for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information. A total of 12 
lysosomes were identified with an average area of 0.70±0.17 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 2.6±0.3. 
 
 
Figure A8. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C12) treated with 3×IC50 of SS-2 (90 µM) for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information. A total of 19 
lysosomes were identified with an average area of 0.67±0.19 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 5.7±0.8. 





Figure A9. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C15) treated with 3×IC50 (90 µM) of SS-2 for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information.  A total of 12 
lysosomes were identified with an average area of 0.58±0.18 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 3.6±0.4. 
 
 
Figure A10. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C16) treated with 5×IC50 (90 µM) of SS-2 for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information.  A total of 12 
lysosomes were identified with an average area of 0.84±0.42 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 1.57±0.14. 





Figure A11. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C17) treated with 5×IC50 (150 µM) of SS-2 for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information.  A total of 11 
lysosomes were identified with an average area of 0.80±0.28 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 1.53±0.12. 
 
 
Figure A12. Synchrotron-XRF elemental maps of a cryo-fixed and freeze-dried A549 cell 
(C18) treated with 5×IC50 (150 µM) of SS-2 for 24 h (no recovery) as represented in 16-
colour setting in ImageJ,4 showing small vesicle-sized co-localisation of Os and Br 
(Chapter 3) as represented identified with red circles. Images were prepared in ImageJ 
using the 16-colour settings, using the multipoint selections tools to identify small 
compartments. Data were acquired using 15 keV energy, 0.1 s exposure, 100 nm stepsize 
with ca. 50×70 nm2 beam size. Data were analysed in PyMCA software,6 and images 
generated in ImageJ.7 Note that, the presented images are shown as using the smoothing 
tool for clarity and presentation purposes, but all analysis was performed on the original 
pixelated mass fraction image. See Appendix Fig. A12 for more information.  A total of 2 
lysosomes were identified with an average area of 0.63±0.05 μm2 and a calculated average 
bromine-to-osmium (Br/Os) ratio of 1.24±0.13. 






Figure A13. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid under dark conditions (protected from light) followed by 24 h in fresh medium (310 
K, 5% CO2; T5, C4_Video_T5, Chapter 4). Images were generated in IMOD imaging 
software,8 showing two different sample views (tilt angles): 0°; (b) +14°. Showing (1) 
mitochondria, (2) nucleolus, (3) nucleus, (4) nuclear membrane, (5) features of 






Figure A14. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid treated with 7 (1 µM) for 2 h under dark conditions (protected from light), followed 
by 24 h recovery in complex-free media (310 K, 5% CO2; T6, C4_Video_T6, Chapter 4). 
Images were generated in IMOD imaging software,8 showing two different sample views 
(tilt angles): 0°; (b) +15°. Showing (1) mitochondria, (2) nucleolus, (3) nucleus, (4) nuclear 
membrane, (5) features of lamellipodium, (6) spherical vesicles, (7) gold nanoparticle 
fiducials (d=250 nm). 
 





Figure A15. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid treated with 7 (1 µM) for 2 h under dark conditions (protected from light), followed 
by recovery in complex-free media (310 K, 5% CO2; T7, C4_Video_T7, Chapter 4). 
Images were generated in IMOD imaging software,8 showing two different sample views 
(tilt angles): 0°; (b) +24°. Showing (1). mitochondria, (2) nucleolus, (3) nucleus, (4) nuclear 
membrane, (5) features of lamellipodium, (6) spherical vesicles, (7) gold nanoparticle 






Figure A16. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid treated with 7 (1 µM) for 2 h under dark conditions (protected from light), followed 
by recovery in complex-free media (310 K, 5% CO2; T8, C4_Video_T8, Chapter 4). 
Images were generated in IMOD imaging software,8 showing two different sample views 
(tilt angles): 0°; (b) +39°. Showing (1) mitochondria, (2) nucleolus, (3) nucleus, (4) nuclear 
membrane, (5) features of lamellipodium, (6) spherical vesicles, (7) gold nanoparticle 
fiducials (d=250 nm). 
 





Figure A17. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid and treated with 7 (1 µM) for 2 h (protected from the light), 10 min irradiation (465 
nm, 4.8 mW/cm2) followed by 24 h recovery in complex-free media (310 K, 5% CO2; T9, 
C4_Video_T9, Chapter 4). Images were generated in IMOD imaging software,8 showing 
two different sample views (tilt angles): 0°; (b) +10°. Showing (1) mitochondria, (2) 
nucleolus, (3) nucleus, (4) nuclear membrane, (5) features of lamellipodium, (6) spherical 







Figure A18. 2D projections of a reconstructed x-ray tomogram (15.8×15.8 μm2) showing 
cellular and organelle morphology of a cryopreserved PC3 cell grown on carbon-gold TEM 
grid and treated with 7 (1 µM) for 2 h (protected from the light), 10 min irradiation (465 
nm) followed by 24 h recovery in complex-free media (310 K, 5% CO2; T10, 
C4_Video_T10, Chapter 4). Images were generated in IMOD imaging software,8 showing 
two different sample views (tilt angles): 0°; (b) +6.5°. Showing (1) mitochondria, (2) 
nucleolus, (3) nucleus, (4) nuclear membrane, (5) features of lamellipodium, (6) spherical 









Figure A19. A cryopreserved PC3 cell grown on carbon-gold TEM grids and exposure to 
dark conditions (2 h, protected from light) and incubated with MitoTracker DeepRed 
(λ=644/665 nm) and Lysotracker Red (λ=577/590nm) from Chapter 5. (a) Brightfield 
image. (b-d) Super-resolution fluorescence images obtained at the cryoSIM facility (B24, 
DLS): (b) LysoTracker Red (lysosomes), (c) MitoTracker Red (mitochondria) and (d) 
overlay of LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji.9 
Blue fluorescence was not observed. 
 
Figure A20. A cryopreserved PC3 cell grown on carbon-gold TEM grids and to dark 
conditions (2 h, protected from light) and incubated with MitoTracker DeepRed 
(λ=644/665 nm) and Lysotracker Red (λ=577/590nm) from Chapter 5. (a) Brightfield 
image. (b-d) Super-resolution fluorescence images obtained at the cryoSIM facility (B24, 
DLS): (b) LysoTracker Red (lysosomes), (c) MitoTracker Red (mitochondria) and (d) 
overlay of LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji.9 
Blue fluorescence was not observed. 





Figure A21. A cryopreserved PC3 cell grown on carbon-gold TEM grids and to dark 
conditions (1 h irradiation, 465 nm) and incubated with MitoTracker DeepRed (λ=644/665 
nm) and Lysotracker Red (λ=577/590nm) from Chapter 5. (a) Brightfield image. (b-d) 
Super-resolution fluorescence images obtained at the cryoSIM facility (B24, DLS): (b) 
LysoTracker Red (lysosomes), (c) MitoTracker Red (mitochondria) and (d) overlay of 
LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji.9 Blue 
fluorescence was not observed. 
 
Figure A22. A cryopreserved PC3 cell grown on carbon-gold TEM grids and to dark 
conditions (1 h irradiation, 465 nm) and incubated with MitoTracker DeepRed (λ=644/665 
nm) and Lysotracker Red (λ=577/590nm) from Chapter 5. (a) Brightfield image. (b-d) 
Super-resolution fluorescence images obtained at the cryoSIM facility (B24, DLS): (b) 
LysoTracker Red (lysosomes), (c) MitoTracker Red (mitochondria) and (d) overlay of 
LysoTracker Red and MitoTracker Deep Red. Images were generated in Fiji.9 Blue 
fluorescence was not observed. 





Figure A23. Two cryopreserved PC3 cells grown on a carbon-gold TEM grids and exposed 
1×IC50 of 12 for 2 h under dark conditions (2 h, protected from light) and incubated with 
MitoTracker DeepRed (λ=644/665 nm) and Lysotracker Red (λ=577/590nm) from 
Chapter 5. (a) Brightfield image. (b-d) Super-resolution fluorescence images obtained at 
the cryoSIM facility (B24, DLS): (b) LysoTracker Red (lysosomes), (c) MitoTracker Red 
(mitochondria) and (d) overlay of LysoTracker Red and MitoTracker Deep Red. Images 
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